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A B S T R A C T
Background
Reducing saturated fat reduces serum cholesterol, but eCects on other intermediate outcomes may be less clear. Additionally, it is unclear
whether the energy from saturated fats eliminated from the diet are more helpfully replaced by polyunsaturated fats, monounsaturated
fats, carbohydrate or protein.
Objectives
To assess the eCect of reducing saturated fat intake and replacing it with carbohydrate (CHO), polyunsaturated (PUFA), monounsaturated
fat (MUFA) and/or protein on mortality and cardiovascular morbidity, using all available randomised clinical trials.
Search methods
We updated our searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid) and Embase (Ovid) on 15 October
2019, and searched Clinicaltrials.gov and WHO International Clinical Trials Registry Platform (ICTRP) on 17 October 2019.
Selection criteria
Included trials fulfilled the following criteria: 1) randomised; 2) intention to reduce saturated fat intake OR intention to alter dietary fats
and achieving a reduction in saturated fat; 3) compared with higher saturated fat intake or usual diet; 4) not multifactorial; 5) in adult
humans with or without cardiovascular disease (but not acutely ill, pregnant or breastfeeding); 6) intervention duration at least 24 months;
7) mortality or cardiovascular morbidity data available.
Data collection and analysis
Two review authors independently assessed inclusion, extracted study data and assessed risk of bias. We performed random-eCects meta-
analyses, meta-regression, subgrouping, sensitivity analyses, funnel plots and GRADE assessment.
Main results
We included 15 randomised controlled trials (RCTs) (16 comparisons, ~59,000 participants), that used a variety of interventions from
providing all food to advice on reducing saturated fat. The included long-term trials suggested that reducing dietary saturated fat reduced
the risk of combined cardiovascular events by 21% (risk ratio (RR) 0.79; 95% confidence interval (CI) 0.66 to 0.93, 11 trials, 53,300
participants of whom 8% had a cardiovascular event, I2 = 65%, GRADE moderate-quality evidence). Meta-regression suggested that greater
reductions in saturated fat (reflected in greater reductions in serum cholesterol) resulted in greater reductions in risk of CVD events,
explaining most heterogeneity between trials. The number needed to treat for an additional beneficial outcome (NNTB) was 56 in primary
prevention trials, so 56 people need to reduce their saturated fat intake for ~four years for one person to avoid experiencing a CVD event.
In secondary prevention trials, the NNTB was 32. Subgrouping did not suggest significant diCerences between replacement of saturated
fat calories with polyunsaturated fat or carbohydrate, and data on replacement with monounsaturated fat and protein was very limited.
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We found little or no eCect of reducing saturated fat on all-cause mortality (RR 0.96; 95% CI 0.90 to 1.03; 11 trials, 55,858 participants) or
cardiovascular mortality (RR 0.95; 95% CI 0.80 to 1.12, 10 trials, 53,421 participants), both with GRADE moderate-quality evidence.
There was little or no eCect of reducing saturated fats on non-fatal myocardial infarction (RR 0.97, 95% CI 0.87 to 1.07) or CHD mortality
(RR 0.97, 95% CI 0.82 to 1.16, both low-quality evidence), but eCects on total (fatal or non-fatal) myocardial infarction, stroke and CHD
events (fatal or non-fatal) were all unclear as the evidence was of very low quality. There was little or no eCect on cancer mortality,
cancer diagnoses, diabetes diagnosis, HDL cholesterol, serum triglycerides or blood pressure, and small reductions in weight, serum total
cholesterol, LDL cholesterol and BMI. There was no evidence of harmful eCects of reducing saturated fat intakes.
Authors' conclusions
The findings of this updated review suggest that reducing saturated fat intake for at least two years causes a potentially important reduction
in combined cardiovascular events. Replacing the energy from saturated fat with polyunsaturated fat or carbohydrate appear to be useful
strategies, while eCects of replacement with monounsaturated fat are unclear. The reduction in combined cardiovascular events resulting
from reducing saturated fat did not alter by study duration, sex or baseline level of cardiovascular risk, but greater reduction in saturated
fat caused greater reductions in cardiovascular events.
P L A I N   L A N G U A G E   S U M M A R Y
E4ect of cutting down on the saturated fat we eat on our risk of heart disease
Review question
We wanted to find out the eCects on health of cutting down on saturated fat in our food (replacing animal fats and hard vegetable fats with
plant oils, unsaturated spreads or starchy foods).
Background
Health guidance suggests that reducing the amount of saturated fat we eat, by cutting down on animal fats, is good for our health. We
wanted to combine all available evidence to see whether following this advice leads to a reduced risk of dying or getting cardiovascular
disease (heart disease or stroke).
Study characteristics
We assessed the eCect of cutting down the amount of saturated fat we eat for at least two years on health outcomes including dying, heart
disease and stroke. We only looked at studies of adults (18 years or older). They included men and women with and without cardiovascular
disease. We did not include studies of acutely ill people or pregnant or breastfeeding women.
Key results
We found 15 studies with over 59,000 participants. The evidence is current to October 2019. The review found that cutting down on
saturated fat led to a 21% reduction in the risk of cardiovascular disease (including heart disease and strokes), but had little eCect on the
risk of dying. The review found that health benefits arose from replacing saturated fats with polyunsaturated fat or starchy foods. The
greater the decrease in saturated fat, and the more serum total cholesterol is reduced, the greater the protection from cardiovascular
events. People who are currently healthy appear to benefit as much as those at increased risk of heart disease or stroke (people with high
blood pressure, high serum cholesterol or diabetes, for example), and people who have already had heart disease or stroke. There was no
diCerence in eCect between men and women.
This means that, if 56 people without cardiovascular disease, or 32 people who already have cardiovascular disease, reduce their saturated
fat for around 4 years, then one person will avoid a cardiovascular event (heart attack or stroke) they would otherwise have experienced.
Quality of the evidence
There is a large body of evidence assessing eCects of reducing saturated fat for at least two years. These studies provide moderate-quality
evidence that reducing saturated fat reduces our risk of cardiovascular disease.
Reduction in saturated fat intake for cardiovascular disease (Review)












































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   E4ect of reducing saturated fat compared to usual saturated fat on CVD risk in adults (note: for the full set of GRADE tables
see additional tables 24 to 28)
Low saturated fat compared with usual saturated fat for CVD risk
Patient or population: people at any baseline risk of CVD
Intervention: lower saturated fat intake
Comparison: higher saturated fat intake
Settings: Any, including community-dwelling and institutions. Included RCTs were conducted in North America, Europe and Australia/New Zealand, no studies































Critical importance. Reducing saturated fat intake
probably makes little or no difference to all-cause
mortality.
Cardiovascular mortality











Critical importance. Reducing saturated fat intake















Critical importance. Reducing saturated fat intake
probably reduces cardiovascular mortality (to a
greater extent with greater cholesterol reduction).
Myocardial infarctions











Critical importance. The effect of reducing saturated
fat intake on risk of myocardial infarction is unclear

















































































































































Critical importance. Reducing saturated fat may
have little or no effect on risk of non-fatal myocar-
dial infarction.
Stroke











Critical importance. The effect of reducing saturat-
ed fat on the risk of stroke is unclear as the evidence
was of very low quality.
CHD mortality










Critical importance. Reducing saturated fat intake
may have little or no effect on CHD mortality.
CHD events











Critical importance. The effect of reducing saturated
fat on risk of CHD events is unclear as the evidence is
of very low quality.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk Ratio; CHD: coronary heart disease.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Minimum study duration was 24 months.
2 Risk of bias. Limiting trials to those at low summary risk of bias also suggested little or no eCect. Not downgraded.
3 Inconsistency. We found no important heterogeneity; I2 ≤ 30%. Not downgraded.
4 Indirectness. These RCTs directly assessed the eCect of lower vs higher saturated fat intake on health outcomes of interest. Participants included men and women with and
without CVD at baseline (also some participants with CVD risk factors like diabetes, or at risk of cancers). However, no trials included participants from developing countries.
Not downgraded.
5 Imprecision. The 95% CI includes both no eCect and a benefit. Downgraded once.
6 Publication bias. The funnel plot, and comparison of fixed- and random-eCects meta-analyses did not suggest major small-study (publication) bias. Not downgraded.
7 Imprecision. The 95% CI includes both harm and benefit. Downgraded once.
8 Risk of bias. Limiting trials to those at low summary risk of bias also suggested that reducing SFA reduced risk of CVD events. Not downgraded.
9 Inconsistency. Although heterogeneity was high, I2 = 65%, this was mostly explained by the degree of cholesterol-lowering (a dose eCect). Not downgraded.
10 Imprecision. The 95% CI includes only benefit. Not downgraded.
11 Publication bias. The funnel plot, and comparison of fixed- and random-eCects meta-analyses suggested some small-study (publication) bias. Downgraded once.






































































































































13 Risk of bias. Limiting trials to those at low summary risk of bias moved the RR slightly away from 1.0, suggesting that reducing SFA reduces the risk of non-fatal MI. This was
also seen in several other sensitivity analyses. Downgraded once.
14 Imprecision. The 95% CI includes both important benefits and important harms. Downgraded twice.
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B A C K G R O U N D
In 1949, Ryle and Russell in Oxford documented a dramatic increase
in coronary heart disease (CHD), and the Registrar General’s
Statistical Tables of 1920 to 1955 showed that there had been a 70-
fold increase in coronary deaths during this 35-year period (Oliver
2000; Ryle 1949). This sudden surge in coronary heart disease
sparked research into its causes. A case-control study published in
1953 of 200 post-myocardial infarction patients and age-matched
controls established that those with disease had higher low-density
lipoprotein (LDL) cholesterol levels (Oliver 1953).
Meanwhile in 1949 in the USA, Gofman had separated lipids
into lipoprotein classes through ultra centrifugation, describing
the LDL as ‘atherosclerogenic’ (Gofman 1949). The following year
Keys 1950 proposed that the concentration of plasma cholesterol
was proportional to dietary saturated fatty acids (SFA) intake.
This relationship was confirmed in work by Hegsted (Hegsted
1965; Hegsted 2000), who published an equation explaining the
relationship in 1965 and subsequently in 2000. The equation
suggests that dietary saturated fat increases serum cholesterol and
so increases cardiovascular (CV) risk, while polyunsaturated fats
(PUFA) reduce both. This has since been further refined:
Δ serum cholesterol (in mg/dL) = 2.16 * Δ dietary saturated fat
intake (as percentage of energy) – 1.65 * Δ dietary PUFA intake (as
percentage of energy, %E) + 6.77 * Δ dietary cholesterol intake (in
units of 100 mg/day) – 0.53
The Seven Countries Study compared CHD mortality in 12,000 men
aged 40 to 59 in seven countries, and found positive correlations
between CHD mortality and total fat intake in 1970, then in
1986 between CHD mortality and saturated fat intake (Keys 1986;
Thorogood 1996).  A migrant study of Japanese men living in
diCerent cultures confirmed in 1974 that men in California had
the diet richest in saturated fat and cholesterol, and the highest
CHD rates, those in Hawaii had intermediate saturated fat and
CHD rates, and those in Japan had a diet lowest in saturated
fat and cholesterol, and the least CHD (Kagan 1974; Robertson
1977).  However, systematic reviews of the observational data
have not confirmed these early studies. SkeaC 2009 included 28
USA and European cohorts (including 6600 CHD deaths among
280,000 participants) investigating the eCects of total, saturated,
monounsaturated, trans and omega-3 fats on CHD deaths and
events. They found no clear relationship between total, saturated
or monounsaturated fat (MUFA) intake and coronary heart disease
events or deaths. There was evidence that trans fats increased both
coronary heart disease events and deaths, and that total PUFAs and
omega-3 fats decreased them. Intervention studies are needed to
clarify cause and eCect, to ensure that confounding is not hiding
true relationships, or suggesting relationships where they do not
exist. Trials also directly address the issue of whether altering
dietary saturated fat in adults is helpful in reducing the risk of CVD in
the general population and in those at high risk. Intervention trials
are crucial in forming the basis of evidence-based practice in this
area.
Most intervention studies have assessed eCects of dietary
interventions on risk factors for heart disease, and separate work
ties the eCect of altering these risk factors to changes in disease
incidence and mortality. Systematic reviews in this area follow the
same pattern. There are systematic reviews of the eCect of dietary
fat advice on serum lipid levels (Brunner 1997; Clarke 1997; Denke
1995; Kodama 2009; Malhotra 2014; Mensink 1992; Mensink 2003;
Rees 2013; Weggemans 2001; Yu-Poth 1999), suggesting that dietary
changes cause changes in serum lipids. There are also systematic
reviews on the eCect of lipid level alterations on CV morbidity and
mortality (Briel 2009; De Caterina 2010; Law 1994; Robinson 2009;
Rubins 1995; Walsh 1995), suggesting that changes in lipids do
aCect CVD risk. Other risk factors dealt with in a similar way are
blood pressure (Bucher 1996; Law 1991; Shah 2007), body weight
or fatness (Astrup 2000; Hession 2009; SIGN 1996), angiographic
measurements (Marchioli 1994), antioxidant intake (Ness 1997),
metabolic profile (Kodama 2009) and alcohol intake (Rimm 1996).
A problem with this two-level approach is that any single dietary
alteration may have eCects over a wide range of risk factors for CVD.
An example of this is the choice of substitution of saturated fats by
carbohydrate, PUFAs, MUFAs or protein in the diet. This choice may
alter lipid profile, and may also aCect blood pressure, body weight,
oxidative state, rate of cholesterol eClux from fibroblasts, insulin
resistance, post-prandial triacylglycerol response, blood clotting
factors, and platelet aggregation. There may also be further risk
factors of which we are not yet aware. Evidence of beneficial eCect
on one risk factor does not rule out an opposite eCect on another
unstudied risk factor, and therefore an overall null (or harmful)
eCect of intervention. While understanding the eCects of dietary
advice on intermediate risk factors helps to ensure diets are truly
altered by advice, and illuminates mechanisms, the best way of
combining the eCects on all of these risk factors is to not study
risk factors, but to study the eCects of dietary change on important
outcomes, on CV morbidity and mortality, and on total mortality.
Substantial randomised controlled trial data on the eCects
of dietary fat on mortality and morbidity do exist and have
been previously reviewed (Abdelhamid 2020; Abdelhamid 2018;
Abdelhamid 2019; Brainard 2020; Brown 2019; Deane 2019; Hanson
2020; Hooper 2018; Hooper 2019; Hooper 2012). A recent very large
trial, the Women's Health Initiative, that included over 2000 women
with, and over 48,000 women without, CVD at baseline for over
eight years (WHI 2006)) has raised many questions about both the
eCects of fat on health and on how we best conduct research to
understand the relationship (Astrup 2011; Michels 2009; Prentice
2007; Stein 2006; Yngve 2006). We incorporated these findings into
an update of a Cochrane review on dietary fat and CVD risk with a
search in 2010 (Hooper 2012), finding reductions in cardiovascular
events in studies that modified dietary fat, and in studies of at least
two years' duration, but not in studies of fat reduction or studies
with less than two years' follow-up.
Why it is important to do this review
Public health dietary advice on prevention of cardiovascular
disease (CVD) has changed over time, with a focus on fat
modification during the 1960s and fat reduction during the 1990s
following the introduction of USA and UK dietary guidance on
fat reduction, limiting saturated fat intake to 10% of energy
(Harcombe 2015). In 2006, recommendations by the American
Heart Association suggested that, among other dietary measures,
Americans should "limit intake of saturated fat to 7% of energy,
trans fat to 1% of energy, and cholesterol to 300 mg/day by
choosing lean meats and vegetable alternatives, fat-free (skim) or
low-fat (1% fat) dairy products and minimise intake of partially
hydrogenated fats" (Lichtenstein 2006). Current American Heart
Association guidelines suggest that Americans should "Aim for
a dietary pattern that achieves 5% to 6% of calories from
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saturated fat" and "Reduce percent of calories from saturated
fat" (both graded as strong evidence on the basis of eCects
on serum lipids - trials with cardiovascular outcomes are not
referenced or discussed, Eckel 2013). European guidance on the
treatment of dyslipidaemia is similarly based on dietary eCects
on lipids, recommending reduction in saturated fats (ESC/EAS
2011) and referencing Mensink 2003, while the Joint British
Societies' guidance on preventing CVD recommends a healthy
diet including low saturated fat intake (Mach 2019), referencing
a variety of evidence including several recent systematic reviews.
This is reflected in UK Scientific Advisory Committee on Nutrition
recommendations that "dietary reference value for saturated fats
remains unchanged: the [population] average contribution of
saturated fatty acids to [total] dietary energy be reduced to no
more than about 10%", and that "saturated fats are substituted
with unsaturated fats. More evidence is available supporting
substitution with PUFA than substitution with MUFA" (SACN 2019).
Recent UK National Institute for Health and Care Excellence(NICE)
guidance suggests that for people at high risk of or with CVD
that they "eat a diet in which total fat intake is 30% or less of
total energy intake, saturated fats are 7% or less of total energy
intake, intake of dietary cholesterol is less than 300 mg/day and
where possible saturated fats are replaced by monounsaturated
and polyunsaturated fats". This statement was based on long-term
randomised controlled trials reporting hard outcomes, and NICE
separately assessed eCects of high polyunsaturated diets, including
four of the trials included in this review (NICE 2014).
We were interested in assessing the direct evidence from trials
of the eCects of reducing saturated fats, and considering what
macronutrients the saturated fats were replaced by, updating
Hooper 2015a. This update also supports a request from the
World Health Organization Nutrition Guidance Expert Advisory
Group (WHO NUGAG) to more accurately assess eCects of reducing
saturated fats on all-cause mortality, CV morbidity and other
health outcomes, and to consider the diCerential eCects on health
outcomes of replacement of the energy from saturated fat by other
fats, carbohydrates or protein.
O B J E C T I V E S
To assess the eCect of reducing saturated fat intake and
replacing it with carbohydrate (CHO), polyunsaturated (PUFA) or
monounsaturated fat (MUFA) and/or protein on mortality and
cardiovascular morbidity, using all available randomised clinical
trials.
Additional World Health Organization Nutrition Guidance Expert
Advisory Group (WHO NUGAG) specific questions included:
1. In adults, what is the eCect in the population of reduced
percentage of energy (%E) intake from saturated fatty acids
(SFA) relative to higher intake for reduction in risk of
noncommunicable diseases (NCDs)?
2. What is the eCect on coronary heart disease mortality and
coronary heart disease events?
3. What is the eCect in the population of replacing SFA with
polyunsaturated fats (PUFAs), monounsaturated fats (MUFAs),
carbohydrates (CHO) (refined versus unrefined), protein or trans
fatty acids (TFAs) relative to no replacement for reduction in risk
of NCDs?
4. What is the eCect in the population of consuming < 10%E as SFA
relative to > 10%E as SFA for reduction in risk of NCDs?
5. What is the eCect in the population of a reduction in %E from
SFA from 10% in gradual increments relative to higher intake for
reduction in risk of NCDs?
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials only. We accepted randomisation
of individuals, or of larger groups (clusters) where there were at
least six of these groups randomised. We excluded studies where
allocation was not truly randomised (e.g. divisions based on days of
the week or first letter of the family name), or where allocation was
not stated as randomised, and no further information was available
from the authors.
Types of participants
We included studies of adults (18 years or older, no upper age
limit) at any risk of cardiovascular disease, with or without
existing cardiovascular disease, using or not using lipid-lowering
medication. Participants could be of either gender, but we excluded
those who were acutely ill, pregnant or lactating.
Types of interventions
We included randomised controlled trials stating an intention
to reduce saturated fat (SFA) intake (by suggesting appropriate
nutrient-based or food-based aims) OR which provided a general
dietary aim, such as improving heart health or reducing total fat,
that also achieved a statistically significant saturated fat reduction
(P < 0.05) during the trial in the intervention arm compared
with the control arm. The intervention had to be dietary advice,
supplementation of fats, oils or modified or low-fat foods, or a
provided diet, compared to higher saturated fat intake which could
be usual diet, higher saturated fat, placebo or a control diet.
Intended duration of the dietary intervention was at least two years
(24 months or 104 weeks).
Types of outcome measures
Primary outcomes
• All-cause mortality (deaths from any cause)
• Cardiovascular (CVD) mortality (deaths from myocardial
infarction, stroke, and/or sudden death)
• Combined CVD events. These included data available on
number of people experiencing any of the following:
cardiovascular death, cardiovascular morbidity (non-fatal
myocardial infarction, angina, stroke, heart failure,
peripheral vascular events, atrial fibrillation) and unplanned
cardiovascular interventions (coronary artery bypass surgery or
angioplasty).
To meet our inclusion criteria, trials had to report either deaths
or CVD events. These could be reported as serious adverse events
(SAEs) or via communication with authors.
Secondary outcomes
• Additional health events; the outcomes CHD mortality and CHD
events were added at the request of the WHO NUGAG group,
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and were not present in the original overarching systematic
review. For each of these, we assessed number of participants
experiencing any of these:
* Myocardial infarction, total (fatal and non-fatal)
* Myocaridal infarction, non-fatal
* Stroke
* CHD mortality, which includes death from myocardial
infarction or sudden CVD death
* CHD events, which include any of the following: fatal or non-
fatal myocardial infarction, angina or sudden CVD death
* type II diabetes incidence
• Blood measures including serum blood lipids
* total cholesterol (TC, mmol/L)
* low-density lipoprotein (LDL) cholesterol, mmol/L
* high-density lipoprotein (HDL) cholesterol, mmol/L




* lipoprotein (a) (Lp(a)), mmol/L
* insulin sensitivity including glucose tolerance (homeostatic
model assessment (HOMA), intravenous glucose tolerance
test (IV-GTT), clamp, glycosylated haemoglobin (HbA1C))




* body weight, kg
* body mass index (BMI, kg/m2)
* systolic blood pressure (sBP, mmHg)
* diastolic blood pressure (dBP, mmHg)
* quality of life (any measure)
As all trials collect data on deaths and cardiovascular events (as
serious adverse events if not as planned outcome measures), we
only included trials where we knew that at least one primary
outcome occurred, by communication with authors if necessary.
Where we knew that at least one primary outcome occurred, we
included the study even where we were unable to use that data in
meta-analysis. We excluded studies where we knew that no primary
outcome events occurred (for a study to be excluded in this way
the paper needed to be very explicit about the lack of all outcomes
or we received confirmation from the authors) and this was noted
as the reason for exclusion. Lack of a single primary outcome
only occurs in very small studies or in young cohorts, so omitting
these studies will make no diCerence to eCect sizes and very little
diCerence to absolute eCect sizes (NNTs etc). All other trials were
considered unclear and where we could not gain clarification on
events from authors, they were classified as “awaiting assessment”.
For composite outcomes (like CVD events), we worked to collect
data on the number of participants in each arm who experienced
any type of CVD event, and did not double-count people (so that a
person experiencing a stroke and two heart attacks during a trial
was counted as one person experiencing CVD events, not as three
CVD events).
We extracted event and continuous outcome data for the latest time
point available within the trial, and always at least 24 months from
inception. We collected change data (with a measure of variance)
for continuous outcomes where these were available, and end data
where change data were not provided in usable format.
Search methods for identification of studies
Electronic searches
The updated searches were run on 15 October 2019 on the following
databases:
• CENTRAL (Issue 10 of 12, 2019, Cochrane Library)
• MEDLINE (Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, MEDLINE Daily and MEDLINE, Ovid, 1946 to October
14, 2019)
• Embase (Ovid, 1980 to 2019 week 41).
For this update, we introduced searches of two trials registers
on 17 October 2019; Clinicaltrials.gov (www.clinicaltrials.gov)
and WHO International Clinical Trials Registry Platform (ICTRP)
(apps.who.int/trialsearch/). The searches are described in
Appendix 1. The RCT filter for MEDLINE was the Cochrane sensitivity
and precision-maximising RCT filter (Lefebvre 2011), and for
Embase, terms as recommended in the Cochrane Handbook were
applied (Lefebvre 2011).
As we were updating another Cochrane review relating to dietary
fat (Hooper 2015b) at the same time, results of the searches for both
reviews were combined and de-duplicated before assessment of
titles and abstracts.
The search to 2014 is described in Hooper 2015a, and previous
searches in Hooper 2012. .
Searching other resources
We searched for recent publications of the included studies, to
ensure the best possible data set for each study.
Data collection and analysis
Selection of studies
Search results were loaded into Covidence so`ware. All authors
independently assessed titles and abstracts from the search,
diCerences were resolved by discussion and, when the findings
were not clear cut, the full text was collected for assessment. We
only rejected articles on initial screen if the author could determine
from the title and abstract that the article was not a report of
a randomised controlled trial; the trial did not address a low or
modified fat diet; the trial was exclusively in children less than 18
years old, pregnant women or the critically ill; the trial was of less
than 24 months duration; or the intervention was multifactorial.
When we could not reject a title/abstract with certainty, we
obtained the full text of the article for further evaluation.
Data extraction and management
We used a data extraction form designed for earlier versions
of this review. We extracted data concerning participants,
interventions and outcomes, trial quality characteristics (Chalmers
1990), data on potential eCect modifiers including participants'
baseline risk of cardiovascular disease, trial duration, intensity
of intervention (dietary advice, diet provided, dietary advice
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plus supplementation, supplementation alone), medications used
(particularly lipid-lowering medication) and smoking status,
numbers of events and total participant years in trial. Where
provided, we collected data on risk factors for cardiovascular
disease including blood pressure, lipids and weight.
We defined baseline risk of cardiovascular disease as follows:
high risk are participants with existing vascular disease including
a history of myocardial infarction, stroke, peripheral vascular
disease, angina, heart failure or previous coronary artery bypass
gra`ing or angioplasty; moderate risk are participants with
a familial risk, dyslipidaemia, diabetes mellitus, hypertension,
chronic renal failure; low risk are other participants or mixed-
population groups. Those at low or moderate risk combined are
primary prevention trials.
Data were extracted independently in duplicate by AA, FOJ and/or
LH, alongside assessment of risk of bias.
Assessment of risk of bias in included studies
We carried out 'Risk of bias' assessment independently in duplicate
as part of data extraction. We assessed trial risk of bias using the
Cochrane tool for assessment of risk of bias (Higgins 2011). For
included RCTs, we also assessed whether each study:
1. was free of systematic diCerences in care,
2. aimed to reduce SFA intake,
3. achieved SFA reduction, or
4. achieved total serum cholesterol reduction.
We used the category 'other bias' to note any further issues of
methodological concern. Funding was not formally a part of our
assessment of bias in RCTs as it is not a core part of the Cochrane
'Risk of bias' tool, but was reported in the Characteristics of
included studies.
Two authors (LH, NM) independently extracted validity data from
studies identified by the previous search, and resolved diCerences
by discussion.
Poorly concealed allocation is associated with a 40% greater eCect
size (Schulz 1995), so randomisation and allocation concealment
are core issues for all trials. Lack of blinding is associated with bias,
though smaller levels of bias than lack of allocation concealment
(Savovic 2012), especially in studies with objectively measured
outcomes (Wood 2008).
For this review, we introduced the concept of summary risk of bias
for whole trials. We considered dietary advice or all-food-provided
type trials to be at low summary risk of bias where we judged
randomisation, allocation concealment, and blinding of outcome
assessors to be adequate. Summary risk of bias was considered
moderate to high in all other included trials.
Measures of treatment e4ect
The eCect measures of choice were risk ratios (RR) for dichotomous
data and mean diCerence (MD) for continuous data.
Unit of analysis issues
We did not include any cluster-randomised trials in this review, as
no relevant studies included at least six clusters.
Where there was more than one relevant intervention arm but only
one control arm, we either pooled the relevant intervention arms to
create a single pairwise comparison (where the intervention arms
were equivalently appropriate for this review) as described in the
Cochrane Handbook (Higgins 2011), or we excluded intervention
arms that were not appropriate for this review, or less appropriate
than another arm. When two arms were appropriate for diCerent
subgroups (Rose corn oil 1965; Rose olive 1965), then we used
the control group once with each intervention arm, and divided
the number of events in the control group, and the number of
participants in the control group, evenly between the two study
comparisons.
In the previous version of this review, data for WHI 2006 were
presented separately for those without baseline CVD, and with
baseline CVD, for most outcomes. This has been altered in this
version of the review, so that both sets of data are presented as a
single trial except when subgrouping by CVD risk. This has the eCect
of representing this study in the same way others are represented
(which is appropriate), and slightly reducing the weight of the WHI
2006 study in random-eCects meta-analysis, altering the numbers
in the analysis.
When assessing event data, we aimed to assess number of
participants experiencing an event (rather than numbers of events),
to avoid counting more than one outcome event for any one
individual within any one comparison. Where we were unclear (for
example, where a paper reported numbers of myocardial infarcts
but not by arm), we asked authors for further information.
Dealing with missing data
Where trials satisfied the inclusion criteria of our review but did
not report mortality and morbidity, or not by study arm, we tried
to contact study authors. This allowed inclusion of studies that
would otherwise have had to be excluded. We excluded studies
which were otherwise relevant but where we could not establish
the presence or absence of primary outcomes, despite multiple
attempts at author contact.
It was o`en unclear whether data on primary or secondary
outcome events may still have been missing, and so we did not
impute data for this review.
Where included studies used methods to infer missing data (such
as carrying the latest measurement forward), then we used these
data in analyses. Where this was not done, we used the data as
presented.
Assessment of heterogeneity
We examined heterogeneity using the I2 test, and considered it
important where greater than 50% (Higgins 2003; Higgins 2011).
Where we identified important clinical or unexplained statistical
heterogeneity, we did not pool but instead summarised the studies
in a narrative format. We used the assessment of heterogeneity
in our GRADE assessments, so that the quality of evidence
was downgraded where heterogeneity was important, and not
explained by subgrouping or meta-regression.
Assessment of reporting biases
We used funnel plots to examine the possibility of small study bias,
including publication bias (Egger 1997), for the primary outcomes
of total mortality and combined cardiovascular events. For this
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update, we also compared findings of fixed- and random-eCects
meta-analysis since the two methods weight small trials diCerently,
and diCerent eCect sizes suggest potential small study bias (Page
2019).
Data synthesis
We carried out data synthesis in the absence of clinical
heterogeneity. We used numbers of events in each study arm,
and total number of participants randomised, where extracted,
and Mantel-Haenszel random-eCects meta-analysis carried out in
Review Manager 5 so`ware, to assess risk ratios. We extracted event
and continuous outcome data for the latest time point available
within the trial, and always at least 24 months from inception.
We excluded trials where we knew that there were no events
in either group. Where trials ran one control group and more
than one included intervention group, we used data from the
intervention group providing the comparison that best assessed
the eCect of altering dietary fat. Where the intervention groups
appeared equal in this respect, we merged the intervention groups
(simply added for dichotomous data, and using the techniques
described in Higgins 2011 for continuous data). We had planned
that if we identified trials randomised by cluster we would reduce
the participant numbers to an "eCective sample size" (as described
by Hauck 1991); however, we found none that were both included
and had cardiovascular events or deaths.
To assess the WHO NUGAG question on the eCect of consuming
< 10%E as SFA relative to > 10%E as SFA on the risk
of noncommunicable diseases (NCDs) in the population, we
combined studies with a control group saturated fat intake of >
10%E and an intervention group saturated fat intake of < 10%E.
To assess the eCect of a reduction in %E from SFA from 10% in
gradual increments relative to higher intake, we repeated this with
saturated fat cut-oCs between 7%E and 13%E.
Subgroup analysis and investigation of heterogeneity
Prespecified analyses included:
ECects of SFA reduction compared with usual or standard diet on all
(primary and secondary) outcomes and potential adverse eCects.
This main analysis addressed the main objective of the review and
the first WHO specific question.
Prespecified subgroups for all outcomes included:
• energy substitution - we intended to subgroup studies according
to the main energy replacement for SFA - PUFA, MUFA, CHO
(refined or unrefined), protein, trans fats, a mixture of these, or
unclear. However, when we presented these data to the WHO
NUGAG group, they suggested that this subgrouping be altered.
They suggested that we use all studies where SFA was reduced
and any of PUFA, MUFA, CHO or protein were statistically
significantly increased (P < 0.05) in the intervention compared to
the control group to assess the eCects of replacement by each,
regardless of whether or not it constituted the main replacement
for SFA. This meant that some studies appeared in more than
one subgroup. As there were almost no data in the studies on
trans fats, or on refined and unrefined carbohydrates, we did not
include a trans group or distinguish by carbohydrate type. This
subgrouping addresses the main objective of the review, and the
third WHO specific question.
Further subgroups, run for primary and CVD health-related
secondary outcomes only, included:
Prespecified:
• Baseline SFA intake, represented by control group SFA intake (up
to 12%E from SFA, > 12 to 15%E, > 15 to 18%E, > 18%E from SFA,
or unclear)
• Sex (men, women and mixed populations)
• Baseline CVD risk (low-risk or general populations, moderate-
risk populations which were defined by risk factors for CVD such
as hypertension or diabetes, high-risk populations with existing
CVD at baseline)
• Duration in study (mean duration in trial up to 24 months, >
24 to 48 months, > 48 months, and unclear). Duration was a
prespecified subgroup that we used in earlier versions of this
review to separate studies with duration of less than two years
from those of at least two years. As we have excluded shorter
studies from this review, and have access to longer studies, we
have explored duration over longer time spans. As some long
studies had a high proportion of participants whose time in trial
was censored, and we wanted to express mean experience of
the trial, we used mean duration of participants in the study,
rather than the formal study duration for this subgrouping, so
that some two-year intervention trials, because they had some
deaths or dropouts, had a mean duration in trial of 21 or 22
months.
WHO NUGAG added subgroups:
• Degree of SFA reduction, represented by the diCerence between
SFA intake in the intervention and control groups during the
study (up to 4%E from SFA reduction achieved, > 4 to 8%
reduction achieved, > 8% reduction achieved, unclear). We
prespecified that we intended to explore the degree of SFA
reduction in meta-regression, but its addition as a subgroup was
post hoc, and requested by the WHO NUGAG group.
• Serum total cholesterol reduction achieved (reduced by a mean
of at least 0.2 mmol/L, reduced by less than 0.2 mmol/L or
unclear). We prespecified that we intended to explore the degree
of serum total cholesterol reduction in meta-regression.
• Ethnic group. InsuCicient information was presented to make
this feasible. Hence, we report ethnicity information in the
Characteristics of included studies.
We explored the eCects of diCerent levels of SFA, PUFAs, MUFAs
and total dietary fats, and CHO achieved in trials (all as diCerence
between the intervention and control groups, as %E, and for
SFA as a percentage of SFA in the intervention compared with
control), baseline SFA intake (as %E), change in total cholesterol
(diCerence between intervention and control groups, in mmol/L),
sex, study duration in months, and baseline CVD risk using meta-
regression on total cardiovascular events. We performed random-
eCects meta-regression (Berkley 1995) using the STATA command
metareg (Sharp 1998; Sterne 2001; Sterne 2009).
To explore the WHO NUGAG specific question about the eCect
of the population consuming < 10%E as SFA relative to > 10%E
SFA, we assessed eCects of all studies where the mean assessed
intervention SFA intake was < 10%E and the mean control SFA
intake was > 10%E. We explored the eCect of reduction of %E
from SFA in gradual increments by using cut-oCs of 7%E (where
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all studies with a mean intervention SFA intake < 7%E and mean
control SFA intake > 7%E were pooled), 8%, 9%, 10%, 11%, 12% and
13%. We omitted studies where SFA intakes were not reported from
these analyses. For each primary outcome, we plotted the pooled
risk ratio of that outcome against the cut-oC, %E from SFA.
Referee-added subgroups:
In response to the suggestion of a referee of this systematic review,
and to better understand the eCect of use of statins since the 1990s,
we subgrouped studies by decade of publication.
Sensitivity analysis
We carried out sensitivity analyses for primary outcomes assessing
the eCect of:
1. Excluding studies which did not state an aim to reduce SFA
2. Excluding studies which did not report SFA intake during the
trial, or did not find a statistically significant reduction in SFA in
the intervention compared to the control
3. Excluding studies where total cholesterol (TC) was not reduced
(statistically significant reduction of TC, or of LDL where TC was
not reported (considered reduced where P < 0.05), or where
reduction was not at least 0.2 mmol/L in intervention compared
to control where variance was not reported)
4. Excluding the largest study (WHI 2006)
5. Analysis run with Mantel-Haenszel fixed-eCect model
6. Analysis run with Peto fixed-eCect model
For this update we also introduced sensitivity analysis excluding
trials not at low summary risk of bias. We used results of these
analysis to inform GRADE assessment of risk of bias.
GRADE
All primary outcomes, and secondary additional health events,
were represented in the 'Summary of findings' table, and
underwent GRADE assessment. The GRADE Working Group has
developed a common, sensible and transparent approach to
grading quality of evidence and strength of recommendations
(www.gradeworkinggroup.org/; GRADE 2004). The evidence within
this systematic review was first assessed using the GRADE system
by the review authors and then discussed and modified by the WHO
NUGAG group.
Outcome data were interpreted as follows:
1. Is there an eCect? (options were ‘increased risk’, ‘decreased risk’,
or ‘little or no eCect’). Our main outcome measure was RR so we
decided on existence of an eCect using RR. RR > 8% (RR < 0.92
or > 1.08) for the highest quality evidence suggested increased
or decreased risk (otherwise little or no eCect). The presence
or not of an eCect was decided on the RR for the main analysis
and sensitivity analyses, the highest quality evidence (the main
analysis, the sensitivity analyses of trials at low summary risk of
bias and at low risk of compliance problems).
2. For continuous outcomes, reducing SFA was considered to have
little or no eCect unless eCect sizes represented at least 5%
change from baseline (or 2% in the case of cumulative outcomes
such as adiposity).
3. Quality of evidence was assessed using GRADE assessment
(GRADE 2004) for key outcomes. We used the five GRADE
considerations (risk of bias, consistency of eCect, imprecision,
indirectness and publication bias) to assess the quality of
the body of evidence as it related to the studies that
contributed data to the meta-analyses for the prespecified
outcomes. We used methods and recommendations described
in Section 8.5 and Chapter 12 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), plus
GRADEpro GDT so`ware (GRADEpro 2015). We justified all
decisions to downgrade the quality of studies using footnotes
and made comments to aid reader's understanding of the
review.
4. Where there was a suggested eCect, the size of eCect was
assessed using the number needed to treat for an additional
beneficial outcome (NNTB), number needed to treat for an
additional harmful outcome (NNTH) or absolute risk reduction
(ARR).
R E S U L T S
Description of studies
Results of the search
Figure 1 displays the flow diagram for inclusion of studies. We
assessed the 7991 titles and abstracts from the updated electronic
search, as well as assessing the 8930 titles and abstracts from the
search for our sister review (Hooper 2015b), which de-duplicated
to 15,314 titles and abstracts. Of these, 530 were considered
potentially relevant to one or both reviews, so were collected as full
text. Ten publications were considered relevant for this systematic
review, and these were grouped into:
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Figure 1.   Study flow diagram for this systematic review (update searches run October 2019).
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Figure 1.   (Continued)
 
• three new publications for two already included trials (WHI 2006;
WINS 2006),
• two publications for one study awaiting assessment (not enough
details to confirm inclusion, ICFAMED), and
• five publications for four ongoing trials (ENAbLE due unclear;
NCT02481466 due 2020; NCT02938832 due 2023; NEW Soul
Study due 2022).
There were no new included trials, but there were new data for WHI
2006 and WINS 2006, as well as the ongoing studies and the study
awaiting assessment. This resulted in an updated review including
15 RCTs (16 comparisons as the Rose trial has two comparisons,
Rose corn oil 1965 and Rose olive 1965).
Included studies
We included 15 randomised controlled trials (RCTs) in the review
(Included studies), and describe them in Characteristics of included
studies. The interventions are compared in Table 1.
The main study papers ranged in publication date from 1965 to
2006, but with supplementary publications included up to 2019.
The RCTs were conducted in North America (six), Europe (seven),
and Australia/New Zealand (two); no studies were carried out in
industrialising or developing countries. Six RCTs included only
people at high risk of cardiovascular disease, four at moderate
risk, and four at low risk (three with raised cancer risk or cancer
diagnosis, one with no specific health risks), while one trial
included participants at low and high CVD risk (WHI 2006, Table 1;
this trial made assessments in each of these groups). Seven studies
included only men, three only women, and five both men and
women. However, as the largest trial (WHI 2006) was in women only,
women are the largest group represented. Trial duration ranged
from two to more than eight years, with a mean duration of 4.7
years.
The form of interventions varied (Table 1). Interventions were
of advice to alter intake in 15 of the 16 intervention arms, and
additional supplements such as oil or other foods were provided
in three trials (four arms: MRC 1968; Oslo Diet-Heart 1966; Rose
corn oil 1965; Rose olive 1965), while all food was provided in a
residential facility in one RCT (Veterans Admin 1969). Of the 15 arms
with an advice element, most interventions were delivered face-to-
face, but this was unclear in three arms (Houtsmuller 1979; Rose
corn oil 1965; Rose olive 1965). Advice was provided individually
in nine intervention arms (followed by later group sessions in two
arms), in groups only in two trials (Ley 2004; WHI 2006), and was
unclear in three RCTs (Black 1994; Houtsmuller 1979; Rose corn oil
1965; Rose olive 1965). Advice was provided by a dietitian in nine
arms, a nutritionist in one, a trained nurse in one and was unclear
in four. Frequency of study visits for advice and follow-up varied
between three times in the first year and twice annually therea`er
up to 18 sessions in the first year and quarterly maintenance visits
therea`er.
Of the 15 included studies (16 intervention arms), 11 RCTs (12
comparisons) provided data on all-cause mortality (including
55,858 participants and 3518 deaths), 10 RCTs (11 comparisons)
on CV mortality (53,421 participants and 1096 cardiovascular
deaths), and 11 RCTs (12 comparisons) on combined cardiovascular
CVD events (53,300 participants, of whom 4476 participants
experienced at least one CVD event) (Table 2). In two included
studies, it was clear that events had occurred, but it was not clear
in which arm(s) the events had occurred (Oxford Retinopathy 1978;
Simon 1997), so that we could not include the data in the meta-
analyses. Secondary health events and other secondary outcomes
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were reported in varying number of studies (between 1 and 15
studies reported on any single outcome, see Table 2 and Table 3).
Excluded studies
We excluded 520 full-text publications at this update, having
assessed the full texts in duplicate. We describe the reasons for
some of these exclusions in Characteristics of excluded studies
tables. We excluded 29 studies where data on events were not
reported in publications and contact with authors confirmed that
there had been no deaths or cardiovascular events, where contact
with authors confirmed that data were not available, or where we
could not establish contact with authors.
Risk of bias in included studies
We display 'Risk of bias' assessments in the individual included
study arms in Figure 2.
 
Figure 2.   Methodological quality summary: review authors' judgements about each methodological quality item
for each included study. Please note that while Rose 1965 (Rose corn oil 1965; Rose olive 1965) appears twice in this
Reduction in saturated fat intake for cardiovascular disease (Review)
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Black 1994 + ? - + + + + - - + ? +
DART 1989 + ? - + + + + - + + + +
Houtsmuller 1979 + ? - + + ? + ? + ? + +
Ley 2004 + + - + + ? + - - + - +
Moy 2001 + ? - + + ? + - + + + +
MRC 1968 + ? - + + ? + - + ? + +
Oslo Diet-Heart 1966 + + - + + + + - + ? + +
Oxford Retinopathy 1978 + + - + + ? + + - + - +
Rose corn oil 1965 + ? - + + ? + + + ? - +
Rose olive 1965 + ? - + + ? + + + ? - +
Simon 1997 + ? - + + ? + - - + + +
STARS 1992 + + - + + ? + - + + + +
Sydney Diet-Heart 1978 + + - + + + + - + + + +
Veterans Admin 1969 + + + + + + + + + + - +
WHI 2006 + + - + + + + - + + + +
WINS 2006 + + - + + + + - - + - +
 
Allocation
All the included trials were randomised controlled trials, and
some detail of the randomisation process was provided for all
studies, so all were considered at low risk of bias. We excluded
those with detected pseudo-random allocation (for example
where participants are randomised according to birth date or
alphabetically from their name). We judged allocation concealment
to be well done in eight RCTs (eight comparisons, Ley 2004; Oslo
Diet-Heart 1966; Oxford Retinopathy 1978; STARS 1992; Sydney
Diet-Heart 1978; Veterans Admin 1969; WHI 2006; WINS 2006), and
unclear in the remainder.
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Blinding
Blinding of participants is not easy in dietary studies, as the
participants usually have to follow instructions to attain the
specific dietary goals. However, it is feasible in some circumstances,
including when food is provided via an institutional setting, or
meals provided at a central setting and remaining meals packed
to take away. It can also be achieved through use of a trial shop,
where very specific food-based dietary advice is provided for all
participants, or where the same dietary advice is provided to both
groups but a diCerent supplement (e.g. dietary advice to reduce
fats, then provision of diCerent oils or fats) is provided. Where
participants are not blinded, it is diCicult to ensure that study
staC, healthcare providers and outcome assessors are blinded. The
single RCT that appears to have had adequate participant and
study personnel blinding was Veterans Admin 1969, and we judged
blinding of participants to be inadequate in the remaining studies.
Blinding of outcome assessment was assessed separately for
mortality and CVD outcomes. Blinding is not relevant in assessing
all-cause mortality, so all trials were considered at low risk of bias
for detection bias for this outcome. For CVD outcomes, nine trials
were at low risk of detection bias, one was at high risk and the
remainder were unclear.
Incomplete outcome data
Assessing whether incomplete outcome data had been addressed
was diCicult, as the primary outcomes for this review (mortality
and cardiovascular events) were o`en reported as dropouts and
exclusions from the original studies, rather than as the primary
outcomes of these trials. When mortality or cardiovascular events
or both were noted in any one study, it is still feasible that some
participants le` that study feeling unwell or because the diet was
inconvenient, so were simply lost to follow-up from the perspective
of the study, and later died or experienced a cardiovascular event.
However, six of the studies checked medical records or death
registers to ensure that such events were all collected (Black 1994,
DART 1989; Oslo Diet-Heart 1966; Sydney Diet-Heart 1978; Veterans
Admin 1969; WINS 2006). Within one study, there was extensive
tracking of medical records, with assessment of health status by
blinded trained adjudicators (WHI 2006), so few major events were
likely to have been missed. In the other eight studies, it is not
possible to know whether additional deaths or cardiovascular
events occurred, that were not counted or ascertained within this
review.
Selective reporting
Assessment of selective reporting is diCicult when the outcome
of interest was simply considered a cause of dropouts in most
included studies. We tried to contact all of the trialists to ask about
deaths and outcome events, but it is possible that some trialists did
not reply as they felt that their data did not reflect the expected or
hoped-for pattern of events. All of the included studies have either
reported that the participants did not experience any of our primary
outcomes, have published their outcome data, or have provided
the data they did possess. For this reason, we have graded all the
included studies as at low risk of selective reporting.
Other potential sources of bias
Systematic di4erences in care. We assessed the studies for risk
of bias in relation to systematic diCerences in care. The three
RCTs (four comparisons) that appeared at low risk of systematic
diCerences in care between the study arms included Rose corn oil
1965; Rose olive 1965; Oxford Retinopathy 1978; Veterans Admin
1969, while 11 RCTs clearly did have diCerences in care, such as
diCerential time provided for those on the intervention to learn
a new diet, and/or diCerential medical follow-up, and one was
unclear (Houtsmuller 1979).
Aim to reduce saturated fat. As several studies did not provide
clear aims for their interventions (other than to alter specific dietary
components, for example), we assessed whether the study stated
an aim to reduce saturated fat. Ten RCTs (11 comparisons) clearly
aimed to reduce saturated fat in their intervention arms, either
directly or indirectly, for example, by stating food goals (DART 1989;
Houtsmuller 1979; Moy 2001; MRC 1968; Oslo Diet-Heart 1966; Rose
corn oil 1965; Rose olive 1965; STARS 1992; Sydney Diet-Heart 1978;
Veterans Admin 1969; WHI 2006), while the remaining five did not
(although they did achieve SFA reduction).
Successful saturated fat reduction. Eleven RCTs (11 comparisons)
assessed SFA intake during the study period and showed that SFA
intake in the intervention arm was statistically significantly lower
than that in the control arm (Black 1994; DART 1989; Ley 2004; Moy
2001; Oxford Retinopathy 1978; Simon 1997; STARS 1992; Sydney
Diet-Heart 1978; Veterans Admin 1969; WHI 2006; WINS 2006). The
remaining studies did not report SFA intake, so we rated them as
unclear.
Successful cholesterol reduction. We would expect saturated fat
reduction to be reflected in total or LDL cholesterol reductions,
which may be more accurate assessments than self-reported
saturated fat intake. Nine RCTs (10 comparisons) provided
information on serum total or LDL cholesterol levels in the
intervention and control arms during the study, and found a
reduction in the intervention arm compared to the control (P <
0.05, or where variances were not provided showed a reduction of
at least 0.2 mmol/L in the mean intervention measure compared
with control). The studies that successfully reduced serum total
cholesterol in lower saturated fat arms compared with higher
saturated fat arms were DART 1989; Houtsmuller 1979; Simon 1997;
STARS 1992; Sydney Diet-Heart 1978; WHI 2006, while Moy 2001 did
not report total cholesterol (TC) but showed statistically significant
reductions in LDL, and two studies (MRC 1968; Oslo Diet-Heart 1966)
did not report variances but did reduce mean TC in the intervention
arm compared with control by at least 0.2 mm0l/L. One study (Black
1994) did not report lipid levels during the study, while five others
did report lipid levels but did not suggest clear diCerences between
lower and higher saturated fat arms (Ley 2004; Oxford Retinopathy
1978; Rose corn oil 1965; Rose olive 1965; Veterans Admin 1969;
WINS 2006).
Dietary changes other than saturated fat. Some trials were
partially confounded by aiming to make dietary changes other than
those directly related to dietary fat intakes; for example, some
studies encouraged intervention participants to make changes to
their fat intake as well as changes to fruit and vegetable or fibre
or salt intakes. In these studies, any eCect on outcomes could be
a result of other dietary changes, not of changes in saturated fat
intake. The 11 studies (12 comparisons) that appeared free of such
diCerences included Black 1994; DART 1989; Houtsmuller 1979; Ley
2004; MRC 1968; Oxford Retinopathy 1978; Rose corn oil 1965; Rose
olive 1965; Simon 1997; Sydney Diet-Heart 1978; Veterans Admin
1969; WINS 2006. This factor was not considered alongside others
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in the formal risk of bias assessment (Figure 2) so is described here.
We did not identify any further methodological issues.
Summary risk of bias. We considered dietary advice or all-food-
provided type trials to be at low summary risk of bias where we
judged randomisation, allocation concealment, and blinding of
outcome assessors to be adequate. For CVD outcomes, five trials
were assessed as at low summary risk of bias: Ley 2004; Sydney
Diet-Heart 1978; Veterans Admin 1969; WHI 2006; WINS 2006. For
all-cause mortality (and lipid outcomes) where blinding of outcome
assessors is not important, a further three trials were also at low
summary risk of bias, eight in total: Ley 2004; Oslo Diet-Heart 1966;
Oxford Retinopathy 1978; STARS 1992; Sydney Diet-Heart 1978;
Veterans Admin 1969; WHI 2006; WINS 2006.
E4ects of interventions
See: Summary of findings 1 ECect of reducing saturated fat
compared to usual saturated fat on CVD risk in adults (note: for the
full set of GRADE tables see additional tables 24 to 28)
Primary outcomes
All-cause mortality
GRADE assessment suggests that reducing saturated fat intake
probably makes little or no diCerence to all-cause mortality
(moderate-quality evidence, downgraded once for imprecision).
There was little or no eCect of lower saturated fat compared to
higher saturated fat intake on mortality (risk ratio (RR) 0.96, 95%
confidence interval (CI) 0.90 to 1.03, I2 = 2%, 55,858 participants,
3518 deaths, 11 RCTs, PeCect = 0.42, Analysis 1.1). This lack of eCect
was confirmed in sensitivity analyses including only trials at low
summary risk of bias (Analysis 1.2), that aimed to reduce saturated
fat (Analysis 1.3), that significantly reduced saturated fat intake
(Analysis 1.4), that achieved a reduction in total or LDL cholesterol
(Analysis 1.5), excluding the largest trial (WHI 2006, Analysis 1.6),
or analysing using Mantel-Haenszel or Peto fixed-eCect analysis
(Analysis 1.7; Analysis 1.8).
Small study bias was assessed using a funnel plot and comparing
the results of fixed- and random-eCects meta-analysis. The funnel
plot did not suggest any small study bias (Figure 3), and the results
of fixed- and random-eCects meta-analyses were very similar,
suggesting that small study bias was not an issue.
 
Figure 3.   Funnel plot of comparison: fat modification or reduction vs usual diet - total mortality.









There was little or no eCect, regardless of what nutrients were used
to replace the saturated fat removed, including replacement with
PUFA, MUFA, CHO and/or protein (Analysis 1.9). ECects did not diCer
by main substitution (Analysis 1.10), study duration (Analysis 1.11),
baseline saturated fat intake (Analysis 1.12), degree of diCerence
in saturated fat between arms (Analysis 1.13), participant sex
Reduction in saturated fat intake for cardiovascular disease (Review)









Cochrane Database of Systematic Reviews
(Analysis 1.14), by baseline CVD risk (Analysis 1.15), by degree of
cholesterol reduction (Analysis 1.16) or by decade of publication
(Analysis 1.17, Chi2 test for diCerences between subgroups all P >
0.05).
Cardiovascular mortality
GRADE assessment suggests that reducing saturated fat intake
probably makes little or no diCerence to cardiovascular mortality
(moderate-quality evidence, downgraded once for imprecision).
There was little or no eCect of SFA reduction on cardiovascular
mortality (RR 0.95, 95% CI 0.80 to 1.12, I2 = 30%, 10 RCTs, 53,421
participants, 1096 cardiovascular deaths, Analysis 1.18). This lack
of eCect was confirmed in sensitivity analyses limiting to trials at
low summary risk of bias (Analysis 1.19), explicitly aiming to reduce
saturated fat (Analysis 1.20), achieving statistically significant
saturated fat reduction (Analysis 1.21), achieving cholesterol
reduction (Analysis 1.22), or running fixed-eCect analysis (Analysis
1.24; Analysis 1.25). However, excluding the largest single trial (WHI
2006) suggested that reducing saturated fat intake reduced the risk
of CVD mortality (Analysis 1.23).
The funnel plot did not suggest small study bias (Figure 4), and the
similarity in eCect sizes between fixed- and random-eCects analysis
suggests that small study bias is not important here.
 
Figure 4.   Funnel plot of comparison: fat modification or reduction vs usual diet - cardiovascular mortality









Subgrouping did not suggest important eCects of reduced SFA on
cardiovascular mortality, regardless of what was substituted for SFA
(Analysis 1.26). When subgrouping by main substitution (Analysis
1.27), duration (Analysis 1.28), baseline SFA intake (Analysis 1.29),
by diCerence in SFA (Analysis 1.30), participant sex (Analysis 1.31),
baseline CVD risk (Analysis 1.32), or degree of cholesterol reduction
(Analysis 1.33), there were no statistically significant diCerences
between subgroups. There was a marginally significant diCerence
between subgroups when ordered by decade of publication, but
no clear pattern of eCect, so we assumed the eCect was probably
spurious (Analysis 1.34). Additionally, eCects did not appear to
relate to statin use, as there was a reduction in risk of CVD mortality
in studies published in the 1960s and a marginal increase in risk
in the one trial published during the 1970s (although the 95%
confidence interval did include 1.0), both well before statins were
in common use (the 4S trial which first showed that use of statins
reduced mortality was published in 1994, 4S 1994).
Cardiovascular events
GRADE assessment suggests that reducing SFA intake probably
reduces cardiovascular events, to a greater extent with greater
cholesterol reduction (moderate-quality evidence, downgraded
once for publication bias).
There was a 21% reduction in cardiovascular events in people who
had reduced SFA compared with those on higher SFA (RR 0.79, 95%
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CI 0.66 to 0.93, I2 = 65%, 11 RCTs, 53,300 participants, 4476 people
with cardiovascular events, PeCect = 0.006, Analysis 1.35). This
protective eCect was confirmed in sensitivity analyses including
only trials at low summary risk of bias (Analysis 1.36), that aimed
to reduce saturated fat (Analysis 1.37), that significantly reduced
saturated fat intake (Analysis 1.38), that achieved a reduction in
total or LDL cholesterol (Analysis 1.39), or excluding the largest trial
(WHI 2006, Analysis 1.40). Analysing using Mantel-Haenszel or Peto
fixed-eCect analysis suggested more marginal protection (Analysis
1.41; Analysis 1.42).
A funnel plot did not suggest severe small-study bias, but it
is possible that a few small studies with more cardiovascular
events in the intervention groups may be missing from the review
(Figure 5). Fixed-eCect analyses suggested smaller eCects (Analysis
1.41; Analysis 1.42), again suggesting that smaller studies with
more cardiovascular events in the intervention groups may be
missing. Adding any such studies back would tend to moderate the
protective eCect of reducing SFA.
 
Figure 5.   Funnel plot of comparison: fat modification or reduction vs usual diet - combined cardiovascular events.









When we subgrouped according to replacement for SFA, the PUFA
replacement group suggested a 27% reduction in cardiovascular
events, while there were no clear eCects of other replacement
groups (Analysis 1.44). However, there were no statistically
significant diCerences between subgroups by main replacement
(Analysis 1.45), by study duration (Analysis 1.46), or baseline CVD
risk (Analysis 1.50). When subgrouping, there was a suggestion of
greater eCects when baseline SFA was higher (Analysis 1.47), with
greater reduction of SFA (Analysis 1.48), in men rather than women
(Analysis 1.49), and with greater cholesterol reduction (Analysis
1.51). There were diCerent eCects by decade of publication, but no
suggestion of a trend or a change following wider introduction of
statins in the mid-1990s (Analysis 1.52).
We further explored the eCects of dietary fats on cardiovascular
events, by using meta-regression of the diCerence between the
control and intervention of total fat intake, SFA intake, MUFA
intake, PUFA intake, CHO intake (all by percentage of energy (%E)),
serum total cholesterol (in mmol/L) achieved in trials, as well
as baseline SFA intake, sex, study duration in months, and CVD
risk of participants at baseline (Table 4). As we included only 13
studies for this outcome, we ran meta-regressions exploring single
explanatory factors at once, and as data were limited, with many
studies not reporting dietary intake data, these analyses were
limited in power to assess outcomes. The data suggested that
greater reductions in total serum cholesterol levels reduced CVD
events more. Greater baseline SFA intake and greater reduction
in SFA were also associated with greater improvement in CVD
events with SFA reduction, and increases in PUFA and MUFA
intakes were slightly protective of CVD events, but none of these
relationships were statistically significant. Overall, the relationship
with serum total cholesterol was clearest (P = 0.04, accounting
for 99% of between-study variation). Sex, study duration and
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baseline cardiovascular risk did not appear to influence eCect size.
Apparent heterogeneity was accounted for by a dose-eCect; where
SFA reduction resulted in greater serum cholesterol reduction, the
reduction in CVD events was greater.
This 21% reduction in risk of CVD events translated into a number
needed to treat for an additional beneficial outcome (NNTB) of 56
in primary prevention trials, so that 56 people need to reduce their
saturated fat intake over around four years for one person to avoid
experiencing a CVD event. In secondary prevention trials, the NNTB
was 32.
Secondary outcomes - health events
Myocardial Infarction (fatal and non-fatal)
GRADE assessment suggested that the eCect of reducing saturated
fat intake on risk of myocardial infarction is unclear as the evidence
was of very low-quality (downgraded once each for risk of bias,
imprecision and publication bias).
There was a small protective eCect of SFA reduction on myocardial
infarction (fatal and non-fatal, RR 0.90, 95% CI 0.80 to 1.01, I2 =
10%, 10 RCTs (11 comparisons) including 53,167 participants, 1714
people experiencing MI, Analysis 2.1). This protective eCect was
slightly modified in sensitivity analyses, and confirmed in analyses
limited to trials that aimed to reduce saturated fat (Analysis 2.3),
that achieved a reduction in total or LDL cholesterol (Analysis 2.5),
and excluding the largest trial (WHI 2006, Analysis 2.6). Sensitivity
analyses including only trials at low summary risk of bias (RR
0.93, 95% CI 0.81 to 1.08, Analysis 2.2), that significantly reduced
saturated fat intake (Analysis 2.4), analysed using Mantel-Haenszel
or Peto fixed-eCect analysis (Analysis 2.7; Analysis 2.8) suggested
little or no eCect, though risk ratios were still all < 1.0.
The funnel plot was diCicult to interpret, but did not raise major
concerns about small-study bias (not shown). While eCects of
random- and fixed-eCect meta-analysis were only slightly diCerent,
they fell each side of the line suggesting an eCect (Analysis 2.7;
Analysis 2.8). There may be a small amount of small study bias.
The protective eCect of replacing SFA with PUFA appeared
to explain the reduction in MI (Analysis 2.9), but there were
no statistically significant diCerences between subgroups by
replacement (Analysis 2.10), duration (Analysis 2.11), baseline
SFA intake (Analysis 2.12), change in SFA intake (Analysis 2.13),
participant sex (Analysis 2.14), baseline CVD risk (Analysis 2.15),
cholesterol reduction (Analysis 2.16) or decade of publication
(Analysis 2.17).
Myocardial Infarction (non-fatal only)
GRADE assessment suggests that reducing saturated fat may have
little or no eCect on risk of non-fatal myocardial infarction (low-
quality evidence, downgraded once each for risk of bias and
imprecision).
There was no clear eCect of SFA reduction compared to usual diet
on non-fatal myocardial infarction (RR 0.97, 95% CI 0.87 to 1.07, I2
= 0%, 7 RCTs, 52,834 participants, 1385 people with at least one
non-fatal MI, Analysis 2.18). This lack of eCect was not altered in
sensitivity analyses retaining only those that aimed to reduce SFA
(Analysis 2.20), those showing a reduction in serum cholesterol
(Analysis 2.22), or fixed-eCect analysis (Analysis 2.24; Analysis 2.25).
However, sensitivity analyses retaining only trials at low summary
risk of bias (RR 0.89, 95% CI 0.58 to 1.35, Analysis 2.19), those
showing a significant reduction in SFA (Analysis 2.21), and omitting
the largest trial (WHI 2006, Analysis 2.23) all suggested a reduction
in non-fatal MI with reduced SFA.
The funnel plot did not raise major concerns about small-study bias
(not shown), and eCects of fixed- and random-eCects analyses were
very similar, reinforcing the lack of small study bias.
Subgrouping by any replacement for SFA suggested reductions in
non-fatal MI when replaced by PUFA, but not other replacements
(Analysis 2.26). Subgrouping by main substitution (Analysis 2.27),
duration (Analysis 2.28), baseline SFA intake (Analysis 2.29), degree
of SFA reduction (Analysis 2.30), sex (Analysis 2.31), baseline CVD
risk (Analysis 2.32), degree of cholesterol reduction (Analysis 2.33)
and decade of publication (Analysis 2.34) did not suggest significant
diCerences between subgroups.
Stroke (any type, fatal or non-fatal)
GRADE assessment suggests that the eCect of reducing SFA
intake on stroke is unclear as the evidence is of very low-quality
(downgraded twice for imprecision and once for risk of bias).
As data on stroke were sparse, it was not possible to tease
out diCerential eCects on ischaemic or haemorrhagic strokes, or
whether a stroke was fatal. For this analysis, we combined all stroke
data from any study. There was little or no eCect of SFA reduction
compared to usual diet on stroke of any type with any outcome
(RR 0.92, 95% CI 0.68 to 1.25, I2 = 9%, 7 RCTs, 50,952 participants,
1118 people with stroke, Analysis 2.35). This lack of eCect was not
altered in sensitivity analyses retaining only those that aimed to
reduce SFA (Analysis 2.37), those showing a reduction in serum
cholesterol (Analysis 2.39), or fixed-eCect analysis (Analysis 2.41;
Analysis 2.42). However, for sensitivity analyses retaining only trials
at low summary risk of bias (RR 0.76, 95% CI 0.42 to 1.38, Analysis
2.36), those showing a significant reduction in SFA (Analysis 2.38),
and omitting the largest trial (WHI 2006, Analysis 2.40) the best
estimate of eCect always suggested a reduction in stroke with
reduced SFA, though they were not statistically significant.
We did not create a funnel plot as the analysis only included
data from seven RCTs, however RRs generated using fixed-eCect
analyses were much closer to 1.0 than the random-eCects meta-
analysis (suggesting a small amount of publication bias), though
both suggested little or no eCect.
Subgrouping by any substitution for SFA suggested reduction in
risk of stroke whether SFA was replaced by PUFA, CHO or protein
(Analysis 2.43). Subgrouping did not suggest significant diCerences
between subgroups by main substitution (Analysis 2.44), duration
(Analysis 2.62), baseline SFA (Analysis 2.46), SFA change (Analysis
2.47), sex (Analysis 2.48), CVD risk (Analysis 2.49), cholesterol
reduction (Analysis 2.50) or decade of publication (Analysis 2.51).
Coronary heart disease (CHD) mortality
GRADE assessment suggests that reducing saturated fat intake may
have little or no eCect on CHD mortality (low-quality evidence,
downgraded twice for imprecision).
Eight RCTs (9 comparisons) suggest little or no eCect of reducing
saturated fat on risk of CHD mortality (RR 0.97, 95% CI 0.82 to 1.16,
I2 = 28%, 53,159 participants, 927 people died of coronary heart
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disease, Analysis 2.52), and this was not altered in any sensitivity
analyses (Analysis 2.53; Analysis 2.54; Analysis 2.55; Analysis 2.56;
Analysis 2.57; Analysis 2.58; Analysis 2.59).
We did not create a funnel plot as the analysis only included
data from seven RCTs, but the results of fixed- and random-eCects
analyses were nearly identical, suggesting that small study bias is
not an issue here.
There was no suggestion of an eCect of reducing SFA on CHD
mortality regardless of what replaced the SFA (Analysis 2.60). There
were no statistically significant diCerences between subgrouping
in any analysis (Analysis 2.61; Analysis 2.62; Analysis 2.63; Analysis
2.64; Analysis 2.65; Analysis 2.66; Analysis 2.67; Analysis 2.68).
Coronary heart disease events
GRADE assessment suggested that the eCect of reducing saturated
fat on CHD events is unclear as the evidence is of very low-
quality (downgraded once each for imprecision, risk of bias and
inconsistency).
There was the suggestion of a 17% reduction in CHD events as a
result of saturated fat reduction in the main analysis (RR 0.83, 95%
CI 0.68 to 1.01, I2 = 62%, 53,199 participants, 2261 people had at
least one coronary heart disease event in 10 RCTs, Analysis 2.69).
This did not diCer in sensitivity analyses (Analysis 2.74; Analysis
2.72; Analysis 2.73; Analysis 2.71; Analysis 2.75; Analysis 2.76) except
when limiting to trials at low summary risk of bias (RR 0.92, 95% CI
0.77 to 1.10, Analysis 2.70).
The funnel plot did not appear unbalanced, and the results of
fixed- and random-eCects analyses were diCerent, though both
suggested that reducing SFA resulted in lower risk of CHD.
Subgrouping by any replacement for SFA suggested that
replacement by PUFA may lead to reduced risk of CHD events
(Analysis 2.77). There were no statistically significant diCerences
between any other subgroups (Analysis 2.78; Analysis 2.79; Analysis
2.80; Analysis 2.81; Analysis 2.82; Analysis 2.83; Analysis 2.84) except
by decade of publication, though this did not suggest any sequence
or step change (Analysis 2.85).
Type 2 diabetes, new diagnoses
Only one RCT reported on diagnosis of diabetes (WHI 2006).
There was little or no eCect of reducing SFA intakes on diagnosis
of diabetes in this study (RR 0.96, 95% CI 0.90 to 1.02, 48,835
participants, 3342 developed diabetes, Analysis 2.86). WHI 2006
was assessed at low summary risk of bias, aimed to reduce SFA, and
demonstrated significant SFA and cholesterol reduction. With only
one trial, we were not able to assess publication bias or carry out
subgrouping.
Secondary outcomes - blood levels
Serum blood lipids
Total cholesterol (TC): There was a reduction in TC in participants
with reduced SFA compared to higher SFA (mean diCerence (MD)
-0.24 mmol/L, 95% CI -0.36 to -0.13, I2 = 60%, 13 RCTs, 7115
participants, Analysis 3.1). We did not conduct sensitivity analyses
or most subgroupings on secondary outcomes, but there was no
clear diCerential eCect on TC depending on the replacement for
SFA (PUFA, MUFA, CHO or a mixture, Analysis 3.2; Analysis 3.3).
The funnel plot did not raise concerns about small-study bias (not
shown).
Low-density lipoprotein (LDL): There was a reduction in LDL
in participants with reduced SFA compared to higher SFA (MD
-0.19 mmol/L, 95% CI -0.33 to -0.05, I2 = 37%, 5 RCTs, 3291
participants, Analysis 3.4). There was no clear diCerential eCect on
LDL depending on the replacement for SFA (PUFA, MUFA, CHO or
a mixture, Analysis 3.5; Analysis 3.6). We could not interpret the
funnel plot due to sparsity of studies (not shown).
High-density lipoprotein (HDL): There was little or no eCect of
reducing SFA intakes on HDL (MD -0.01 mmol/L, 95% CI -0.02 to 0.01,
I2 = 0%, 7 RCTs, 5147 participants, Analysis 3.7). There was no clear
diCerential eCect on HDL depending on the replacement for SFA
(PUFA, MUFA, CHO or a mixture, Analysis 3.8; Analysis 3.9). We could
not interpret the funnel plot due to sparsity of studies (not shown).
Triglycerides (TG): There was little or no eCect of reducing SFA
intakes on TG (MD -0.08 mmol/L, 95% CI -0.21 to 0.04, I2 = 51%,
7 RCTs, 3845 participants, Analysis 3.10). There was no clear
diCerential eCect on TG depending on the replacement for SFA
(PUFA, MUFA, CHO or a mixture, Analysis 3.11; Analysis 3.12). We
could not interpret the funnel plot due to sparsity of studies (not
shown).
TG/HDL ratio: We did not find any studies that reported TG/HDL
ratio.
TC/HDL ratio: Only three RCTs reported on TC/HDL ratio. There
was little or no eCect of reducing SFA intakes on TC/HDL (MD -0.10,
95% CI -0.33 to 0.13, I2 = 24%, 2985 participants, Analysis 3.13).
There were no clear diCerential eCects of replacement on TC/HDL
(Analysis 3.14; Analysis 3.15). We could not interpret the funnel plot
due to sparsity of studies (not shown).
LDL/HDL ratio: Only one RCT reported on LDL/HDL ratio. There was
no clear eCect of reducing SFA intakes on LDL/HDL in this study (MD
-0.36, 95% CI -0.92 to 0.20, 50 participants, Analysis 3.16). This study
replaced SFA with CHO (mainly) and PUFA.
Lipoprotein (a) (Lp(a)): Only two RCTs reported on lipoprotein (a),
but these included 28,820 participants. There was little or no eCect
of reducing SFA intakes on Lp(a) (MD 0.00, 95% CI -0.00 to 0.00, I2
= 0%, Analysis 3.17). There was no suggestion of diCerential eCects
of replacement on Lp(a) (Analysis 3.18; Analysis 3.19). We could not
interpret the funnel plot due to sparsity of studies (not shown).
Homeostatic model assessment (HOMA): Only one RCT reported
on the eCects of reducing SFA on insulin resistance using HOMA.
There was little or no eCect of reducing SFA intakes compared to
usual diet on HOMA in this study (MD -0.00, 95% CI -0.04 to 0.04,
2832 participants, Analysis 3.20).
Glucose at two hours post-glucose tolerance test (GTT): Only
three RCTs reported on glucose two hours post-GTT. There was
a reduction in glucose a`er reducing SFA intakes compared to
usual diet (MD -1.69 mmol/L, 95% CI -2.55 to -0.82, I2 = 45%, 249
participants, Analysis 3.20). We could not interpret the funnel plot
due to sparsity of studies (not shown).
HbA1c (glycosylated haemoglobin): HbA1c was not measured in
any included RCT.
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Secondary outcomes - other outcomes and potential harms
There was little or no eCect of reducing SFA intakes on cancer
diagnoses of any type (RR 0.94, 95% CI 0.83 to 1.07, I2 = 33%,
4 RCTs, 52,294 participants, 5476 cancer diagnoses, Analysis 4.1);
cancer deaths (RR 1.00, 95% CI 0.61 to 1.64, I2 = 49%, 5 RCTs,
52,283 participants, 2472 cancer deaths, Analysis 4.2); systolic
blood pressure (MD -0.19 mmHg, 95% CI -1.36 to 0.97, I2 = 0%, 5
RCTs, 3812 participants, Analysis 4.5); diastolic blood pressure (MD
-0.36 mmHg, 95% CI -1.03 to 0.32, I2 = 0%, 5 RCTs, 3812 participants,
Analysis 4.6).
There was evidence that reducing SFA intake resulted in small
reductions in body weight (MD -1.97 kg, 95% CI -3.67 to -0.27, I2 =
72%, 6 RCTs, 4541 participants, Analysis 4.3), and body mass index
(MD -0.50, 95% CI -0.82 to -0.19, I2 = 55%, 6 RCTs, 5553 participants,
Analysis 4.4).
Only one RCT reported assessing quality of life. The Women's
Health Initiative (WHI 2006) assessed quality of life at baseline
using the SF-36 tool). They found that being in the lower SFA arm
resulted in a small improvement in Global Quality of Life at trial
close-out (on a scale of 0 worst to 10 best, MD 0.04, 95% CI 0.01 to
0.07, Analysis 4.7). This very small eCect (less than 1% change) was
statistically significant but unlikely to be relevant to individuals.
However, it suggests no reduction in quality of life in those reducing
their saturated fat.
Other results
To assess the eCect in the population of consuming < 10%E as SFA
relative to > 10%E as SFA for reduction in risk of noncommunicable
diseases (NCDs), we combined studies with a control group
saturated fat intake of > 10%E and an intervention group saturated
fat intake of < 10%E for all-cause mortality, cardiovascular
and coronary heart disease mortality and events, myocardial
infarctions, non-fatal myocardial infarctions, and stroke. To assess
the eCect in the population of a reduction in %E from SFA from
10% in gradual increments relative to higher intake we repeated
this with saturated fat cut-oCs between 7%E and 13%E. The data
for these cut-oCs are shown in Table 5, and were plotted for
a visual overview (Figure 6). The figure suggests reductions in
cardiovascular outcomes in studies where saturated fat intake
was greater than 10%E in control groups, and less than 10%E in
intervention groups.
 
Figure 6.   Exploration of saturated fat cut-o4s
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Additional WHO NUGAG specific questions:
In adults what is the e)ect in the population of reduced
percentage of energy (%E) intake from saturated fatty
acids (SFA) relative to higher intake for reduction in risk of
noncommunicable diseases (NCDs)?
We found that reducing saturated fat for at least two years
suggested no clear eCects on all-cause or cardiovascular
mortality, but a 21% reduction in combined cardiovascular events.
Heterogeneity in this result was partially explained by greater
reductions in cardiovascular events in studies with greater serum
total cholesterol reductions (implying greater reductions in SFA
intake). ECects of reducing SFA on other cardiovascular and cancer
outcomes were either very small or unclear (as the evidence was
of very low quality), but it should be noted that risk ratios were all
1.0 or lower - no harm was indicated. ECects on NCD risk factors
were small but positive (serum total cholesterol, LDL cholesterol,
systolic and diastolic blood pressure, weight and BMI) or neutral
(HDL cholesterol and TGs).
What is the e)ect of reducing SFA on coronary heart disease
mortality and coronary heart disease events?
We found little or no eCect of reducing SFA on non-fatal MI and CHD
events, but the evidence on MI, stroke and CHD events was of very
low quality. However, all risk ratios were less than 1.0.
What is the e)ect in the population of replacing SFA with PUFAs,
MUFAs, CHO (refined versus unrefined), protein or trans fatty
acids (TFAs) relative to no replacement for reduction in risk of
NCDs?
We found greater reductions in cardiovascular events in studies
that replaced saturated fats by PUFAs or CHO than in studies with
replacement with MUFAs or protein, where there was little evidence
of any eCect.
What is the e)ect of replacing some saturated fat with PUFA on
risk of CVD in adults?
There is moderate-quality evidence that replacing saturated fat
with PUFA probably reduces the risk of CVD events. Replacing SFA
with PUFA also appears to reduce the risk of total MI, non-fatal
MI, stroke and CHD events, but has little or no eCect on all-cause
mortality, CVD mortality and CHD mortality.
What is the e)ect of replacing some saturated fat with MUFA on
risk of CVD in adults?
The evidence for eCects of replacing SFA with MUFA was very
limited, so assessment of health eCects was not possible.
What is the e)ect of replacing some saturated fat with CHO on risk
of CVD in adults?
While studies that replaced SFA with CHO reduced CVD events
and stroke, eCects on all-cause mortality and other CVD outcomes
suggested little or no eCect.
What is the e)ect of replacing some saturated fat with protein on
risk of CVD in adults?
There was no evidence suggesting that replacing SFA with protein
reduced all-cause mortality or any CVD outcomes, but the evidence
was limited.
What is the e)ect in the population of consuming < 10%E as SFA
relative to > 10%E as SFA for reduction in risk of NCDs?
Cut-oC data were diCicult to interpret, and confidence intervals
were wide, but they suggested greater reductions in cardiovascular
events in studies where saturated fat intake was greater than 10%E
in control groups, and less than 10%E in intervention groups (see
Figure 6).
What is the e)ect in the population of a reduction in %E from
SFA from 10% in gradual increments relative to higher intake for
reduction in risk of NCDs?
The data from RCTs are too limited to be able to address this
question.
D I S C U S S I O N
Summary of main results
This systematic review of long-term randomised controlled trials of
SFA reduction suggests that reducing saturated fat for at least two
years probably has little or no eCect on all-cause or cardiovascular
mortality, but probably caused a 21% (95% CI 7 to 34%, I2 =
65%, moderate-quality evidence) reduction in people experiencing
cardiovascular events. The heterogeneity in this relationship was
explained by greater reduction in CVD events in trials with greater
serum cholesterol lowering. This eCect on cardiovascular events
was retained in sensitivity analyses. Subgrouping suggested that
there was a 27% (95% CI 8 to 42%) reduction in cardiovascular
events in studies that replaced saturated fats by PUFAs, and a
16% (95% CI -6 to 33%) reduction in studies replacing with CHO,
with little information on the eCect of replacing with MUFAs or
protein. The diCerence between subgroups was not statistically
significant. We could not explore data on trans fats. Meta-regression
and subgrouping suggested that greater reductions in SFA intake,
greater reductions in total serum cholesterol levels, higher baseline
SFA intake and greater increases in PUFA and MUFA intakes reduced
CVD events more, but the strongest factor was the degree of
cholesterol lowering. This clearly indicates that the cardiovascular
eCects of reducing saturated fat rely on changes in atherosclerosis
via serum cholesterol. The degree of cholesterol lowering reflects
greater reduction in SFA and greater increase in PUFA (Hegsted
2000).
There may be little or no eCect of SFA reduction on non-fatal MI or
CHD mortality (both low-quality evidence), and eCects on fatal and
non-fatal MI, stroke and CHD events were unclear (as the evidence
was of very low-quality). However, risk ratios were less than 1.00 for
all of these. While we found small reductions in body weight and
body mass index with advice to reduce saturated fats, there was
little or no eCect on diabetes diagnoses, cancer diagnoses or cancer
deaths, or on systolic or diastolic blood pressure.
Reducing saturated fat caused reductions in serum total and LDL
cholesterol, which did not diCer according to type of replacement.
There was little or no eCect of saturated fat reduction on serum
HDL cholesterol or triglyceride. Data on lipid ratios, Lp(a) and HOMA
were very limited and eCects unclear, but SFA reduction appears to
reduce glucose two hours a`er a glucose load.
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Overall completeness and applicability of evidence
The review included adult participants at varying levels of risk
of cardiovascular disease, men and women, with mean ages
from 46 to 66 years at baseline, in free-living and institutional
settings, and across the past 50 years. All the studies were
conducted in industrialised countries, and no data were available
from developing or transitional countries. The eCectiveness of
SFA reduction has been well assessed, with trials of at least 24
months including more than 50,000 participants for all primary
and secondary CVD outcomes. Three thousand five hundred
and eighteen participants in the included trials died, 1096 died
of a cardiovascular cause, and 4476 experienced at least one
cardiovascular event.
The external validity of the review in industrialised countries,
men and women, people with low, moderate and high risk of
cardiovascular disease was high, but it is not clear how this
evidence relates to diets in developing and transitional countries.
Quality of the evidence
All 15 trials (16 comparisons) included were randomised controlled
trials, allocation concealment was judged well done in eight RCTs
and blinding of outcome assessors adequate in nine trials assessing
CVD outcomes (and all trials assessing all-cause mortality). Blinding
of participants is diCicult and expensive in dietary fat trials, but
was adequate in one trial. We judged incomplete outcome data
not to be a problem in seven RCTs, and selective reporting was
not a problem in any trial. Three trials were free of diCerences in
care between the intervention and control arms, 10 RCTs stated an
aim to reduce saturated fat, 11 showed evidence they had reduced
SFA intake (all studies did one or the other), and nine studies
showed clear reductions in total cholesterol. Five trials were at low
summary risk of bias.
The lack of blinding of participants in most dietary trials is unlikely
to alter outcome assessment when outcomes include death and
cardiovascular events, but lack of blinding in the participants may
have led those in the control groups to alter their lifestyle and
dietary practices (for example, feeling that they have not been
helped to reduce their cardiovascular risk, they may act to reduce
their own risk by altering other lifestyle behaviours such as smoking
or exercise, leading to a potential lessening of the apparent eCect
of the dietary intervention). Systematic diCerences in care between
arms may have led to intervention groups receiving additional
support in areas like self eCicacy and gaining support from new
social circles, potentially beneficial to health regardless of dietary
fat intake, or gaining additional healthcare professional time,
possibly leading to earlier diagnosis and treatment of other risk
factors such as raised blood pressure. Additional dietary messages
such as those around fruit and vegetable intake, fibre, alcohol and
sugars, present in many studies, may have been protective, or may
have diluted the eCect or attainability or both of the saturated fat
goals.
The quality of evidence balances the uncertainty over allocation
concealment, lack of blinding and presence of systematic
diCerences in care and additional dietary diCerences between arms
(Figure 2) with the scale and consistency of the evidence across
studies and across decades, despite very diCerent designs and
design flaws. For this reason, there is moderate-quality evidence
that the interventions that reduce dietary saturated fat intake
reduce the risk of cardiovascular events.
Complex interventions
With complex interventions, such as dietary interventions, there
are additional questions that need to be asked about included
studies. Important issues to consider include defining the
intervention, searching for and identifying all relevant studies,
selecting studies for inclusion and data synthesis (Lenz 2007;
Sheppherd 2009), as well as questions around whether the
intended intervention was realised in study participants during the
study.
For this review, we have worked to define the interventions clearly
(see Characteristics of included studies), providing information
on the type of intervention, stating the study aims and methods
for each arm and the assessed total and saturated fat intakes
attained within the study. However, while we have characterised
the interventions, no two studies that reduced SFA had exactly
the same dietary goals for the intervention groups. Methods of
attaining the dietary goals varied from providing a whole diet over
several years (in studies based in institutions) to providing advice
on diet alongside supplementary foods such as margarines or oils,
to providing dietary advice with or without supplementary support
in the way of group sessions, cooking classes, shopping tours,
feedback, self-eCicacy sessions and/or individual counselling. We
aimed to use this variety to support generalisability for the eCects
of the interventions.
We aimed to identify all the relevant studies through use of a
broad search strategy, which was time-consuming. However, we
believe that we have included most relevant trials. We also carefully
defined acceptable interventions for each arm, to simplify decisions
on inclusion, and the two independent assessors o`en agreed. We
augmented data synthesis by subgrouping and meta-regression, to
help us understand the eCects of individual elements of dietary fat
changes.
A study that sets out to assess the eCect of a 30% reduction in
saturated fat intake may attain this level of reduction in some
participants, exceed it in some and not achieve it at all in others.
The actual mean change attained in the intervention group may
be less dramatic than that aimed for, and the participants in the
control group may also reduce their saturated fat intake by a small
amount, narrowing the diCerence in saturated fat between the
groups further and so reducing the scale of any outcome. This
can be dealt with in the systematic review if we meta-regress
the diCerence in saturated fat intake between the intervention
and control group with the scale of the outcome (assuming a
linear dose response), still allowing us to understand the eCect
of altering saturated fat intake. However, it is diCicult to measure
actual saturated fat intake achieved. Some trials did not report it,
either because they did not assess it, or did assess it but didn't
report this relatively uninteresting outcome. Other trials did report
the results of asking people what they were eating, using a food
frequency questionnaire or several 24-hour food recalls. However,
there is good evidence to believe that asking people how they are
eating may produce somewhat biased information (Kristal 2005;
Schatzkin 2003), and this may be a greater problem where the
participant has been recently urged to eat in a particular way, as in
a dietary trial. Assessment of change in total cholesterol is a way
to get over self-reporting of dietary intake as reducing saturated
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fat reduces total and LDL cholesterol. This review suggests that
the relationship between saturated fat reduction and CVD events is
moderated by the degree of cholesterol lowering, which is exactly
what would be expected of a true eCect.
The interventions used in the studies included in this review were
varied, with some participants given all their food over a long
period of time in an institutional setting, while most participants
were given advice on how to achieve dietary changes, with or
without the support of supplements such as oils and foods (Table
1). Advice was provided by a variety of health professionals,
and with diCerent levels of intensity. The eCect of this was
that diCerent degrees of saturated fat reduction were achieved
in diCerent studies. The level of compliance with interventions
involving long-term behaviour change, such as those used in these
studies, can vary widely. This is likely to attenuate the pooled
eCect and bias it towards the null. Insofar as we were able to
understand this issue, subgrouping and meta-regression suggested
that greater reductions in saturated fats were associated with
greater reductions in the risk of cardiovascular disease events. This
suggestion of a dose response strengthens our belief that there is a
true eCect of reducing saturated fat on CVD events.
Potential biases in the review process
In compiling the included studies, we worked hard to locate
randomised studies that altered dietary SFA intake for at least
24 months, even when cardiovascular events were not reported
in study publications, or where such events were reported
incidentally as reasons for participant dropouts. We attempted
to contact all authors of potentially includable studies to verify
the presence or absence of our outcomes. In many studies, no
outcomes relevant to this review occurred or were recorded, and
the numbers of events occurring within single studies varied from
none to over 2500 deaths, over 500 cardiovascular deaths, and over
3000 participants experiencing at least one cardiovascular event
(all within WHI 2006, the largest single study with almost 50,000
female participants for many years).
The number of cardiovascular deaths across the review was
relatively small (1096), so while we can be quite confident in
reporting a reduction in participants experiencing cardiovascular
events (4476 events) with SFA reduction, and a lack of eCect on total
mortality (3518 deaths) within the studies' time scales, the eCect
on cardiovascular mortality is less clear. The risk ratio of 0.94 (95%
CI 0.78 to 1.13, Analysis 1.18) may translate into a small protective
eCect, but this is unclear.
The lack of eCect on individual cardiovascular events is harder to
explain; there were 1714 people experiencing MIs, 1118 strokes and
1385 non-fatal MIs, 2472 cancer deaths, 3342 diabetes diagnoses
and 5476 cancer diagnoses. Lack of clear eCects on any of these
outcomes is surprising, given the eCects on total cardiovascular
events, but may be due to the relatively short timescale of the
included studies, compared to a usual lifespan during which risks
of chronic illnesses develop over decades, and to relatively small
reductions in saturated fat (and serum cholesterol) in some trials.
There are diCiculties in finding data on the number of people
experiencing composite end points such as cardiovascular events.
This end point represents the number of people experiencing any
of the following: cardiovascular death, cardiovascular morbidity
(non-fatal myocardial infarction, angina, stroke, heart failure,
peripheral vascular events, atrial fibrillation) and unplanned
cardiovascular interventions (coronary artery bypass surgery or
angioplasty). Adding up the number of events is easy, but a
single participant may have experienced a stroke, an MI and
atrial fibrillation during a trial - and we need to take care not to
count this individual three times. So finding such composite end
point data involves using the best published composite end point
data and supplementing this with author contact where possible.
We have underestimated such composite end points rather than
overestimated them where exact data are not available. Added to
this complex picture, it needs to be remembered that definitions
and diagnoses of some end points have altered over time.
Where the funnel plots and comparison of fixed- and random-
eCects meta-analyses suggest small-study bias, we have
downgraded the quality of the evidence in GRADE, but eCects of any
such small study bias appear small.
Some trials were partially confounded by aiming to make dietary
changes other than those directly related to dietary fat intakes;
for example, some studies encouraged intervention participants
to make changes to their fat intake as well as changes to fruit
and vegetable, fibre or salt intakes. In these studies, any eCect
on outcomes could be a result of other dietary changes, not of
changes in saturated fat intake. The 11 studies (12 comparisons)
that appeared free of such diCerences included Black 1994; DART
1989; Houtsmuller 1979; Ley 2004; MRC 1968; Oxford Retinopathy
1978; Rose corn oil 1965; Rose olive 1965; Simon 1997; Sydney
Diet-Heart 1978; Veterans Admin 1969; WINS 2006. On the basis
of reviewer comments, we assessed eCects of reducing saturated
fat intake on combined CVD events including only these trials
free of additional interventions. Omitting trials with additional
interventions (Oslo Diet-Heart 1966; STARS 1992; WHI 2006) leaves
eight studies (nine arms) randomising 3998 participants of whom
750 experienced a CVD event, suggesting a similar reduction in CVD
events (RR 0.80, 95% CI 0.64 to 0.99, I2 = 48%, Analysis 1.43) to
the main analysis (RR 0.79, 95% CI 0.66 to 0.93, I2 = 65%, > 53,000
participants randomised, Analysis 1.35). This suggests that eCects
on combined CVD events are not driven by interventions other than
reductions in saturated fats and any energy replacements.
One surprising element of this review is the lack of new
trials identified in the update, and small numbers of potential
ongoing trials. This is likely to be because well-powered trials on
cardiovascular end points will need to be large and carried out over
several years, so expensive. As the eCects of saturated fats are felt to
be established and understood, trialists and funders may feel that
the money would be better invested in answering other questions.
For most of the ongoing trials, information is limited and these
trials may or may not be included when fully published. Perhaps
the current evidence set is as definitive as we will achieve during
the 'statin era'.
Agreements and disagreements with other studies or
reviews
In this review, saturated fat reduction had little or no eCect on
all-cause or cardiovascular mortality but did appear to reduce the
risk of cardiovascular events by 21%, although eCects on MI and
stroke individually were less clear. This result was rather diCerent
from those of Siri-Tarino 2010, who systematically reviewed cohort
studies that assessed relationships between saturated fat and
cardiovascular events. They included 21 studies and did not
find associations between saturated fat intake and cardiovascular
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disease (RR 1.0, 95% CI 0.89 to 1.11). However, this meta-analysis
has been criticised (Katan 2010; Scarborough 2010; Stamler 2010),
as results of half of the studies included in their meta-analysis were
adjusted for serum cholesterol concentrations, while there is an
established relation between saturated fat intake and cholesterol
level. The studies included in the meta-analysis also varied widely
in the method used to assess intake, as half of the studies collected
one-day intake data. However, as with our review, they found
no relationship between saturated fat intake and coronary heart
disease (RR 1.07, 95% CI 0.96 to 1.19) or stroke (RR 0.81, 95% CI 0.62
to 1.05, Siri-Tarino 2010).
In this review, we found that replacing saturated fat with PUFAs
(a modified-fat diet) appeared more protective of cardiovascular
events than replacement with carbohydrates (a low-fat diet,
Analysis 1.44; Analysis 1.45). This was similar to results within our
closely allied systematic review assessing health eCects of total
fat reduction, where modified-fat diets were protective and low-fat
diets were not (Hooper 2012). Meta-regression did not suggest any
relationship between either PUFAs or MUFAs and cardiovascular
events in this review, although the analysis was underpowered.
Alonso 2006 suggested a protective role for MUFA from olive oil, but
not from meat sources (the main source of MUFA in the USA and
Northern Europe). Our systematic review was not able to explore
this issue as we included only one small study (underpowered
to assess health outcomes on its own) that replaced SFA with
MUFA, using an olive oil supplement (Rose olive 1965). A review by
MozaCarian 2010, which again included very similar studies to the
last version of this review, with the Finnish Mental Hospital study
and Women's Health Initiative data added, stated that their findings
provided evidence that consuming PUFAs in place of saturated
fat would reduce coronary heart disease. However, their evidence
for this was limited, as they found that modifying fat reduced
the risk of myocardial infarction or coronary heart disease death
(combined) by 19% (similar to our result). As the mean increase
in PUFAs in these studies was 9.9% of energy, they infer an eCect
of increasing PUFAs by 5% of energy of 10% reduction in risk
of myocardial infarction or coronary heart disease death. They
provided no suggestion or evidence of a relationship between
degree of PUFAs increase and level of risk reduction. Another
review carried out during updating of the Nordic Nutritional
Recommendations (Schwab 2014) included observational as well
as intervention studies, and concluded that there was convincing
evidence that partial replacement of SFA with PUFA decreases risk
of CVD while replacement with CHO is associated with increased
CVD risk. The review included studies performed solely in white
participants or with a clear white majority.
Within the meta-regression, we hoped to combine studies that
eCectively altered saturated fat by diCerent degrees, so that
studies that reduced saturated fat very little and studies that
reduced it a great deal would all oCer data points for the
meta-regression against mortality and morbidity end points, and
similarly for total fat, polyunsaturated, monounsaturated and trans
fats. Unfortunately many of the included studies did not report
data on assessed dietary intake during the trial, reducing the
quantity of data available to understand the relationships. Another
limitation in understanding eCects of individual classes of fatty
acids on mortality and morbidity (both in trials and in observational
studies) was our ability to correctly assess participants' intake.
We could overcome this by using biomarkers such as serum LDL
cholesterol (diCerences between the LDL concentration in the
intervention and control arms could be seen as a reasonable and
independent approximation of saturated fat intake); however, as
many studies were carried out in the 1960s to 1990s, few measured
and reported LDL cholesterol. We used meta-regression with serum
total cholesterol (although this is a composite marker and so less
related to saturated fat intake), but although this was available for
more studies than LDL it was not available for all studies. Despite
the limited data, there was a clear suggestion from meta-regression
that there was greater reduction of risk of cardiovascular events in
studies with greater total serum cholesterol reduction, supporting
the central role of serum lipids in the link between dietary saturated
fats and cardiovascular events.
Participants' level of risk
As the rate of events is higher in high-risk groups (by definition),
it should require smaller sample sizes and shorter follow-up
to observe an eCect of an intervention in a high-risk group of
participants (Davey Smith 1993). There have been suggestions
that randomised controlled trials are unsuitable for assessing the
eCectiveness of interventions with very modest levels of eCect
in low-risk populations, because of the huge numbers of person-
years of observation needed to gain suCicient statistical power to
avoid Type II errors (Ebrahim 1997). However, with the publication
of the Women's Health Initiative trial (WHI 2006) we now have
data on more people experiencing cardiovascular events who were
originally at low risk of cardiovascular disease than in people with
moderate or high risk. The same is true for cardiovascular deaths
and total mortality.
When end points such as total mortality are used, the situation
becomes more diCicult, as in low-risk groups the proportion of
deaths which are unrelated to cardiovascular disease (and perhaps
unlikely to be influenced by dietary fat changes) rises, again diluting
any diCerences in the numbers of deaths between intervention
and control groups. It is more likely that changes in cardiovascular
deaths will be seen than in total mortality. The trend is certainly
in this direction, with the pooled risk ratio for total mortality 0.96
(95% CI 0.90 to 1.03, Analysis 1.1), and for cardiovascular mortality
RR 0.94 (95% CI 0.78 to 1.13, Analysis 1.18). Our best estimate is
that SFA reduction results in a reduction of 6% in deaths due to
cardiovascular disease, and a reduction of 4% in total deaths, but
these are small eCects with wide confidence intervals.
The high-risk participants all showed evidence of cardiovascular
disease at baseline. Under current guidelines, most high-risk
participants with raised lipid levels should be on lipid-lowering
medication (Grundy 2019; NICE 2014; O'Gara 2014). This raises the
question of whether there is any additional advantage of adherence
to a reduced SFA diet in addition to statin therapy. Little evidence
exists at present to answer this question. However, in all parts
of the world where drug budgets are restricted and use of lipid-
lowering medication remains rationed even for those at high risk,
the use of reduced SFA diets would appear to be a cost-eCective
option leading to considerable reductions in cardiovascular events
for populations (and so in health budgets) in only a few years.
Low-risk participants are unlikely to be on lipid-lowering
medication under current guidelines. The suggestion of protection
of low-risk individuals from cardiovascular events with a reduction
of roughly 21% of events in just a few years of intervention, as there
is no evidence that eCects in the low-CVD-risk group are diCerent
from eCects in the higher-risk groups, would appear to merit
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continued public health action. Recent guidelines recommend
saturated fat reduction in general populations (SACN 2019).
A factor that may aCect participant risk of cardiovascular disease,
and also the eCectiveness of reducing saturated fat intake, that
has altered over time is the level of use of statins to control serum
lipids in people at moderate and high risk of CVD. The 4S 1994 trial,
which was the first trial to show that use of statins could reduce
mortality in people with coronary heart disease, was published in
1994 and led to an explosion of the use of statins. For most health
outcomes, we saw no clear eCect of a decade of publication on
risk, but for combined CVD events and CHD events, there were
diCerences between subgroups. For combined CVD events, there
were reductions in risk with reduced saturated fat intakes in the
1960s, 1970s and 1990s (both trials published early in the decade),
but no clear eCect of reducing saturated fat in the 1980s (one trial
with 283 events) or 2000s (three large trials). It is possible (but not
clear) that participants in the trials published in the 2000s were
protected by higher levels of statin use (statins were allowed in
participants in the largest trial, WHI 2006).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Evidence supports the reduction of saturated fat to reduce risk
of combined cardiovascular events in people with and without
existing cardiovascular disease, in men and women, over at least
two years and in industrialised countries. Little or no eCect of
saturated fat reduction was seen on all-cause and cardiovascular
mortality, at least on this timescale.
Practical ways to achieve reductions in dietary saturated fat include
switching to lower fat dairy foods and cutting oC meat fats, as well
as reducing intake of foods high in saturated fats such as cakes,
biscuits, pies and pastries, butter, ghee, lard, palm oil, sausages
and cured meats, hard cheese, cream, ice cream, milkshakes and
chocolate (for further details see NHS 2020).
Implications for research
To complement this review of long-term RCTs, we need reviews of
metabolic studies to clarify the eCects of specific replacements for
saturated fat in the diet, and systematic reviews of cohort studies
to clarify longer-term eCects of saturated fat reductions.
The financial implications (costs and savings) of appropriate advice
and legislation to modify fat intake in those at various levels of
cardiovascular risk should be assessed and reflected in health
policy. Whilst interventions to alter dietary fat intake in individuals
at high cardiovascular risk have been fairly successful, such health
promotion initiatives in the general population have been less
successful. Further work is needed to help high- and low-risk
individuals to make eCective changes to reduce saturated fat
and to maintain these changes over their lifetimes. Research into
the eCects of legislation to alter fat contents of foods, improved
labelling, pricing initiatives and improved availability of healthier
foods, linking food production and processing into the health
agenda, may yield huge advances in this area.
It is not clear whether there is an additional benefit of reducing
saturated fat in those at high risk of cardiovascular disease who are
on lipid-lowering medication. Further research to examine the need
for maintenance of reduced saturated fat whilst on lipid-lowering
medication would be useful, but not as useful as understanding
specific dietary fat replacements for saturated fat. However, we did
not identify any relevant ongoing trials in our searches.
All future trials should be of at least 2 years duration (preferably
longer), employ excellent methodology in terms of randomisation
and allocation concealment, blinding of outcome assessors, high-
quality assessment of macronutrients and micronutrients during
the trial in both arms, and equivalent attention and health
professional time to participants in both arms.
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Summary risk of bias: moderate to high
Participants People with non-melanoma skin cancer (USA)
CVD risk: low
Control: randomised 67, analysed 58
Intervention: randomised 66, analysed 57
Mean years in trial: 1.9
% male: control 67%, intervention 54%
Age: mean control 52.3 (SD 13.2), intervention 50.6 (SD 9.7)
Ethnicity: white 100% (excluded from study if of Asian, Black, Hispanic or American Indian ancestry)
Statins use allowed: Unclear
% taking statins: Not reported
Interventions Reduced fat vs usual diet
Control aims: no dietary advice
Intervention aims: total fat 20%E, protein 15%E, CHO 65%E
Control methods: no dietary change, 4-month intervals clinic examination by dermatologist
Intervention methods: 8 x weekly classes plus monthly follow-up sessions, with behavioural techniques
being taught following individual approach (not clear if in a group or individual). 4-month intervals clin-
ic examination by dermatologist
Intervention delivered face-to-face by a dietitian
Total fat intake, %E ("during study" months 4 - 24): cont 37.8 (SD 4.1), int 20.7 (SD 5.5) (mean difference
-17.10, 95% CI -18.88 to -15.32) significant reduction
Saturated fat intake, %E ("during study", months 4 - 24): cont 12.8 (SD 2.0), int 6.6 (SD 1.8),
(mean difference -6.20, 95% CI -6.90 to -5.50) significant reduction
PUFA intake, %E ("during study", months 4 - 24): cont 7.8 (SD 1.4), int 4.5 (SD 1.3), (mean difference
-3.30, 95% CI -3.79 to -2.81) significant reduction
PUFA n-3 intake: not reported
PUFA n-6 intake: Linoleic acid, cont 16.9 (SD 5.6) g, int 8.5 (SD 3.3) g
MUFA intake, %E ("during study", months 4 - 24): cont 14.4 (SD 1.7), int 7.6 (SD 2.2), (mean difference
-6.80, 95% CI -7.52 to -6.08) significant reduction
Black 1994 
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CHO intake, %E ("during study", months 4 - 24): cont 44.6 (SD 6.9), int 60.3 (SD 6.3), (mean difference
15.70, 95% CI 13.29 to 18.11) significant increase
Protein intake, %E ("during study", months 4 - 24): cont 15.7 (SD 2.4), int 17.7 (SD 2.2), (mean difference
2.00, 95% CI 1.16 to 2.84) significant increase
Trans fat intake: not reported
Replacement for saturated fat: CHO and protein (by dietary aims and achievements), main is CHO
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: incidence of actinic keratosis and non-melanoma skin cancer
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: cardiovascular deaths
Secondary outcomes: cancer deaths (none)
Tertiary outcomes: none (weight data provided, but no variance info)
Notes Study duration 24 months.
Study aim was to achieve low-fat diet, but the study achieved a statistically significant reduction in sat-
urated fat intake in the low-fat group compared to control.
SFA reduction achieved.
Total serum cholesterol: not reported
At 2 years control -1.5 kg n = 50?, intervention -1 kg n = 51?
Trial dates: Study dates not reported (but still recruiting at first publication in 1994)
Funding: National Cancer Institute
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "list of randomly generated numbers"
Allocation concealment
(selection bias)





High risk Dietary advice provided, so participants not blinded
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Low risk "examined .... by dermatologists unaware of their treatment assignments".
Deaths (all-cause and CVD) not considered relevant to the intervention
Blinding of outcome as-
sessment (detection bias)
Low risk Blinding is not relevant in assessment of mortality
Black 1994  (Continued)
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Low risk Low risk for all-cause and CVD mortality. Unclear for other outcomes
Selective reporting (re-
porting bias)
Low risk Not relevant for primary and secondary outcomes as all trialists asked for data
Free of systematic differ-
ence in care?
High risk Minor, all have 4-monthly clinic visits, the intervention group had 8 behaviour-
al technique classes that the control group did not have
Stated aim to reduce SFA High risk Aim to reduce SFA not stated
Achieved SFA reduction Low risk Statistically significant SFA reduction achieved
Achieved TC reduction Unclear risk Not reported






Diet And Reinfarction Trial (DART)
Summary risk of bias: moderate to high
Participants Men recovering from an MI (UK)
CVD risk: high
Control: randomised 1015, analysed unclear
Intervention: randomised 1018, analysed unclear
Mean years in trial: control 1.9, randomised 1.9
% male: 100%
Age: mean control 56.8, intervention 56.4 (< 70)
Ethnicity: not stated
Statins use allowed? Unclear, but there do not appear to have been any medication-based exclusion
criteria and included participants were taking anti-hypertensives, anti-anginals, anti-coagulants, an-
ti-platelet, digoxin and "other cardiac drugs".
% taking statins: Not reported, but only 5.4% were taking "other cardiac drugs" which may have includ-
ed statins.
Interventions Reduced and modified fat vs usual diet
Control aims: no dietary advice on fat, weight reducing advice if BMI > 30
Intervention aims: reduce fat intake to 30%E, increase P/S to 1.0, weight-reducing advice if BMI > 30
Note: This was a factorial trial, and so some in each group were randomised to increased fatty fish and/
or increased cereal fibre.
Control methods: dietitians provided 'sensible eating' advice without specific information on fats.
DART 1989 
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Intervention methods: dietitians provided the participants and their wives with initial individual advice
and a diet information sheet; participants were revisited for further advice, recipes, encouragement at
1, 3, 6, 9, 12, 15, 18 and 21 months.
Intervention delivered individually face-to-face by a dietitian
Total fat intake, %E (through study): cont 35 (SD 6), int 31 (SD 7) (mean difference -4.00, 95% CI -4.57 to
-3.43) significant reduction
Saturated fat intake, %E (through study): cont 15 (SD3), int 11 (SD3), (mean difference -4.00, 95%
CI -4.26 to -3.74) significant reduction
PUFA intake (through study)⁑: cont 7 (SD unclear), int 9 (SD unclear), (mean difference 2.00, 95% CI
1.57 to 2.43 assuming SDs of 5) significant increase
PUFA n-3 intake: EPA, cont 0.6 (SD 0.7) g/wk, Int 2.4 (SD 1.4) g/wk
PUFA n-6 intake: not reported
MUFA intake (through study)⁑: cont 13 (SD unclear), int 11 (SD unclear) (mean difference -2.00, 95%
CI -2.43 to -1.57 assuming SDs of 5) significant reduction
CHO intake (through study): cont 44 (SD 6), int 46 (SD 7) (mean difference 2.00, 95% CI 1.43 to 2.57) sig-
nificant increase
Protein intake (through study): cont 17 (SD 4), int 18 (SD 4) (mean difference 1.00, 95% CI 0.65 to 1.35)
significant increase
Trans fat intake: not reported
Replacement for saturated fat: PUFA and CHO (by dietary aims), PUFA, CHO and protein (by di-
etary achievements), main PUFA
Style: diet advice
Setting: community
⁑Estimated by subtraction (assuming total fat = SFA + PUFA + MUFA) or using the ratio (assuming P/
S = PUFA/SFA)
Outcomes Stated trial outcomes: mortality, reinfarction
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: cardiovascular deaths (including stroke deaths)
plus non-fatal MI
Secondary outcomes: cancer deaths, total MI, non-fatal MI, CHD mortality, CHD events (total MI)
Tertiary outcomes: total and HDL cholesterol
Notes Study duration: 24 months
Study aim was to achieve low fat diet with raised P/S ratio and saturated fat intake in the intervention
group was significantly lower than in the control group.
SFA reduction aimed and achieved.
Total serum cholesterol, difference between intervention and control, mmol/L: -0.26 (95% CI
-0.36 to -0.16), statistically significant reduction
Trial dates: Study dates not reported (published in 1989)
Funding: Welsh Scheme for the Development of Health and Social Research, Welsh Heart Research
Foundation, Flora Project, Health Promotion Research Trust. (Seven Seas Health Care and Duncan
DART 1989  (Continued)
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Flockhart provided the MaxEPA capsules and Norgene provided 'Fybranta' tablets - but these were not
used in the comparison discussed in this systematic review)
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised using sealed envelopes
Allocation concealment
(selection bias)





High risk Very difficult to blind trials where participants need to make their own dietary
changes
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Low risk Quote: "outcome assessors were not aware of study allocation" (Prof Burr, per-
sonal communication). Method of blinding not stated
Blinding of outcome as-
sessment (detection bias)
All-cause mortality








Low risk Not relevant for primary and secondary outcomes as we asked all trialists for
data
Free of systematic differ-
ence in care?
High risk Different levels of advice appear to have been provided. See control and inter-
vention methods in the Interventions section of the table of Characteristics of
included studies
Stated aim to reduce SFA Low risk Aim to reduce SFA stated
Achieved SFA reduction Low risk SFA reduction achieved
Achieved TC reduction Low risk Statistically significant TC fall






Summary risk of bias: moderate to high
Participants Adults with newly-diagnosed diabetes (the Netherlands)
Houtsmuller 1979 
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CVD risk: moderate
Control: 51 randomised, unclear how many analysed (all analysed re deaths)
Intervention: 51 randomised, unclear how many analysed (all re deaths)
Mean years in trial: unclear (max duration 6 years)
% male: 56% overall
Age: mean unclear
Baseline total fat intake: unclear
Baseline saturated fat intake: unclear
Ethnicity: not stated
Statins use allowed? Unclear
% taking statins: Not reported (probably none as too early, pre-1980)
Interventions Modified fat vs usual diet
Control aims: SFA 35%E, CHO 50%E, protein 15%E
Intervention aims: total fat 40%E, 1/3 linoleic acid, CHO 45%E, protein 15%E
Control methods: unclear, surveyed by dietitian
Intervention methods: unclear, surveyed by dietitian
Intervention appears to be delivered by dietitian but no clear details on format or frequency
Total fat intake: not reported
Saturated fat intake: not reported (mean difference unclear)
PUFA intake: not reported
PUFA n-3 intake: not reported
PUFA n-6 intake: not reported
MUFA intake: not reported
CHO intake: not reported
Protein intake: not reported
Trans fat intake: not reported
Replacement for saturated fat: mainly PUFA (based on dietary aims)
Style: diet advice?
Setting: community
Outcomes Stated trial outcomes: progression of diabetic retinopathy
Data available on total mortality? no
Cardiovascular mortality? no
Events available for combined cardiovascular events: total MI and angina
Secondary outcomes: total cholesterol, TGs (data read oC graph), CHD mortality (fatal MI), CHD events
(MI, angina)
Notes Study duration 6 years. Study aim was for control group to take 35%E as saturated fat, and the inter-
vention group 40%E from fat, of which 33% was from linoleic acid (so saturated fat < 27%E), but satu-
rated fat intake during trial not reported
Houtsmuller 1979  (Continued)
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SFA reduction aimed (unclear whether achieved).
Total serum cholesterol, difference between intervention and control, mmol/L: -0.47(95% CI
-0.76 to -0.18), statistically significant reduction
Trial dates: Study recruitment 1973 to (unclear)
Funding: Dutch Heart Foundation
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants matched in pairs then randomised
Allocation concealment
(selection bias)





High risk Unclear, though unlikely as dietary advice provided
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Unclear risk Blinding of outcome assessors not mentioned
Blinding of outcome as-
sessment (detection bias)
All-cause mortality




Unclear risk Unclear, deaths, cancer and CV events are dropouts, trialists asked for data -
unclear if any data missing
Selective reporting (re-
porting bias)
Low risk Not relevant for primary and secondary outcomes as we asked all trialists for
data
Free of systematic differ-
ence in care?
Unclear risk Level and type of intervention unclear. See control and intervention methods
in the Interventions section of the table of Characteristics of included studies
Stated aim to reduce SFA Low risk Aim to reduce SFA stated
Achieved SFA reduction Unclear risk SFA intake not reported
Achieved TC reduction Low risk Statistically significant TC fall
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Methods RCT
Summary risk of bias: low
Participants People with impaired glucose intolerance or high normal blood glucose (New Zealand)
CVD risk: moderate
Control: unclear how many randomised (176 between both groups), unclear how many analysed (112
between both groups at 5 years)
Intervention: as above
Mean years in trial: 4.1 over whole trial
% male: control 80%, intervention 68%
Age: mean control 52.0 (SE 0.8), intervention 52.5 (SE 0.8)
Ethnicity: European 67% int, 77% control, Maori 11% int, 7% control, Pacific islander 20% int, 13% con-
trol, Other 3% int, 4% control (outcomes not provided by ethnicity)
Statins use allowed? Unclear
% taking statins: Not reported
Interventions Reduced fat vs usual diet
Control aims: usual diet
Intervention aims: reduced fat diet (no specific goal stated)
Control methods: usual intake plus general advice on healthy eating consistent with the New Zealand
guidelines and standard dietary information for people with nutrition-related problems upon entering
the trial
Intervention methods: monthly small group meetings to follow a 1-year structured programme aimed
at reducing fat in the diet, includes education, personal goal-setting, self-monitoring
Total fat intake, %E (at 1 year): int 26.1 (SD 7.7), cont 33.6 (SD 7.8) (mean difference -7.50, 95% CI -10.37
to -4.63) significant reduction
Intervention delivered in small face-to-face groups but unclear by whom
Saturated fat intake, %E (at 1 year): cont 13.4 (SD 4.7), int 10.0 (SD 4.2) (mean difference -3.40,
95% CI -5.05 to -1.75) significant reduction
PUFA intake, %E (at 1 year): cont 4.8 (SD 1.6), int 4.0 (SD 1.4) (mean difference -0.80, 95% CI -1.36 to
-0.24) significant reduction
PUFA n-3 intake: not reported
PUFA n-6 intake: not reported
MUFA intake, %E (at 1 year): cont 11.8 (SD 3.1), int 8.9 (SD 2.8) (mean difference -2.90, 95% CI -3.99 to
-1.81) significant reduction
CHO intake, %E (at 1 year): cont 45.8 (SD 10.9), int 54.2 (SD 10.5) (mean difference 8.40, 95% CI 4.44 to
12.36) significant increase
Protein intake, %E (at 1 year): cont 16.6 (SD 3.9), int 18.4 (SD 3.5), (mean difference 1.80, 95% CI 0.43 to
3.17) significant increase
Trans fat intake: not reported
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Outcomes Stated trial outcomes: lipids, glucose, blood pressure
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: MI, angina, stroke, heart failure
Secondary outcomes: total MI, stroke, cancer diagnoses, cancer deaths, CHD events (MI or angina)
Tertiary outcomes: weight, total, LDL and HDL cholesterol, TGs, BP
Notes Study duration over 4 years
Study aim was to reduce total fat (not saturated fat), but saturated fat intake in the intervention group
was significantly lower than in the control group.
SFA reduction achieved
Total serum cholesterol, difference between intervention and control, mmol/L: -0.05 (95% CI
-0.46 to 0.36), NO statistically significant reduction and smaller than 0.20
Trial dates: Recruitment 1988 to 1990
Funding: National Heart Foundation of New Zealand, Auckland Medical Research Foundation, Lotteries
Medical Board and the Health Research Council of New Zealand
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Unmarked opaque envelopes were opened by the person recruiting, unable to
alter allocation later (trial author stated in their reply to us that randomisation
and preparation of the envelopes was by people not involved in recruitment).
Allocation concealment
(selection bias)






High risk Dietary advice, not blinded
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Low risk Trial authors stated that outcome assessors were blinded.
Blinding of outcome as-
sessment (detection bias)
All-cause mortality




Unclear risk Unclear, deaths, cancer and CV events are dropouts, trialists were asked for
data - unclear if any data missing
Selective reporting (re-
porting bias)
Low risk Not relevant for primary and secondary outcomes as we asked all trialists for
data
Free of systematic differ-
ence in care?
High risk See control and intervention methods in the Interventions section of the table
of Characteristics of included studies
Ley 2004  (Continued)
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Stated aim to reduce SFA High risk Aim to reduce SFA not stated
Achieved SFA reduction Low risk SFA reduction achieved
Achieved TC reduction High risk TC fall small (0.05 mmol/L only) and not statistically significant






Summary risk of bias: moderate to high
Participants Middle-aged siblings of people with early CHD, with at least 1 CVD risk factor (USA)
CVD risk: moderate
Control: randomised 132, analysed 118
Intervention: randomised 135, analysed 117
Mean years in trial: 1.9
% male: control 49%, intervention 55%
Age: control mean 45.7 (SD 7), intervention 46.2 (SD 7)
Ethnicity: African-American 18% int, 25% control (remainder of group ethnicity not described, and out-
comes not presented by ethnicity)
Statins use allowed? Unclear (raised LDL cholesterol was a condition of entry, so use of statins probably
minimal)
% taking statins: Not reported
Interventions Reduced fat intake vs usual diet
Control aim: usual care
Intervention aim: total fat 40 g/d or less
Control methods: usual physician care with risk factor management at 0, 1 and 2 years
Intervention methods: Individualised counselling by trained nurse, appointments 6 - 8 weekly for 2
years
Intervention delivered individually, face-to-face by a trained nurse.
Total fat intake, %E (at 2 years): int 34.1 (SD unclear), cont 38.0 (SD unclear) (mean difference -3.90,
95% CI -6.46 to -1.34 assuming SDs of 10) significant reduction
Saturated fat intake, %E (at 2 years): int 11.5 (SD unclear), cont 14.4 (SD unclear) (mean differ-
ence -2.90, 95% CI -4.18 to -1.62 assuming SDs of 5) significant reduction
PUFA intake: not reported
PUFA n-3 intake: not reported
PUFA n-6 intake: not reported
MUFA intake: not reported
CHO intake: not reported
Moy 2001 
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Protein intake: not reported
Trans fat intake: not reported
Replacement for saturated fat: unclear
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: dietary intake
Data available on total mortality? yes, no deaths
Cardiovascular mortality? yes, no deaths
Events available for combined cardiovascular events: total MI, stroke, unstable angina, PVD and PTCA
Secondary outcomes: cancer diagnoses (no events), cancer deaths (none), stroke, total and non-fatal
MI, CHD mortality (none), CHD events (MI or angina)
Tertiary outcomes: BMI, HDL and LDL cholesterol, TG
Notes Study duration 2 years
Study aim was to reduce total fat based on ATPII dietary guidelines, and preliminary work established
that this intervention reduced saturated fat and dietary cholesterol, and saturated fat intake was signif-
icantly lower than in the control group
SFA reduction aimed and achieved
Total serum cholesterol not reported, but LDL was, difference between intervention and control,
mmol/L: -0.29 (95% CI -0.54 to -0.04), statistically significant reduction
Trial dates: Study recruitment 1991 to 1994
Funding: National Institute of Nursing Research, General Clinical Research Center of the National Insti-
tutes of Health
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomly assigned via computerised schema after all eligible siblings from a
family had been screened
Allocation concealment
(selection bias)





High risk Participants clear about their allocation
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
High risk Trialists clear about allocation
Blinding of outcome as-
sessment (detection bias)
All-cause mortality
Low risk Blinding is not relevant in assessment of mortality.
Moy 2001  (Continued)
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Unclear risk Unclear, deaths, cancer and CV events are dropouts, trialists were asked for
data - unclear if any data missing
Selective reporting (re-
porting bias)
Low risk Not relevant for primary and secondary outcomes as all trialists asked for data
Free of systematic differ-
ence in care?
High risk Differences in frequency of follow-up, but unclear what differences in care oc-
curred between the physician and nurse-led care. See control and interven-
tion methods in Interventions section of the table of Characteristics of includ-
ed studies
Stated aim to reduce SFA Low risk Aim to reduce SFA stated
Achieved SFA reduction Low risk SFA reduction achieved
Achieved TC reduction Low risk Statistically significant LDL fall (though TC not reported)






Medical Research Council (MRC)
Summary risk of bias: moderate to high
Participants Free-living men who have survived a first MI (UK)
CVD risk: high
Control: randomised 194, analysed 181 at 2 years
Intervention: randomised 199, analysed 172 at 2 years
Mean years in trial: control 3.7, intervention 3.8
% male: 100
Age: unclear (all < 60)
Ethnicity: not stated
Statins use allowed? Unclear (anti-coagulants allowed, but few other medications appear to have been
used)
% taking statins: Not reported (probably none as too early, pre-1980)
Interventions Modified fat vs usual diet
Control aims: usual diet
Intervention aims: reduce dietary fat to 35 g fat per day, add 84 g soya oil per day
Control methods: usual diet plus reducing diet (reduced CHO) for weight management for overweight
men
Intervention methods: instructed to follow a dietary regimen removing saturated fat from the diet plus
daily dose of 85 g soya oil; half of it had to be taken unheated. Reduced CHO diet for weight manage-
ment in overweight men
Intervention appears to be delivered and supervised by trial dietitian but unclear how often.
MRC 1968 
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Total fat intake, %E (at 3.5 years): int 46 (SD unclear), cont 43 (SD unclear) (mean difference 3.00, 95%
CI 0.91 to 5.09 assuming SDs of 10) significant increase
Saturated fat intake: not reported (mean difference unclear)
PUFA intake: not reported
PUFA n-3 intake: not reported
PUFA n-6 intake: not reported
MUFA intake: not reported
CHO intake: not reported
Protein intake: not reported
Trans fat intake: not reported
Replacement for saturated fat: mainly PUFA (based on dietary goals)
Style: diet advice & supplement (soy oil)
Setting: community
Outcomes Stated trial outcomes: MI or sudden death
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: cardiovascular deaths and fatal or non-fatal MI
Secondary outcomes: total and non-fatal MI, stroke, cancer deaths, CHD mortality, CHD events (CHD
mortality or non-fatal MI)
Tertiary outcomes: none (data for weight, total cholesterol and BP, but no variance info)
Notes Study duration over 6 years
Study aim: for intervention "saturated fats were replaced by polyunsaturated fats", but saturated fat
intakes during trial were not reported.
SFA reduction aimed
Total serum cholesterol, difference between intervention and control, mmol/L: -0.64 (95% CI un-
clear), reduction > 0.20
For all, data at 4 years, control n = 89, intervention n = 88
Weight change: control -3 kg, intervention 0 kg
Total cholesterol change: control -0.47 mmol/L, intervention -1.11 mmol/L
Systolic BP change: control 0 mmHg, intervention +2 mmHg
Diastolic BP change: control +3 mmHg, intervention -1 mmHg
Trial dates: Study recruitment 1960 to 1965, analysed 1967
Funding: Medical Research Council
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions.
Risk of bias
Bias Authors' judgement Support for judgement
MRC 1968  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk Quote: "using random numbers, by blocks within hospitals"
Allocation concealment
(selection bias)





High risk Big changes to fat intake in intervention group while control group ate their
usual diet
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Low risk Quote: "Suspected relapses were assessed at regular intervals by a review
committee unaware of the patients diet group".
Blinding of outcome as-
sessment (detection bias)
All-cause mortality




Unclear risk Data collection was thorough, but some participants dropped out and contact
was lost, so some events may have been missed.
Selective reporting (re-
porting bias)
Low risk Not relevant for primary and secondary outcomes as all trialists were asked for
data
Free of systematic differ-
ence in care?
High risk Unlikely as control group continued diet as usual, intervention group were
likely to have had additional contact. See control and intervention methods in
the Interventions section of the table of Characteristics of included studies
Stated aim to reduce SFA Low risk Aim to reduce SFA stated
Achieved SFA reduction Unclear risk SFA intake not reported
Achieved TC reduction Low risk Although statistical significance was not reported or calculable, TC in the in-
tervention group was 0.64 mmol/L lower than in the control group, a large fall
(and almost certainly statistically significant).







Summary risk of bias: moderate to high for CVD outcomes, low for all-cause mortality
Participants Men with previous MI (Norway)
CVD risk: high
Control: randomised 206, analysed 148 (at 5 years)
Intervention: randomised 206, analysed 152 (at 5 years)
Mean years in trial: control 4.3, intervention 4.3
% male: 100
Oslo Diet-Heart 1966 
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Age: mean control 56.3, intervention 56.2 (all 30 - 67)
Ethnicity: ethnicity not mentioned
Statins use allowed? Unclear (medications not mentioned as exclusion criteria, most appeared to be on
anti-coagulant medications, statins not mentioned)
% taking statins: Not reported (probably none as too early, pre-1980)
Interventions Modified fat diet vs control
Control aims: no dietary advice but direct questions answered, supplement = 1 vitamin tablet daily
Intervention aims: reduce meat and dairy fats, increase fish, vegetables, supplement - 1 vitamin tablet
daily, 0.5 L soy bean oil per week (free to 25% of participants), sardines in cod liver oil (free at certain
times to encourage compliance)
Control methods: usual diet
Intervention methods: continuous instruction and supervision by dietitian, including home visits, let-
ters and phone calls
Total fat intake: unclear (note - intake of total fat, carbohydrate, protein and sugar was assessed in 17
"especially conscientious and positive" as well as intelligent dieters, but this was not reported here as
unlikely to be representative, and lacking control group data)
Saturated fat intake: unclear (mean difference unclear)
PUFA intake: unclear
PUFA n-3 intake: not reported




Trans fat intake: unclear
Replacement for saturated fat: PUFA (based on dietary goals)
Style: diet advice and supplement (food)
Setting: community
Outcomes Stated trial outcomes: coronary heart disease morbidity and mortality
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: total MI, sudden death, stroke, angina
Secondary outcomes: non-fatal and total MI, stroke, CHD mortality (fatal MI and sudden death), CHD
events (MI, angina and sudden death)
Tertiary outcomes: weight, total cholesterol, systolic and diastolic BP (but no variance information was
provided)
Notes Study duration over 4 years
Study aim was to reduce serum cholesterol by a diet "low in saturated fats and in cholesterol, and rich
in highly unsaturated fats", saturated fat intakes during study were not reported
SFA reduction aimed (reduction unclear as not measured except in a highly compliant subgroup)
Oslo Diet-Heart 1966  (Continued)
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Total serum cholesterol, difference between intervention and control, mmol/L: -1.07 (95% CI un-
clear), reduction > 0.20
Weight change from baseline was -0.5 kg in the control group (n ~ 155), -2.5 kg in the intervention group
(n ~ 160) at 51 months
Total cholesterol change from baseline was -0.46 mmol/L in the control group and -1.53 mmol/L in the
intervention group at 51 months
Systolic BP at baseline was 153.8 mmHg in control and 159.0 in intervention, and mean sBP through tri-
al was 154.3 mmHg in control and 158.2 mmHg in the intervention group.
Diastolic BP at baseline was 93.5 mmHg in control and 97.1 mmHg in intervention, through trial mean
dBP was 95.5 mmHg in control and 98.6 mmHg in intervention participants
Trial dates: Recruitment 1956 to 1958
Funding: Det Norske Råd for Hjerte- og karsyk-dommer, A/S Freia Chokoladefabriks Arbeidsfond for
Ernærings-forskning, JL Tiedemanns Tobaksfabrik Joh H Andresens medisinske fond, plus A/S Farma-
cöytisk Industri provided a multivitamin free of charge, DE-NO-FA and Lillleborg Fabriker provided soy
bean oil at reduced prices, the Research Laboratory of the Norwegian Canning Industry, Stavanger Pre-
serving Co and Kommendal Packing Comp provided Norwegian sardines in cod liver oil free to those in
the intervention group.
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "table of random numbers used", by Prof Knut Westlund
Allocation concealment
(selection bias)
Low risk Randomisation appears to have occurred before medical examination with-






High risk Participants were aware of their allocation as was the main trialist.
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Unclear risk Outcomes were categorised by a diagnostic board, but their blinded status
was unclear.
Blinding of outcome as-
sessment (detection bias)
All-cause mortality




Low risk The participants who could not be directly followed up for the 5 years were fol-
lowed until death or study end through personal interviews, or contact with
their physicians or relatives.
Selective reporting (re-
porting bias)
Low risk Not relevant for primary and secondary outcomes as all trialists were asked for
data
Oslo Diet-Heart 1966  (Continued)
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Free of systematic differ-
ence in care?
High risk Dietetic input level very different, although medical care appeared similar. See
control and intervention methods in the Interventions section of the table of
Characteristics of included studies
Stated aim to reduce SFA Low risk Aim to reduce SFA stated
Achieved SFA reduction Unclear risk SFA intake not reported
Achieved TC reduction Low risk Although statistical significance was not reported or calculable, TC in the in-
tervention group was 1.07 mmol/L lower than in the control group, a large fall
(and almost certainly statistically significant).






Summary risk of bias: moderate to high for CVD outcomes, low for all-cause mortality
Participants Newly-diagnosed non-insulin-dependent diabetics (UK)
CVD risk: moderate
Control: number randomised unclear (249 split between the 2 groups, 125?), number analysed for mor-
tality unclear (all but 2 overall at 16 years)
Intervention: number randomised unclear (249 split between the 2 groups, 125?), number analysed as
above
Mean years in trial: overall 9.3?
% male: overall 49%
Age: mean overall 47.1 (all < 65)
Ethnicity: not stated
Statins use allowed? Unclear
% taking statins: Not reported (probably none as too early, pre-1980)
Interventions Reduced and modified dietary fat vs average diet
Control aims: total fat 40%E, PUFA 12%E, protein 20%E, CHO 40%E (reducing simple sugars), 1500 kcal/
day
Intervention aims: total fat 26%E, PUFA 16%E, protein 20%E, CHO 54%E (reducing simple sugars), 1500
kcal/day
Control methods: dietary advice from diabetes dietitian
Intervention methods: dietary advice from diabetes dietitian
Total fat intake, %E (at 7 - 9 years)§: int 32 (SD unclear), cont 41 (SD unclear) (mean difference -9.00,
95% CI -11.48 to -6.52 assuming SDs of 10) significant reduction
Saturated fat intake, %E (at 7 - 9 years)§: int 10.7 (SD unclear), cont 20.4 (SD unclear) (mean dif-
ference -9.70, 95% CI -10.94 to -8.46 assuming SD of 5) significant reduction
PUFA intake, %E (at 7 - 9 years)§: int 11.8 (SD unclear), cont 2.1 (SD unclear) (mean difference 9.70, 95%
CI 8.46 to 10.94 assuming SDs of 5) significant increase
PUFA n-3 intake: not reported
Oxford Retinopathy 1978 
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PUFA n-6 intake: not reported
MUFA intake, %E (at 7 - 9 years)§: int 9.5 (SD unclear), cont 18.6 (SD unclear) (mean difference -9.10,
95% CI -10.34 to 7.86 assuming SDs of 5) significant reduction
Carbohydrate intake: not reported
Protein intake: not reported
Trans fat intake: not reported
Replacement for saturated fat: PUFA and CHO (based on dietary goals and achievements)
Style: diet advice
Setting: community (outpatients clinic)
§validity of these data is questionable as it represents only 3 intervention and 3 control participants.
Source: Lopez-Espinoza 1984
Outcomes Stated trial outcomes: retinopathy
Data available on total mortality? yes, but unable to ascertain from which intervention groups (34
deaths at 10 years)
Cardiovascular mortality? no
Events available for combined cardiovascular events: none
Secondary outcomes: none
Tertiary outcomes: BMI, total cholesterol
Notes Study duration over 9 years
Study aim was to reduce total fat and increase PUFAs (so reducing saturates), and saturated fat intake
in the intervention group was significantly lower than in the control group
SFA reduction achieved
Total serum cholesterol, difference between intervention and control, mmol/L: 0.07 (95% CI -0.34
to 0.48), NO statistically significant reduction and smaller than 0.20
Trial dates: Recruitment 1973 to 1976
Funding: Oxford Diabetes Trust, British Diabetic Association, International Sugar Research Foundation
Inc
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










High risk Participants were not blinded.
Oxford Retinopathy 1978  (Continued)
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Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Unclear risk Unclear whether physicians blinded to allocation
Blinding of outcome as-
sessment (detection bias)
All-cause mortality








Low risk Not relevant for primary and secondary outcomes as all trialists were asked for
data
Free of systematic differ-
ence in care?
Low risk Dietetic advice for both groups. See control and intervention methods in the
Interventions section of the table of Characteristics of included studies
Stated aim to reduce SFA High risk Aim to reduce SFA not stated
Achieved SFA reduction Low risk SFA reduction achieved
Achieved TC reduction High risk No statistically significant TC fall, and difference only 0.07 mmol/L






Summary risk of bias: moderate to high
Participants Men (?) with angina or following MI (UK)
CVD risk: high
Control: randomised 26, analysed 18
Intervention - corn: randomised 26, analysed 13
Mean years in trial: control 1.7, corn 1.5
% male: unclear (100%?)
Age: mean control 58.8, corn 52.6 (all < 70)
Ethnicity: not stated
Statins use allowed? Unclear (anti-coagulants not allowed, but all participants received conventional
treatments at the discretion of their physicians)
% taking statins: Not reported (probably none as too early, pre-1980)
Interventions Modified fat vs usual diet
Control aims: usual diet
Intervention aims - corn: restrict dietary fat, plus 80 g/day corn oil provided
Control methods: usual physician care plus follow-up clinic monthly, then every 2 months, no dietary
fat advice or oil provided
Rose corn oil 1965 
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Intervention methods: usual physician care plus follow-up clinic monthly, then every 2 months, dietary
fat advice plus oil provided
Unclear how the advice was delivered or by whom
Total fat intake, %E (at 18 months): corn 50.5 (SD unclear), cont 32.6 (SD unclear) (mean difference
17.90, 95% CI 10.77 to 25.03 assuming SDs of 10) significant increase
Saturated fat intake: unclear (mean difference unclear)
PUFA intake: unclear
PUFA n-3 intake: not reported
PUFA n-6 intake: not reported
MUFA intake: unclear
CHO intake, %E (at 18 months): corn 36.5 (SD unclear), cont 51.5 (|SD unclear) (mean difference -15.00,
95% CI -29.27 to -0.73 assuming SDs of 20) significant reduction
Protein intake, %E (at 18 months): corn 11.0 (SD unclear), cont 13.2 (SD unclear) (mean difference -2.20,
95% CI -5.77 to 1.37 assuming SDs of 5) no significant difference
Trans fat intake: unclear
Replacement for saturated fat: mainly PUFA (based on aims and achievements)
Style: diet advice and supplement (oil)
Setting: community
Outcomes Stated trial outcomes: cardiac events
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: cardiovascular deaths, non-fatal MI, angina,
stroke
Secondary outcomes: stroke (none), non-fatal and total MI, CHD mortality (fatal MI and sudden death),
CHD events (all MI and sudden death)
Tertiary outcomes: total cholesterol
Notes Study duration 2 years
Study aim was to reduce total fat (by restricting fatty meat, sausages, pastry, ice cream, cheese, cake,
milk, eggs and butter) and prescribe vegetable oil (so reducing saturates), but saturated fat intakes
during intervention were not reported.
SFA reduction aimed (but unclear whether achieved as SFA intake not reported)
Total serum cholesterol, difference between intervention and control, mmol/L: -0.58 (95% CI
-1.42 to 0.26), NO statistically significant reduction but > 0.20
Trial dates: unclear, published in 1965
Funding: probably unfunded (they thank the Paddington General Hospital for clinic facilities, and St
Mary's and Paddington General Hospital physicians for referral of patients, but no funding acknowl-
edged)
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions.
Risk of bias
Rose corn oil 1965  (Continued)
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Trial was stated as "randomised" but without further detail, apart from use of
a sealed envelope as below.
Allocation concealment
(selection bias)
Unclear risk When a new participant was accepted for the trial a sealed envelope was
opened containing the allocation instructions. In the case of participants allo-





High risk The physicians in charge knew which participants were receiving oil, but they
did not know until the end of the trial the kind of oil that they were receiving.
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Low risk The electrocardiograms were assessed without the knowledge of the partici-
pant's treatment group.
Blinding of outcome as-
sessment (detection bias)
All-cause mortality




Unclear risk Some lost to follow-up by 2 years, so some events may have been missed
Selective reporting (re-
porting bias)
Low risk Not relevant for primary and secondary outcomes as all trialists were asked for
data.
Free of systematic differ-
ence in care?
Low risk All received conventional treatments at the discretion of the physicians, all at-
tended a special follow-up clinic. See control and intervention methods in the
Interventions section of the table of Characteristics of included studies
Stated aim to reduce SFA Low risk Aim to reduce SFA stated
Achieved SFA reduction Unclear risk SFA intake not reported
Achieved TC reduction High risk Although the TC in the intervention group was 0.58 mmol/L lower than in the
control group, this was not statistically significant in this small study.
Other bias Low risk None noted





Summary risk of bias: moderate to high
Participants Men (?) with angina or following MI (UK)
CVD risk: high
Control: randomised 26, analysed 18
Intervention - olive: randomised 28, analysed 12
Mean years in trial: control 1.7, olive 1.5
Rose olive 1965 
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% male: unclear (100%?)
Age: mean control 58.8, olive 55.0 (all < 70)
Ethnicity: Not stated
Statins use allowed? Unclear (anti-coagulants not allowed, but all participants received conventional
treatments at the discretion of their physicians)
% taking statins: Not reported (probably none as too early, pre-1980)
Interventions Modified fat vs usual diet
Control aims: usual diet
Intervention aims - olive: restrict dietary fat, plus 80 g/day olive oil provided
Control methods: usual physician care plus follow-up clinic monthly, then every 2 months, no dietary
fat advice or oil provided
Intervention methods: usual physician care plus follow-up clinic monthly, then every 2 months, dietary
fat advice plus oil provided
Unclear how the advice was delivered or by whom
Total fat intake, %E (at 18 months): olive 46.2 (SD unclear), cont 32.6 (SD unclear) (mean difference
13.60, 95% CI 6.30 to 20.90 assuming SDs of 10) significant increase
Saturated fat intake: unclear (mean difference unclear)
PUFA intake: unclear
PUFA n-3 intake: not reported
PUFA n-6 intake: not reported
MUFA intake: unclear
CHO intake, %E (at 18 months): olive 42.2 (SD unclear), cont 51.5 (SD unclear) (mean difference -9.30,
95% CI -23.91 to 5.31 assuming SDs of 20) no significant difference
Protein intake, %E (at 18 months): olive 9.6 (SD unclear), cont 13.2 (SD unclear) (mean difference -3.60,
95% CI -7.25 to 0.05 assuming SDs of 5) no significant difference
Trans fat intake: unclear
Replacement for saturated fat: mainly MUFA (based on dietary aims)
Style: diet advice and supplement (oil)
Setting: community
Outcomes Stated trial outcomes: cardiac events
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: cardiovascular deaths, non-fatal MI, angina,
stroke
Secondary outcomes: stroke (none), non-fatal and total MI, CHD mortality (fatal MI and sudden death),
CHD events (all MI and sudden death)
Tertiary outcomes: total cholesterol
Notes Study duration 2 years
Rose olive 1965  (Continued)
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Study aim was to reduce total fat (by restricting fatty meat, sausages, pastry, ice cream, cheese, cake,
milk, eggs and butter) and prescribe vegetable oil (so reducing saturates), but saturated fat intakes
during intervention were not reported
SFA reduction aimed (but unclear whether achieved as SFA intake not reported)
Total serum cholesterol, difference between intervention and control, mmol/L: 0.30 (95% CI -0.93
to 1.53), NO statistically significant reduction, mean total cholesterol rose
Trial dates: unclear, published in 1965
Funding: probably unfunded (they thank the Paddington General Hospital for clinic facilities, and St
Mary's and Paddington General Hospital physicians for referral of patients, but no funding acknowl-
edged)
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Trial was stated as "randomised" but without further detail, apart from use of
a sealed envelope as below.
Allocation concealment
(selection bias)
Unclear risk When a new participant was accepted for the trial a sealed envelope was
opened containing the allocation instructions. In the case of participants allo-





High risk The physicians in charge knew which participants were receiving oil, but they
did not know until the end of the trial the kind of oil that they were receiving.
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Low risk The electrocardiograms were assessed without the knowledge of the partici-
pant's treatment group.
Blinding of outcome as-
sessment (detection bias)
All-cause mortality




Unclear risk Some lost to follow-up by 2 years, so some events may have been missed
Selective reporting (re-
porting bias)
Low risk Not relevant for primary and secondary outcomes as all trialists were asked for
data.
Free of systematic differ-
ence in care?
Low risk All received conventional treatments at the discretion of the physicians, all at-
tended a special follow-up clinic. See control and intervention methods in the
Interventions section of the table of Characteristics of included studies
Stated aim to reduce SFA Low risk Aim to reduce SFA stated
Achieved SFA reduction Unclear risk SFA intake not reported
Achieved TC reduction High risk Although the TC in the intervention group was 0.58 mmol/L lower than in the
control group, this was not statistically significant in this small study.
Rose olive 1965  (Continued)
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Summary risk of bias: moderate to high
Participants Women with a high risk of breast cancer (USA)
CVD risk: low
Control: randomised 96, analysed 75
Intervention: randomised 98, analysed 72
Mean years in trial: control 1.8, intervention 1.7
% male: 0
Age: mean control 46, intervention 46
Ethnicity: White 89%, African-American 9%, Hispanic 2%
Statins use allowed? No (those on lipid-lowering medications were excluded)
% taking statins: 0%
Interventions Reduced fat vs usual diet
Control aims: usual diet
Intervention aims: total fat 15%E
Control methods: continued usual diet
Intervention methods: Bi-weekly individual dietetic appointments over 3 months followed by month-
ly individual or group appointments, including education, goal-setting, evaluation, feedback and self-
monitoring
Intervention delivered face-to-face by a dietitian
Total fat intake, %E (at 12 months)§: int 17.6 (SD 5.8), cont 33.8 (SD 7.4) (mean difference -16.20, 95% CI
-18.34 to -14.06) significant reduction
Saturated fat intake, %E (at 12 months)§: int 6.0 (SD 3.0), cont 12.1 (SD 5.2) (mean difference
-6.10, 95% CI -7.47 to -4.73) significant reduction
PUFA intake, %E (at 12 months)§: int 3.8 (SD 1.7), cont 7.3 (SD 4.1) (mean difference -3.50, 95% CI -4.51
to -2.49) significant reduction
PUFA n-3 intake: not reported
PUFA n-6 intake: not reported
MUFA intake, %E (at 12 months)§: int 6.1 (SD 3.0), cont 12.8 (SD 6.3) (mean difference -6.70, 95% CI -8.29
to -5.11) significant reduction
CHO intake: not reported
Protein intake: not reported
Trans fat intake: not reported
Replacement for saturated fat: unclear, either carbohydrate or protein (based on aims and
achievements)
Simon 1997 
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Outcomes Stated trial outcomes: intervention feasibility
Data available on total mortality? yes (2 deaths, but not clear in which arms)
Cardiovascular mortality? no
Events available for combined cardiovascular events: none
Secondary outcomes: cancer diagnosis (8 diagnoses, but not clear in which arms)
Tertiary outcomes: weight, total, LDL and HDL cholesterol, TGs
Notes Study duration 2 years
Study aim was to reduce total fat to 15%E (saturated fat not mentioned), but saturated fat intake in the
intervention group was significantly lower than in the control group
SFA reduction achieved
Total serum cholesterol, difference between intervention and control, mmol/L: -0.34 (95% CI
-0.64 to -0.04), statistically significant reduction
Trial dates: Recruitment 1987 to 1989
Funding: Marilyn J Smith Fund, Harper-Grace Hospitals, the Wesley Foundation, National Cancer Insti-
tute, Karmanos Cancer Institute Core Grant, the United Foundation of Detroit
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions except PN Kim who was affiliated with Wesley Health Strategies (now Health Strategies,
which offers a "full-service health and fitness centre with an educated fitness staC and spacious work-
out areas", see healthstrategiesfitness.com/)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation method not clearly described, but participants were stratified
by age and randomised (block size 2).
Allocation concealment
(selection bias)





High risk Participants knew their allocation.
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Unclear risk Unclear whether physicians knew allocations
Blinding of outcome as-
sessment (detection bias)
All-cause mortality




Unclear risk Unclear, deaths, cancer and CV events are dropouts - unclear if any data miss-
ing
Simon 1997  (Continued)
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Selective reporting (re-
porting bias)
Low risk Not relevant for primary and secondary outcomes as all trialists were asked for
data
Free of systematic differ-
ence in care?
High risk Very different contact time with dietitian, but medical appointments same in
both groups. See control and intervention methods in the Interventions sec-
tion of the table of Characteristics of included studies
Stated aim to reduce SFA High risk Aim to reduce SFA not stated
Achieved SFA reduction Low risk SFA reduction achieved
Achieved TC reduction Low risk Statistically significant TC fall






St Thomas' Atherosclerosis Regression Study (STARS)
Summary risk of bias: moderate to high for CVD outcomes, low for all-cause mortality
Participants Men with angina referred for angiography (UK)
CVD risk: high
Control: unclear how many randomised (30?), analysed 24
Intervention: unclear how many randomised (30?), analysed 26
Mean years in trial: control 2.9, intervention 3.0
% male: 100%
Age: mean control 53.9, intervention 48.9 (all < 66)
Ethnicity: not stated
Statins use allowed? No (1 arm of the trial, not described here, prescribed cholestyramine)
% taking statins: 0%
Interventions Reduced and modified fat diet vs usual diet
Control aims: no diet intervention but advised to lose weight if BMI > 25
Intervention aims: total fat 27%E, SFA 8 - 10%E, omega-3 and omega-6 PUFA 8%E, increase in plant-de-
rived soluble fibre, dietary cholesterol 100 mg/1000 kcal, advised to lose weight if BMI > 25
Control methods: usual care but no formal dietetic counselling. They were counselled against smoking
if appropriate and advised about daily exercise level.
Intervention methods: Usual care plus dietetic individual assessment of diet and advice. Further dietet-
ic counselling and food stuCs were given to participants who did not achieve or maintain certain levels
of serum cholesterol reduction
Initial intervention was delivered individually face-to-face by a dietitian and follow-up by a clinician.
Total fat intake, %E (through study): int 27 (SD 7), cont 37 (SD 5) (mean difference -10.00, 95% CI -13.35
to -6.65) significant reduction
Saturated fat intake, %E (through study): int 9 (SD 3), cont 16 (SD 4) (mean difference -7.00, 95%
CI -8.97 to -5.03) significant reduction
STARS 1992 
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PUFA intake, %E (through study)§: int 7 (SD 2), cont 5 (SD 2) (mean difference 2.00, 95% CI 0.89 to 3.11)
significant increase
PUFA n-3 intake: not reported
PUFA n-6 intake: not reported
MUFA intake, %E (through study)§: int 10 (SD 4), cont 17 (SD 5) (mean difference -7.00, 95% CI -9.52 to
-4.48) significant reduction
CHO intake, %E (through study)§: int 49 (SD 7), cont 41 (SD 7) (mean difference 8.00, 95% CI 4.12 to
11.88) significant increase
Protein intake, %E (through study)§: int 19 (SD 4), cont 18 (SD 2) (mean difference 1.00, 95% CI -0.73 to
2.73) no significant effect
Trans fat intake: not reported




Outcomes Stated trial outcomes: angiography
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: cardiovascular deaths, non-fatal MI, angina,
stroke, CABG, angioplasty, stroke, total MI, CHD events, plus cancer deaths (none)
Secondary outcomes: total, HDL, LDL cholesterol, TGs, total/HDL and LDL/HDL ratios, 2-hour post-load
glucose (weight and BP "remained similar" but were not reported, Lp(a) reported but as geometric
means)
Notes Study duration: 3 years
Study aim was to reduce saturated fats (to 8 - 10%E), and saturated fat intake in the intervention group
was significantly reduced
SFA reduction aimed and achieved
Total serum cholesterol, difference between intervention and control, mmol/L: -0.76 (95% CI
-1.19 to -0.33), statistically significant reduction
Trial dates: Study dates not reported (published in 1992)
Funding: Unilever plc, the Chemical Pathology Fund of St Thomas' Hospital, and Bristol-Meyers Ltd
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "blinded random cards issued centrally by statistician advisor"
Allocation concealment
(selection bias)
Low risk "blinded random cards issued centrally by statistician advisor"
STARS 1992  (Continued)
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High risk Participant blinding: inadequate
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Unclear risk Physician blinding: unclear
Blinding of outcome as-
sessment (detection bias)
All-cause mortality








Low risk Not relevant for primary and secondary outcomes as all trialists were asked for
data
Free of systematic differ-
ence in care?
High risk Usual care in both groups, dietetic counselling only in the intervention group.
See control and intervention methods in the Interventions section of the table
of Characteristics of included studies
Stated aim to reduce SFA Low risk Aim to reduce SFA stated
Achieved SFA reduction Low risk SFA reduction achieved
Achieved TC reduction Low risk Statistically significant TC fall







Summary risk of bias: moderate to high
Participants Men with previous MI (Australia)
CVD risk: high
Control: randomised 237, analysed 221 at 2 years
Intervention: randomised 221, analysed 205 at 2 years
Mean years in trial: control 4.3, intervention 4.3
% male: 100
Age: mean control 49.1 (SD 6.5), intervention 48.7 (SD 6.8)
Ethnicity: not stated
Statins use allowed? Unclear (use of medication did not appear to be an exclusion criteria)
% taking statins: Not reported (probably none as too early, pre-1980)
Interventions Modified fat diet vs usual diet
Sydney Diet-Heart 1978 
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Control aims: reduction in energy if overweight, no other specific dietary advice, allowed to use PUFA
margarine instead of butter
Intervention aims: SFA 10%E, PUFA 15%E, reduction in energy if overweight, dietary chol < 300 mg/day
Control methods: no specific dietary instruction (except re weight)
Intervention methods: advised and tutored individually, diet assessed 3 times in 1st year and twice an-
nually thereafter
Intervention was delivered face-to-face individually but unclear by whom
Total fat intake, %E ("during follow-up"): int 38.3 (SD 5.9), cont 38.1 (SD 5.4) (mean difference 0.20, 95%
CI -0.88 to 1.28) no significant difference
Saturated fat intake, %E ("during follow-up"): int 9.8 (SD 2.6), cont 13.5 (SD 3.2) (mean difference
-3.70, 95% CI -4.25 to -3.15) significant reduction
PUFA intake, %E ("during follow-up"): int 15.1 (SD 4.3), cont 8.9 (SD 3.5) (mean difference 6.20, 95% CI
5.45 to 6.95) significant increase
PUFA n-3 intake: not reported
PUFA n-6 intake: not reported
MUFA intake, %E ("during follow-up"): int 11.5 (SD 2.1), cont 13.8 (SD 2.5) (mean difference -2.30, 95%
CI -2.74 to -1.86) significant reduction
CHO intake, %E ("during follow-up"): int 40.9 (SD 7.3), cont 40.3 (SD 7.3) (mean difference 0.60, 95% CI
-0.79 to 1.99) no significant difference
Protein intake, %E ("during follow-up"): int 15.2 (SD 2.8), cont 15.7 (SD 3.4) (mean difference -0.50, 95%
CI -1.09 to 0.09) no significant difference
Trans fat intake: not reported
Primary replacement for saturated fat: mainly PUFA (based on dietary aims and achievements)
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: cardiovascular mortality and morbidity
Data available on total mortality? yes
Cardiovascular mortality? yes (exact events included not stated)
Events available for combined cardiovascular events: none
Secondary outcomes: CHD deaths (exact events included not stated)
Tertiary outcomes: total cholesterol, TG, BMI, sBP, dBP
Notes Study duration 7 years
Study aim was saturated fat 10%E, and saturated fat intake in the intervention group was less than
80% of that in the control (73%)
SFA reduction aimed and achieved
Total serum cholesterol, difference between intervention and control, mmol/L: -0.30 (95% CI
-0.51 to -0.09), statistically significant reduction
Trial dates: Recruitment 1966 to [unclear] and followed for 2 to 7 years
Funding: Life Insurance Medical Research Fund of Australia and New Zealand
Sydney Diet-Heart 1978  (Continued)
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Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "table of random numbers ... generated by a research assistant and









High risk Very difficult to blind trials where participants need to make their own dietary
changes
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Low risk Initially masked to group assignment (though success of blinding not checked)
Blinding of outcome as-
sessment (detection bias)
All-cause mortality




Low risk Survival analysis used
Selective reporting (re-
porting bias)
Low risk Not relevant for primary and secondary outcomes as all trialists were asked for
data
Free of systematic differ-
ence in care?
High risk Advice and follow-up in intervention group, not in control. See control and in-
tervention methods in the Interventions section of the table of Characteristics
of included studies
Stated aim to reduce SFA Low risk Aim to reduce SFA stated
Achieved SFA reduction Low risk SFA reduction achieved
Achieved TC reduction Low risk Statistically significant TC fall






Summary risk of bias: moderate to high
Participants Men living at the Veterans Administration Center (USA)
CVD risk: low
Veterans Admin 1969 
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Control: randomised 422, analysed 422
Intervention: randomised 424, analysed 424
Mean years in trial: control 3.7, intervention 3.7
% male: 100
Age: mean control 65.6, intervention 65.4 (all 54 - 88)
Ethnicity: White 90%, African-American 7%, Asian 1%, Mexican 1%, other 1%
Statins use allowed? Unclear (only 4 participants were taking nicotinic acid, 17 diuretics, 56 digitalis,
none on heparin)
% taking statins: Not reported (probably none as too early, pre-1980)
Interventions Modified fat vs usual diet
Control aims: provided, total fat 40%E
Intervention aims: total fat 40%E, ⅔ of SFA replaced by unsaturated fats, dietary chol reduced
Control methods: whole diet provided
Intervention methods: whole diet provided
Total fat intake, %E (during trial): int 38.9 (SD unclear), cont 40 (SD unclear) (mean difference -1.10,
95% CI -2.45 to 0.25 assuming SDs of 10) no significant difference
Saturated fat intake, %E (during trial): int 8.3 (SD unclear), cont 18.5 (SD unclear) (mean differ-
ence -10.20, 95% CI -10.87 to -9.53 assuming SDs of 5) significant reduction
PUFA intake, %E (during trial)§: int 16.0 (SD ?), cont 4.9 (SD 0.10) (mean difference 11.10, 95% CI 10.62
to 11.58 assuming missing SD was 5) significant increase
PUFA n-3 intake: not reported
PUFA n-6 intake: not reported
MUFA intake, %E (during trial)⁑: not reported, approx int 14.0, cont 17.2 (mean difference -3.20,
95% CI -3.87 to -2.53) significant reduction
CHO intake, %E (during trial)⁑: not reported, approx int 45.9, cont 44.8 (mean difference 1.10, 95%
CI -1.60 to 3.80 assuming SDs of 20) no significant difference
Protein intake, %E (during trial)§: int 15.2 (SD ?), cont 15.2 (SD ?) (mean difference 0.00, 95% CI -0.67 to
0.67 assuming SDs of 5) no significant difference
Trans fat intake: not reported




⁑Estimated by subtraction (assuming total fat = SFA + PUFA + MUFA or energy intake = energy from
fat + CHO + protein)
Outcomes Stated trial outcomes: mortality, heart disease
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: sudden death, definite MI, definite stroke, angina,
PVD events
Secondary outcomes: cancer deaths, cancer diagnoses, stroke, non-fatal MI, total MI, CHD deaths (fatal
MI and sudden death due to CHD), CHD events (any MI or sudden death due to CHD)
Veterans Admin 1969  (Continued)
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Tertiary outcomes: none (some data on total cholesterol, but no variance info)
Notes Study duration over 8 years
Study aim was to replace 66% of saturated fat by unsaturated fats, and saturated fat intake in the in-
tervention group was significantly lower than in control
SFA reduction aimed and achieved
Total serum cholesterol, difference between intervention and control, mmol/L: -0.37 (95% CI
-0.77 to 0.03), NO statistically significant reduction but reduction > 0.20
Trial dates: Recruitment 1959 to 1967
Funding: Veterans Administration, Arthur Dodd Fuller Foundation, National Heart Institute, Los Angeles
County Heart Association, plus gi`s of foods from Mazola corn oil and Mazola margarine, the National
Soybean Processors Association, Pitman-Moore Company (Emdee margarine) and Hi-SaC Imitation Ice-
cream from Frozen Desserts Company. Edgmar Farms donated milk refrigeration equipment.
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "table of random numbers used"
Allocation concealment
(selection bias)





Low risk Institution provided diet in a masked fashion.
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Low risk Physician knowledge of allocation was assessed and found similar to random.
Blinding of outcome as-
sessment (detection bias)
All-cause mortality




Low risk All followed up via Veterans Admin system
Selective reporting (re-
porting bias)
Low risk Not relevant for primary and secondary outcomes as all trialists were asked for
data
Free of systematic differ-
ence in care?
Low risk All ate centre food as usual. See control and intervention methods in the Inter-
ventions section of the table of Characteristics of included studies
Stated aim to reduce SFA Low risk Aim to reduce SFA stated
Achieved SFA reduction Low risk SFA reduction achieved
Achieved TC reduction High risk No statistically significant TC fall, though fall was > 0.20 mmol/L
Veterans Admin 1969  (Continued)
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Women's Health Initiative (WHI)
Summary risk of bias: low
Participants Postmenopausal women aged 50 - 79 with or without CVD at baseline (USA)
CVD risk: low in those without CVD at baseline, high in those with CVD
Control without CVD at baseline: randomised 29,294, analysed 29,294
Intervention without CVD at baseline: randomised 19,541, analysed 19,541
Control with CVD at baseline: randomised 1369, analysed 1369
Intervention with CVD at baseline: randomised 908, analysed 908
Mean years in trial: control 8.1, intervention 8.1
% male: 0
Age: mean (both with and without CVD at baseline) int 62.3 (SD 6.9), control 62.3 (SD 6.9)
Ethnicity (women both with and without CVD at baseline): white 82%, black 11%, Asian or Pacific Islan-
der 2%, unknown 1%, American Indian or Alaskan native < 1%. No statistically significant effects of the
intervention on CHD events was seen for any ethnic subgroup.
Statins use allowed? Yes
% taking statins: 12% of women recruited were on lipid-lowering medication (these were a mixture of
participants with and without CVD at baseline).
Interventions Reduced fat vs usual diet
Control: diet-related education materials
Intervention: low-fat diet (20%E from fat), reduce saturated fat to 7%E with increased fruit and vegeta-
bles
Control methods: given copy of 'Dietary Guidelines for Americans'
Intervention methods: 18 group sessions with trained and certified nutritionists in the 1st year, quarter-
ly maintenance sessions thereafter, focusing on diet and behaviour modification
Intervention delivered face-to-face in a group by nutritionists
Intake data all relate to the full WHI cohort (not divided by whether participants have CVD at baseline
or not)
Total fat intake, %E (at 6 years): int 28.8 (SD 8.4), cont 37.0 (SD 7.3) (mean difference -8.20, 95% CI -8.34
to -8.06) significant reduction
Saturated fat intake, %E (at 6 years): int 9.5 (SD3.2), cont 12.4 (SD3.1) (mean difference -2.90,
95% CI -2.96 to -2.84 for full WHI population) significant reduction
PUFA intake, %E (at 6 years)§: int 6.3 (SD?), cont 7.6 (SD?) (mean difference -1.30, 95% CI -1.72 to -0.88
assuming missing SDs were 5) significant reduction
PUFA n-3 intake: not reported
PUFA n-6 intake: not reported
WHI 2006 
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MUFA intake, %E (at 6 years)§: int 11.1 (SD?), cont 14.3 (SD?) (mean difference -3.20, 95% CI -3.62 to
-2.78 assuming unclear SDs were 5) significant reduction
CHO intake, %E (at 6 years)§: int 53.9 (SD?), cont 46.3 (SD?) (mean difference 7.60, 95% CI 5.91 to 9.29
assuming SDs of 20) significant increase
Protein intake, %E (at 6 years)§: int 17.7 (SD?), cont 17.0 (SD?) (mean difference 0.70, 95% CI 0.28 to
1.12 assuming SDs of 5) significant increase
Trans fat intake, %E (at 6 years)§: int 1.8 (SD?), cont 2.4 (SD?) (mean difference unclear, no SDs as-
sumed)




§Amongst the 881 intervention and 1373 control participants with blood samples at baseline, with or
without CVD at baseline (Howard 2010)
Outcomes Stated trial outcomes: breast cancer, mortality, other cancers, cardiovascular events, diabetes
Data available on total mortality? yes*
Cardiovascular mortality? yes
Events available for combined cardiovascular events: CHD, stroke, heart failure, angina, peripheral vas-
cular disease, revascularisation, pulmonary embolism, DVT
Secondary outcomes: cancer deaths*, cancer diagnoses*, stroke, non-fatal MI, diabetes diagnosis*
Tertiary outcomes: weight, BMI, total, LDL and HDL cholesterol, TGs, systolic and diastolic BP (Lp(a)
and HOMA reported as geometric means)
* these are only available for the whole cohort, not split between low and high CVD risk groups
Notes Study duration over 8 years
Study aim was to reduce total fat to 20%E, reduce saturated fat to 7%E and increase fruit and veg-
etable intake (Patterson 2003), and saturated fat intake in the intervention group was significantly low-
er than in control
SFA reduction aimed and achieved
Total serum cholesterol, difference between intervention and control, mmol/L: -0.09 (95% CI
-0.15 to -0.02), statistically significant reduction
Trial dates: Recruitment was between 1993 and 1998
Funding: National Heart, Lung and Blood Institute of the National Institutes of Health
Declarations of Interest of primary researchers: Declarations varied from paper to paper, but this is a
typical one from Beresford 2006 "Dr Black has received research grants from Pfizer and AstraZeneca,
was on the speakers bureaus for Pfizer, Novartis, Sanofi-Aventis, Bristol-Meyers Squibb, Searle, Phar-
macia, and Boehringer and served as a consultant of on an advisory board for Myogen, Merck Sharp
and Dohme, Novartis, Mylan-Bertek, Pfizer, Bristol-Meyers Squibb, and Sanofi-Aventis. Dr Howard has
served on the advisory boards of Merck, Schering Plough, and the Egg Nutrition Council, has received
research support from Merck and Pfizer, and has consulted for General Millls. Dr Assaf is an employee of
Pfizer. No other disclosures were reported."
Risk of bias
Bias Authors' judgement Support for judgement
WHI 2006  (Continued)
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Random sequence genera-
tion (selection bias)









High risk Participants aware of allocation
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Low risk Trained clinic staC, who were responsible for anthropometric assessments and
administration of FFQs, were blinded to treatment assignments to the extent
practical. The dietary intervention staC did not conduct clinical assessments,
and clinic staC were not permitted to
participate in any intervention activities; participants were instructed not to
discuss nutrition activities with clinic staC.
Blinding of outcome as-
sessment (detection bias)
All-cause mortality




Low risk ITT analysis
Selective reporting (re-
porting bias)
Low risk Trials register 1999, study completion 2005, but outcomes not stated in trials
register. However, outcomes were well published; trialists were asked for data.
Free of systematic differ-
ence in care?
High risk Intervention participants received 18 group sessions with behavioural mod-
ification plus quarterly maintenance sessions thereafter; control groups re-
ceived a leaflet. See control and intervention methods in the Interventions
section of the table of Characteristics of included studies
Stated aim to reduce SFA Low risk Aim to reduce SFA stated
Achieved SFA reduction Low risk SFA reduction achieved
Achieved TC reduction Low risk Statistically significant TC fall






Women's Intervention Nutrition Study (WINS)
Summary risk of bias: low
Participants Women with localised resected breast cancer (USA)
CVD risk: low
Control: 1462 randomised, 1462 analysed
WINS 2006 
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Intervention: 975 randomised, 975 analysed
Mean years in trial: overall 5.0
% men: 0
Age: control mean 58.5 (95% CI 43.6 to 73.4), intervention mean 58.6 (95% CI 44.4 to 72.8) (all post-
menopausal)
Ethnicity: 85% white, 5% black, 4% Hispanic, 5% Asian or Pacific Islander, < 1% American Indian or un-
known (no outcome data based on ethnicity)
Statins use allowed? Not stated (statins not mentioned in inclusion or exclusion criteria within trial pro-
tocol)
% taking statins: Not reported
Interventions Reduced fat intake vs usual diet
Control aims: minimal nutritional counselling focused on nutritional adequacy
Intervention aims: total fat 15 - 20%E
Control methods: 1 baseline dietetic session plus 3-monthly sessions
Intervention methods: 8 bi-weekly individual dietetic sessions plus 3-monthly contact and optional
monthly group sessions, incorporating individual fat gram goals, social cognitive theory, self-monitor-
ing, goal-setting, modelling, social support and relapse prevention and management
Intervention was delivered face-to-face individually by trained dietitian
Total fat intake, %E (at 1 year): int 20.3 (SD 8.1), cont 29.2 (SD 7.4) (mean difference -8.90, 95% CI -9.53
to -8.27)
Total fat intake, %E (at 5 years): int 23.2 (SD 8.4) n = 380, cont 31.2 (SD 8.9) n = 648 (mean difference
-8.00, 95% CI -9.09 to -6.91) significant reduction
Saturated fat intake*, %E (at 1 year): int 6.4 (SD 0.14 [4.4]), cont 9.8 (SD 0.15 [5.7]) (mean differ-
ence -3.40, 95% CI -3.80 to -3.00 assuming reported SDs were actually SEs) significant reduction
PUFA intake*, %E (at 1 year): int 4.5 (SD 0.09 (2.8)), cont 6.4 (SD 0.10 (3.8)) (mean difference -1.90, 95%
CI -2.16 to -1.64) significant reduction
PUFA n-3 intake: not reported by study arm
PUFA n-6 intake: not reported by study arm
MUFA intake*, %E (at 1 year): int 7.6 (SD 0.14 (4.4)), cont 11.5 (SD 0.16 (6.1)) (mean difference -3.90, 95%
CI -4.32 to -3.48) significant reduction
CHO intake, %E (at 6 months): int 60.8 (SD 19.6), cont 50.5 (SD 14.8) (mean difference 10.30, 95% CI 8.85
to 11.75) significant increase
Protein intake, %E (at 6 months): int 19.1 (SD 5.2), cont 17.6 (SD 4.1) (mean difference 1.50, 95% CI 1.11
to 1.89) significant increase
Trans fat intake: not reported
Replacement for saturated fat: CHO and protein (based on dietary achievement)
Style: dietary advice
Setting: community
*SDs appear incorrect, probably SEs?
Outcomes Stated trial outcomes: dietary fat intake, total cholesterol, weight and waist measurement
WINS 2006  (Continued)
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Data available on total mortality? yes
Cardiovascular mortality? no
Events available for combined cardiovascular events: none
Secondary outcomes: cancer diagnoses
Tertiary outcomes: weight, BMI, total cholesterol
Notes Study duration 5 years
Study aim was to reduce total fat to 15 - 20%E
SFA reduction achieved
Total serum cholesterol, difference between intervention and control, mmol/L: -0.14 (95% CI
-0.34 to 0.05), NO statistically significant reduction and reduction < 0.20
Trial dates: Recruitment 1994 to 2001
Funding: National Cancer Institute, Breast Cancer Research Foundation, American Institute for Cancer
Research
Declarations of Interest of primary researchers: none stated, all authors worked for academic or health
institutions except that Njeri Karanja worked for Kaiser Permanente Center for Health Research, Bette
Caan for Kaiser Permanente Medical Group, and Barbara L Winters for Campbell's Soup Company.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random stratified permuted block design, carried out at the statistical coordi-
nating centre of WINS
Allocation concealment
(selection bias)
Low risk Random stratified permuted block design, carried out at the statistical coordi-





High risk Not for dietary advice and participants
Blinding of outcome as-
sessment (detection bias)
CVD outcomes
Low risk All outcomes assessed by the blinded outcome committee
Blinding of outcome as-
sessment (detection bias)
All-cause mortality




Low risk All assessed
Selective reporting (re-
porting bias)
Low risk Not relevant for primary and secondary outcomes as all trialists were asked for
data
Free of systematic differ-
ence in care?
High risk Differences in attention - more time for those in intervention group. See con-
trol and intervention methods in the Interventions section of the table of Char-
acteristics of included studies
WINS 2006  (Continued)
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Stated aim to reduce SFA High risk Aim to reduce SFA not stated
Achieved SFA reduction Low risk SFA reduction achieved
Achieved TC reduction High risk No statistically significant TC fall
Other bias Low risk None noted
WINS 2006  (Continued)
%E: percent of total energy intake
ATPII: Adult treatment panel II
BMI: body mass index (weight in kg/ height in m, squared)
BP: blood pressure
CABG: coronary artery bypass gra`






DART: Diet And Reinfarction Trial
dBP: diastolic blood pressure
DVT: deep vein thrombosis
EPA: eicosapentaenoic acid
GPs: general practitioners
HDL: high density lipoprotein
HOMA: homeostatic model assessment
int: intervention group
ITT: Intention to treat analysis
LDL: low density lipoprotein
Lp(a): lipoprotein (a)
MI: myocardial infarction
MRC: Medical Research Council
MUFA: monounsaturated fat
P/S: polyunsaturated/saturated fat ratio
PCTA: percutaneous transluminal coronary angioplasty
PUFA: polyunsaturated fat
PVD: peripheral vascular disease
RCT: randomised controlled trial








WHI: Women's Health Initiative
WINS: Women's Intervention Nutrition Study
 
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Agewall 2001 Multifactorial intervention
Ammerman 2003 No appropriate control group (and not low fat vs modified fat)
Anderson 1990 Follow-up less than 24 months
Aquilani 2000 No appropriate control group (and not low fat vs modified fat)
Arntzenius 1985 No appropriate control group (and not low fat vs modified fat)
Aro 1990 Intervention and randomised follow-up less than 6 months
ASSIST 2001 Intervention was not dietary fat modification or low fat diet.
Australian Polyp Prev 95 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Azadbakht 2007 Follow-up less than 24 months
Bakx 1997 Multifactorial intervention
Ball 1965 Study aim was to assess effects of a low-fat diet and methods stated that the "nature of the fat con-
sumed was not altered". Saturated fat content of diet was not reported.
Barnard 2009 Weight reduction encouraged in the conventional diet, but not in the vegan diet arm
Barndt 1977 No appropriate control group (and not low fat vs modified fat)
Baron 1990 Multifactorial intervention
Barr 1990 Intervention and randomised follow-up less than 6 months
Barsotti 1991 Complex paper in Italian; unclear whether cardiovascular events occurred; contact with authors
not established
Baumann 1982 Intervention and randomised follow-up less than 6 months
BDIT Pilot Studies 1996 Study aim was to reduce total fat intake to 15%E with no specific intervention on saturated fat. Sat-
urated fat in intervention group was more than 80% of that in the control group.
Beckmann 1995 Intervention was not dietary fat modification or low-fat diet.
beFIT 1997 Follow-up less than 24 months
Beresford 1992 Intervention and randomised follow-up less than 6 months
Bergstrom 1967 Intervention and randomised follow-up less than 6 months
Bierenbaum 1963 No appropriate control group (and not low fat vs modified fat)
Bloemberg 1991 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Bloomgarden 1987 Multifactorial intervention
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Study Reason for exclusion
Bonk 1975 Trial, unclear if randomised; contact could not be established with trialists
Bonnema 1995 No appropriate control group (and not low fat vs modified fat)
Bosaeus 1992 Intervention and randomised follow-up less than 6 months
Boyd 1988 Follow-up less than 24 months
BREACPNT Individual microbiome-based dietary advice vs Mediterranean diet (no suggestion of saturated fat
reduction in either arm)
Brehm 2009 Unclear whether any relevant events occurred, not able to contact trialists
Brensike 1982 No appropriate control group (and not low fat vs modified fat)
BRIDGES 2001 Follow-up less than 24 months
Broekmans 2003 Intervention was not dietary fat modification or low fat diet.
Brown 1984 No appropriate control group (and not low fat vs modified fat)
Bruce 1994 No appropriate control group (and not low fat vs modified fat)
Bruno 1983 Multifactorial intervention
Butcher 1990 Intervention and randomised follow-up less than 6 months
Byers 1995 No appropriate control group (and not low fat vs modified fat)
Caggiula 1996 No appropriate control group (and not low fat vs modified fat)
Canadian DBCP 1997 Unable to establish contact with authors to provide data on numbers of deaths and CV events
CARMEN 2000 Follow-up less than 24 months
CARMEN substudy 2002 Follow-up less than 24 months
Casas-Agustench 2013 Less than 24 months duration
Cerin 1993 Intervention and randomised follow-up less than 6 months
Chan 1993 Intervention and randomised follow-up less than 6 months
Chapman 1950 Intervention and randomised follow-up less than 6 months
Charbonnier 1975 Intervention and randomised follow-up less than 6 months
Cheng 2004 Intervention and randomised follow-up less than 6 months
Chiostri 1988 Intervention and randomised follow-up less than 6 months
Choudhury 1984 Intervention and randomised follow-up less than 6 months
Clark 1997 Multifactorial intervention
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Study Reason for exclusion
Cli`on 1992 Intervention and randomised follow-up less than 6 months
Cobb 1991 Intervention and randomised follow-up less than 6 months
Cohen 1991 Intervention was not dietary fat modification or low fat diet.
Cole 1988 Intervention and randomised follow-up less than 6 months
Colquhoun 1990 Intervention and randomised follow-up less than 6 months
Consolazio 1946 Intervention and randomised follow-up less than 6 months
Cox 1996 Multifactorial intervention
Cro` 1986 Intervention was not dietary fat modification or low fat diet.
Curzio 1989 Follow-up less than 24 months
Da Qing IGT 1997 Intervention was not dietary fat modification or low-fat diet.
Dalgard 2001 No appropriate control group (and not low fat vs modified fat)
DAS 2000 No appropriate control group (and not low fat vs modified fat)
DASH 1997 Intervention and randomised follow-up less than 6 months
Davey Smith 2005 Multifactorial intervention
De Boer 1983 Intervention and randomised follow-up less than 6 months
De Bont 1981 Neither mortality nor cardiovascular morbidity data available as study data have been lost
DeBusk 1994 Multifactorial intervention
DEER 1998 Duration 1 year only
Delahanty 2001 No appropriate control group (and not low fat vs modified fat)
Delius 1969 Intervention was not dietary fat modification or low fat diet.
Demark 1990 Intervention and randomised follow-up less than 6 months
Dengel 1995 No appropriate control group (and not low fat vs modified fat)
Denke 1994 Intervention and randomised follow-up less than 6 months
Diabetes CCT 1995 Intervention was not dietary fat modification or low fat diet.
Diet & Hormone Study 2003 Duration 1 year only
DIET 1998 Multifactorial intervention
Ding 1992 Intervention and randomised follow-up less than 6 months
DIPI 2018 Less than 24 months duration
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Study Reason for exclusion
DIRECT 2009 Unable to establish contact with authors to establish whether relevant events occurred; multiple
publications checked and no relevant outcomes found
DO IT 2006 Intervention aim was for a "mediterranean diet" with total fat 27 - 30%E, protein 15 - 18%E, CHO 50
- 55%E, no specific aim to reduce saturated fat (though polyunsaturated margarine given to inter-
vention group), and intervention group saturated fat was more than 80% of that in the control.
Dobs 1991 No appropriate control group (and not low fat vs modified fat)
Due 2008 Follow-up less than 24 months
DuCield 1982 Multifactorial intervention
Dullaart 1992 Study authors confirmed that no deaths or cardiovascular events occurred during the study.
Eating Patterns 1997 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Ehnholm 1982 Intervention and randomised follow-up less than 6 months
Ehnholm 1984 Intervention and randomised follow-up less than 6 months
Eisenberg 1990 Intervention and randomised follow-up less than 6 months
Elder 2000 No appropriate control group (and not low fat vs modified fat)
Ellegard 1991 Intervention and randomised follow-up less than 6 months
Esposito 2003 No appropriate control group (and not low fat vs modified fat)
Esposito 2004 Unable to establish contact with authors to assess whether any relevant events occurred
EUROACTION 2008 Multifactorial intervention
FARIS 1997 Multifactorial intervention
Fasting HGS 1997 No appropriate control group (and not low fat vs modified fat)
Ferrara 2000 No appropriate control group (and not low fat vs modified fat)
Fielding 1995 Intervention and randomised follow-up less than 6 months
Finnish Diabet Prev 2000 Multifactorial intervention
Finnish Mental Hosp 1972 Not randomised (cluster-randomised, but < 6 clusters)
Fisher 1981 Intervention and randomised follow-up less than 6 months
FIT Heart 2011 Authors confirmed that differences between intervention and control groups included smoking
and physical activity, as well as dietary changes.
Fleming 2002 No appropriate control group (and not low fat vs modified fat)
Fortmann 1988 Intervention was not dietary fat modification or low fat diet.
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Foster 2003 Weight reduction in 1 arm but not the other
Frenkiel 1986 Follow-up less than 24 months
FRESH START 2007 Participants were newly diagnosed with cancer.
Gambera 1995 Intervention and randomised follow-up less than 6 months
Gaullier 2007 No appropriate control group (and not low fat vs modified fat)
Ginsberg 1988 Intervention and randomised follow-up less than 6 months
Gjone 1972 Intervention and randomised follow-up less than 6 months
Glatzel 1966 No appropriate control group (and not low fat vs modified fat)
Goodpaster 1999 No appropriate control group (and not low fat vs modified fat)
Grundy 1986 Intervention and randomised follow-up less than 6 months
Hardcastle 2008 Multifactorial intervention
Harris 1990 Intervention and randomised follow-up less than 6 months
Hartman 1993 No appropriate control group (and not low fat vs modified fat)
Hartwell 1986 No appropriate control group (and not low fat vs modified fat)
Hashim 1960 Intervention and randomised follow-up less than 6 months
Haufe 2011 Aim was to reduce total fat or reduce carbohydrate, but no saturated fat aims were stated, and ef-
fects of the diets on saturated fat intakes were unclear.
Haynes 1984 Intervention was not dietary fat modification or low fat diet.
Heber 1991 Intervention and randomised follow-up less than 6 months
Heine 1989 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Hellenius 1995 The study aimed for weight loss in 1 arm and not in the comparison arm.
Heller 1993 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Hildreth 1951 No appropriate control group (and not low fat vs modified fat)
Holm 1990 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Horlick 1957 Intervention and randomised follow-up less than 6 months
Horlick 1960 Intervention and randomised follow-up less than 6 months
Howard 1977 Intervention and randomised follow-up less than 6 months
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Hunninghake 1990 Intervention and randomised follow-up less than 6 months
Hutchison 1983 No appropriate control group (and not low fat vs modified fat)
Hyman 1998 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Iacono 1981 Not randomised; Intervention and randomised follow-up less than 6 months
IMPACT 1995 Multifactorial intervention
Iso 1991 No appropriate control group (and not low fat vs modified fat)
Ives 1993 Multifactorial intervention
Jalkanen 1991 Multifactorial intervention
Jerusalem Nut 1992 Intervention and randomised follow-up less than 6 months
Jula 1990 Multifactorial intervention
Junker 2001 Intervention and randomised follow-up less than 6 months
Karmally 1990 Intervention and randomised follow-up less than 6 months
Karvetti 1992 Multifactorial intervention
Kastarinen 2002 Multifactorial intervention
Kather 1985 Intervention and randomised follow-up less than 6 months
Katzel 1995 Intervention was not dietary fat modification or low fat diet.
Kawamura 1993 Intervention and randomised follow-up less than 6 months
Keidar 1988 Intervention and randomised follow-up less than 6 months
Kempner 1948 No appropriate control group (and not low fat vs modified fat)
Keys 1957a Intervention and randomised follow-up less than 6 months
Keys 1957b Intervention and randomised follow-up less than 6 months
Keys 1957c Intervention and randomised follow-up less than 6 months
Khan 2003 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
King 2000 Intervention and randomised follow-up less than 6 months
Kingsbury 1961 Intervention and randomised follow-up less than 6 months
KNOTA Numerous publications checked, but no relevant outcome data found. Trialists not contacted.
Koopman 1990 Intervention and randomised follow-up less than 6 months
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Koranyi 1963 Unclear whether randomised, unable to contact authors to discuss
Korhonen 2003 Multifactorial intervention
Kriketos 2001 Intervention and randomised follow-up less than 6 months
Kris 1994 Intervention and randomised follow-up less than 6 months
Kristal 1997 Multifactorial intervention
Kromhout 1987 No appropriate control group (and not low fat vs modified fat)
Kummel 2008 Intervention was not dietary fat modification or low-fat diet.
Laitinen 1993 Multifactorial intervention
Laitinen 1994 Multifactorial intervention
Lean 1997 Follow-up less than 24 months
Leduc 1994 Multifactorial intervention
Lewis 1958 Intervention and randomised follow-up less than 6 months
Lewis 1981 Intervention and randomised follow-up less than 6 months
Lewis 1985 Multifactorial intervention
Lichtenstein 2002 Intervention and randomised follow-up less than 6 months
Lim 2010 Unable to establish contact with authors to gain access to data on health outcomes (none reported
in paper)
Linko 1957 Intervention and randomised follow-up less than 6 months
Lipid Res Clinic 1984 No appropriate control group (and not low fat vs modified fat)
Little 1990 Intervention and randomised follow-up less than 6 months
Little 2004 Intervention was not dietary fat modification or low-fat diet.
Lottenberg 1996 Intervention and randomised follow-up less than 6 months
Luszczynska 2007 No appropriate control group (and not low fat vs modified fat)
Lyon Diet Heart 1994 Intervention was not dietary fat modification or low-fat diet.
Lysikova 2003 Intervention and randomised follow-up less than 6 months
Macdonald 1972 Intervention and randomised follow-up less than 6 months
Mansel 1990 Intervention was not dietary fat modification or low-fat diet
MARGARIN 2002 No appropriate control group (and not low fat vs modified fat)
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Marniemi 1990 Both intervention groups aimed to lose weight, while the control group did not.
Mattson 1985 Intervention and randomised follow-up less than 6 months
McAuley 2005 Follow-up less than 24 months
McCarron 1997 Intervention and randomised follow-up less than 6 months
McCarron 2001 Intervention was not dietary fat modification or low-fat diet.
McKeown-Eyssen 1994 Intervention aim was to reduce total fat and increase dietary fibre (saturated fat not mentioned),
and no saturated fat intakes during trial reported.
McManus 2001 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
McNamara 1981 Intervention and randomised follow-up less than 6 months
Medi-RIVAGE 2004 Weight reduction for some low-fat diet participants (those with BMI > 25) but not in Mediterranean
group
MeDiet 2002 Follow-up less than 24 months
MEDINA Less than 24 months duration
Mensink 1987 Intervention and randomised follow-up less than 6 months
Mensink 1989 Intervention and randomised follow-up less than 6 months
Mensink 1990a Intervention and randomised follow-up less than 6 months
Mensink 1990b Intervention and randomised follow-up less than 6 months
Metroville Health 2003 Unable to establish contact with authors to assess whether any relevant events occurred
Michalsen 2006 Diet plus stress management vs no intervention
Miettinen 1994 Intervention and randomised follow-up less than 6 months
Millar 1973 No appropriate control group (and not low fat vs modified fat)
Miller 1998 Intervention and randomised follow-up less than 6 months
Miller 2001 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Milne 1994 No appropriate control group (and not low fat vs modified fat) - the high CHO diet was neither 'usu-
al' or 'low fat' to compare with the modified fat diet.
Minnesota Coronary 1989 Although the study proceeded for over 4 years, participants (patients) came and went and mean
follow-up was only 1 year.
Minnesota HHP 1990 No appropriate control group (and not low fat vs modified fat)
Mojonnier 1980 Unable to establish contact with authors to assess whether any relevant events occurred
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Mokuno 1988 Intervention and randomised follow-up less than 6 months
Mortensen 1983 Intervention and randomised follow-up less than 6 months
Mottalib 2018 Less than 24 months duration
MRFIT substudy 1986 Intervention and randomised follow-up less than 6 months
MSDELTA 1995 Intervention and randomised follow-up less than 6 months
MSFAT 1997 Follow-up less than 24 months
Mujeres Felices 2003 Diet and breast self-examination vs no intervention
Mutanen 1997 Intervention and randomised follow-up less than 6 months
Muzio 2007 Intervention and randomised follow-up less than 6 months
Naglak 2000 Unable to establish contact with authors to assess whether any relevant events occurred
NAS 1987 Intervention and randomised follow-up less than 6 months
National Diet Heart 1968 Follow-up less than 24 months
NCEP weight 1991 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
NCT01954472 Study withdrawn (not completed)
NCT03068078 Less than 24 months duration
Neil 1995 No appropriate control group (and not low fat vs modified fat)
Neverov 1997 Multifactorial intervention
Next Step 1995 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Nordoy 1971 Intervention and randomised follow-up less than 6 months
Norway Veg Oil 1968 No appropriate control group (and not low fat vs modified fat)
Nutri-AGEs 2015 Less than 24 months duration
Nutrition Breast Health Follow-up less than 24 months
O'Brien 1976 Intervention and randomised follow-up less than 6 months
ODES 2006 The study aimed for weight loss in 1 arm and not in the other arm.
Oldroyd 2001 Multifactorial intervention
Ole Study 2002 Follow-up less than 24 months
OLIVE 1997 Unable to establish contact with authors to assess whether any relevant events occurred
Reduction in saturated fat intake for cardiovascular disease (Review)









Cochrane Database of Systematic Reviews
Study Reason for exclusion
ORIGIN 2008 Intervention was not dietary fat modification or low-fat diet.
Oslo Study 2004 Multifactorial intervention
Pascale 1995 Multifactorial intervention
PEP 2001 Multifactorial intervention
PHYLLIS 1993 No appropriate control group (and not low fat vs modified fat)
Pilkington 1960 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Polyp Prevention 1996 Intervention aim was to reduce total fat and increase dietary fibre, fruit and vegetables (saturated
fat not mentioned), and no saturated fat intakes during trial reported.
POUNDS LOST 2009 All study arms (low or high total fat) prescribed low saturated fat intake (8%E); no usual fat com-
parator.
PREDIMED 2008 Total fat goals in the low-fat arm were unclear and authors confirmed that aims were nonspecific (if
aims < 30%E, this study would be included).
PREMIER 2003 Follow-up less than 24 months
Pritchard 2002 The study aimed for weight loss in 1 arm and not in the comparison arm.
Puget Sound EP 2000 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Rabast 1979 Intervention and randomised follow-up less than 6 months
Rabkin 1981 Intervention and randomised follow-up less than 6 months
Radack 1990 Intervention and randomised follow-up less than 6 months
Rasmussen 1995 Intervention and randomised follow-up less than 6 months
Reaven 2001 Intervention and randomised follow-up less than 6 months
Reid 2002 No appropriate control group (and not low fat vs modified fat)
Renaud 1986 Not randomised
Rivellese 1994 Follow-up less than 24 months
Rivellese 2003 Intervention and randomised follow-up less than 6 months
Roderick 1997 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Roman CHD prev 1986 Multifactorial intervention
Rose 1987 No appropriate control group (and not low fat vs modified fat)
Sarkkinen 1995 Follow-up less than 24 months
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Schaefer 1995a Intervention and randomised follow-up less than 6 months
Schaefer 1995b Intervention and randomised follow-up less than 6 months
Schectman 1996 Multifactorial intervention
Schlierf 1995 Multifactorial intervention
Seppanen-Laakso 1992 Intervention and randomised follow-up less than 6 months
Seppelt 1996 Follow-up less than 24 months
Singh 1991 Multifactorial intervention
Singh 1992 No appropriate control group (and not low fat vs modified fat)
Sirtori 1992 Intervention and randomised follow-up less than 6 months
SLIM 2008 Multifactorial intervention
Sopotsinskaia 1992 The study aimed for weight loss in 1 arm and not in the comparison arm.
Soul Food Light Less than 24 months duration
Stanford NAP 1997 Intervention and randomised follow-up less than 6 months
Stanford Weight 1994 The study aimed for weight loss in 1 arm and not in the comparison arm.
Starmans 1995 Intervention and randomised follow-up less than 6 months
Steinbach 1996 Multifactorial intervention
Steptoe 2001 No appropriate control group (and not low fat vs modified fat)
Stevens 2002 Diet plus breast self examination vs no intervention
Stevenson 1988 No appropriate control group (and not low fat vs modified fat)
Strychar 2009 Follow-up less than 24 months
Sweeney 2004 Intervention was not dietary fat modification or low fat diet.
Søndergaard 2003 Follow-up less than 24 months
TAIM 1992 Intervention was not dietary fat modification or low fat diet.
Tapsell 2004 Unable to establish contact with authors to assess whether any relevant events occurred
THIS DIET 2008 All study arms prescribed low saturated fat intake, no usual fat comparator
TOHP I 1992 Multifactorial intervention
TONE 1997 Intervention was not dietary fat modification or low-fat diet.
Toobert 2003 Multifactorial intervention
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Towle 1994 Intervention and randomised follow-up less than 6 months
TRANSFACT 2006 Intervention and randomised follow-up less than 6 months
Treatwell 1992 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Tromsø Heart 1989 Multifactorial intervention
Troyer 2010 Longest duration only 12 months
UK PDS 1996 No appropriate control group (and not low fat vs modified fat)
Urbach 1952 No appropriate control group (and not low fat vs modified fat)
Uusitupa 1993 Multifactorial intervention
VASTKOST 2012 Publications reported than no participants died or experienced CVD during the trial.
Vavrikova 1958 Intervention and randomised follow-up less than 6 months
Verheiden 2003 Unable to establish contact with authors to assess whether any relevant events occurred
WAHA 2016 15%E from walnuts vs usual diet (neither arm aimed to reduce saturated fat intake)
Wass 1981 Intervention and randomised follow-up less than 6 months
Wassertheil 1985 Intervention was not dietary fat modification or low fat diet.
WATCH 1999 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Watts 1988 Intervention and randomised follow-up less than 6 months
Weintraub 1992 No appropriate control group (and not low fat vs modified fat)
Westman 2006 Intervention was not dietary fat modification or low fat diet.
Weststrate 1998 Intervention and randomised follow-up less than 6 months
WHEL 2007 Study aimed to reduce total fat, but saturated fat goals were not mentioned, and saturated fat in-
take in the intervention group was more than 80% of that in the control (81%).
WHO primary prev 1979 Multifactorial intervention
WHT 1990 Neither mortality nor cardiovascular morbidity data available as such data were not collected in
the study
WHT Feasibility 2003 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at
least 1 author)
Wilke 1974 Intervention and randomised follow-up less than 6 months
Williams 1990 Intervention was not dietary fat modification or low-fat diet.
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Williams 1992 Intervention was not dietary fat modification or low-fat diet.
Williams 1994 Intervention was not dietary fat modification or low-fat diet.
Wilmot 1952 No appropriate control group (and not low fat vs modified fat)
Wing 1998 No appropriate control group (and not low fat vs modified fat)
WINS UK 2011 Stated aim was to reduce total fat by 50%; no saturated fat aims
WOMAN 2007 Lifestyle intervention included exercise and weight as well as diet.
Wood 1988 Intervention was not dietary fat modification or low-fat diet.
Woollard 2003 Multifactorial intervention including smoking, weight, exercise and alcohol components
Working Well 1996 Multifactorial intervention






Characteristics of studies awaiting classification [ordered by study ID]
 
Methods A Mediterranean diet for preventing heart failure and atrial fibrillation in hypertensive patients (IC-
FAMED)
RCT, 24 months
Participants People with hypertension aged 55 to 75 years at high cardiovascular risk, but without existing CVD
Interventions MedDiet: Mediterranean-style diet, dietary advice (individual and group) every three months
LFD: Low-fat diet according to American Heart Association guidelines, dietary advice (individual
and group) every three months
Outcomes Primary: heart failure and/or atrial fibrillation
Secondary: echocardiographic variables & BP variables
Actual outcomes from abstracts: MedDiet: 5 CVD events (atrial fibrillation (AF) 2; ischaemic heart
disease (IHD) 2; stroke 1), LFD: 11 CVD events (AF 6, IHD 2, stroke 3). The crude rate for the occur-
rence of events per 1000 patient-months of follow-up was 197 (95% CI: 06–46) for MedDiet, 451
(95% CI: 3–8.1) for LFD. The HR for patients with MedDiet compared to LFD was 044 (95% CI: 015–
126, P > 005).
Notes Trials registration: ISRCTN27497769
Enrollment began in 2012; appears to have completed in 2017; abstract and poster publications on-
ly to date
Awaiting assessment because: Unclear whether one arm was higher in saturated fat than the other,
awaiting fuller publication to assess
ICFAMED 
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ICFAMED: A Mediterranean diet for preventing heart failure and atrial fibrillation in hypertensive patients
IHD: Ischaemic heart disease
LFD: low fat diet
MedDiet: Mediterranean style diet
RCT: randomised controlled trial
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name ENAbLE
Methods RCT, 2 x 2 diet and physical activity interventions, duration unclear
Participants Stroke survivors able to walk independently
Interventions AusMed diet, adaptation of the Mediterranean diet to the Australian context, including provision of
starter foods, menu plans and regular counselling
Comparator unclear
Telehealth-delivered physical activity and diet interventions in both arms
Outcomes Primary: sBP
Secondary: lipid profiles and glycaemic control
Starting date Mid 2019, planned completion date unclear
Contact information Coralie English, University of Western Australia (first author of abstract)
Notes Trial registration not found
Unclear whether the intervention was truly lower vs higher saturated fat as saturated fat goals not




Study name Combined Portfolio diet and Exercise study (PortfolioEx)
Methods RCT, 2 x 2 factorial design with exercise intervention, 36 months
Participants Men and postmenopausal women with BMI up to 40 kg/m2 with measurable arterial thickening
Interventions Lower saturated fat: advice on a therapeutic diet appropriate for hypercholesterolemia (ie < 7%
of energy from saturated fat, < 200 mg/d cholesterol) PLUS the combination of viscous fibres, soy
protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index
foods
Higher saturated fat: advice to follow a DASH-like diet of whole grains, and low-fat dairy products
with fruits and vegetables
Both arms with or without instruction on the Laval exercise program — a standardised physical ac-
tivity/exercise component supervised by trained kinesiologists (exercise physiologists)
NCT02481466 due 2020 
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Outcomes Primary: maximum vessel wall volume of the carotid arteries
Secondary: composite end point of myocardial infarction, revascularization, cardiovascular hospi-
talisation, cardiovascular mortality and stroke; atrial fibrillation; BP; and vessel outcomes
Starting date Nov 2016, planned completion Dec 2022
Contact information PI: David J Jenkins, MD, NutritionProject@smh.ca, Risk Factor Modification Centre, St. Michael's
Hospital
Notes Trials registration: NCT02481466
Unclear whether the intervention was truly lower vs higher saturated fat as saturated fat goals not




Study name Does the advice to eat a mediterranean diet with low carbohydrate intake, compared with a low-fat
diet, reduce diabetes and cardiovascular disease (CardioDiet)
Methods RCT, 36 months
Participants Adults with ischaemic heart disease followed up at cardiac rehabilitation units
Interventions Mediterranean diet with an energy content (E%) from carbohydrates between 25-30%
Traditional low-fat diet with 45-60 E% from carbohydrates
Outcomes Primary: diabetes incidence
Secondary: CVD disease, quality of life
Starting date Oct 2016, planned completion Oct 2023
Contact information PI: Fredrik H Nystrom, Professor, MD, University Hospital, Linkoeping, fredrik.nystrom@regionos-
tergotland.se
Notes Trials registration NCT02938832





Study name Nutritious Eating With Soul (NEW Soul) study
Methods RCT, 24 months
Participants African-American adults aged 18-65 years with BMI 25- 49.9 kg/m2
Interventions Lower saturated fat: plant-based vegan diet, instructing participants to favour a diet built around
whole grains, fruits, vegetables, and legumes, supplemented by the Oldways African Heritage and
Health programme, which includes a food pyramid guide. A Taste of African Heritage (ATAH) six-les-
son nutrition and cooking programme has an online course for health professionals and cooking
NEW Soul Study due 2022 
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instructors (all research and restaurant team members will complete this course). Interventions in-
clude intervention meetings, physical activity, and podcasts/mailings.
Higher saturated fat: low-fat omnivorous diet, supplemented by the Oldways African Heritage and
Health programme, which includes a food pyramid guide. A Taste of African Heritage (ATAH) six-les-
son nutrition and cooking programme has an online course for health professionals and cooking
instructors (all research and restaurant team members will complete this course). Interventions in-
clude intervention meetings, physical activity, and podcasts/mailings.
Outcomes Primary: CVD events
Secondary: CVD risk factors (including LDL & BP), body weight
Starting date May 2018, planned completion June 2022
Contact information PI: Brie Turner-McGrievy, Associate Professor, University of South Carolina
Trial website: https://newsoul.org/
Notes Trials registration NCT03354377
Unclear whether the intervention was truly lower vs higher saturated fat as saturated fat goals not
provided
NEW Soul Study due 2022  (Continued)
ATAH: A Taste of African Heritage
AusMed: Australian style Mediterranean diet
BMI: body mass index
BP: blood pressure
CVD: cardiovascular disease
DASH: Dietary Approaches to Stop Hypertension
E: energy
LDL: low density lipoprotein
PorColioEx: Combined Portfolio diet and Exercise study
RCT: randomised controlled trial
sBP: systolic blood pressure
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   SFA reduction vs usual diet - primary outcomes





Statistical method Effect size
1.1 ALL-CAUSE MORTALITY 12 55858 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.90, 1.03]
1.2 All-cause mortality, SA low summary risk
of bias
7 53219 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.84, 1.08]
1.3 All-cause mortality, SA aim to reduce SFA 9 53112 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.89, 1.06]
1.4 All-cause mortality, SA statistically signif-
icant SFA reduction
8 54973 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.92, 1.04]
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Statistical method Effect size
1.5 All-cause mortality, SA TC reduction 8 53073 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.88, 1.07]
1.6 All-cause mortality, SA excluding WHI 11 7023 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.83, 1.07]
1.7 All-cause mortality, SA Mantel-Haenszel
fixed-effect
12 55858 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.91, 1.03]
1.8 All-cause mortality, SA Peto fixed-effect 12 55858 Peto Odds Ratio (Peto, Fixed,
95% CI)
0.96 [0.90, 1.04]
1.9 All-cause mortality, subgroup by any
substitution
12   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.9.1 replaced by PUFA 7 4238 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.82, 1.13]
1.9.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
3.00 [0.33, 26.99]
1.9.3 replaced by CHO 6 53669 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.90, 1.04]
1.9.4 replaced by protein 5 53614 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.90, 1.04]
1.9.5 replacement unclear 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
1.10 All-cause mortality, subgroup by main
substitution
12   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.10.1 replaced by PUFA 6 4183 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.82, 1.14]
1.10.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
3.00 [0.33, 26.99]
1.10.3 replaced by CHO 5 51636 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.90, 1.04]
1.10.4 replaced by protein 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
1.10.5 replacement unclear 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
1.11 All-cause mortality, subgroup by dura-
tion
12 55858 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.90, 1.03]
1.11.1 up to 24mo 4 2246 Risk Ratio (M-H, Random, 95%
CI)
0.99 [0.78, 1.26]
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Statistical method Effect size
1.11.2 >24 to 48mo 3 1294 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.83, 1.12]
1.11.3 >48mo 4 52142 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.79, 1.16]
1.11.4 unclear duration 1 176 Risk Ratio (M-H, Random, 95%
CI)
0.33 [0.07, 1.61]
1.12 All-cause mortality, subgroup by base-
line SFA
12 55858 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.90, 1.03]
1.12.1 up to 12%E SFA baseline 1 2437 Risk Ratio (M-H, Random, 95%
CI)
0.90 [0.67, 1.21]
1.12.2 >12 to 15%E SFA baseline 5 51635 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.86, 1.19]
1.12.3 >15 to 18%E SFA baseline 1 55 Risk Ratio (M-H, Random, 95%
CI)
0.35 [0.04, 3.12]
1.12.4 >18%E SFA baseline 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.83, 1.15]
1.12.5 unclear 4 885 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.62, 1.04]
1.13 All-cause mortality, subgroup by SFA
change
12 55858 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.90, 1.03]
1.13.1 up to 4%E difference 5 53939 Risk Ratio (M-H, Random, 95%
CI)
0.99 [0.86, 1.13]
1.13.2 >4 to 8%E difference 2 188 Risk Ratio (M-H, Random, 95%
CI)
0.41 [0.08, 2.07]
1.13.3 >8%E difference 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.83, 1.15]
1.13.4 unclear 4 885 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.62, 1.04]
1.14 All-cause mortality, subgroup by sex 12 55858 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.90, 1.03]
1.14.1 Men 9 4410 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.83, 1.11]
1.14.2 Women 2 51272 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.90, 1.05]
1.14.3 Mixed, men and women 1 176 Risk Ratio (M-H, Random, 95%
CI)
0.33 [0.07, 1.61]
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Statistical method Effect size
1.15 All-cause mortality, subgroup by CVD
risk
12 55858 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.90, 1.03]
1.15.1 Low CVD risk 4 52251 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.91, 1.04]
1.15.2 Moderate CVD risk 1 176 Risk Ratio (M-H, Random, 95%
CI)
0.33 [0.07, 1.61]
1.15.3 Existing CVD disease 7 3431 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.76, 1.24]
1.16 All-cause mortality, subgroup by TC re-
duction
12   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.16.1 serum chol reduced by at least
0.2mmol/L
7 4238 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.81, 1.14]
1.16.2 serum chol reduced by <0.2mmol/L 4 51487 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.90, 1.04]
1.16.3 serum chol reduction unclear 1 133 Risk Ratio (M-H, Random, 95%
CI)
0.51 [0.05, 5.46]
1.17 All-cause mortality, subgroup decade of
publication
12 55858 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.90, 1.03]
1.17.1 1960s 5 1731 Risk Ratio (M-H, Random, 95%
CI)
0.92 [0.80, 1.07]
1.17.2 1970s 1 458 Risk Ratio (M-H, Random, 95%
CI)
1.49 [0.95, 2.34]
1.17.3 1980s 1 2033 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.76, 1.25]
1.17.4 1990s 2 188 Risk Ratio (M-H, Random, 95%
CI)
0.41 [0.08, 2.07]
1.17.5 2000s 3 51448 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.88, 1.05]
1.18 CARDIOVASCULAR MORTALITY 11 53421 Risk Ratio (M-H, Random, 95%
CI)
0.94 [0.78, 1.13]
1.19 CVD mortality, SA low summary risk of
bias
4 50315 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.67, 1.38]
1.20 CVD mortality, SA aim to reduce SFA 9 53112 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.79, 1.14]
1.21 CVD mortality, SA statistically signifi-
cant SFA reduction
7 52536 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.75, 1.21]
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1.22 CVD mortality, SA TC reduction 8 53073 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.78, 1.15]
1.23 CVD mortality, SA excluding WHI 10 4586 Risk Ratio (M-H, Random, 95%
CI)
0.92 [0.72, 1.18]
1.24 CVD mortality, SA Mantel-Haenszel
fixed-effect
11 53421 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.85, 1.07]
1.25 CVD mortality, SA Peto fixed-effect 11 53421 Peto Odds Ratio (Peto, Fixed,
95% CI)
0.95 [0.84, 1.08]
1.26 CVD mortality, subgroup by any substi-
tution
11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.26.1 replaced by PUFA 7 4251 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.73, 1.25]
1.26.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
3.00 [0.33, 26.99]
1.26.3 replace by CHO 5 51232 Risk Ratio (M-H, Random, 95%
CI)
0.99 [0.85, 1.14]
1.26.4 replaced by protein 4 51177 Risk Ratio (M-H, Random, 95%
CI)
0.99 [0.86, 1.14]
1.26.5 replacement unclear 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
1.27 CVD mortality, subgroup by main sub-
stitution
11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.27.1 replaced by PUFA 6 4196 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.73, 1.28]
1.27.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
3.00 [0.33, 26.99]
1.27.3 replace by CHO 4 49199 Risk Ratio (M-H, Random, 95%
CI)
0.78 [0.42, 1.46]
1.27.4 replaced by protein 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
1.27.5 replacement unclear 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
1.28 CVD mortality, subgroup by duration 11 53447 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.78, 1.16]
1.28.1 up to 24mo 4 2272 Risk Ratio (M-H, Random, 95%
CI)
1.26 [0.54, 2.94]
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1.28.2 >24 to 48mo 3 1294 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.57, 1.08]
1.28.3 >48 mo 3 49705 Risk Ratio (M-H, Random, 95%
CI)
1.02 [0.73, 1.43]
1.28.4 unclear duration 1 176 Risk Ratio (M-H, Random, 95%
CI)
0.25 [0.03, 2.19]
1.29 CVD mortality, subgroup by baseline
SFA
11 53447 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.78, 1.16]
1.29.1 up to 12%E SFA baseline 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
1.29.2 >12 to 15%E SFA baseline 5 51635 Risk Ratio (M-H, Random, 95%
CI)
1.06 [0.84, 1.32]
1.29.3 >15 to 18%E SFA baseline 1 55 Risk Ratio (M-H, Random, 95%
CI)
0.35 [0.04, 3.12]
1.29.4 >18%E SFA baseline 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.70 [0.51, 0.96]
1.29.5 unclear 4 911 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.61, 1.66]
1.30 CVD mortality, subgroup by SFA change 11 53447 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.78, 1.16]
1.30.1 up to 4%E difference 4 51502 Risk Ratio (M-H, Random, 95%
CI)
1.07 [0.85, 1.33]
1.30.2 >4 to 8%E difference 2 188 Risk Ratio (M-H, Random, 95%
CI)
0.29 [0.05, 1.70]
1.30.3 >8%E difference 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.70 [0.51, 0.96]
1.30.4 unclear 4 911 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.61, 1.66]
1.31 CVD mortality, subgroup by sex 11 53447 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.78, 1.16]
1.31.1 Men 9 4436 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.73, 1.25]
1.31.2 Women 1 48835 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.84, 1.19]
1.31.3 Mixed, men and women 1 176 Risk Ratio (M-H, Random, 95%
CI)
0.25 [0.03, 2.19]
Reduction in saturated fat intake for cardiovascular disease (Review)









Cochrane Database of Systematic Reviews





Statistical method Effect size
1.32 CVD mortality, subgroup by CVD risk 11 53447 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.80, 1.14]
1.32.1 Low CVD risk 3 47537 Risk Ratio (M-H, Random, 95%
CI)
0.84 [0.60, 1.16]
1.32.2 Moderate CVD risk 1 176 Risk Ratio (M-H, Random, 95%
CI)
0.25 [0.03, 2.19]
1.32.3 Existing CVD disease 8 5734 Risk Ratio (M-H, Random, 95%
CI)
1.04 [0.83, 1.31]
1.33 CVD mortality, subgroup by TC reduc-
tion
11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.33.1 serum chol reduced by at least
0.2mmol/L
7 4251 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.73, 1.25]
1.33.2 serum chol reduced by <0.2mmol/L 3 49063 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.47, 2.01]
1.33.3 serum chol reduction unclear 1 133 Risk Ratio (M-H, Random, 95%
CI)
0.20 [0.01, 4.15]
1.34 CVD mortality, subgroup decade of
publication
11 53421 Risk Ratio (M-H, Random, 95%
CI)
0.94 [0.78, 1.13]
1.34.1 1960s 5 1731 Risk Ratio (M-H, Random, 95%
CI)
0.78 [0.63, 0.97]
1.34.2 1970s 1 458 Risk Ratio (M-H, Random, 95%
CI)
1.59 [0.99, 2.55]
1.34.3 1980s 1 2033 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.77, 1.31]
1.34.4 1990s 2 188 Risk Ratio (M-H, Random, 95%
CI)
0.29 [0.05, 1.70]
1.34.5 2000s 2 49011 Risk Ratio (M-H, Random, 95%
CI)
0.78 [0.27, 2.21]
1.35 COMBINED CARDIOVASCULAR EVENTS 12 53300 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.66, 0.93]
1.36 CVD events, SA low summary risk of
bias
3 49857 Risk Ratio (M-H, Random, 95%
CI)
0.89 [0.75, 1.07]
1.37 CVD events, SA aim to reduce SFA 10 52991 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.66, 0.95]
1.38 CVD events, SA statistically significant
SFA reduction
7 52313 Risk Ratio (M-H, Random, 95%
CI)
0.85 [0.71, 1.02]
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1.39 CVD events, SA TC reduction 9 52952 Risk Ratio (M-H, Random, 95%
CI)
0.78 [0.65, 0.94]
1.40 CVD events, SA excluding WHI 11 4465 Risk Ratio (M-H, Random, 95%
CI)
0.75 [0.61, 0.91]
1.41 CVD events, SA Mantel-Haenszel fixed-
effect
12 53300 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.88, 0.99]
1.42 CVD events, SA Peto fixed-effect 12 53300 Peto Odds Ratio (Peto, Fixed,
95% CI)
0.92 [0.87, 0.98]
1.43 CVD events, SA excluding trials with ad-
ditional interventions
9 3998 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.64, 0.99]
1.44 CVD events, subgroup by any substitu-
tion
12   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.44.1 replaced by PUFA 7 3895 Risk Ratio (M-H, Random, 95%
CI)
0.73 [0.58, 0.92]
1.44.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.53, 1.89]
1.44.3 replace by CHO 5 51232 Risk Ratio (M-H, Random, 95%
CI)
0.84 [0.67, 1.06]
1.44.4 replaced by protein 4 51177 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.91, 1.03]
1.44.5 replacement unclear 1 235 Risk Ratio (M-H, Random, 95%
CI)
1.68 [0.41, 6.87]
1.45 CVD events, subgroup by main substitu-
tion
12   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.45.1 replaced by PUFA 6 3840 Risk Ratio (M-H, Random, 95%
CI)
0.78 [0.62, 0.97]
1.45.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.53, 1.89]
1.45.3 replace by CHO 4 49199 Risk Ratio (M-H, Random, 95%
CI)
0.67 [0.39, 1.16]
1.45.4 replaced by protein 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
1.45.5 replacement unclear 1 235 Risk Ratio (M-H, Random, 95%
CI)
1.68 [0.41, 6.87]
1.46 CVD events, subgroup by duration 12 53300 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.66, 0.93]
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1.46.1 up to 24mo 5 2481 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.78, 1.16]
1.46.2 >24 to 48mo 3 1294 Risk Ratio (M-H, Random, 95%
CI)
0.73 [0.56, 0.95]
1.46.3 >48mo 2 49247 Risk Ratio (M-H, Random, 95%
CI)
0.85 [0.63, 1.16]
1.46.4 unclear duration 2 278 Risk Ratio (M-H, Random, 95%
CI)
0.43 [0.17, 1.08]
1.47 CVD events, subgroup by baseline SFA 12 53300 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.66, 0.93]
1.47.1 up to 12%E SFA baseline 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
1.47.2 >12 to 15%E SFA baseline 5 51412 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.91, 1.03]
1.47.3 >15 to 18%E SFA baseline 1 55 Risk Ratio (M-H, Random, 95%
CI)
0.41 [0.22, 0.78]
1.47.4 >18%E SFA baseline 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.63, 1.00]
1.47.5 unclear 5 987 Risk Ratio (M-H, Random, 95%
CI)
0.72 [0.51, 1.03]
1.48 CVD events, subgroup by SFA change 12 53300 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.66, 0.93]
1.48.1 up to 4%E difference 4 51279 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.91, 1.03]
1.48.2 >4 to 8%E difference 2 188 Risk Ratio (M-H, Random, 95%
CI)
0.40 [0.22, 0.74]
1.48.3 >8%E difference 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.63, 1.00]
1.48.4 unclear 5 987 Risk Ratio (M-H, Random, 95%
CI)
0.72 [0.51, 1.03]
1.49 CVD events, subgroup by sex 12 53300 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.66, 0.93]
1.49.1 Men 8 3952 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.69, 0.93]
1.49.2 Women 1 48835 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.92, 1.04]
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1.49.3 Mixed, men and women 3 513 Risk Ratio (M-H, Random, 95%
CI)
0.59 [0.23, 1.49]
1.50 CVD events, subgroup by CVD risk 12 53300 Risk Ratio (M-H, Random, 95%
CI)
0.83 [0.72, 0.96]
1.50.1 Low CVD risk 3 47537 Risk Ratio (M-H, Random, 95%
CI)
0.89 [0.75, 1.06]
1.50.2 Moderate CVD risk 3 513 Risk Ratio (M-H, Random, 95%
CI)
0.59 [0.23, 1.49]
1.50.3 Existing CVD disease 7 5250 Risk Ratio (M-H, Random, 95%
CI)
0.86 [0.71, 1.05]
1.51 CVD events, subgroup by TC reduction 12   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.51.1 serum chol reduced by at least
0.2mmol/L
8 4117 Risk Ratio (M-H, Random, 95%
CI)
0.74 [0.59, 0.92]
1.51.2 serum chol reduced by <0.2mmol/L 3 49050 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.91, 1.04]
1.51.3 serum chol reduction unclear 1 133 Risk Ratio (M-H, Random, 95%
CI)
0.20 [0.01, 4.15]
1.52 CVD events, subgroup decade of publi-
cation
12 53300 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.66, 0.93]
1.52.1 1960s 5 1731 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.69, 0.91]
1.52.2 1970s 1 102 Risk Ratio (M-H, Random, 95%
CI)
0.27 [0.14, 0.52]
1.52.3 1980s 1 2033 Risk Ratio (M-H, Random, 95%
CI)
0.92 [0.74, 1.15]
1.52.4 1990s 2 188 Risk Ratio (M-H, Random, 95%
CI)
0.40 [0.22, 0.74]
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Heterogeneity: Tau² = 0.00; Chi² = 11.25, df = 11 (P = 0.42); I² = 2%
Test for overall effect: Z = 1.01 (P = 0.31)










































































M-H, Random, 95% CI
0.51 [0.05 , 5.46]
0.98 [0.76 , 1.25]
0.33 [0.07 , 1.61]
0.88 [0.55 , 1.41]
0.74 [0.54 , 1.02]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.35 [0.04 , 3.12]
1.49 [0.95 , 2.34]
0.98 [0.83 , 1.15]
0.98 [0.90 , 1.05]
0.90 [0.67 , 1.21]
0.96 [0.90 , 1.03]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
(2) All-cause mortality during trial, Chlebowski 2015
 
 
Analysis 1.2.   Comparison 1: SFA reduction vs usual diet - primary











Heterogeneity: Tau² = 0.01; Chi² = 9.25, df = 6 (P = 0.16); I² = 35%
Test for overall effect: Z = 0.77 (P = 0.44)

















































M-H, Random, 95% CI
0.33 [0.07 , 1.61]
0.74 [0.54 , 1.02]
0.35 [0.04 , 3.12]
1.49 [0.95 , 2.34]
0.98 [0.83 , 1.15]
0.98 [0.90 , 1.05]
0.90 [0.67 , 1.21]
0.95 [0.84 , 1.08]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
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Analysis 1.3.   Comparison 1: SFA reduction vs usual diet - primary













Heterogeneity: Tau² = 0.00; Chi² = 8.94, df = 8 (P = 0.35); I² = 11%
Test for overall effect: Z = 0.69 (P = 0.49)



























































M-H, Random, 95% CI
0.98 [0.76 , 1.25]
0.88 [0.55 , 1.41]
0.74 [0.54 , 1.02]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.35 [0.04 , 3.12]
1.49 [0.95 , 2.34]
0.98 [0.83 , 1.15]
0.98 [0.90 , 1.05]
0.97 [0.89 , 1.06]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
 
 
Analysis 1.4.   Comparison 1: SFA reduction vs usual diet - primary outcomes,












Heterogeneity: Tau² = 0.00; Chi² = 6.69, df = 7 (P = 0.46); I² = 0%
Test for overall effect: Z = 0.68 (P = 0.50)






















































M-H, Random, 95% CI
0.51 [0.05 , 5.46]
0.98 [0.76 , 1.25]
0.33 [0.07 , 1.61]
0.35 [0.04 , 3.12]
1.49 [0.95 , 2.34]
0.98 [0.83 , 1.15]
0.98 [0.90 , 1.05]
0.90 [0.67 , 1.21]
0.98 [0.92 , 1.04]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
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Analysis 1.5.   Comparison 1: SFA reduction vs usual diet - primary












Heterogeneity: Tau² = 0.00; Chi² = 8.79, df = 7 (P = 0.27); I² = 20%
Test for overall effect: Z = 0.63 (P = 0.53)






















































M-H, Random, 95% CI
0.98 [0.76 , 1.25]
0.88 [0.55 , 1.41]
0.74 [0.54 , 1.02]
5.31 [0.32 , 89.44]
0.35 [0.04 , 3.12]
1.49 [0.95 , 2.34]
0.98 [0.83 , 1.15]
0.98 [0.90 , 1.05]
0.97 [0.88 , 1.07]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
 
 
Analysis 1.6.   Comparison 1: SFA reduction vs usual diet - primary















Heterogeneity: Tau² = 0.00; Chi² = 11.10, df = 10 (P = 0.35); I² = 10%
Test for overall effect: Z = 0.87 (P = 0.39)





































































M-H, Random, 95% CI
0.51 [0.05 , 5.46]
0.98 [0.76 , 1.25]
0.33 [0.07 , 1.61]
0.88 [0.55 , 1.41]
0.74 [0.54 , 1.02]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.35 [0.04 , 3.12]
1.49 [0.95 , 2.34]
0.98 [0.83 , 1.15]
0.90 [0.67 , 1.21]
0.95 [0.83 , 1.07]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
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Analysis 1.7.   Comparison 1: SFA reduction vs usual diet - primary
















Heterogeneity: Chi² = 11.25, df = 11 (P = 0.42); I² = 2%
Test for overall effect: Z = 1.01 (P = 0.31)










































































M-H, Fixed, 95% CI
0.51 [0.05 , 5.46]
0.98 [0.76 , 1.25]
0.33 [0.07 , 1.61]
0.88 [0.55 , 1.41]
0.74 [0.54 , 1.02]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.35 [0.04 , 3.12]
1.49 [0.95 , 2.34]
0.98 [0.83 , 1.15]
0.98 [0.90 , 1.05]
0.90 [0.67 , 1.21]
0.97 [0.91 , 1.03]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
 
 
Analysis 1.8.   Comparison 1: SFA reduction vs usual diet - primary
















Heterogeneity: Chi² = 13.01, df = 11 (P = 0.29); I² = 15%
Test for overall effect: Z = 1.00 (P = 0.32)










































































Peto, Fixed, 95% CI
0.52 [0.05 , 5.05]
0.98 [0.74 , 1.29]
0.35 [0.09 , 1.45]
0.86 [0.50 , 1.50]
0.66 [0.43 , 1.02]
5.09 [0.70 , 37.06]
1.50 [0.17 , 13.11]
0.36 [0.05 , 2.71]
1.59 [0.95 , 2.68]
0.96 [0.73 , 1.27]
0.97 [0.90 , 1.06]
0.89 [0.65 , 1.22]
0.96 [0.90 , 1.04]
Peto Odds Ratio
Peto, Fixed, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
 
 
Reduction in saturated fat intake for cardiovascular disease (Review)









Cochrane Database of Systematic Reviews
Analysis 1.9.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 9: All-cause mortality, subgroup by any substitution
Study or Subgroup










Heterogeneity: Tau² = 0.01; Chi² = 8.06, df = 6 (P = 0.23); I² = 26%
Test for overall effect: Z = 0.46 (P = 0.64)





Test for overall effect: Z = 0.98 (P = 0.33)









Heterogeneity: Tau² = 0.00; Chi² = 3.19, df = 5 (P = 0.67); I² = 0%
Test for overall effect: Z = 0.91 (P = 0.36)








Heterogeneity: Tau² = 0.00; Chi² = 2.34, df = 4 (P = 0.67); I² = 0%





Test for overall effect: Not applicable
































































































































M-H, Random, 95% CI
0.98 [0.76 , 1.25]
0.88 [0.55 , 1.41]
0.74 [0.54 , 1.02]
2.32 [0.30 , 17.92]
0.35 [0.04 , 3.12]
1.49 [0.95 , 2.34]
0.98 [0.83 , 1.15]
0.96 [0.82 , 1.13]
3.00 [0.33 , 26.99]
3.00 [0.33 , 26.99]
0.51 [0.05 , 5.46]
0.98 [0.76 , 1.25]
0.33 [0.07 , 1.61]
0.35 [0.04 , 3.12]
0.98 [0.90 , 1.05]
0.90 [0.67 , 1.21]
0.97 [0.90 , 1.04]
0.51 [0.05 , 5.46]
0.98 [0.76 , 1.25]
0.33 [0.07 , 1.61]
0.98 [0.90 , 1.05]
0.90 [0.67 , 1.21]
0.97 [0.90 , 1.04]
Not estimable
Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
(2) All-cause mortality during trial, Chlebowski 2015
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Analysis 1.10.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 10: All-cause mortality, subgroup by main substitution
Study or Subgroup









Heterogeneity: Tau² = 0.01; Chi² = 7.23, df = 5 (P = 0.20); I² = 31%
Test for overall effect: Z = 0.39 (P = 0.70)





Test for overall effect: Z = 0.98 (P = 0.33)








Heterogeneity: Tau² = 0.00; Chi² = 3.17, df = 4 (P = 0.53); I² = 0%
Test for overall effect: Z = 0.90 (P = 0.37)









Test for overall effect: Not applicable




























































































M-H, Random, 95% CI
0.98 [0.76 , 1.25]
0.88 [0.55 , 1.41]
0.74 [0.54 , 1.02]
2.32 [0.30 , 17.92]
1.49 [0.95 , 2.34]
0.98 [0.83 , 1.15]
0.97 [0.82 , 1.14]
3.00 [0.33 , 26.99]
3.00 [0.33 , 26.99]
0.51 [0.05 , 5.46]
0.33 [0.07 , 1.61]
0.35 [0.04 , 3.12]
0.98 [0.90 , 1.05]
0.90 [0.67 , 1.21]




M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
(2) All-cause mortality during trial, Chlebowski 2015
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Analysis 1.11.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 11: All-cause mortality, subgroup by duration
Study or Subgroup
1.11.1 up to 24mo
Black 1994
DART 1989




Heterogeneity: Tau² = 0.00; Chi² = 1.82, df = 3 (P = 0.61); I² = 0%
Test for overall effect: Z = 0.08 (P = 0.94)






Heterogeneity: Tau² = 0.00; Chi² = 1.02, df = 2 (P = 0.60); I² = 0%








Heterogeneity: Tau² = 0.02; Chi² = 6.63, df = 3 (P = 0.08); I² = 55%






Test for overall effect: Z = 1.37 (P = 0.17)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 11.25, df = 11 (P = 0.42); I² = 2%
Test for overall effect: Z = 1.01 (P = 0.31)






























































































M-H, Random, 95% CI
0.51 [0.05 , 5.46]
0.98 [0.76 , 1.25]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.99 [0.78 , 1.26]
0.88 [0.55 , 1.41]
0.35 [0.04 , 3.12]
0.98 [0.83 , 1.15]
0.96 [0.83 , 1.12]
0.74 [0.54 , 1.02]
1.49 [0.95 , 2.34]
0.98 [0.90 , 1.05]
0.90 [0.67 , 1.21]
0.96 [0.79 , 1.16]
0.33 [0.07 , 1.61]
0.33 [0.07 , 1.61]
0.96 [0.90 , 1.03]
Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
(2) All-cause mortality during trial, Chlebowski 2015
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Analysis 1.12.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 12: All-cause mortality, subgroup by baseline SFA
Study or Subgroup





Test for overall effect: Z = 0.71 (P = 0.48)








Heterogeneity: Tau² = 0.01; Chi² = 5.48, df = 4 (P = 0.24); I² = 27%
Test for overall effect: Z = 0.11 (P = 0.92)





Test for overall effect: Z = 0.95 (P = 0.34)













Heterogeneity: Tau² = 0.00; Chi² = 2.50, df = 3 (P = 0.47); I² = 0%
Test for overall effect: Z = 1.67 (P = 0.10)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 11.25, df = 11 (P = 0.42); I² = 2%
Test for overall effect: Z = 1.01 (P = 0.31)



































































































M-H, Random, 95% CI
0.90 [0.67 , 1.21]
0.90 [0.67 , 1.21]
0.51 [0.05 , 5.46]
0.98 [0.76 , 1.25]
0.33 [0.07 , 1.61]
1.49 [0.95 , 2.34]
0.98 [0.90 , 1.05]
1.01 [0.86 , 1.19]
0.35 [0.04 , 3.12]
0.35 [0.04 , 3.12]
0.98 [0.83 , 1.15]
0.98 [0.83 , 1.15]
0.88 [0.55 , 1.41]
0.74 [0.54 , 1.02]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.80 [0.62 , 1.04]
0.96 [0.90 , 1.03]
Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause mortality during trial, Chlebowski 2015
(2) All-cause death during study, Prentice 2017
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Analysis 1.13.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 13: All-cause mortality, subgroup by SFA change
Study or Subgroup








Heterogeneity: Tau² = 0.01; Chi² = 5.53, df = 4 (P = 0.24); I² = 28%
Test for overall effect: Z = 0.17 (P = 0.87)





Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 1 (P = 0.82); I² = 0%














Heterogeneity: Tau² = 0.00; Chi² = 2.50, df = 3 (P = 0.47); I² = 0%
Test for overall effect: Z = 1.67 (P = 0.10)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 11.25, df = 11 (P = 0.42); I² = 2%
Test for overall effect: Z = 1.01 (P = 0.31)






























































































M-H, Random, 95% CI
0.98 [0.76 , 1.25]
0.33 [0.07 , 1.61]
1.49 [0.95 , 2.34]
0.98 [0.90 , 1.05]
0.90 [0.67 , 1.21]
0.99 [0.86 , 1.13]
0.51 [0.05 , 5.46]
0.35 [0.04 , 3.12]
0.41 [0.08 , 2.07]
0.98 [0.83 , 1.15]
0.98 [0.83 , 1.15]
0.88 [0.55 , 1.41]
0.74 [0.54 , 1.02]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.80 [0.62 , 1.04]
0.96 [0.90 , 1.03]
Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
(2) All-cause mortality during trial, Chlebowski 2015
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Analysis 1.14.   Comparison 1: SFA reduction vs usual diet - primary














Heterogeneity: Tau² = 0.01; Chi² = 9.20, df = 8 (P = 0.33); I² = 13%






Heterogeneity: Tau² = 0.00; Chi² = 0.28, df = 1 (P = 0.59); I² = 0%
Test for overall effect: Z = 0.79 (P = 0.43)





Test for overall effect: Z = 1.37 (P = 0.17)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 11.25, df = 11 (P = 0.42); I² = 2%
Test for overall effect: Z = 1.01 (P = 0.31)

























































































M-H, Random, 95% CI
0.51 [0.05 , 5.46]
0.98 [0.76 , 1.25]
0.88 [0.55 , 1.41]
0.74 [0.54 , 1.02]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.35 [0.04 , 3.12]
1.49 [0.95 , 2.34]
0.98 [0.83 , 1.15]
0.96 [0.83 , 1.11]
0.98 [0.90 , 1.05]
0.90 [0.67 , 1.21]
0.97 [0.90 , 1.05]
0.33 [0.07 , 1.61]
0.33 [0.07 , 1.61]
0.96 [0.90 , 1.03]
Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
(2) All-cause mortality during trial, Chlebowski 2015
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Analysis 1.15.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 15: All-cause mortality, subgroup by CVD risk
Study or Subgroup







Heterogeneity: Tau² = 0.00; Chi² = 0.58, df = 3 (P = 0.90); I² = 0%
Test for overall effect: Z = 0.84 (P = 0.40)





Test for overall effect: Z = 1.37 (P = 0.17)










Heterogeneity: Tau² = 0.03; Chi² = 8.89, df = 6 (P = 0.18); I² = 33%
Test for overall effect: Z = 0.26 (P = 0.79)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 11.25, df = 11 (P = 0.42); I² = 2%
Test for overall effect: Z = 1.01 (P = 0.31)

























































































M-H, Random, 95% CI
0.51 [0.05 , 5.46]
0.98 [0.83 , 1.15]
0.98 [0.90 , 1.05]
0.90 [0.67 , 1.21]
0.97 [0.91 , 1.04]
0.33 [0.07 , 1.61]
0.33 [0.07 , 1.61]
0.98 [0.76 , 1.25]
0.88 [0.55 , 1.41]
0.74 [0.54 , 1.02]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.35 [0.04 , 3.12]
1.49 [0.95 , 2.34]
0.97 [0.76 , 1.24]
0.96 [0.90 , 1.03]
Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
(2) All-cause mortality during trial, Chlebowski 2015
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Analysis 1.16.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 16: All-cause mortality, subgroup by TC reduction
Study or Subgroup










Heterogeneity: Tau² = 0.01; Chi² = 8.76, df = 6 (P = 0.19); I² = 32%
Test for overall effect: Z = 0.42 (P = 0.67)







Heterogeneity: Tau² = 0.00; Chi² = 2.21, df = 3 (P = 0.53); I² = 0%
Test for overall effect: Z = 0.84 (P = 0.40)





Test for overall effect: Z = 0.56 (P = 0.58)




















































































M-H, Random, 95% CI
0.98 [0.76 , 1.25]
0.88 [0.55 , 1.41]
0.74 [0.54 , 1.02]
5.31 [0.32 , 89.44]
0.35 [0.04 , 3.12]
1.49 [0.95 , 2.34]
0.98 [0.83 , 1.15]
0.96 [0.81 , 1.14]
0.33 [0.07 , 1.61]
1.50 [0.17 , 13.05]
0.98 [0.90 , 1.05]
0.90 [0.67 , 1.21]
0.97 [0.90 , 1.04]
0.51 [0.05 , 5.46]
0.51 [0.05 , 5.46]
Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
(2) All-cause mortality during trial, Chlebowski 2015
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Analysis 1.17.   Comparison 1: SFA reduction vs usual diet - primary










Heterogeneity: Tau² = 0.00; Chi² = 4.09, df = 4 (P = 0.39); I² = 2%


















Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 1 (P = 0.82); I² = 0%







Heterogeneity: Tau² = 0.00; Chi² = 2.05, df = 2 (P = 0.36); I² = 3%
Test for overall effect: Z = 0.79 (P = 0.43)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 11.25, df = 11 (P = 0.42); I² = 2%
Test for overall effect: Z = 1.01 (P = 0.31)



































































































M-H, Random, 95% CI
0.88 [0.55 , 1.41]
0.74 [0.54 , 1.02]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.98 [0.83 , 1.15]
0.92 [0.80 , 1.07]
1.49 [0.95 , 2.34]
1.49 [0.95 , 2.34]
0.98 [0.76 , 1.25]
0.98 [0.76 , 1.25]
0.51 [0.05 , 5.46]
0.35 [0.04 , 3.12]
0.41 [0.08 , 2.07]
0.33 [0.07 , 1.61]
0.98 [0.90 , 1.05]
0.90 [0.67 , 1.21]
0.97 [0.88 , 1.05]
0.96 [0.90 , 1.03]
Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours lower SFA Favours higher SFA
Footnotes
(1) All-cause death during study, Prentice 2017
(2) All-cause mortality during trial, Chlebowski 2015
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Analysis 1.18.   Comparison 1: SFA reduction vs usual diet -















Heterogeneity: Tau² = 0.03; Chi² = 15.67, df = 10 (P = 0.11); I² = 36%
Test for overall effect: Z = 0.68 (P = 0.49)





































































M-H, Random, 95% CI
0.20 [0.01 , 4.15]
1.01 [0.77 , 1.31]
0.25 [0.03 , 2.19]
1.05 [0.63 , 1.75]
0.73 [0.50 , 1.06]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.35 [0.04 , 3.12]
1.59 [0.99 , 2.55]
0.70 [0.51 , 0.96]
1.00 [0.84 , 1.19]
0.94 [0.78 , 1.13]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) In participants with and without CVD at baseline
 
 
Analysis 1.19.   Comparison 1: SFA reduction vs usual diet - primary








Heterogeneity: Tau² = 0.08; Chi² = 9.96, df = 3 (P = 0.02); I² = 70%
Test for overall effect: Z = 0.21 (P = 0.83)


































M-H, Random, 95% CI
0.25 [0.03 , 2.19]
1.59 [0.99 , 2.55]
0.70 [0.51 , 0.96]
1.00 [0.84 , 1.19]
0.96 [0.67 , 1.38]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) In participants with and without CVD at baseline
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Analysis 1.20.   Comparison 1: SFA reduction vs usual diet - primary













Heterogeneity: Tau² = 0.03; Chi² = 13.22, df = 8 (P = 0.10); I² = 39%
Test for overall effect: Z = 0.54 (P = 0.59)



























































M-H, Random, 95% CI
1.01 [0.77 , 1.31]
1.05 [0.63 , 1.75]
0.73 [0.50 , 1.06]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.35 [0.04 , 3.12]
1.59 [0.99 , 2.55]
0.70 [0.51 , 0.96]
1.00 [0.84 , 1.19]
0.95 [0.79 , 1.14]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) In participants with and without CVD at baseline
 
 
Analysis 1.21.   Comparison 1: SFA reduction vs usual diet - primary outcomes,











Heterogeneity: Tau² = 0.04; Chi² = 11.92, df = 6 (P = 0.06); I² = 50%
Test for overall effect: Z = 0.40 (P = 0.69)

















































M-H, Random, 95% CI
0.20 [0.01 , 4.15]
1.01 [0.77 , 1.31]
0.25 [0.03 , 2.19]
0.35 [0.04 , 3.12]
1.59 [0.99 , 2.55]
0.70 [0.51 , 0.96]
1.00 [0.84 , 1.19]
0.95 [0.75 , 1.21]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) In participants with and without CVD at baseline
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Analysis 1.22.   Comparison 1: SFA reduction vs usual diet -












Heterogeneity: Tau² = 0.03; Chi² = 13.05, df = 7 (P = 0.07); I² = 46%
Test for overall effect: Z = 0.54 (P = 0.59)






















































M-H, Random, 95% CI
1.01 [0.77 , 1.31]
1.05 [0.63 , 1.75]
0.73 [0.50 , 1.06]
5.31 [0.32 , 89.44]
0.35 [0.04 , 3.12]
1.59 [0.99 , 2.55]
0.70 [0.51 , 0.96]
1.00 [0.84 , 1.19]
0.95 [0.78 , 1.15]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) In participants with and without CVD at baseline
 
 
Analysis 1.23.   Comparison 1: SFA reduction vs usual diet -














Heterogeneity: Tau² = 0.05; Chi² = 15.03, df = 9 (P = 0.09); I² = 40%
Test for overall effect: Z = 0.65 (P = 0.52)
































































M-H, Random, 95% CI
0.20 [0.01 , 4.15]
1.01 [0.77 , 1.31]
0.25 [0.03 , 2.19]
1.05 [0.63 , 1.75]
0.73 [0.50 , 1.06]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.35 [0.04 , 3.12]
1.59 [0.99 , 2.55]
0.70 [0.51 , 0.96]
0.92 [0.72 , 1.18]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
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Analysis 1.24.   Comparison 1: SFA reduction vs usual diet - primary















Heterogeneity: Chi² = 15.67, df = 10 (P = 0.11); I² = 36%
Test for overall effect: Z = 0.83 (P = 0.41)





































































M-H, Fixed, 95% CI
0.20 [0.01 , 4.15]
1.01 [0.77 , 1.31]
0.25 [0.03 , 2.19]
1.05 [0.63 , 1.75]
0.73 [0.50 , 1.06]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.35 [0.04 , 3.12]
1.59 [0.99 , 2.55]
0.70 [0.51 , 0.96]
1.00 [0.84 , 1.19]
0.95 [0.85 , 1.07]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) In participants with and without CVD at baseline
 
 
Analysis 1.25.   Comparison 1: SFA reduction vs usual diet - primary















Heterogeneity: Chi² = 18.54, df = 10 (P = 0.05); I² = 46%
Test for overall effect: Z = 0.82 (P = 0.41)





































































Peto, Fixed, 95% CI
0.14 [0.01 , 2.19]
1.01 [0.75 , 1.35]
0.29 [0.05 , 1.73]
1.06 [0.59 , 1.90]
0.67 [0.42 , 1.07]
5.09 [0.70 , 37.06]
1.50 [0.17 , 13.11]
0.36 [0.05 , 2.71]
1.70 [0.99 , 2.90]
0.66 [0.46 , 0.95]
1.00 [0.84 , 1.19]
0.95 [0.84 , 1.08]
Peto Odds Ratio
Peto, Fixed, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) In participants with and without CVD at baseline
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Analysis 1.26.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 26: CVD mortality, subgroup by any substitution
Study or Subgroup










Heterogeneity: Tau² = 0.06; Chi² = 13.37, df = 6 (P = 0.04); I² = 55%
Test for overall effect: Z = 0.34 (P = 0.73)





Test for overall effect: Z = 0.98 (P = 0.33)








Heterogeneity: Tau² = 0.00; Chi² = 3.51, df = 4 (P = 0.48); I² = 0%
Test for overall effect: Z = 0.19 (P = 0.85)







Heterogeneity: Tau² = 0.00; Chi² = 2.63, df = 3 (P = 0.45); I² = 0%





Test for overall effect: Not applicable






















































































































M-H, Random, 95% CI
1.01 [0.77 , 1.31]
1.05 [0.63 , 1.75]
0.73 [0.50 , 1.06]
4.64 [0.58 , 37.15]
0.35 [0.04 , 3.12]
1.59 [0.99 , 2.55]
0.70 [0.51 , 0.96]
0.95 [0.73 , 1.25]
3.00 [0.33 , 26.99]
3.00 [0.33 , 26.99]
0.20 [0.01 , 4.15]
1.01 [0.77 , 1.31]
0.25 [0.03 , 2.19]
0.35 [0.04 , 3.12]
1.00 [0.84 , 1.19]
0.99 [0.85 , 1.14]
0.20 [0.01 , 4.15]
1.01 [0.77 , 1.31]
0.25 [0.03 , 2.19]
1.00 [0.84 , 1.19]
0.99 [0.86 , 1.14]
Not estimable
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Women with and without CVD at baseline
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Analysis 1.27.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 27: CVD mortality, subgroup by main substitution
Study or Subgroup









Heterogeneity: Tau² = 0.06; Chi² = 12.62, df = 5 (P = 0.03); I² = 60%
Test for overall effect: Z = 0.22 (P = 0.82)





Test for overall effect: Z = 0.98 (P = 0.33)







Heterogeneity: Tau² = 0.12; Chi² = 3.47, df = 3 (P = 0.32); I² = 14%
Test for overall effect: Z = 0.78 (P = 0.43)









Test for overall effect: Not applicable























































































M-H, Random, 95% CI
1.01 [0.77 , 1.31]
1.05 [0.63 , 1.75]
0.73 [0.50 , 1.06]
4.64 [0.58 , 37.15]
1.59 [0.99 , 2.55]
0.70 [0.51 , 0.96]
0.97 [0.73 , 1.28]
3.00 [0.33 , 26.99]
3.00 [0.33 , 26.99]
0.20 [0.01 , 4.15]
0.25 [0.03 , 2.19]
0.35 [0.04 , 3.12]
1.00 [0.84 , 1.19]




M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Women with and without CVD at baseline
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Analysis 1.28.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 28: CVD mortality, subgroup by duration
Study or Subgroup
1.28.1 up to 24mo
Black 1994
DART 1989




Heterogeneity: Tau² = 0.26; Chi² = 4.07, df = 3 (P = 0.25); I² = 26%
Test for overall effect: Z = 0.54 (P = 0.59)






Heterogeneity: Tau² = 0.01; Chi² = 2.33, df = 2 (P = 0.31); I² = 14%







Heterogeneity: Tau² = 0.06; Chi² = 6.40, df = 2 (P = 0.04); I² = 69%






Test for overall effect: Z = 1.25 (P = 0.21)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.04; Chi² = 17.36, df = 10 (P = 0.07); I² = 42%
Test for overall effect: Z = 0.53 (P = 0.60)

























































































M-H, Random, 95% CI
0.20 [0.01 , 4.15]
1.01 [0.77 , 1.31]
4.64 [0.58 , 37.15]
3.00 [0.33 , 26.99]
1.26 [0.54 , 2.94]
1.05 [0.63 , 1.75]
0.35 [0.04 , 3.12]
0.70 [0.51 , 0.96]
0.79 [0.57 , 1.08]
0.73 [0.50 , 1.06]
1.59 [0.99 , 2.55]
1.00 [0.84 , 1.19]
1.02 [0.73 , 1.43]
0.25 [0.03 , 2.19]
0.25 [0.03 , 2.19]
0.95 [0.78 , 1.16]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Women with and without CVD at baseline
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Analysis 1.29.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 29: CVD mortality, subgroup by baseline SFA
Study or Subgroup




Test for overall effect: Not applicable








Heterogeneity: Tau² = 0.02; Chi² = 6.12, df = 4 (P = 0.19); I² = 35%
Test for overall effect: Z = 0.48 (P = 0.63)





Test for overall effect: Z = 0.95 (P = 0.34)













Heterogeneity: Tau² = 0.10; Chi² = 5.16, df = 3 (P = 0.16); I² = 42%
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.04; Chi² = 17.36, df = 10 (P = 0.07); I² = 42%
Test for overall effect: Z = 0.53 (P = 0.60)





























































































M-H, Random, 95% CI
Not estimable
0.20 [0.01 , 4.15]
1.01 [0.77 , 1.31]
0.25 [0.03 , 2.19]
1.59 [0.99 , 2.55]
1.00 [0.84 , 1.19]
1.06 [0.84 , 1.32]
0.35 [0.04 , 3.12]
0.35 [0.04 , 3.12]
0.70 [0.51 , 0.96]
0.70 [0.51 , 0.96]
1.05 [0.63 , 1.75]
0.73 [0.50 , 1.06]
4.64 [0.58 , 37.15]
3.00 [0.33 , 26.99]
1.00 [0.61 , 1.66]
0.95 [0.78 , 1.16]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Women with and without CVD at baseline
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Analysis 1.30.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 30: CVD mortality, subgroup by SFA change
Study or Subgroup







Heterogeneity: Tau² = 0.02; Chi² = 5.00, df = 3 (P = 0.17); I² = 40%
Test for overall effect: Z = 0.56 (P = 0.57)





Heterogeneity: Tau² = 0.00; Chi² = 0.08, df = 1 (P = 0.78); I² = 0%














Heterogeneity: Tau² = 0.10; Chi² = 5.16, df = 3 (P = 0.16); I² = 42%
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.04; Chi² = 17.36, df = 10 (P = 0.07); I² = 42%
Test for overall effect: Z = 0.53 (P = 0.60)

























































































M-H, Random, 95% CI
1.01 [0.77 , 1.31]
0.25 [0.03 , 2.19]
1.59 [0.99 , 2.55]
1.00 [0.84 , 1.19]
1.07 [0.85 , 1.33]
0.20 [0.01 , 4.15]
0.35 [0.04 , 3.12]
0.29 [0.05 , 1.70]
0.70 [0.51 , 0.96]
0.70 [0.51 , 0.96]
1.05 [0.63 , 1.75]
0.73 [0.50 , 1.06]
4.64 [0.58 , 37.15]
3.00 [0.33 , 26.99]
1.00 [0.61 , 1.66]
0.95 [0.78 , 1.16]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Women with and without CVD at baseline
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Analysis 1.31.   Comparison 1: SFA reduction vs usual diet -














Heterogeneity: Tau² = 0.06; Chi² = 15.45, df = 8 (P = 0.05); I² = 48%






Test for overall effect: Z = 0.02 (P = 0.98)





Test for overall effect: Z = 1.25 (P = 0.21)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.04; Chi² = 17.36, df = 10 (P = 0.07); I² = 42%
Test for overall effect: Z = 0.53 (P = 0.60)




















































































M-H, Random, 95% CI
0.20 [0.01 , 4.15]
1.01 [0.77 , 1.31]
1.05 [0.63 , 1.75]
0.73 [0.50 , 1.06]
4.64 [0.58 , 37.15]
3.00 [0.33 , 26.99]
0.35 [0.04 , 3.12]
1.59 [0.99 , 2.55]
0.70 [0.51 , 0.96]
0.96 [0.73 , 1.25]
1.00 [0.84 , 1.19]
1.00 [0.84 , 1.19]
0.25 [0.03 , 2.19]
0.25 [0.03 , 2.19]
0.95 [0.78 , 1.16]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Women with and without CVD at baseline
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Analysis 1.32.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 32: CVD mortality, subgroup by CVD risk
Study or Subgroup






Heterogeneity: Tau² = 0.04; Chi² = 4.33, df = 2 (P = 0.11); I² = 54%
Test for overall effect: Z = 1.06 (P = 0.29)





Test for overall effect: Z = 1.25 (P = 0.21)











Heterogeneity: Tau² = 0.03; Chi² = 10.41, df = 7 (P = 0.17); I² = 33%
Test for overall effect: Z = 0.37 (P = 0.71)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.03; Chi² = 17.45, df = 11 (P = 0.10); I² = 37%
Test for overall effect: Z = 0.50 (P = 0.61)

























































































M-H, Random, 95% CI
0.20 [0.01 , 4.15]
0.70 [0.51 , 0.96]
0.99 [0.81 , 1.20]
0.84 [0.60 , 1.16]
0.25 [0.03 , 2.19]
0.25 [0.03 , 2.19]
1.01 [0.77 , 1.31]
1.05 [0.63 , 1.75]
0.73 [0.50 , 1.06]
4.64 [0.58 , 37.15]
3.00 [0.33 , 26.99]
0.35 [0.04 , 3.12]
1.59 [0.99 , 2.55]
1.05 [0.72 , 1.53]
1.04 [0.83 , 1.31]
0.96 [0.80 , 1.14]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Women without CVD at baseline
(2) Women with CVD at baseline
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Analysis 1.33.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 33: CVD mortality, subgroup by TC reduction
Study or Subgroup










Heterogeneity: Tau² = 0.06; Chi² = 13.37, df = 6 (P = 0.04); I² = 55%
Test for overall effect: Z = 0.34 (P = 0.73)






Heterogeneity: Tau² = 0.16; Chi² = 2.53, df = 2 (P = 0.28); I² = 21%
Test for overall effect: Z = 0.09 (P = 0.93)





Test for overall effect: Z = 1.04 (P = 0.30)















































































M-H, Random, 95% CI
1.01 [0.77 , 1.31]
1.05 [0.63 , 1.75]
0.73 [0.50 , 1.06]
4.64 [0.58 , 37.15]
0.35 [0.04 , 3.12]
1.59 [0.99 , 2.55]
0.70 [0.51 , 0.96]
0.95 [0.73 , 1.25]
0.25 [0.03 , 2.19]
3.00 [0.33 , 26.99]
1.00 [0.84 , 1.19]
0.97 [0.47 , 2.01]
0.20 [0.01 , 4.15]
0.20 [0.01 , 4.15]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Women with and without CVD at baseline
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Analysis 1.34.   Comparison 1: SFA reduction vs usual diet - primary










Heterogeneity: Tau² = 0.00; Chi² = 4.07, df = 4 (P = 0.40); I² = 2%


















Heterogeneity: Tau² = 0.00; Chi² = 0.08, df = 1 (P = 0.78); I² = 0%






Heterogeneity: Tau² = 0.34; Chi² = 1.55, df = 1 (P = 0.21); I² = 36%
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.03; Chi² = 15.67, df = 10 (P = 0.11); I² = 36%
Test for overall effect: Z = 0.68 (P = 0.49)






























































































M-H, Random, 95% CI
1.05 [0.63 , 1.75]
0.73 [0.50 , 1.06]
5.31 [0.32 , 89.44]
1.50 [0.17 , 13.05]
0.70 [0.51 , 0.96]
0.78 [0.63 , 0.97]
1.59 [0.99 , 2.55]
1.59 [0.99 , 2.55]
1.01 [0.77 , 1.31]
1.01 [0.77 , 1.31]
0.20 [0.01 , 4.15]
0.35 [0.04 , 3.12]
0.29 [0.05 , 1.70]
0.25 [0.03 , 2.19]
1.00 [0.84 , 1.19]
0.78 [0.27 , 2.21]
0.94 [0.78 , 1.13]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Women with and without CVD at baseline
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Analysis 1.35.   Comparison 1: SFA reduction vs usual diet - primary
















Heterogeneity: Tau² = 0.04; Chi² = 31.72, df = 11 (P = 0.0008); I² = 65%
Test for overall effect: Z = 2.72 (P = 0.006)










































































M-H, Random, 95% CI
0.20 [0.01 , 4.15]
0.92 [0.74 , 1.15]
0.27 [0.14 , 0.52]
0.69 [0.34 , 1.40]
0.82 [0.62 , 1.07]
1.68 [0.41 , 6.87]
0.71 [0.55 , 0.92]
1.16 [0.59 , 2.29]
1.10 [0.48 , 2.50]
0.41 [0.22 , 0.78]
0.79 [0.63 , 1.00]
0.98 [0.92 , 1.04]
0.79 [0.66 , 0.93]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
 
 
Analysis 1.36.   Comparison 1: SFA reduction vs usual diet - primary







Heterogeneity: Tau² = 0.01; Chi² = 3.88, df = 2 (P = 0.14); I² = 48%
Test for overall effect: Z = 1.21 (P = 0.23)





























M-H, Random, 95% CI
0.69 [0.34 , 1.40]
0.79 [0.63 , 1.00]
0.98 [0.92 , 1.04]
0.89 [0.75 , 1.07]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
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Analysis 1.37.   Comparison 1: SFA reduction vs usual diet -














Heterogeneity: Tau² = 0.04; Chi² = 30.07, df = 9 (P = 0.0004); I² = 70%
Test for overall effect: Z = 2.51 (P = 0.01)
































































M-H, Random, 95% CI
0.92 [0.74 , 1.15]
0.27 [0.14 , 0.52]
0.82 [0.62 , 1.07]
1.68 [0.41 , 6.87]
0.71 [0.55 , 0.92]
1.16 [0.59 , 2.29]
1.10 [0.48 , 2.50]
0.41 [0.22 , 0.78]
0.79 [0.63 , 1.00]
0.98 [0.92 , 1.04]
0.79 [0.66 , 0.95]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
 
 
Analysis 1.38.   Comparison 1: SFA reduction vs usual diet - primary











Heterogeneity: Tau² = 0.02; Chi² = 12.43, df = 6 (P = 0.05); I² = 52%
Test for overall effect: Z = 1.77 (P = 0.08)

















































M-H, Random, 95% CI
0.20 [0.01 , 4.15]
0.92 [0.74 , 1.15]
0.69 [0.34 , 1.40]
1.68 [0.41 , 6.87]
0.41 [0.22 , 0.78]
0.79 [0.63 , 1.00]
0.98 [0.92 , 1.04]
0.85 [0.71 , 1.02]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
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Analysis 1.39.   Comparison 1: SFA reduction vs usual diet -













Heterogeneity: Tau² = 0.04; Chi² = 29.91, df = 8 (P = 0.0002); I² = 73%
Test for overall effect: Z = 2.58 (P = 0.010)



























































M-H, Random, 95% CI
0.92 [0.74 , 1.15]
0.27 [0.14 , 0.52]
0.82 [0.62 , 1.07]
1.68 [0.41 , 6.87]
0.71 [0.55 , 0.92]
1.16 [0.59 , 2.29]
0.41 [0.22 , 0.78]
0.79 [0.63 , 1.00]
0.98 [0.92 , 1.04]
0.78 [0.65 , 0.94]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
 
 
Analysis 1.40.   Comparison 1: SFA reduction vs usual diet -















Heterogeneity: Tau² = 0.04; Chi² = 20.51, df = 10 (P = 0.02); I² = 51%
Test for overall effect: Z = 2.93 (P = 0.003)





































































M-H, Random, 95% CI
0.20 [0.01 , 4.15]
0.92 [0.74 , 1.15]
0.27 [0.14 , 0.52]
0.69 [0.34 , 1.40]
0.82 [0.62 , 1.07]
1.68 [0.41 , 6.87]
0.71 [0.55 , 0.92]
1.16 [0.59 , 2.29]
1.10 [0.48 , 2.50]
0.41 [0.22 , 0.78]
0.79 [0.63 , 1.00]
0.75 [0.61 , 0.91]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
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Analysis 1.41.   Comparison 1: SFA reduction vs usual diet - primary
















Heterogeneity: Chi² = 31.72, df = 11 (P = 0.0008); I² = 65%
Test for overall effect: Z = 2.44 (P = 0.01)










































































M-H, Fixed, 95% CI
0.20 [0.01 , 4.15]
0.92 [0.74 , 1.15]
0.27 [0.14 , 0.52]
0.69 [0.34 , 1.40]
0.82 [0.62 , 1.07]
1.68 [0.41 , 6.87]
0.71 [0.55 , 0.92]
1.16 [0.59 , 2.29]
1.10 [0.48 , 2.50]
0.41 [0.22 , 0.78]
0.79 [0.63 , 1.00]
0.98 [0.92 , 1.04]
0.93 [0.88 , 0.99]
Risk Ratio
M-H, Fixed, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
 
 
Analysis 1.42.   Comparison 1: SFA reduction vs usual diet -
















Heterogeneity: Chi² = 41.53, df = 11 (P < 0.0001); I² = 74%
Test for overall effect: Z = 2.44 (P = 0.01)










































































Peto, Fixed, 95% CI
0.14 [0.01 , 2.19]
0.91 [0.71 , 1.17]
0.16 [0.07 , 0.36]
0.65 [0.29 , 1.47]
0.73 [0.49 , 1.11]
1.69 [0.41 , 6.90]
0.58 [0.39 , 0.87]
1.34 [0.36 , 4.90]
1.17 [0.31 , 4.44]
0.19 [0.07 , 0.55]
0.73 [0.54 , 0.99]
0.98 [0.91 , 1.05]
0.92 [0.87 , 0.98]
Peto Odds Ratio
Peto, Fixed, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
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Analysis 1.43.   Comparison 1: SFA reduction vs usual diet - primary outcomes,













Heterogeneity: Tau² = 0.04; Chi² = 15.39, df = 8 (P = 0.05); I² = 48%
Test for overall effect: Z = 2.01 (P = 0.04)



























































M-H, Random, 95% CI
0.20 [0.01 , 4.15]
0.92 [0.74 , 1.15]
0.27 [0.14 , 0.52]
0.69 [0.34 , 1.40]
0.82 [0.62 , 1.07]
1.68 [0.41 , 6.87]
1.16 [0.59 , 2.29]
1.10 [0.48 , 2.50]
0.79 [0.63 , 1.00]
0.80 [0.64 , 0.99]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
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Analysis 1.44.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 44: CVD events, subgroup by any substitution
Study or Subgroup










Heterogeneity: Tau² = 0.06; Chi² = 19.30, df = 6 (P = 0.004); I² = 69%
Test for overall effect: Z = 2.68 (P = 0.007)





Test for overall effect: Z = 0.00 (P = 1.00)








Heterogeneity: Tau² = 0.03; Chi² = 9.20, df = 4 (P = 0.06); I² = 57%
Test for overall effect: Z = 1.46 (P = 0.14)







Heterogeneity: Tau² = 0.00; Chi² = 2.20, df = 3 (P = 0.53); I² = 0%






Test for overall effect: Z = 0.72 (P = 0.47)




























































































































M-H, Random, 95% CI
0.92 [0.74 , 1.15]
0.27 [0.14 , 0.52]
0.82 [0.62 , 1.07]
0.71 [0.55 , 0.92]
1.27 [0.72 , 2.23]
0.41 [0.22 , 0.78]
0.79 [0.63 , 1.00]
0.73 [0.58 , 0.92]
1.00 [0.53 , 1.89]
1.00 [0.53 , 1.89]
0.20 [0.01 , 4.15]
0.92 [0.74 , 1.15]
0.69 [0.34 , 1.40]
0.41 [0.22 , 0.78]
0.98 [0.92 , 1.04]
0.84 [0.67 , 1.06]
0.20 [0.01 , 4.15]
0.92 [0.74 , 1.15]
0.69 [0.34 , 1.40]
0.98 [0.92 , 1.04]
0.97 [0.91 , 1.03]
1.68 [0.41 , 6.87]
1.68 [0.41 , 6.87]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
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Analysis 1.45.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 45: CVD events, subgroup by main substitution
Study or Subgroup









Heterogeneity: Tau² = 0.05; Chi² = 15.17, df = 5 (P = 0.010); I² = 67%
Test for overall effect: Z = 2.25 (P = 0.02)





Test for overall effect: Z = 0.00 (P = 1.00)







Heterogeneity: Tau² = 0.17; Chi² = 9.04, df = 3 (P = 0.03); I² = 67%
Test for overall effect: Z = 1.44 (P = 0.15)










Test for overall effect: Z = 0.72 (P = 0.47)





























































































M-H, Random, 95% CI
0.92 [0.74 , 1.15]
0.27 [0.14 , 0.52]
0.82 [0.62 , 1.07]
0.71 [0.55 , 0.92]
1.27 [0.72 , 2.23]
0.79 [0.63 , 1.00]
0.78 [0.62 , 0.97]
1.00 [0.53 , 1.89]
1.00 [0.53 , 1.89]
0.20 [0.01 , 4.15]
0.69 [0.34 , 1.40]
0.41 [0.22 , 0.78]
0.98 [0.92 , 1.04]
0.67 [0.39 , 1.16]
Not estimable
1.68 [0.41 , 6.87]
1.68 [0.41 , 6.87]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
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Analysis 1.46.   Comparison 1: SFA reduction vs usual diet -
primary outcomes, Outcome 46: CVD events, subgroup by duration
Study or Subgroup








Heterogeneity: Tau² = 0.00; Chi² = 2.17, df = 4 (P = 0.70); I² = 0%
Test for overall effect: Z = 0.45 (P = 0.65)






Heterogeneity: Tau² = 0.03; Chi² = 3.97, df = 2 (P = 0.14); I² = 50%






Heterogeneity: Tau² = 0.04; Chi² = 5.62, df = 1 (P = 0.02); I² = 82%






Heterogeneity: Tau² = 0.32; Chi² = 3.59, df = 1 (P = 0.06); I² = 72%
Test for overall effect: Z = 1.80 (P = 0.07)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.04; Chi² = 31.72, df = 11 (P = 0.0008); I² = 65%
Test for overall effect: Z = 2.72 (P = 0.006)






























































































M-H, Random, 95% CI
0.20 [0.01 , 4.15]
0.92 [0.74 , 1.15]
1.68 [0.41 , 6.87]
1.16 [0.59 , 2.29]
1.10 [0.48 , 2.50]
0.96 [0.78 , 1.16]
0.82 [0.62 , 1.07]
0.41 [0.22 , 0.78]
0.79 [0.63 , 1.00]
0.73 [0.56 , 0.95]
0.71 [0.55 , 0.92]
0.98 [0.92 , 1.04]
0.85 [0.63 , 1.16]
0.27 [0.14 , 0.52]
0.69 [0.34 , 1.40]
0.43 [0.17 , 1.08]
0.79 [0.66 , 0.93]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
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Analysis 1.47.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 47: CVD events, subgroup by baseline SFA
Study or Subgroup




Test for overall effect: Not applicable








Heterogeneity: Tau² = 0.00; Chi² = 2.79, df = 4 (P = 0.59); I² = 0%
Test for overall effect: Z = 0.94 (P = 0.35)





Test for overall effect: Z = 2.75 (P = 0.006)














Heterogeneity: Tau² = 0.09; Chi² = 12.08, df = 4 (P = 0.02); I² = 67%
Test for overall effect: Z = 1.80 (P = 0.07)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.04; Chi² = 31.72, df = 11 (P = 0.0008); I² = 65%
Test for overall effect: Z = 2.72 (P = 0.006)


































































































M-H, Random, 95% CI
Not estimable
0.20 [0.01 , 4.15]
0.92 [0.74 , 1.15]
0.69 [0.34 , 1.40]
1.68 [0.41 , 6.87]
0.98 [0.92 , 1.04]
0.97 [0.91 , 1.03]
0.41 [0.22 , 0.78]
0.41 [0.22 , 0.78]
0.79 [0.63 , 1.00]
0.79 [0.63 , 1.00]
0.27 [0.14 , 0.52]
0.82 [0.62 , 1.07]
0.71 [0.55 , 0.92]
1.16 [0.59 , 2.29]
1.10 [0.48 , 2.50]
0.72 [0.51 , 1.03]
0.79 [0.66 , 0.93]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
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Analysis 1.48.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 48: CVD events, subgroup by SFA change
Study or Subgroup







Heterogeneity: Tau² = 0.00; Chi² = 1.76, df = 3 (P = 0.62); I² = 0%
Test for overall effect: Z = 0.92 (P = 0.36)





Heterogeneity: Tau² = 0.00; Chi² = 0.22, df = 1 (P = 0.64); I² = 0%















Heterogeneity: Tau² = 0.09; Chi² = 12.08, df = 4 (P = 0.02); I² = 67%
Test for overall effect: Z = 1.80 (P = 0.07)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.04; Chi² = 31.72, df = 11 (P = 0.0008); I² = 65%
Test for overall effect: Z = 2.72 (P = 0.006)






























































































M-H, Random, 95% CI
0.92 [0.74 , 1.15]
0.69 [0.34 , 1.40]
1.68 [0.41 , 6.87]
0.98 [0.92 , 1.04]
0.97 [0.91 , 1.03]
0.20 [0.01 , 4.15]
0.41 [0.22 , 0.78]
0.40 [0.22 , 0.74]
0.79 [0.63 , 1.00]
0.79 [0.63 , 1.00]
0.27 [0.14 , 0.52]
0.82 [0.62 , 1.07]
0.71 [0.55 , 0.92]
1.16 [0.59 , 2.29]
1.10 [0.48 , 2.50]
0.72 [0.51 , 1.03]
0.79 [0.66 , 0.93]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
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Analysis 1.49.   Comparison 1: SFA reduction vs usual diet -













Heterogeneity: Tau² = 0.01; Chi² = 9.23, df = 7 (P = 0.24); I² = 24%






Test for overall effect: Z = 0.68 (P = 0.50)






Heterogeneity: Tau² = 0.46; Chi² = 6.93, df = 2 (P = 0.03); I² = 71%
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.04; Chi² = 31.72, df = 11 (P = 0.0008); I² = 65%
Test for overall effect: Z = 2.72 (P = 0.006)

























































































M-H, Random, 95% CI
0.20 [0.01 , 4.15]
0.92 [0.74 , 1.15]
0.82 [0.62 , 1.07]
0.71 [0.55 , 0.92]
1.16 [0.59 , 2.29]
1.10 [0.48 , 2.50]
0.41 [0.22 , 0.78]
0.79 [0.63 , 1.00]
0.80 [0.69 , 0.93]
0.98 [0.92 , 1.04]
0.98 [0.92 , 1.04]
0.27 [0.14 , 0.52]
0.69 [0.34 , 1.40]
1.68 [0.41 , 6.87]
0.59 [0.23 , 1.49]
0.79 [0.66 , 0.93]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
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Analysis 1.50.   Comparison 1: SFA reduction vs usual diet -
primary outcomes, Outcome 50: CVD events, subgroup by CVD risk
Study or Subgroup






Heterogeneity: Tau² = 0.01; Chi² = 3.32, df = 2 (P = 0.19); I² = 40%
Test for overall effect: Z = 1.28 (P = 0.20)






Heterogeneity: Tau² = 0.46; Chi² = 6.93, df = 2 (P = 0.03); I² = 71%
Test for overall effect: Z = 1.13 (P = 0.26)










Heterogeneity: Tau² = 0.04; Chi² = 16.43, df = 6 (P = 0.01); I² = 63%
Test for overall effect: Z = 1.45 (P = 0.15)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.03; Chi² = 34.25, df = 12 (P = 0.0006); I² = 65%
Test for overall effect: Z = 2.50 (P = 0.01)






























































































M-H, Random, 95% CI
0.20 [0.01 , 4.15]
0.79 [0.63 , 1.00]
0.95 [0.89 , 1.03]
0.89 [0.75 , 1.06]
0.27 [0.14 , 0.52]
0.69 [0.34 , 1.40]
1.68 [0.41 , 6.87]
0.59 [0.23 , 1.49]
0.92 [0.74 , 1.15]
0.82 [0.62 , 1.07]
0.71 [0.55 , 0.92]
1.16 [0.59 , 2.29]
1.10 [0.48 , 2.50]
0.41 [0.22 , 0.78]
1.09 [0.94 , 1.27]
0.86 [0.71 , 1.05]
0.83 [0.72 , 0.96]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Women without CVD at baseline
(2) Women with CVD at baseline
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Analysis 1.51.   Comparison 1: SFA reduction vs usual diet - primary
outcomes, Outcome 51: CVD events, subgroup by TC reduction
Study or Subgroup











Heterogeneity: Tau² = 0.05; Chi² = 18.95, df = 7 (P = 0.008); I² = 63%
Test for overall effect: Z = 2.73 (P = 0.006)






Heterogeneity: Tau² = 0.00; Chi² = 1.02, df = 2 (P = 0.60); I² = 0%
Test for overall effect: Z = 0.75 (P = 0.45)





Test for overall effect: Z = 1.04 (P = 0.30)




















































































M-H, Random, 95% CI
0.92 [0.74 , 1.15]
0.27 [0.14 , 0.52]
0.82 [0.62 , 1.07]
1.68 [0.41 , 6.87]
0.71 [0.55 , 0.92]
1.16 [0.59 , 2.29]
0.41 [0.22 , 0.78]
0.79 [0.63 , 1.00]
0.74 [0.59 , 0.92]
0.69 [0.34 , 1.40]
1.10 [0.48 , 2.50]
0.98 [0.92 , 1.04]
0.98 [0.91 , 1.04]
0.20 [0.01 , 4.15]
0.20 [0.01 , 4.15]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
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Analysis 1.52.   Comparison 1: SFA reduction vs usual diet - primary










Heterogeneity: Tau² = 0.00; Chi² = 2.56, df = 4 (P = 0.63); I² = 0%


















Heterogeneity: Tau² = 0.00; Chi² = 0.22, df = 1 (P = 0.64); I² = 0%







Heterogeneity: Tau² = 0.00; Chi² = 1.51, df = 2 (P = 0.47); I² = 0%
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.04; Chi² = 31.72, df = 11 (P = 0.0008); I² = 65%
Test for overall effect: Z = 2.72 (P = 0.006)



































































































M-H, Random, 95% CI
0.82 [0.62 , 1.07]
0.71 [0.55 , 0.92]
1.16 [0.59 , 2.29]
1.10 [0.48 , 2.50]
0.79 [0.63 , 1.00]
0.79 [0.69 , 0.91]
0.27 [0.14 , 0.52]
0.27 [0.14 , 0.52]
0.92 [0.74 , 1.15]
0.92 [0.74 , 1.15]
0.20 [0.01 , 4.15]
0.41 [0.22 , 0.78]
0.40 [0.22 , 0.74]
0.69 [0.34 , 1.40]
1.68 [0.41 , 6.87]
0.98 [0.92 , 1.04]
0.98 [0.91 , 1.04]
0.79 [0.66 , 0.93]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Total CVD during study period, Prentice 2017
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Comparison 2.   SFA reduction vs usual diet - secondary health events





Statistical method Effect size
2.1 MYOCARDIAL INFARCTION 11 53167 Risk Ratio (M-H, Random, 95%
CI)
0.90 [0.80, 1.01]
2.2 MI, SA by low summary risk of bias 3 49857 Risk Ratio (M-H, Random, 95%
CI)
0.93 [0.81, 1.08]
2.3 MI, SA aim to reduce SFA 10 52991 Risk Ratio (M-H, Random, 95%
CI)
0.89 [0.78, 1.02]
2.4 MI, SA statistically significant SFA re-
duction
6 52180 Risk Ratio (M-H, Random, 95%
CI)
0.94 [0.85, 1.04]
2.5 MI, SA by TC reduction 9 52952 Risk Ratio (M-H, Random, 95%
CI)
0.88 [0.77, 1.01]
2.6 MI, SA excluding WHI 10 4332 Risk Ratio (M-H, Random, 95%
CI)
0.85 [0.73, 0.98]
2.7 MI, SA Mantel-Haenszel fixed-effect 11 53167 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.84, 1.01]
2.8 MI, SA Peto fixed-effect 11 53167 Peto Odds Ratio (Peto, Fixed,
95% CI)
0.92 [0.83, 1.01]
2.9 MI, subgroup by any substitution 11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.9.1 replaced by PUFA 7 3895 Risk Ratio (M-H, Random, 95%
CI)
0.83 [0.67, 1.02]
2.9.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
1.40 [0.51, 3.85]
2.9.3 replace by CHO 4 51099 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.86, 1.06]
2.9.4 replaced by protein 3 51044 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.86, 1.07]
2.9.5 replacement unclear 1 235 Risk Ratio (M-H, Random, 95%
CI)
2.02 [0.19, 21.94]
2.10 MI, subgroup by main substitution 11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.10.1 replaced by PUFA 6 3840 Risk Ratio (M-H, Random, 95%
CI)
0.83 [0.67, 1.04]
2.10.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
1.40 [0.51, 3.85]
2.10.3 replace by CHO 3 49066 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.86, 1.09]
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Statistical method Effect size
2.10.4 replaced by protein 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.10.5 replacement unclear 1 235 Risk Ratio (M-H, Random, 95%
CI)
2.02 [0.19, 21.94]
2.11 MI, subgroup by duration 11 53167 Risk Ratio (M-H, Random, 95%
CI)
0.90 [0.80, 1.01]
2.11.1 up to 24mo 4 2348 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.77, 1.17]
2.11.2 >24 to 48mo 3 1294 Risk Ratio (M-H, Random, 95%
CI)
0.83 [0.64, 1.06]
2.11.3 >48mo 2 49247 Risk Ratio (M-H, Random, 95%
CI)
0.81 [0.54, 1.24]
2.11.4 unclear 2 278 Risk Ratio (M-H, Random, 95%
CI)
0.41 [0.02, 7.73]
2.12 MI, subgroup by baseline SFA 11 53167 Risk Ratio (M-H, Random, 95%
CI)
0.90 [0.80, 1.01]
2.12.1 up to 12%E SFA baseline 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.12.2 >12 to 15%E SFA baseline 4 51279 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.87, 1.07]
2.12.3 >15 to 18%E SFA baseline 1 55 Risk Ratio (M-H, Random, 95%
CI)
0.52 [0.05, 5.39]
2.12.4 >18%E SFA baseline 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.76 [0.55, 1.05]
2.12.5 unclear 5 987 Risk Ratio (M-H, Random, 95%
CI)
0.84 [0.54, 1.30]
2.13 MI, subgroup by SFA change 11 53167 Risk Ratio (M-H, Random, 95%
CI)
0.90 [0.80, 1.01]
2.13.1 up to 4%E difference 4 51279 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.87, 1.07]
2.13.2 >4 to 8%E difference 1 55 Risk Ratio (M-H, Random, 95%
CI)
0.52 [0.05, 5.39]
2.13.3 >8%E difference 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.76 [0.55, 1.05]
2.13.4 unclear 5 987 Risk Ratio (M-H, Random, 95%
CI)
0.84 [0.54, 1.30]
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Statistical method Effect size
2.14 MI, subgroup by sex 11 53167 Risk Ratio (M-H, Random, 95%
CI)
0.90 [0.80, 1.01]
2.14.1 Men 7 3819 Risk Ratio (M-H, Random, 95%
CI)
0.85 [0.73, 0.98]
2.14.2 Women 1 48835 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.86, 1.09]
2.14.3 Mixed, men and women 3 513 Risk Ratio (M-H, Random, 95%
CI)
0.75 [0.13, 4.47]
2.15 MI, subgroup by CVD risk 11 53167 Risk Ratio (M-H, Random, 95%
CI)
0.90 [0.80, 1.01]
2.15.1 Low CVD risk 2 49681 Risk Ratio (M-H, Random, 95%
CI)
0.90 [0.72, 1.13]
2.15.2 Moderate CVD risk 3 513 Risk Ratio (M-H, Random, 95%
CI)
0.75 [0.13, 4.47]
2.15.3 Existing CVD disease 6 2973 Risk Ratio (M-H, Random, 95%
CI)
0.87 [0.74, 1.03]
2.16 MI, subgroup by TC reduction 11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.16.1 serum chol reduced by at least
0.2mmol/L
8 4117 Risk Ratio (M-H, Random, 95%
CI)
0.83 [0.70, 0.98]
2.16.2 serum chol reduced by <0.2mmol/L 3 49050 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.87, 1.10]
2.16.3 serum chol reduction unclear 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.17 MI, subgroup decade of publication 11 53167 Risk Ratio (M-H, Random, 95%
CI)
0.90 [0.80, 1.01]
2.17.1 1960s 5 1731 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.64, 1.00]
2.17.2 1970s 1 102 Risk Ratio (M-H, Random, 95%
CI)
0.08 [0.00, 1.33]
2.17.3 1980s 1 2033 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.73, 1.14]
2.17.4 1990s 1 55 Risk Ratio (M-H, Random, 95%
CI)
0.52 [0.05, 5.39]
2.17.5 2000s 3 49246 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.87, 1.10]
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Statistical method Effect size
2.18 NON-FATAL MYOCARDIAL INFARCTION 8 52834 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.87, 1.07]
2.19 Non-fatal MI, SA by low summary risk
of bias
2 49681 Risk Ratio (M-H, Random, 95%
CI)
0.89 [0.58, 1.35]
2.20 Non-fatal MI, SA aim to reduce SFA 8 52834 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.87, 1.07]
2.21 Non-fatal MI, SA statistically signifi-
cant SFA reduction
4 51949 Risk Ratio (M-H, Random, 95%
CI)
0.90 [0.72, 1.14]
2.22 Non-fatal MI, SA by TC reduction 7 52795 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.87, 1.07]
2.23 Non-fatal MI, SA excluding WHI 7 3999 Risk Ratio (M-H, Random, 95%
CI)
0.81 [0.64, 1.04]
2.24 Non-fatal MI, SA Mantel-Haenszel
fixed-effect
8 52834 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.87, 1.08]
2.25 Non-fatal MI, SA Peto fixed-effect 8 52834 Peto Odds Ratio (Peto, Fixed,
95% CI)
0.97 [0.87, 1.08]
2.26 Non-fatal MI, subgroup by any substi-
tution
8   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.26.1 replaced by PUFA 5 3738 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.63, 1.03]
2.26.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
1.20 [0.42, 3.45]
2.26.3 replace by CHO 2 50868 Risk Ratio (M-H, Random, 95%
CI)
0.93 [0.72, 1.21]
2.26.4 replaced by protein 2 50868 Risk Ratio (M-H, Random, 95%
CI)
0.93 [0.72, 1.21]
2.26.5 replacement unclear 1 235 Risk Ratio (M-H, Random, 95%
CI)
2.02 [0.19, 21.94]
2.27 Non-fatal MI, subgroup by main sub-
stitution
8   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.27.1 replaced by PUFA 5 3738 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.63, 1.03]
2.27.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
1.20 [0.42, 3.45]
2.27.3 replace by CHO 1 48835 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.90, 1.13]
Reduction in saturated fat intake for cardiovascular disease (Review)









Cochrane Database of Systematic Reviews





Statistical method Effect size
2.27.4 replaced by protein 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.27.5 replacement unclear 1 235 Risk Ratio (M-H, Random, 95%
CI)
2.02 [0.19, 21.94]
2.28 Non-fatal MI, subgroup by duration 8 52834 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.87, 1.07]
2.28.1 up to 24mo 4 2348 Risk Ratio (M-H, Random, 95%
CI)
0.83 [0.57, 1.22]
2.28.2 >24 to 48mo 2 1239 Risk Ratio (M-H, Random, 95%
CI)
0.82 [0.53, 1.27]
2.28.3 >48mo 2 49247 Risk Ratio (M-H, Random, 95%
CI)
0.99 [0.88, 1.12]
2.28.4 unclear 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.29 Non-fatal MI, subgroup by baseline
SFA
8 52834 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.87, 1.07]
2.29.1 up to 12%E SFA baseline 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.29.2 >12 to 15%E SFA baseline 3 51103 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.83, 1.13]
2.29.3 >15 to 18%E SFA baseline 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.29.4 >18%E SFA baseline 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.62 [0.31, 1.21]
2.29.5 unclear 4 885 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.65, 1.27]
2.30 Non-fatal MI, subgroup by SFA change 8 52834 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.87, 1.07]
2.30.1 up to 4%E difference 3 51103 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.83, 1.13]
2.30.2 >4 to 8%E difference 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.30.3 >8%E difference 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.62 [0.31, 1.21]
2.30.4 unclear 4 885 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.65, 1.27]
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Statistical method Effect size
2.31 Non-fatal MI, subgroup by sex 8 52834 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.87, 1.07]
2.31.1 Men 6 3764 Risk Ratio (M-H, Random, 95%
CI)
0.81 [0.63, 1.03]
2.31.2 Women 1 48835 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.90, 1.13]
2.31.3 Mixed, men and women 1 235 Risk Ratio (M-H, Random, 95%
CI)
2.02 [0.19, 21.94]
2.32 Non-fatal MI, subgroup by CVD risk 8 52834 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.80, 1.13]
2.32.1 Low CVD risk 2 47404 Risk Ratio (M-H, Random, 95%
CI)
0.87 [0.68, 1.12]
2.32.2 Moderate CVD risk 1 235 Risk Ratio (M-H, Random, 95%
CI)
2.02 [0.19, 21.94]
2.32.3 Existing CVD disease 6 5195 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.76, 1.31]
2.33 Non-fatal MI, subgroup by TC reduc-
tion
8   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.33.1 serum chol reduced by at least
0.2mmol/L
6 3960 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.62, 1.03]
2.33.2 serum chol reduced by <0.2mmol/L 2 48874 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.90, 1.13]
2.33.3 serum chol reduction unclear 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.34 Non-fatal MI, subgroup decade of pub-
lication
8 52834 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.87, 1.07]
2.34.1 1960s 5 1731 Risk Ratio (M-H, Random, 95%
CI)
0.84 [0.62, 1.13]
2.34.2 1970s 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.34.3 1980s 1 2033 Risk Ratio (M-H, Random, 95%
CI)
0.74 [0.48, 1.14]
2.34.4 1990s 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.34.5 2000s 2 49070 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.90, 1.13]
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Statistical method Effect size
2.35 STROKE 7 50952 Risk Ratio (M-H, Random, 95%
CI)
0.92 [0.68, 1.25]
2.36 Stroke, SA by low summary risk of bias 3 49857 Risk Ratio (M-H, Random, 95%
CI)
0.76 [0.42, 1.38]
2.37 Stroke, SA aim to reduce SFA 6 50776 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.90, 1.14]
2.38 Stroke, SA statistically significant SFA
reduction
5 50147 Risk Ratio (M-H, Random, 95%
CI)
0.83 [0.55, 1.25]
2.39 Stroke, SA by TC reduction 6 50776 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.90, 1.14]
2.40 Stroke, SA excluding WHI 6 2117 Risk Ratio (M-H, Random, 95%
CI)
0.63 [0.35, 1.14]
2.41 Stroke, SA Mantel-Haenszel fixed-ef-
fect
7 50952 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.89, 1.13]
2.42 Stroke, SA Peto fixed-effect 7 50952 Peto Odds Ratio (Peto, Fixed,
95% CI)
1.01 [0.89, 1.14]
2.43 Stroke, subgroup by any substitution 7   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.43.1 replaced by PUFA 4 1706 Risk Ratio (M-H, Random, 95%
CI)
0.68 [0.37, 1.27]
2.43.2 replaced by MUFA 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.43.3 replace by CHO 3 49066 Risk Ratio (M-H, Random, 95%
CI)
0.73 [0.29, 1.87]
2.43.4 replaced by protein 2 49011 Risk Ratio (M-H, Random, 95%
CI)
0.65 [0.15, 2.75]
2.43.5 replacement unclear 1 235 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.06, 15.93]
2.44 Stroke, subgroup by main substitution 7   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.44.1 replaced by PUFA 3 1651 Risk Ratio (M-H, Random, 95%
CI)
0.92 [0.31, 2.69]
2.44.2 replaced by MUFA 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.44.3 replace by CHO 3 49066 Risk Ratio (M-H, Random, 95%
CI)
0.73 [0.29, 1.87]
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2.44.4 replaced by protein 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.44.5 replacement unclear 1 235 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.06, 15.93]
2.45 Stroke, subgroup by duration 6 50559 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.67, 1.23]
2.45.1 up to 24mo 1 235 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.06, 15.93]
2.45.2 >24 to 48mo 2 901 Risk Ratio (M-H, Random, 95%
CI)
0.57 [0.30, 1.11]
2.45.3 >48mo 2 49247 Risk Ratio (M-H, Random, 95%
CI)
1.03 [0.91, 1.16]
2.45.4 unclear duration 1 176 Risk Ratio (M-H, Random, 95%
CI)
0.20 [0.02, 1.68]
2.46 Stroke, subgroup by baseline SFA 6 50559 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.67, 1.23]
2.46.1 up to 12%E SFA baseline 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.46.2 >12 to 15%E SFA baseline 3 49246 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.50, 1.66]
2.46.3 >15 to 18%E SFA baseline 1 55 Risk Ratio (M-H, Random, 95%
CI)
0.35 [0.01, 8.12]
2.46.4 >18%E SFA baseline 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.59 [0.30, 1.15]
2.46.5 unclear 1 412 Risk Ratio (M-H, Random, 95%
CI)
2.00 [0.18, 21.89]
2.47 Stroke, subgroup by SFA change 6 50559 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.67, 1.23]
2.47.1 up to 4%E difference 3 49246 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.50, 1.66]
2.47.2 >4 to 8%E difference 1 55 Risk Ratio (M-H, Random, 95%
CI)
0.35 [0.01, 8.12]
2.47.3 >8%E difference 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.59 [0.30, 1.15]
2.47.4 unclear 1 412 Risk Ratio (M-H, Random, 95%
CI)
2.00 [0.18, 21.89]
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2.48 Stroke, subgroup by sex 6 50559 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.67, 1.23]
2.48.1 Men 3 1313 Risk Ratio (M-H, Random, 95%
CI)
0.63 [0.33, 1.18]
2.48.2 Women 1 48835 Risk Ratio (M-H, Random, 95%
CI)
1.03 [0.91, 1.16]
2.48.3 Mixed, men and women 2 411 Risk Ratio (M-H, Random, 95%
CI)
0.37 [0.07, 1.97]
2.49 Stroke, subgroup by CVD risk 6 50559 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.89, 1.11]
2.49.1 Low CVD risk 2 47404 Risk Ratio (M-H, Random, 95%
CI)
0.86 [0.52, 1.42]
2.49.2 Moderate CVD risk 2 411 Risk Ratio (M-H, Random, 95%
CI)
0.37 [0.07, 1.97]
2.49.3 Existing CVD disease 3 2744 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.86, 1.18]
2.50 Stroke, subgroup by TC reduction 7   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.50.1 serum chol reduced by at least
0.2mmol/L
5 1941 Risk Ratio (M-H, Random, 95%
CI)
0.70 [0.38, 1.28]
2.50.2 serum chol reduced by <0.2mmol/L 2 49011 Risk Ratio (M-H, Random, 95%
CI)
0.65 [0.15, 2.75]
2.50.3 serum chol reduction unclear 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.51 Stroke, subgroup decade of publica-
tion
7 50952 Risk Ratio (M-H, Random, 95%
CI)
0.92 [0.68, 1.25]
2.51.1 1960s 3 1651 Risk Ratio (M-H, Random, 95%
CI)
0.92 [0.31, 2.69]
2.51.2 1970s 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.51.3 1980s 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.51.4 1990s 1 55 Risk Ratio (M-H, Random, 95%
CI)
0.35 [0.01, 8.12]
2.51.5 2000s 3 49246 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.50, 1.66]
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2.52 CORONARY HEART DISEASE MORTALI-
TY
9 53159 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.82, 1.16]
2.53 CHD mortality, SA by low summary
risk of bias
3 50139 Risk Ratio (M-H, Random, 95%
CI)
1.05 [0.77, 1.43]
2.54 CHD mortality, SA aim to reduce SFA 9 53159 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.82, 1.16]
2.55 CHD mortality, SA statistically signifi-
cant SFA reduction
4 52172 Risk Ratio (M-H, Random, 95%
CI)
1.02 [0.84, 1.24]
2.56 CHD mortality, SA by TC reduction 8 53120 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.81, 1.16]
2.57 CHD mortality, SA excluding WHI 8 4324 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.76, 1.24]
2.58 CHD mortality, SA Mantel-Haenszel
fixed-effect
9 53159 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.86, 1.10]
2.59 CHD mortality, SA Peto fixed-effect 9 53159 Peto Odds Ratio (Peto, Fixed,
95% CI)
0.97 [0.85, 1.11]
2.60 CHD mortality, subgroup by any sub-
stitution
9   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.60.1 replaced by PUFA 7 4298 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.74, 1.28]
2.60.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
3.00 [0.33, 26.99]
2.60.3 replaced by CHO 2 50868 Risk Ratio (M-H, Random, 95%
CI)
0.99 [0.85, 1.16]
2.60.4 replaced by protein 2 50868 Risk Ratio (M-H, Random, 95%
CI)
0.99 [0.85, 1.16]
2.60.5 replacement unclear 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.61 CHD mortality, subgroup by main sub-
stitution
9   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.61.1 replaced by PUFA 7 4298 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.74, 1.28]
2.61.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
3.00 [0.33, 26.99]
2.61.3 replaced by CHO 1 48835 Risk Ratio (M-H, Random, 95%
CI)
0.99 [0.82, 1.20]
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2.61.4 replaced by protein 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.61.5 replacement unclear 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.62 CHD mortality, subgroup by duration 9   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.62.1 up to 24mo 3 2113 Risk Ratio (M-H, Random, 95%
CI)
1.02 [0.78, 1.33]
2.62.2 >24 to 48months 2 1239 Risk Ratio (M-H, Random, 95%
CI)
0.87 [0.64, 1.19]
2.62.3 >48 months 3 49705 Risk Ratio (M-H, Random, 95%
CI)
1.02 [0.72, 1.45]
2.62.4 unclear duration 1 102 Risk Ratio (M-H, Random, 95%
CI)
0.09 [0.01, 1.60]
2.63 CHD mortality, subgroup by baseline
SFA
9   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.63.1 up to 12%E SFA baseline 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.63.2 >12% to 15%E SFA baseline 3 51326 Risk Ratio (M-H, Random, 95%
CI)
1.07 [0.86, 1.34]
2.63.3 >15 to 18%E SFA baseline 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.63.4 >18%E SFA baseline 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.82 [0.55, 1.21]
2.63.5 unclear 5 987 Risk Ratio (M-H, Random, 95%
CI)
0.85 [0.56, 1.29]
2.64 CHD mortality, subgroup by SFA
change
9   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.64.1 up to 4%E difference 3 51326 Risk Ratio (M-H, Random, 95%
CI)
1.07 [0.86, 1.34]
2.64.2 >4 to 8%E difference 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.64.3 >8%E difference 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.82 [0.55, 1.21]
2.64.4 unclear 5 987 Risk Ratio (M-H, Random, 95%
CI)
0.85 [0.56, 1.29]
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2.65 CHD mortality, subgroup by sex 9   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.65.1 Men 7 4222 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.79, 1.23]
2.65.2 Women 1 48835 Risk Ratio (M-H, Random, 95%
CI)
0.99 [0.82, 1.20]
2.65.3 Mixed, men and women 1 102 Risk Ratio (M-H, Random, 95%
CI)
0.09 [0.01, 1.60]
2.66 CHD mortality, subgroup by CVD risk 9   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.66.1 Low CVD risk 2 47404 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.78, 1.16]
2.66.2 Moderate CVD risk 1 102 Risk Ratio (M-H, Random, 95%
CI)
0.09 [0.01, 1.60]
2.66.3 Existing CVD disease 7 5653 Risk Ratio (M-H, Random, 95%
CI)
1.03 [0.83, 1.27]
2.67 CHD mortality, subgroup by TC reduc-
tion
9   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.67.1 serum chol reduced by at least
0.2mmol/L
7 4285 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.75, 1.24]
2.67.2 serum chol reduced by <0.2mmol/L 2 48874 Risk Ratio (M-H, Random, 95%
CI)
0.99 [0.82, 1.20]
2.67.3 serum chol reduction unclear 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.68 CHD mortality, subgroup decade of
publication
9 53159 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.82, 1.16]
2.68.1 1960s 5 1731 Risk Ratio (M-H, Random, 95%
CI)
0.84 [0.66, 1.06]
2.68.2 1970s 2 560 Risk Ratio (M-H, Random, 95%
CI)
0.54 [0.03, 9.26]
2.68.3 1980s 1 2033 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.76, 1.30]
2.68.4 1990s 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.68.5 2000s 1 48835 Risk Ratio (M-H, Random, 95%
CI)
0.99 [0.82, 1.20]
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2.69 CORONARY HEART DISEASE EVENTS 11 53199 Risk Ratio (M-H, Random, 95%
CI)
0.83 [0.68, 1.01]
2.70 CHD events, SA by low summary risk
of bias
3 49857 Risk Ratio (M-H, Random, 95%
CI)
0.92 [0.77, 1.10]
2.71 CHD events, SA excluding WHI 10 4364 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.62, 1.03]
2.72 CHD events, SA statistically significant
SFA reduction
6 52212 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.77, 1.06]
2.73 CHD events, SA by TC reduction 9 52984 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.65, 0.99]
2.74 CHD events, SA aim to reduce SFA 10 53023 Risk Ratio (M-H, Random, 95%
CI)
0.82 [0.67, 1.00]
2.75 CHD events, SA Mantel-Haenszel fixed-
effect
11 53199 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.84, 0.99]
2.76 CHD events, SA Peto fixed-effect 11 53199 Peto Odds Ratio (Peto, Fixed,
95% CI)
0.90 [0.83, 0.99]
2.77 CHD events, subgroup by any substi-
tution
11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.77.1 replaced by PUFA 7 3895 Risk Ratio (M-H, Random, 95%
CI)
0.76 [0.57, 1.00]
2.77.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
1.50 [0.62, 3.61]
2.77.3 replaced by CHO 4 51104 Risk Ratio (M-H, Random, 95%
CI)
0.93 [0.78, 1.11]
2.77.4 replaced by protein 3 51044 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.88, 1.05]
2.77.5 replacement unclear 1 267 Risk Ratio (M-H, Random, 95%
CI)
2.93 [0.31, 27.84]
2.78 CHD events, subgroup by main substi-
tution
11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.78.1 replaced by PUFA 6 3840 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.60, 1.04]
2.78.2 replaced by MUFA 1 52 Risk Ratio (M-H, Random, 95%
CI)
1.50 [0.62, 3.61]
2.78.3 replaced by CHO 3 49071 Risk Ratio (M-H, Random, 95%
CI)
0.82 [0.39, 1.72]
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2.78.4 replaced by protein 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.78.5 replacement unclear 1 267 Risk Ratio (M-H, Random, 95%
CI)
2.93 [0.31, 27.84]
2.79 CHD events, subgroup by duration 11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.79.1 up to 24 months 4 2380 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.76, 1.35]
2.79.2 >24 to 48 months 3 1294 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.55, 1.13]
2.79.3 >48 months 2 49247 Risk Ratio (M-H, Random, 95%
CI)
0.85 [0.63, 1.15]
2.79.4 unclear duration 2 278 Risk Ratio (M-H, Random, 95%
CI)
0.60 [0.10, 3.58]
2.80 CHD events, subgroup by baseline SFA 11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.80.1 up to 12%E SFA baseline 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.80.2 >12 to 15%E SFA baseline 4 51311 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.88, 1.06]
2.80.3 >15 to 18%E SFA baseline 1 55 Risk Ratio (M-H, Random, 95%
CI)
0.31 [0.10, 1.01]
2.80.4 >18%E SFA baseline 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.77 [0.56, 1.04]
2.80.5 unclear 5 987 Risk Ratio (M-H, Random, 95%
CI)
0.78 [0.49, 1.26]
2.81 CHD events, subgroup by SFA change 11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.81.1 up to 4%E difference 4 51311 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.88, 1.06]
2.81.2 >4 to 8%E difference 1 55 Risk Ratio (M-H, Random, 95%
CI)
0.31 [0.10, 1.01]
2.81.3 >8%E difference 1 846 Risk Ratio (M-H, Random, 95%
CI)
0.77 [0.56, 1.04]
2.81.4 unclear 5 987 Risk Ratio (M-H, Random, 95%
CI)
0.78 [0.49, 1.26]
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2.82 CHD events, subgroup by sex 11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.82.1 Men 7 3819 Risk Ratio (M-H, Random, 95%
CI)
0.84 [0.70, 1.02]
2.82.2 Women 1 48835 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.87, 1.07]
2.82.3 Mixed, men and women 3 545 Risk Ratio (M-H, Random, 95%
CI)
0.88 [0.18, 4.36]
2.83 CHD events, subgroup by CVD risk 11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.83.1 Low CVD risk 2 47404 Risk Ratio (M-H, Random, 95%
CI)
0.90 [0.76, 1.05]
2.83.2 Moderate CVD risk 3 545 Risk Ratio (M-H, Random, 95%
CI)
0.88 [0.18, 4.36]
2.83.3 Existing CVD disease 7 5250 Risk Ratio (M-H, Random, 95%
CI)
0.94 [0.75, 1.16]
2.84 CHD events, subgroup by TC reduction 11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.84.1 serum chol reduced by at least
0.2mmol/L
8 4149 Risk Ratio (M-H, Random, 95%
CI)
0.76 [0.58, 0.99]
2.84.2 serum chol reduced by <0.2mmol/L 3 49050 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.88, 1.08]
2.84.3 serum chol reduction unclear 0 0 Risk Ratio (M-H, Random, 95%
CI)
Not estimable
2.85 CHD events, subgroup decade of pub-
lication
11 53201 Risk Ratio (M-H, Random, 95%
CI)
0.83 [0.68, 1.01]
2.85.1 1960s 5 1731 Risk Ratio (M-H, Random, 95%
CI)
0.84 [0.68, 1.05]
2.85.2 1970s 1 102 Risk Ratio (M-H, Random, 95%
CI)
0.27 [0.14, 0.52]
2.85.3 1980s 1 2033 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.73, 1.14]
2.85.4 1990s 1 57 Risk Ratio (M-H, Random, 95%
CI)
0.33 [0.10, 1.09]
2.85.5 2000s 3 49278 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.88, 1.08]
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Analysis 2.1.   Comparison 2: SFA reduction vs usual diet -















Heterogeneity: Tau² = 0.00; Chi² = 11.07, df = 10 (P = 0.35); I² = 10%
Test for overall effect: Z = 1.72 (P = 0.09)





































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.08 [0.00 , 1.33]
1.33 [0.31 , 5.78]
0.95 [0.64 , 1.41]
2.02 [0.19 , 21.94]
0.63 [0.43 , 0.92]
1.39 [0.45 , 4.31]
1.75 [0.42 , 7.27]
0.52 [0.05 , 5.39]
0.76 [0.55 , 1.05]
0.97 [0.86 , 1.09]
0.90 [0.80 , 1.01]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
 
 
Analysis 2.2.   Comparison 2: SFA reduction vs usual diet - secondary







Heterogeneity: Tau² = 0.00; Chi² = 2.19, df = 2 (P = 0.33); I² = 9%
Test for overall effect: Z = 0.94 (P = 0.35)





























M-H, Random, 95% CI
1.33 [0.31 , 5.78]
0.76 [0.55 , 1.05]
0.97 [0.86 , 1.09]
0.93 [0.81 , 1.08]
Risk Ratio
M-H, Random, 95% CI
0.5 0.7 1 1.5 2
Favours lower SFA Favours higher SFA
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Analysis 2.3.   Comparison 2: SFA reduction vs usual diet -














Heterogeneity: Tau² = 0.01; Chi² = 10.83, df = 9 (P = 0.29); I² = 17%
Test for overall effect: Z = 1.72 (P = 0.09)
































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.08 [0.00 , 1.33]
0.95 [0.64 , 1.41]
2.02 [0.19 , 21.94]
0.63 [0.43 , 0.92]
1.39 [0.45 , 4.31]
1.75 [0.42 , 7.27]
0.52 [0.05 , 5.39]
0.76 [0.55 , 1.05]
0.97 [0.86 , 1.09]
0.89 [0.78 , 1.02]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
 
 
Analysis 2.4.   Comparison 2: SFA reduction vs usual diet - secondary










Heterogeneity: Tau² = 0.00; Chi² = 2.91, df = 5 (P = 0.71); I² = 0%
Test for overall effect: Z = 1.23 (P = 0.22)












































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
1.33 [0.31 , 5.78]
2.02 [0.19 , 21.94]
0.52 [0.05 , 5.39]
0.76 [0.55 , 1.05]
0.97 [0.86 , 1.09]
0.94 [0.85 , 1.04]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
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Analysis 2.5.   Comparison 2: SFA reduction vs usual diet -













Heterogeneity: Tau² = 0.01; Chi² = 10.04, df = 8 (P = 0.26); I² = 20%
Test for overall effect: Z = 1.79 (P = 0.07)



























































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.08 [0.00 , 1.33]
0.95 [0.64 , 1.41]
2.02 [0.19 , 21.94]
0.63 [0.43 , 0.92]
1.39 [0.45 , 4.31]
0.52 [0.05 , 5.39]
0.76 [0.55 , 1.05]
0.97 [0.86 , 1.09]
0.88 [0.77 , 1.01]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
 
 














Heterogeneity: Tau² = 0.00; Chi² = 9.07, df = 9 (P = 0.43); I² = 1%
Test for overall effect: Z = 2.18 (P = 0.03)
































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.08 [0.00 , 1.33]
1.33 [0.31 , 5.78]
0.95 [0.64 , 1.41]
2.02 [0.19 , 21.94]
0.63 [0.43 , 0.92]
1.39 [0.45 , 4.31]
1.75 [0.42 , 7.27]
0.52 [0.05 , 5.39]
0.76 [0.55 , 1.05]
0.85 [0.73 , 0.98]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
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Analysis 2.7.   Comparison 2: SFA reduction vs usual diet - secondary















Heterogeneity: Chi² = 11.07, df = 10 (P = 0.35); I² = 10%
Test for overall effect: Z = 1.73 (P = 0.08)





































































M-H, Fixed, 95% CI
0.91 [0.73 , 1.14]
0.08 [0.00 , 1.33]
1.33 [0.31 , 5.78]
0.95 [0.64 , 1.41]
2.02 [0.19 , 21.94]
0.63 [0.43 , 0.92]
1.39 [0.45 , 4.31]
1.75 [0.42 , 7.27]
0.52 [0.05 , 5.39]
0.76 [0.55 , 1.05]
0.97 [0.86 , 1.09]
0.92 [0.84 , 1.01]
Risk Ratio
M-H, Fixed, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
 
 
Analysis 2.8.   Comparison 2: SFA reduction vs usual diet -















Heterogeneity: Chi² = 14.59, df = 10 (P = 0.15); I² = 31%
Test for overall effect: Z = 1.73 (P = 0.08)





































































Peto, Fixed, 95% CI
0.90 [0.70 , 1.16]
0.12 [0.02 , 0.63]
1.34 [0.30 , 6.07]
0.94 [0.57 , 1.54]
1.98 [0.20 , 19.18]
0.56 [0.35 , 0.90]
1.53 [0.37 , 6.39]
1.88 [0.40 , 8.96]
0.52 [0.05 , 5.22]
0.72 [0.49 , 1.06]
0.97 [0.86 , 1.10]
0.92 [0.83 , 1.01]
Peto Odds Ratio
Peto, Fixed, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
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Analysis 2.9.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 9: MI, subgroup by any substitution
Study or Subgroup










Heterogeneity: Tau² = 0.02; Chi² = 8.40, df = 6 (P = 0.21); I² = 29%
Test for overall effect: Z = 1.79 (P = 0.07)





Test for overall effect: Z = 0.65 (P = 0.51)







Heterogeneity: Tau² = 0.00; Chi² = 0.69, df = 3 (P = 0.88); I² = 0%
Test for overall effect: Z = 0.79 (P = 0.43)






Heterogeneity: Tau² = 0.00; Chi² = 0.43, df = 2 (P = 0.81); I² = 0%






Test for overall effect: Z = 0.58 (P = 0.56)


















































































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.08 [0.00 , 1.33]
0.95 [0.64 , 1.41]
0.63 [0.43 , 0.92]
1.67 [0.64 , 4.34]
0.52 [0.05 , 5.39]
0.76 [0.55 , 1.05]
0.83 [0.67 , 1.02]
1.40 [0.51 , 3.85]
1.40 [0.51 , 3.85]
0.91 [0.73 , 1.14]
1.33 [0.31 , 5.78]
0.52 [0.05 , 5.39]
0.97 [0.86 , 1.09]
0.96 [0.86 , 1.06]
0.91 [0.73 , 1.14]
1.33 [0.31 , 5.78]
0.97 [0.86 , 1.09]
0.96 [0.86 , 1.07]
2.02 [0.19 , 21.94]
2.02 [0.19 , 21.94]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
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Analysis 2.10.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 10: MI, subgroup by main substitution
Study or Subgroup









Heterogeneity: Tau² = 0.03; Chi² = 8.23, df = 5 (P = 0.14); I² = 39%
Test for overall effect: Z = 1.63 (P = 0.10)





Test for overall effect: Z = 0.65 (P = 0.51)






Heterogeneity: Tau² = 0.00; Chi² = 0.45, df = 2 (P = 0.80); I² = 0%
Test for overall effect: Z = 0.46 (P = 0.64)










Test for overall effect: Z = 0.58 (P = 0.56)
























































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.08 [0.00 , 1.33]
0.95 [0.64 , 1.41]
0.63 [0.43 , 0.92]
1.67 [0.64 , 4.34]
0.76 [0.55 , 1.05]
0.83 [0.67 , 1.04]
1.40 [0.51 , 3.85]
1.40 [0.51 , 3.85]
1.33 [0.31 , 5.78]
0.52 [0.05 , 5.39]
0.97 [0.86 , 1.09]
0.97 [0.86 , 1.09]
Not estimable
2.02 [0.19 , 21.94]
2.02 [0.19 , 21.94]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
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Analysis 2.11.   Comparison 2: SFA reduction vs usual diet -
secondary health events, Outcome 11: MI, subgroup by duration
Study or Subgroup
2.11.1 up to 24mo
DART 1989
Moy 2001




Heterogeneity: Tau² = 0.00; Chi² = 1.65, df = 3 (P = 0.65); I² = 0%
Test for overall effect: Z = 0.50 (P = 0.62)






Heterogeneity: Tau² = 0.00; Chi² = 0.91, df = 2 (P = 0.63); I² = 0%






Heterogeneity: Tau² = 0.07; Chi² = 4.50, df = 1 (P = 0.03); I² = 78%






Heterogeneity: Tau² = 3.31; Chi² = 3.47, df = 1 (P = 0.06); I² = 71%
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 11.07, df = 10 (P = 0.35); I² = 10%
Test for overall effect: Z = 1.72 (P = 0.09)

























































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
2.02 [0.19 , 21.94]
1.39 [0.45 , 4.31]
1.75 [0.42 , 7.27]
0.95 [0.77 , 1.17]
0.95 [0.64 , 1.41]
0.52 [0.05 , 5.39]
0.76 [0.55 , 1.05]
0.83 [0.64 , 1.06]
0.63 [0.43 , 0.92]
0.97 [0.86 , 1.09]
0.81 [0.54 , 1.24]
0.08 [0.00 , 1.33]
1.33 [0.31 , 5.78]
0.41 [0.02 , 7.73]
0.90 [0.80 , 1.01]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
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Analysis 2.12.   Comparison 2: SFA reduction vs usual diet -
secondary health events, Outcome 12: MI, subgroup by baseline SFA
Study or Subgroup




Test for overall effect: Not applicable







Heterogeneity: Tau² = 0.00; Chi² = 0.80, df = 3 (P = 0.85); I² = 0%
Test for overall effect: Z = 0.74 (P = 0.46)





Test for overall effect: Z = 0.55 (P = 0.58)














Heterogeneity: Tau² = 0.09; Chi² = 6.98, df = 4 (P = 0.14); I² = 43%
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 11.07, df = 10 (P = 0.35); I² = 10%
Test for overall effect: Z = 1.72 (P = 0.09)





























































































M-H, Random, 95% CI
Not estimable
0.91 [0.73 , 1.14]
1.33 [0.31 , 5.78]
2.02 [0.19 , 21.94]
0.97 [0.86 , 1.09]
0.96 [0.87 , 1.07]
0.52 [0.05 , 5.39]
0.52 [0.05 , 5.39]
0.76 [0.55 , 1.05]
0.76 [0.55 , 1.05]
0.08 [0.00 , 1.33]
0.95 [0.64 , 1.41]
0.63 [0.43 , 0.92]
1.39 [0.45 , 4.31]
1.75 [0.42 , 7.27]
0.84 [0.54 , 1.30]
0.90 [0.80 , 1.01]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
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Analysis 2.13.   Comparison 2: SFA reduction vs usual diet -
secondary health events, Outcome 13: MI, subgroup by SFA change
Study or Subgroup







Heterogeneity: Tau² = 0.00; Chi² = 0.80, df = 3 (P = 0.85); I² = 0%
Test for overall effect: Z = 0.74 (P = 0.46)




















Heterogeneity: Tau² = 0.09; Chi² = 6.98, df = 4 (P = 0.14); I² = 43%
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 11.07, df = 10 (P = 0.35); I² = 10%
Test for overall effect: Z = 1.72 (P = 0.09)

























































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
1.33 [0.31 , 5.78]
2.02 [0.19 , 21.94]
0.97 [0.86 , 1.09]
0.96 [0.87 , 1.07]
0.52 [0.05 , 5.39]
0.52 [0.05 , 5.39]
0.76 [0.55 , 1.05]
0.76 [0.55 , 1.05]
0.08 [0.00 , 1.33]
0.95 [0.64 , 1.41]
0.63 [0.43 , 0.92]
1.39 [0.45 , 4.31]
1.75 [0.42 , 7.27]
0.84 [0.54 , 1.30]
0.90 [0.80 , 1.01]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
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Analysis 2.14.   Comparison 2: SFA reduction vs usual diet -












Heterogeneity: Tau² = 0.00; Chi² = 5.46, df = 6 (P = 0.49); I² = 0%






Test for overall effect: Z = 0.47 (P = 0.64)






Heterogeneity: Tau² = 1.27; Chi² = 4.04, df = 2 (P = 0.13); I² = 51%
Test for overall effect: Z = 0.31 (P = 0.75)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 11.07, df = 10 (P = 0.35); I² = 10%
Test for overall effect: Z = 1.72 (P = 0.09)




















































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.95 [0.64 , 1.41]
0.63 [0.43 , 0.92]
1.39 [0.45 , 4.31]
1.75 [0.42 , 7.27]
0.52 [0.05 , 5.39]
0.76 [0.55 , 1.05]
0.85 [0.73 , 0.98]
0.97 [0.86 , 1.09]
0.97 [0.86 , 1.09]
0.08 [0.00 , 1.33]
1.33 [0.31 , 5.78]
2.02 [0.19 , 21.94]
0.75 [0.13 , 4.47]
0.90 [0.80 , 1.01]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
 
 
Reduction in saturated fat intake for cardiovascular disease (Review)









Cochrane Database of Systematic Reviews
Analysis 2.15.   Comparison 2: SFA reduction vs usual diet -
secondary health events, Outcome 15: MI, subgroup by CVD risk
Study or Subgroup





Heterogeneity: Tau² = 0.02; Chi² = 1.98, df = 1 (P = 0.16); I² = 49%
Test for overall effect: Z = 0.91 (P = 0.36)






Heterogeneity: Tau² = 1.27; Chi² = 4.04, df = 2 (P = 0.13); I² = 51%
Test for overall effect: Z = 0.31 (P = 0.75)









Heterogeneity: Tau² = 0.00; Chi² = 4.90, df = 5 (P = 0.43); I² = 0%
Test for overall effect: Z = 1.62 (P = 0.10)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 11.07, df = 10 (P = 0.35); I² = 10%
Test for overall effect: Z = 1.72 (P = 0.09)




















































































M-H, Random, 95% CI
0.76 [0.55 , 1.05]
0.97 [0.86 , 1.09]
0.90 [0.72 , 1.13]
0.08 [0.00 , 1.33]
1.33 [0.31 , 5.78]
2.02 [0.19 , 21.94]
0.75 [0.13 , 4.47]
0.91 [0.73 , 1.14]
0.95 [0.64 , 1.41]
0.63 [0.43 , 0.92]
1.39 [0.45 , 4.31]
1.75 [0.42 , 7.27]
0.52 [0.05 , 5.39]
0.87 [0.74 , 1.03]
0.90 [0.80 , 1.01]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
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Analysis 2.16.   Comparison 2: SFA reduction vs usual diet -
secondary health events, Outcome 16: MI, subgroup by TC reduction
Study or Subgroup











Heterogeneity: Tau² = 0.01; Chi² = 7.68, df = 7 (P = 0.36); I² = 9%
Test for overall effect: Z = 2.17 (P = 0.03)






Heterogeneity: Tau² = 0.00; Chi² = 0.82, df = 2 (P = 0.66); I² = 0%
Test for overall effect: Z = 0.37 (P = 0.71)




Test for overall effect: Not applicable














































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.08 [0.00 , 1.33]
0.95 [0.64 , 1.41]
2.02 [0.19 , 21.94]
0.63 [0.43 , 0.92]
1.39 [0.45 , 4.31]
0.52 [0.05 , 5.39]
0.76 [0.55 , 1.05]
0.83 [0.70 , 0.98]
1.33 [0.31 , 5.78]
1.75 [0.42 , 7.27]
0.97 [0.86 , 1.09]
0.98 [0.87 , 1.10]
Not estimable
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
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Analysis 2.17.   Comparison 2: SFA reduction vs usual diet - secondary










Heterogeneity: Tau² = 0.01; Chi² = 4.43, df = 4 (P = 0.35); I² = 10%

























Heterogeneity: Tau² = 0.00; Chi² = 0.53, df = 2 (P = 0.77); I² = 0%
Test for overall effect: Z = 0.41 (P = 0.68)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 11.07, df = 10 (P = 0.35); I² = 10%
Test for overall effect: Z = 1.72 (P = 0.09)






























































































M-H, Random, 95% CI
0.95 [0.64 , 1.41]
0.63 [0.43 , 0.92]
1.39 [0.45 , 4.31]
1.75 [0.42 , 7.27]
0.76 [0.55 , 1.05]
0.80 [0.64 , 1.00]
0.08 [0.00 , 1.33]
0.08 [0.00 , 1.33]
0.91 [0.73 , 1.14]
0.91 [0.73 , 1.14]
0.52 [0.05 , 5.39]
0.52 [0.05 , 5.39]
1.33 [0.31 , 5.78]
2.02 [0.19 , 21.94]
0.97 [0.86 , 1.09]
0.98 [0.87 , 1.10]
0.90 [0.80 , 1.01]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
 
Reduction in saturated fat intake for cardiovascular disease (Review)









Cochrane Database of Systematic Reviews
 
Analysis 2.18.   Comparison 2: SFA reduction vs usual diet - secondary












Heterogeneity: Tau² = 0.00; Chi² = 5.11, df = 7 (P = 0.65); I² = 0%
Test for overall effect: Z = 0.62 (P = 0.54)






















































M-H, Random, 95% CI
0.74 [0.48 , 1.14]
0.97 [0.58 , 1.64]
2.02 [0.19 , 21.94]
0.77 [0.47 , 1.27]
1.08 [0.33 , 3.53]
1.50 [0.35 , 6.43]
0.62 [0.31 , 1.21]
1.01 [0.90 , 1.13]
0.97 [0.87 , 1.07]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
 
 
Analysis 2.19.   Comparison 2: SFA reduction vs usual diet - secondary






Heterogeneity: Tau² = 0.06; Chi² = 1.95, df = 1 (P = 0.16); I² = 49%
Test for overall effect: Z = 0.56 (P = 0.57)
























M-H, Random, 95% CI
0.62 [0.31 , 1.21]
1.01 [0.90 , 1.13]
0.89 [0.58 , 1.35]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
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Analysis 2.20.   Comparison 2: SFA reduction vs usual diet - secondary












Heterogeneity: Tau² = 0.00; Chi² = 5.11, df = 7 (P = 0.65); I² = 0%
Test for overall effect: Z = 0.62 (P = 0.54)






















































M-H, Random, 95% CI
0.74 [0.48 , 1.14]
0.97 [0.58 , 1.64]
2.02 [0.19 , 21.94]
0.77 [0.47 , 1.27]
1.08 [0.33 , 3.53]
1.50 [0.35 , 6.43]
0.62 [0.31 , 1.21]
1.01 [0.90 , 1.13]
0.97 [0.87 , 1.07]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
 
 
Analysis 2.21.   Comparison 2: SFA reduction vs usual diet - secondary health








Heterogeneity: Tau² = 0.02; Chi² = 3.94, df = 3 (P = 0.27); I² = 24%
Test for overall effect: Z = 0.87 (P = 0.39)


































M-H, Random, 95% CI
0.74 [0.48 , 1.14]
2.02 [0.19 , 21.94]
0.62 [0.31 , 1.21]
1.01 [0.90 , 1.13]
0.90 [0.72 , 1.14]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
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Analysis 2.22.   Comparison 2: SFA reduction vs usual diet - secondary











Heterogeneity: Tau² = 0.00; Chi² = 4.76, df = 6 (P = 0.57); I² = 0%
Test for overall effect: Z = 0.66 (P = 0.51)

















































M-H, Random, 95% CI
0.74 [0.48 , 1.14]
0.97 [0.58 , 1.64]
2.02 [0.19 , 21.94]
0.77 [0.47 , 1.27]
1.08 [0.33 , 3.53]
0.62 [0.31 , 1.21]
1.01 [0.90 , 1.13]
0.97 [0.87 , 1.07]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
 
 
Analysis 2.23.   Comparison 2: SFA reduction vs usual diet - secondary











Heterogeneity: Tau² = 0.00; Chi² = 2.79, df = 6 (P = 0.83); I² = 0%
Test for overall effect: Z = 1.64 (P = 0.10)

















































M-H, Random, 95% CI
0.74 [0.48 , 1.14]
0.97 [0.58 , 1.64]
2.02 [0.19 , 21.94]
0.77 [0.47 , 1.27]
1.08 [0.33 , 3.53]
1.50 [0.35 , 6.43]
0.62 [0.31 , 1.21]
0.81 [0.64 , 1.04]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
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Analysis 2.24.   Comparison 2: SFA reduction vs usual diet - secondary












Heterogeneity: Chi² = 5.11, df = 7 (P = 0.65); I² = 0%
Test for overall effect: Z = 0.61 (P = 0.54)






















































M-H, Fixed, 95% CI
0.74 [0.48 , 1.14]
0.97 [0.58 , 1.64]
2.02 [0.19 , 21.94]
0.77 [0.47 , 1.27]
1.08 [0.33 , 3.53]
1.50 [0.35 , 6.43]
0.62 [0.31 , 1.21]
1.01 [0.90 , 1.13]
0.97 [0.87 , 1.08]
Risk Ratio
M-H, Fixed, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
 
 
Analysis 2.25.   Comparison 2: SFA reduction vs usual diet - secondary












Heterogeneity: Chi² = 5.21, df = 7 (P = 0.63); I² = 0%
Test for overall effect: Z = 0.61 (P = 0.54)






















































Peto, Fixed, 95% CI
0.73 [0.47 , 1.14]
0.97 [0.54 , 1.76]
1.98 [0.20 , 19.18]
0.75 [0.42 , 1.32]
1.11 [0.24 , 5.03]
1.58 [0.31 , 8.06]
0.61 [0.31 , 1.21]
1.01 [0.89 , 1.13]
0.97 [0.87 , 1.08]
Peto Odds Ratio
Peto, Fixed, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
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Analysis 2.26.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 26: Non-fatal MI, subgroup by any substitution
Study or Subgroup








Heterogeneity: Tau² = 0.00; Chi² = 2.14, df = 4 (P = 0.71); I² = 0%
Test for overall effect: Z = 1.72 (P = 0.09)





Test for overall effect: Z = 0.34 (P = 0.73)





Heterogeneity: Tau² = 0.02; Chi² = 1.79, df = 1 (P = 0.18); I² = 44%
Test for overall effect: Z = 0.55 (P = 0.58)





Heterogeneity: Tau² = 0.02; Chi² = 1.79, df = 1 (P = 0.18); I² = 44%






Test for overall effect: Z = 0.58 (P = 0.56)

























































































M-H, Random, 95% CI
0.74 [0.48 , 1.14]
0.97 [0.58 , 1.64]
0.77 [0.47 , 1.27]
1.30 [0.47 , 3.59]
0.62 [0.31 , 1.21]
0.80 [0.63 , 1.03]
1.20 [0.42 , 3.45]
1.20 [0.42 , 3.45]
0.74 [0.48 , 1.14]
1.01 [0.90 , 1.13]
0.93 [0.72 , 1.21]
0.74 [0.48 , 1.14]
1.01 [0.90 , 1.13]
0.93 [0.72 , 1.21]
2.02 [0.19 , 21.94]
2.02 [0.19 , 21.94]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
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Analysis 2.27.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 27: Non-fatal MI, subgroup by main substitution
Study or Subgroup








Heterogeneity: Tau² = 0.00; Chi² = 2.14, df = 4 (P = 0.71); I² = 0%
Test for overall effect: Z = 1.72 (P = 0.09)





Test for overall effect: Z = 0.34 (P = 0.73)





Test for overall effect: Z = 0.10 (P = 0.92)










Test for overall effect: Z = 0.58 (P = 0.56)









































































M-H, Random, 95% CI
0.74 [0.48 , 1.14]
0.97 [0.58 , 1.64]
0.77 [0.47 , 1.27]
1.30 [0.47 , 3.59]
0.62 [0.31 , 1.21]
0.80 [0.63 , 1.03]
1.20 [0.42 , 3.45]
1.20 [0.42 , 3.45]
1.01 [0.90 , 1.13]
1.01 [0.90 , 1.13]
Not estimable
2.02 [0.19 , 21.94]
2.02 [0.19 , 21.94]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
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Analysis 2.28.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 28: Non-fatal MI, subgroup by duration
Study or Subgroup
2.28.1 up to 24mo
DART 1989
Moy 2001




Heterogeneity: Tau² = 0.00; Chi² = 1.62, df = 3 (P = 0.65); I² = 0%
Test for overall effect: Z = 0.94 (P = 0.35)





Heterogeneity: Tau² = 0.01; Chi² = 1.11, df = 1 (P = 0.29); I² = 10%






Heterogeneity: Tau² = 0.00; Chi² = 1.01, df = 1 (P = 0.31); I² = 1%





Test for overall effect: Not applicable
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 5.11, df = 7 (P = 0.65); I² = 0%
Test for overall effect: Z = 0.62 (P = 0.54)









































































M-H, Random, 95% CI
0.74 [0.48 , 1.14]
2.02 [0.19 , 21.94]
1.08 [0.33 , 3.53]
1.50 [0.35 , 6.43]
0.83 [0.57 , 1.22]
0.97 [0.58 , 1.64]
0.62 [0.31 , 1.21]
0.82 [0.53 , 1.27]
0.77 [0.47 , 1.27]
1.01 [0.90 , 1.13]
0.99 [0.88 , 1.12]
Not estimable
0.97 [0.87 , 1.07]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
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Analysis 2.29.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 29: Non-fatal MI, subgroup by baseline SFA
Study or Subgroup




Test for overall effect: Not applicable






Heterogeneity: Tau² = 0.00; Chi² = 2.14, df = 2 (P = 0.34); I² = 6%
Test for overall effect: Z = 0.35 (P = 0.73)




Test for overall effect: Not applicable













Heterogeneity: Tau² = 0.00; Chi² = 1.01, df = 3 (P = 0.80); I² = 0%
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 5.11, df = 7 (P = 0.65); I² = 0%
Test for overall effect: Z = 0.62 (P = 0.54)













































































M-H, Random, 95% CI
Not estimable
0.74 [0.48 , 1.14]
2.02 [0.19 , 21.94]
1.01 [0.90 , 1.13]
0.97 [0.83 , 1.13]
Not estimable
0.62 [0.31 , 1.21]
0.62 [0.31 , 1.21]
0.97 [0.58 , 1.64]
0.77 [0.47 , 1.27]
1.08 [0.33 , 3.53]
1.50 [0.35 , 6.43]
0.91 [0.65 , 1.27]
0.97 [0.87 , 1.07]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
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Analysis 2.30.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 30: Non-fatal MI, subgroup by SFA change
Study or Subgroup






Heterogeneity: Tau² = 0.00; Chi² = 2.14, df = 2 (P = 0.34); I² = 6%
Test for overall effect: Z = 0.35 (P = 0.73)


















Heterogeneity: Tau² = 0.00; Chi² = 1.01, df = 3 (P = 0.80); I² = 0%
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 5.11, df = 7 (P = 0.65); I² = 0%
Test for overall effect: Z = 0.62 (P = 0.54)









































































M-H, Random, 95% CI
0.74 [0.48 , 1.14]
2.02 [0.19 , 21.94]
1.01 [0.90 , 1.13]
0.97 [0.83 , 1.13]
Not estimable
0.62 [0.31 , 1.21]
0.62 [0.31 , 1.21]
0.97 [0.58 , 1.64]
0.77 [0.47 , 1.27]
1.08 [0.33 , 3.53]
1.50 [0.35 , 6.43]
0.91 [0.65 , 1.27]
0.97 [0.87 , 1.07]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
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Analysis 2.31.   Comparison 2: SFA reduction vs usual diet -











Heterogeneity: Tau² = 0.00; Chi² = 2.23, df = 5 (P = 0.82); I² = 0%






Test for overall effect: Z = 0.10 (P = 0.92)





Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 5.11, df = 7 (P = 0.65); I² = 0%
Test for overall effect: Z = 0.62 (P = 0.54)





































































M-H, Random, 95% CI
0.74 [0.48 , 1.14]
0.97 [0.58 , 1.64]
0.77 [0.47 , 1.27]
1.08 [0.33 , 3.53]
1.50 [0.35 , 6.43]
0.62 [0.31 , 1.21]
0.81 [0.63 , 1.03]
1.01 [0.90 , 1.13]
1.01 [0.90 , 1.13]
2.02 [0.19 , 21.94]
2.02 [0.19 , 21.94]
0.97 [0.87 , 1.07]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
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Analysis 2.32.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 32: Non-fatal MI, subgroup by CVD risk
Study or Subgroup





Heterogeneity: Tau² = 0.01; Chi² = 1.23, df = 1 (P = 0.27); I² = 19%
Test for overall effect: Z = 1.11 (P = 0.27)





Test for overall effect: Z = 0.58 (P = 0.56)









Heterogeneity: Tau² = 0.04; Chi² = 7.63, df = 5 (P = 0.18); I² = 34%
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.02; Chi² = 11.03, df = 8 (P = 0.20); I² = 27%
Test for overall effect: Z = 0.56 (P = 0.57)










































































M-H, Random, 95% CI
0.62 [0.31 , 1.21]
0.91 [0.80 , 1.04]
0.87 [0.68 , 1.12]
2.02 [0.19 , 21.94]
2.02 [0.19 , 21.94]
0.74 [0.48 , 1.14]
0.97 [0.58 , 1.64]
0.77 [0.47 , 1.27]
1.08 [0.33 , 3.53]
1.50 [0.35 , 6.43]
1.37 [1.03 , 1.83]
1.00 [0.76 , 1.31]
0.95 [0.80 , 1.13]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Women with CVD at baseline
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Analysis 2.33.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 33: Non-fatal MI, subgroup by TC reduction
Study or Subgroup









Heterogeneity: Tau² = 0.00; Chi² = 2.09, df = 5 (P = 0.84); I² = 0%
Test for overall effect: Z = 1.76 (P = 0.08)





Heterogeneity: Tau² = 0.00; Chi² = 0.29, df = 1 (P = 0.59); I² = 0%
Test for overall effect: Z = 0.14 (P = 0.89)




Test for overall effect: Not applicable































































M-H, Random, 95% CI
0.74 [0.48 , 1.14]
0.97 [0.58 , 1.64]
2.02 [0.19 , 21.94]
0.77 [0.47 , 1.27]
1.08 [0.33 , 3.53]
0.62 [0.31 , 1.21]
0.80 [0.62 , 1.03]
1.50 [0.35 , 6.43]
1.01 [0.90 , 1.13]
1.01 [0.90 , 1.13]
Not estimable
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
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Analysis 2.34.   Comparison 2: SFA reduction vs usual diet - secondary










Heterogeneity: Tau² = 0.00; Chi² = 2.01, df = 4 (P = 0.73); I² = 0%






















Heterogeneity: Tau² = 0.00; Chi² = 0.33, df = 1 (P = 0.57); I² = 0%
Test for overall effect: Z = 0.13 (P = 0.90)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 5.11, df = 7 (P = 0.65); I² = 0%
Test for overall effect: Z = 0.62 (P = 0.54)













































































M-H, Random, 95% CI
0.97 [0.58 , 1.64]
0.77 [0.47 , 1.27]
1.08 [0.33 , 3.53]
1.50 [0.35 , 6.43]
0.62 [0.31 , 1.21]
0.84 [0.62 , 1.13]
Not estimable
0.74 [0.48 , 1.14]
0.74 [0.48 , 1.14]
Not estimable
2.02 [0.19 , 21.94]
1.01 [0.90 , 1.13]
1.01 [0.90 , 1.13]
0.97 [0.87 , 1.07]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Non-fatal MI during trial, Prentice 2017
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Heterogeneity: Tau² = 0.03; Chi² = 6.59, df = 6 (P = 0.36); I² = 9%
Test for overall effect: Z = 0.52 (P = 0.60)

















































M-H, Random, 95% CI
0.20 [0.02 , 1.68]
4.88 [0.24 , 100.89]
1.01 [0.06 , 15.93]
2.00 [0.18 , 21.89]
0.35 [0.01 , 8.12]
0.59 [0.30 , 1.15]
1.03 [0.91 , 1.16]
0.92 [0.68 , 1.25]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
 
 
Analysis 2.36.   Comparison 2: SFA reduction vs usual diet - secondary







Heterogeneity: Tau² = 0.15; Chi² = 4.80, df = 2 (P = 0.09); I² = 58%
Test for overall effect: Z = 0.91 (P = 0.36)





























M-H, Random, 95% CI
0.20 [0.02 , 1.68]
0.59 [0.30 , 1.15]
1.03 [0.91 , 1.16]
0.76 [0.42 , 1.38]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
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Analysis 2.37.   Comparison 2: SFA reduction vs usual diet -










Heterogeneity: Tau² = 0.00; Chi² = 4.36, df = 5 (P = 0.50); I² = 0%
Test for overall effect: Z = 0.22 (P = 0.83)












































M-H, Random, 95% CI
4.88 [0.24 , 100.89]
1.01 [0.06 , 15.93]
2.00 [0.18 , 21.89]
0.35 [0.01 , 8.12]
0.59 [0.30 , 1.15]
1.03 [0.91 , 1.16]
1.01 [0.90 , 1.14]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
 
 
Analysis 2.38.   Comparison 2: SFA reduction vs usual diet - secondary









Heterogeneity: Tau² = 0.06; Chi² = 5.24, df = 4 (P = 0.26); I² = 24%
Test for overall effect: Z = 0.89 (P = 0.37)







































M-H, Random, 95% CI
0.20 [0.02 , 1.68]
1.01 [0.06 , 15.93]
0.35 [0.01 , 8.12]
0.59 [0.30 , 1.15]
1.03 [0.91 , 1.16]
0.83 [0.55 , 1.25]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
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Analysis 2.39.   Comparison 2: SFA reduction vs usual diet -










Heterogeneity: Tau² = 0.00; Chi² = 4.36, df = 5 (P = 0.50); I² = 0%
Test for overall effect: Z = 0.22 (P = 0.83)












































M-H, Random, 95% CI
4.88 [0.24 , 100.89]
1.01 [0.06 , 15.93]
2.00 [0.18 , 21.89]
0.35 [0.01 , 8.12]
0.59 [0.30 , 1.15]
1.03 [0.91 , 1.16]
1.01 [0.90 , 1.14]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
 
 
Analysis 2.40.   Comparison 2: SFA reduction vs usual diet -










Heterogeneity: Tau² = 0.00; Chi² = 4.06, df = 5 (P = 0.54); I² = 0%
Test for overall effect: Z = 1.53 (P = 0.13)












































M-H, Random, 95% CI
0.20 [0.02 , 1.68]
4.88 [0.24 , 100.89]
1.01 [0.06 , 15.93]
2.00 [0.18 , 21.89]
0.35 [0.01 , 8.12]
0.59 [0.30 , 1.15]
0.63 [0.35 , 1.14]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
 
 
Reduction in saturated fat intake for cardiovascular disease (Review)
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Analysis 2.41.   Comparison 2: SFA reduction vs usual diet - secondary











Heterogeneity: Chi² = 6.59, df = 6 (P = 0.36); I² = 9%
Test for overall effect: Z = 0.11 (P = 0.92)

















































M-H, Fixed, 95% CI
0.20 [0.02 , 1.68]
4.88 [0.24 , 100.89]
1.01 [0.06 , 15.93]
2.00 [0.18 , 21.89]
0.35 [0.01 , 8.12]
0.59 [0.30 , 1.15]
1.03 [0.91 , 1.16]
1.01 [0.89 , 1.13]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
 
 
Analysis 2.42.   Comparison 2: SFA reduction vs usual diet -











Heterogeneity: Chi² = 8.65, df = 6 (P = 0.19); I² = 31%
Test for overall effect: Z = 0.11 (P = 0.92)

















































Peto, Fixed, 95% CI
0.25 [0.05 , 1.29]
7.24 [0.45 , 116.22]
1.01 [0.06 , 16.22]
1.95 [0.20 , 18.89]
0.14 [0.00 , 7.07]
0.58 [0.30 , 1.15]
1.03 [0.91 , 1.16]
1.01 [0.89 , 1.14]
Peto Odds Ratio
Peto, Fixed, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
 
 
Reduction in saturated fat intake for cardiovascular disease (Review)
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Analysis 2.43.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 43: Stroke, subgroup by any substitution
Study or Subgroup







Heterogeneity: Tau² = 0.00; Chi² = 2.78, df = 3 (P = 0.43); I² = 0%
Test for overall effect: Z = 1.20 (P = 0.23)




Test for overall effect: Not applicable






Heterogeneity: Tau² = 0.30; Chi² = 2.73, df = 2 (P = 0.26); I² = 27%
Test for overall effect: Z = 0.65 (P = 0.51)





Heterogeneity: Tau² = 0.75; Chi² = 2.27, df = 1 (P = 0.13); I² = 56%






Test for overall effect: Z = 0.01 (P = 1.00)



















































































M-H, Random, 95% CI
4.88 [0.24 , 100.89]
2.00 [0.18 , 21.89]
0.35 [0.01 , 8.12]
0.59 [0.30 , 1.15]
0.68 [0.37 , 1.27]
Not estimable
0.20 [0.02 , 1.68]
0.35 [0.01 , 8.12]
1.03 [0.91 , 1.16]
0.73 [0.29 , 1.87]
0.20 [0.02 , 1.68]
1.03 [0.91 , 1.16]
0.65 [0.15 , 2.75]
1.01 [0.06 , 15.93]
1.01 [0.06 , 15.93]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
 
Reduction in saturated fat intake for cardiovascular disease (Review)
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Analysis 2.44.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 44: Stroke, subgroup by main substitution
Study or Subgroup






Heterogeneity: Tau² = 0.30; Chi² = 2.60, df = 2 (P = 0.27); I² = 23%
Test for overall effect: Z = 0.16 (P = 0.87)




Test for overall effect: Not applicable






Heterogeneity: Tau² = 0.30; Chi² = 2.73, df = 2 (P = 0.26); I² = 27%
Test for overall effect: Z = 0.65 (P = 0.51)










Test for overall effect: Z = 0.01 (P = 1.00)



































































M-H, Random, 95% CI
4.88 [0.24 , 100.89]
2.00 [0.18 , 21.89]
0.59 [0.30 , 1.15]
0.92 [0.31 , 2.69]
Not estimable
0.20 [0.02 , 1.68]
0.35 [0.01 , 8.12]
1.03 [0.91 , 1.16]
0.73 [0.29 , 1.87]
Not estimable
1.01 [0.06 , 15.93]
1.01 [0.06 , 15.93]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
Reduction in saturated fat intake for cardiovascular disease (Review)
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Analysis 2.45.   Comparison 2: SFA reduction vs usual diet -
secondary health events, Outcome 45: Stroke, subgroup by duration
Study or Subgroup





Test for overall effect: Z = 0.01 (P = 1.00)





Heterogeneity: Tau² = 0.00; Chi² = 0.10, df = 1 (P = 0.75); I² = 0%






Heterogeneity: Tau² = 0.00; Chi² = 0.30, df = 1 (P = 0.59); I² = 0%






Test for overall effect: Z = 1.48 (P = 0.14)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.03; Chi² = 5.56, df = 5 (P = 0.35); I² = 10%
Test for overall effect: Z = 0.62 (P = 0.54)
































































M-H, Random, 95% CI
1.01 [0.06 , 15.93]
1.01 [0.06 , 15.93]
0.35 [0.01 , 8.12]
0.59 [0.30 , 1.15]
0.57 [0.30 , 1.11]
2.00 [0.18 , 21.89]
1.03 [0.91 , 1.16]
1.03 [0.91 , 1.16]
0.20 [0.02 , 1.68]
0.20 [0.02 , 1.68]
0.91 [0.67 , 1.23]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
 
 
Reduction in saturated fat intake for cardiovascular disease (Review)
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Analysis 2.46.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 46: Stroke, subgroup by baseline SFA
Study or Subgroup




Test for overall effect: Not applicable






Heterogeneity: Tau² = 0.10; Chi² = 2.27, df = 2 (P = 0.32); I² = 12%
Test for overall effect: Z = 0.30 (P = 0.76)





Test for overall effect: Z = 0.66 (P = 0.51)











Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.03; Chi² = 5.56, df = 5 (P = 0.35); I² = 10%
Test for overall effect: Z = 0.62 (P = 0.54)




































































M-H, Random, 95% CI
Not estimable
0.20 [0.02 , 1.68]
1.01 [0.06 , 15.93]
1.03 [0.91 , 1.16]
0.91 [0.50 , 1.66]
0.35 [0.01 , 8.12]
0.35 [0.01 , 8.12]
0.59 [0.30 , 1.15]
0.59 [0.30 , 1.15]
2.00 [0.18 , 21.89]
2.00 [0.18 , 21.89]
0.91 [0.67 , 1.23]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
 
Reduction in saturated fat intake for cardiovascular disease (Review)
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Analysis 2.47.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 47: Stroke, subgroup by SFA change
Study or Subgroup






Heterogeneity: Tau² = 0.10; Chi² = 2.27, df = 2 (P = 0.32); I² = 12%
Test for overall effect: Z = 0.30 (P = 0.76)

















Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.03; Chi² = 5.56, df = 5 (P = 0.35); I² = 10%
Test for overall effect: Z = 0.62 (P = 0.54)
































































M-H, Random, 95% CI
0.20 [0.02 , 1.68]
1.01 [0.06 , 15.93]
1.03 [0.91 , 1.16]
0.91 [0.50 , 1.66]
0.35 [0.01 , 8.12]
0.35 [0.01 , 8.12]
0.59 [0.30 , 1.15]
0.59 [0.30 , 1.15]
2.00 [0.18 , 21.89]
2.00 [0.18 , 21.89]
0.91 [0.67 , 1.23]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
 
 
Reduction in saturated fat intake for cardiovascular disease (Review)
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Analysis 2.48.   Comparison 2: SFA reduction vs usual diet -








Heterogeneity: Tau² = 0.00; Chi² = 1.08, df = 2 (P = 0.58); I² = 0%






Test for overall effect: Z = 0.46 (P = 0.65)





Heterogeneity: Tau² = 0.00; Chi² = 0.84, df = 1 (P = 0.36); I² = 0%
Test for overall effect: Z = 1.17 (P = 0.24)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.03; Chi² = 5.56, df = 5 (P = 0.35); I² = 10%
Test for overall effect: Z = 0.62 (P = 0.54)



























































M-H, Random, 95% CI
2.00 [0.18 , 21.89]
0.35 [0.01 , 8.12]
0.59 [0.30 , 1.15]
0.63 [0.33 , 1.18]
1.03 [0.91 , 1.16]
1.03 [0.91 , 1.16]
0.20 [0.02 , 1.68]
1.01 [0.06 , 15.93]
0.37 [0.07 , 1.97]
0.91 [0.67 , 1.23]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
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Analysis 2.49.   Comparison 2: SFA reduction vs usual diet -
secondary health events, Outcome 49: Stroke, subgroup by CVD risk
Study or Subgroup





Heterogeneity: Tau² = 0.09; Chi² = 2.45, df = 1 (P = 0.12); I² = 59%
Test for overall effect: Z = 0.60 (P = 0.55)





Heterogeneity: Tau² = 0.00; Chi² = 0.84, df = 1 (P = 0.36); I² = 0%
Test for overall effect: Z = 1.17 (P = 0.24)






Heterogeneity: Tau² = 0.00; Chi² = 0.76, df = 2 (P = 0.68); I² = 0%
Test for overall effect: Z = 0.11 (P = 0.91)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 5.44, df = 6 (P = 0.49); I² = 0%
Test for overall effect: Z = 0.08 (P = 0.94)
































































M-H, Random, 95% CI
0.59 [0.30 , 1.15]
1.02 [0.87 , 1.21]
0.86 [0.52 , 1.42]
0.20 [0.02 , 1.68]
1.01 [0.06 , 15.93]
0.37 [0.07 , 1.97]
2.00 [0.18 , 21.89]
0.35 [0.01 , 8.12]
1.01 [0.86 , 1.18]
1.01 [0.86 , 1.18]
1.00 [0.89 , 1.11]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) Women without CVD at baseline
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Analysis 2.50.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 50: Stroke, subgroup by TC reduction
Study or Subgroup








Heterogeneity: Tau² = 0.00; Chi² = 2.85, df = 4 (P = 0.58); I² = 0%
Test for overall effect: Z = 1.17 (P = 0.24)





Heterogeneity: Tau² = 0.75; Chi² = 2.27, df = 1 (P = 0.13); I² = 56%
Test for overall effect: Z = 0.59 (P = 0.56)




Test for overall effect: Not applicable


























































M-H, Random, 95% CI
4.88 [0.24 , 100.89]
1.01 [0.06 , 15.93]
2.00 [0.18 , 21.89]
0.35 [0.01 , 8.12]
0.59 [0.30 , 1.15]
0.70 [0.38 , 1.28]
0.20 [0.02 , 1.68]
1.03 [0.91 , 1.16]
0.65 [0.15 , 2.75]
Not estimable
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
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Analysis 2.51.   Comparison 2: SFA reduction vs usual diet - secondary








Heterogeneity: Tau² = 0.30; Chi² = 2.60, df = 2 (P = 0.27); I² = 23%























Heterogeneity: Tau² = 0.10; Chi² = 2.27, df = 2 (P = 0.32); I² = 12%
Test for overall effect: Z = 0.30 (P = 0.76)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.03; Chi² = 6.59, df = 6 (P = 0.36); I² = 9%
Test for overall effect: Z = 0.52 (P = 0.60)








































































M-H, Random, 95% CI
4.88 [0.24 , 100.89]
2.00 [0.18 , 21.89]
0.59 [0.30 , 1.15]
0.92 [0.31 , 2.69]
Not estimable
Not estimable
0.35 [0.01 , 8.12]
0.35 [0.01 , 8.12]
0.20 [0.02 , 1.68]
1.01 [0.06 , 15.93]
1.03 [0.91 , 1.16]
0.91 [0.50 , 1.66]
0.92 [0.68 , 1.25]
Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours lower SFA Favours higher SFA
Footnotes
(1) During trial, Prentice 2017
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Analysis 2.52.   Comparison 2: SFA reduction vs usual diet - secondary













Heterogeneity: Tau² = 0.02; Chi² = 11.18, df = 8 (P = 0.19); I² = 28%
Test for overall effect: Z = 0.32 (P = 0.75)



























































M-H, Random, 95% CI
1.00 [0.76 , 1.30]
0.09 [0.01 , 1.60]
0.97 [0.58 , 1.64]
0.74 [0.51 , 1.08]
2.32 [0.30 , 17.92]
3.63 [0.20 , 65.44]
1.63 [1.00 , 2.67]
0.82 [0.55 , 1.21]
0.99 [0.82 , 1.20]
0.97 [0.82 , 1.16]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
 
 
Analysis 2.53.   Comparison 2: SFA reduction vs usual diet - secondary







Heterogeneity: Tau² = 0.04; Chi² = 4.83, df = 2 (P = 0.09); I² = 59%
Test for overall effect: Z = 0.30 (P = 0.76)





























M-H, Random, 95% CI
1.63 [1.00 , 2.67]
0.82 [0.55 , 1.21]
0.99 [0.82 , 1.20]
1.05 [0.77 , 1.43]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
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Analysis 2.54.   Comparison 2: SFA reduction vs usual diet - secondary













Heterogeneity: Tau² = 0.02; Chi² = 11.18, df = 8 (P = 0.19); I² = 28%
Test for overall effect: Z = 0.32 (P = 0.75)



























































M-H, Random, 95% CI
1.00 [0.76 , 1.30]
0.09 [0.01 , 1.60]
0.97 [0.58 , 1.64]
0.74 [0.51 , 1.08]
2.32 [0.30 , 17.92]
3.63 [0.20 , 65.44]
1.63 [1.00 , 2.67]
0.82 [0.55 , 1.21]
0.99 [0.82 , 1.20]
0.97 [0.82 , 1.16]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
 
 
Analysis 2.55.   Comparison 2: SFA reduction vs usual diet - secondary health








Heterogeneity: Tau² = 0.01; Chi² = 4.84, df = 3 (P = 0.18); I² = 38%
Test for overall effect: Z = 0.19 (P = 0.85)


































M-H, Random, 95% CI
1.00 [0.76 , 1.30]
1.63 [1.00 , 2.67]
0.82 [0.55 , 1.21]
0.99 [0.82 , 1.20]
1.02 [0.84 , 1.24]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
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Analysis 2.56.   Comparison 2: SFA reduction vs usual diet - secondary












Heterogeneity: Tau² = 0.02; Chi² = 10.38, df = 7 (P = 0.17); I² = 33%
Test for overall effect: Z = 0.36 (P = 0.72)






















































M-H, Random, 95% CI
1.00 [0.76 , 1.30]
0.09 [0.01 , 1.60]
0.97 [0.58 , 1.64]
0.74 [0.51 , 1.08]
2.32 [0.30 , 17.92]
1.63 [1.00 , 2.67]
0.82 [0.55 , 1.21]
0.99 [0.82 , 1.20]
0.97 [0.81 , 1.16]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
 
 
Analysis 2.57.   Comparison 2: SFA reduction vs usual diet - secondary












Heterogeneity: Tau² = 0.04; Chi² = 11.13, df = 7 (P = 0.13); I² = 37%
Test for overall effect: Z = 0.22 (P = 0.82)






















































M-H, Random, 95% CI
1.00 [0.76 , 1.30]
0.09 [0.01 , 1.60]
0.97 [0.58 , 1.64]
0.74 [0.51 , 1.08]
2.32 [0.30 , 17.92]
3.63 [0.20 , 65.44]
1.63 [1.00 , 2.67]
0.82 [0.55 , 1.21]
0.97 [0.76 , 1.24]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
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Analysis 2.58.   Comparison 2: SFA reduction vs usual diet - secondary













Heterogeneity: Chi² = 11.18, df = 8 (P = 0.19); I² = 28%
Test for overall effect: Z = 0.45 (P = 0.65)



























































M-H, Fixed, 95% CI
1.00 [0.76 , 1.30]
0.09 [0.01 , 1.60]
0.97 [0.58 , 1.64]
0.74 [0.51 , 1.08]
2.32 [0.30 , 17.92]
3.63 [0.20 , 65.44]
1.63 [1.00 , 2.67]
0.82 [0.55 , 1.21]
0.99 [0.82 , 1.20]
0.97 [0.86 , 1.10]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
 
 
Analysis 2.59.   Comparison 2: SFA reduction vs usual diet - secondary













Heterogeneity: Chi² = 14.72, df = 8 (P = 0.06); I² = 46%
Test for overall effect: Z = 0.44 (P = 0.66)



























































Peto, Fixed, 95% CI
1.00 [0.74 , 1.34]
0.12 [0.02 , 0.75]
0.97 [0.54 , 1.76]
0.69 [0.43 , 1.10]
2.21 [0.35 , 13.90]
4.87 [0.41 , 57.37]
1.74 [1.00 , 3.02]
0.80 [0.52 , 1.23]
0.99 [0.81 , 1.20]
0.97 [0.85 , 1.11]
Peto Odds Ratio
Peto, Fixed, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
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Analysis 2.60.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 60: CHD mortality, subgroup by any substitution
Study or Subgroup










Heterogeneity: Tau² = 0.06; Chi² = 11.81, df = 6 (P = 0.07); I² = 49%
Test for overall effect: Z = 0.18 (P = 0.86)





Test for overall effect: Z = 0.98 (P = 0.33)





Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.11 (P = 0.91)





Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%





Test for overall effect: Not applicable





























































































M-H, Random, 95% CI
1.00 [0.76 , 1.30]
0.09 [0.01 , 1.60]
0.97 [0.58 , 1.64]
0.74 [0.51 , 1.08]
4.64 [0.58 , 37.15]
1.63 [1.00 , 2.67]
0.82 [0.55 , 1.21]
0.98 [0.74 , 1.28]
3.00 [0.33 , 26.99]
3.00 [0.33 , 26.99]
1.00 [0.76 , 1.30]
0.99 [0.82 , 1.20]
0.99 [0.85 , 1.16]
1.00 [0.76 , 1.30]
0.99 [0.82 , 1.20]
0.99 [0.85 , 1.16]
Not estimable
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
 
Reduction in saturated fat intake for cardiovascular disease (Review)
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Analysis 2.61.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 61: CHD mortality, subgroup by main substitution
Study or Subgroup










Heterogeneity: Tau² = 0.06; Chi² = 11.81, df = 6 (P = 0.07); I² = 49%
Test for overall effect: Z = 0.18 (P = 0.86)





Test for overall effect: Z = 0.98 (P = 0.33)





Test for overall effect: Z = 0.12 (P = 0.90)









Test for overall effect: Not applicable













































































M-H, Random, 95% CI
1.00 [0.76 , 1.30]
0.09 [0.01 , 1.60]
0.97 [0.58 , 1.64]
0.74 [0.51 , 1.08]
4.64 [0.58 , 37.15]
1.63 [1.00 , 2.67]
0.82 [0.55 , 1.21]
0.98 [0.74 , 1.28]
3.00 [0.33 , 26.99]
3.00 [0.33 , 26.99]
0.99 [0.82 , 1.20]




M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
Reduction in saturated fat intake for cardiovascular disease (Review)









Cochrane Database of Systematic Reviews
 
 
Analysis 2.62.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 62: CHD mortality, subgroup by duration
Study or Subgroup
2.62.1 up to 24mo
DART 1989




Heterogeneity: Tau² = 0.00; Chi² = 1.40, df = 2 (P = 0.50); I² = 0%
Test for overall effect: Z = 0.16 (P = 0.87)





Heterogeneity: Tau² = 0.00; Chi² = 0.29, df = 1 (P = 0.59); I² = 0%







Heterogeneity: Tau² = 0.06; Chi² = 6.22, df = 2 (P = 0.04); I² = 68%






Test for overall effect: Z = 1.64 (P = 0.10)










































































M-H, Random, 95% CI
1.00 [0.76 , 1.30]
2.32 [0.30 , 17.92]
3.63 [0.20 , 65.44]
1.02 [0.78 , 1.33]
0.97 [0.58 , 1.64]
0.82 [0.55 , 1.21]
0.87 [0.64 , 1.19]
0.74 [0.51 , 1.08]
1.63 [1.00 , 2.67]
0.99 [0.82 , 1.20]
1.02 [0.72 , 1.45]
0.09 [0.01 , 1.60]
0.09 [0.01 , 1.60]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
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Analysis 2.63.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 63: CHD mortality, subgroup by baseline SFA
Study or Subgroup




Test for overall effect: Not applicable






Heterogeneity: Tau² = 0.02; Chi² = 3.58, df = 2 (P = 0.17); I² = 44%
Test for overall effect: Z = 0.63 (P = 0.53)




Test for overall effect: Not applicable














Heterogeneity: Tau² = 0.05; Chi² = 4.98, df = 4 (P = 0.29); I² = 20%
Test for overall effect: Z = 0.76 (P = 0.45)













































































M-H, Random, 95% CI
Not estimable
1.00 [0.76 , 1.30]
1.63 [1.00 , 2.67]
0.99 [0.82 , 1.20]
1.07 [0.86 , 1.34]
Not estimable
0.82 [0.55 , 1.21]
0.82 [0.55 , 1.21]
0.09 [0.01 , 1.60]
0.97 [0.58 , 1.64]
0.74 [0.51 , 1.08]
2.32 [0.30 , 17.92]
3.63 [0.20 , 65.44]
0.85 [0.56 , 1.29]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
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Cochrane Database of Systematic Reviews
 
Analysis 2.64.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 64: CHD mortality, subgroup by SFA change
Study or Subgroup






Heterogeneity: Tau² = 0.02; Chi² = 3.58, df = 2 (P = 0.17); I² = 44%
Test for overall effect: Z = 0.63 (P = 0.53)



















Heterogeneity: Tau² = 0.05; Chi² = 4.98, df = 4 (P = 0.29); I² = 20%
Test for overall effect: Z = 0.76 (P = 0.45)









































































M-H, Random, 95% CI
1.00 [0.76 , 1.30]
1.63 [1.00 , 2.67]
0.99 [0.82 , 1.20]
1.07 [0.86 , 1.34]
Not estimable
0.82 [0.55 , 1.21]
0.82 [0.55 , 1.21]
0.09 [0.01 , 1.60]
0.97 [0.58 , 1.64]
0.74 [0.51 , 1.08]
2.32 [0.30 , 17.92]
3.63 [0.20 , 65.44]
0.85 [0.56 , 1.29]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
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Analysis 2.65.   Comparison 2: SFA reduction vs usual diet - secondary












Heterogeneity: Tau² = 0.02; Chi² = 8.55, df = 6 (P = 0.20); I² = 30%






Test for overall effect: Z = 0.12 (P = 0.90)





Test for overall effect: Z = 1.64 (P = 0.10)





































































M-H, Random, 95% CI
1.00 [0.76 , 1.30]
0.97 [0.58 , 1.64]
0.74 [0.51 , 1.08]
2.32 [0.30 , 17.92]
3.63 [0.20 , 65.44]
1.63 [1.00 , 2.67]
0.82 [0.55 , 1.21]
0.98 [0.79 , 1.23]
0.99 [0.82 , 1.20]
0.99 [0.82 , 1.20]
0.09 [0.01 , 1.60]
0.09 [0.01 , 1.60]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
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Analysis 2.66.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 66: CHD mortality, subgroup by CVD risk
Study or Subgroup





Heterogeneity: Tau² = 0.00; Chi² = 0.81, df = 1 (P = 0.37); I² = 0%
Test for overall effect: Z = 0.48 (P = 0.63)





Test for overall effect: Z = 1.64 (P = 0.10)










Heterogeneity: Tau² = 0.02; Chi² = 7.69, df = 6 (P = 0.26); I² = 22%
Test for overall effect: Z = 0.24 (P = 0.81)










































































M-H, Random, 95% CI
0.82 [0.55 , 1.21]
1.00 [0.80 , 1.26]
0.95 [0.78 , 1.16]
0.09 [0.01 , 1.60]
0.09 [0.01 , 1.60]
1.00 [0.76 , 1.30]
0.97 [0.58 , 1.64]
0.74 [0.51 , 1.08]
2.32 [0.30 , 17.92]
3.63 [0.20 , 65.44]
1.63 [1.00 , 2.67]
1.05 [0.68 , 1.61]
1.03 [0.83 , 1.27]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Women without CVD at baseline
(2) Women with CVD at baseline
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Analysis 2.67.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 67: CHD mortality, subgroup by TC reduction
Study or Subgroup










Heterogeneity: Tau² = 0.04; Chi² = 10.31, df = 6 (P = 0.11); I² = 42%
Test for overall effect: Z = 0.29 (P = 0.77)





Heterogeneity: Tau² = 0.00; Chi² = 0.78, df = 1 (P = 0.38); I² = 0%
Test for overall effect: Z = 0.07 (P = 0.95)




Test for overall effect: Not applicable




































































M-H, Random, 95% CI
1.00 [0.76 , 1.30]
0.09 [0.01 , 1.60]
0.97 [0.58 , 1.64]
0.74 [0.51 , 1.08]
2.32 [0.30 , 17.92]
1.63 [1.00 , 2.67]
0.82 [0.55 , 1.21]
0.96 [0.75 , 1.24]
3.63 [0.20 , 65.44]
0.99 [0.82 , 1.20]
0.99 [0.82 , 1.20]
Not estimable
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
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Analysis 2.68.   Comparison 2: SFA reduction vs usual diet - secondary










Heterogeneity: Tau² = 0.00; Chi² = 2.72, df = 4 (P = 0.61); I² = 0%






Heterogeneity: Tau² = 3.35; Chi² = 4.03, df = 1 (P = 0.04); I² = 75%

















Test for overall effect: Z = 0.12 (P = 0.90)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.02; Chi² = 11.18, df = 8 (P = 0.19); I² = 28%
Test for overall effect: Z = 0.32 (P = 0.75)



















































































M-H, Random, 95% CI
0.97 [0.58 , 1.64]
0.74 [0.51 , 1.08]
2.32 [0.30 , 17.92]
3.63 [0.20 , 65.44]
0.82 [0.55 , 1.21]
0.84 [0.66 , 1.06]
0.09 [0.01 , 1.60]
1.63 [1.00 , 2.67]
0.54 [0.03 , 9.26]
1.00 [0.76 , 1.30]
1.00 [0.76 , 1.30]
Not estimable
0.99 [0.82 , 1.20]
0.99 [0.82 , 1.20]
0.97 [0.82 , 1.16]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD death during trial, Prentice 2017
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Analysis 2.69.   Comparison 2: SFA reduction vs usual diet - secondary















Heterogeneity: Tau² = 0.05; Chi² = 26.44, df = 10 (P = 0.003); I² = 62%
Test for overall effect: Z = 1.82 (P = 0.07)





































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.27 [0.14 , 0.52]
1.67 [0.41 , 6.76]
0.97 [0.69 , 1.37]
2.93 [0.31 , 27.84]
0.71 [0.55 , 0.92]
1.86 [0.63 , 5.47]
1.50 [0.49 , 4.62]
0.31 [0.10 , 1.01]
0.77 [0.56 , 1.04]
0.97 [0.87 , 1.07]
0.83 [0.68 , 1.01]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
 
 
Analysis 2.70.   Comparison 2: SFA reduction vs usual diet - secondary







Heterogeneity: Tau² = 0.01; Chi² = 2.64, df = 2 (P = 0.27); I² = 24%
Test for overall effect: Z = 0.90 (P = 0.37)





























M-H, Random, 95% CI
1.67 [0.41 , 6.76]
0.77 [0.56 , 1.04]
0.97 [0.87 , 1.07]
0.92 [0.77 , 1.10]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
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Analysis 2.71.   Comparison 2: SFA reduction vs usual diet -














Heterogeneity: Tau² = 0.07; Chi² = 22.03, df = 9 (P = 0.009); I² = 59%
Test for overall effect: Z = 1.72 (P = 0.09)
































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.27 [0.14 , 0.52]
1.67 [0.41 , 6.76]
0.97 [0.69 , 1.37]
2.93 [0.31 , 27.84]
0.71 [0.55 , 0.92]
1.86 [0.63 , 5.47]
1.50 [0.49 , 4.62]
0.31 [0.10 , 1.01]
0.77 [0.56 , 1.04]
0.80 [0.62 , 1.03]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
 
 
Analysis 2.72.   Comparison 2: SFA reduction vs usual diet - secondary health










Heterogeneity: Tau² = 0.01; Chi² = 7.12, df = 5 (P = 0.21); I² = 30%
Test for overall effect: Z = 1.23 (P = 0.22)












































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
1.67 [0.41 , 6.76]
2.93 [0.31 , 27.84]
0.31 [0.10 , 1.01]
0.77 [0.56 , 1.04]
0.97 [0.87 , 1.07]
0.91 [0.77 , 1.06]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
 
 
Reduction in saturated fat intake for cardiovascular disease (Review)









Cochrane Database of Systematic Reviews
Analysis 2.73.   Comparison 2: SFA reduction vs usual diet - secondary













Heterogeneity: Tau² = 0.05; Chi² = 24.92, df = 8 (P = 0.002); I² = 68%
Test for overall effect: Z = 2.05 (P = 0.04)



























































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.27 [0.14 , 0.52]
0.97 [0.69 , 1.37]
2.93 [0.31 , 27.84]
0.71 [0.55 , 0.92]
1.86 [0.63 , 5.47]
0.31 [0.10 , 1.01]
0.77 [0.56 , 1.04]
0.97 [0.87 , 1.07]
0.80 [0.65 , 0.99]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
 
 
Analysis 2.74.   Comparison 2: SFA reduction vs usual diet - secondary














Heterogeneity: Tau² = 0.05; Chi² = 25.71, df = 9 (P = 0.002); I² = 65%
Test for overall effect: Z = 1.92 (P = 0.05)
































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.27 [0.14 , 0.52]
0.97 [0.69 , 1.37]
2.93 [0.31 , 27.84]
0.71 [0.55 , 0.92]
1.86 [0.63 , 5.47]
1.50 [0.49 , 4.62]
0.31 [0.10 , 1.01]
0.77 [0.56 , 1.04]
0.97 [0.87 , 1.07]
0.82 [0.67 , 1.00]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
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Analysis 2.75.   Comparison 2: SFA reduction vs usual diet - secondary















Heterogeneity: Chi² = 26.44, df = 10 (P = 0.003); I² = 62%
Test for overall effect: Z = 2.24 (P = 0.03)





































































M-H, Fixed, 95% CI
0.91 [0.73 , 1.14]
0.27 [0.14 , 0.52]
1.67 [0.41 , 6.76]
0.97 [0.69 , 1.37]
2.93 [0.31 , 27.84]
0.71 [0.55 , 0.92]
1.86 [0.63 , 5.47]
1.50 [0.49 , 4.62]
0.31 [0.10 , 1.01]
0.77 [0.56 , 1.04]
0.97 [0.87 , 1.07]
0.91 [0.84 , 0.99]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
 
 
Analysis 2.76.   Comparison 2: SFA reduction vs usual diet - secondary















Heterogeneity: Chi² = 33.99, df = 10 (P = 0.0002); I² = 71%
Test for overall effect: Z = 2.25 (P = 0.02)





































































Peto, Fixed, 95% CI
0.90 [0.70 , 1.16]
0.16 [0.07 , 0.36]
1.68 [0.41 , 6.93]
0.97 [0.61 , 1.52]
2.69 [0.37 , 19.30]
0.58 [0.39 , 0.87]
2.30 [0.60 , 8.85]
1.70 [0.41 , 7.04]
0.26 [0.08 , 0.90]
0.73 [0.51 , 1.05]
0.97 [0.87 , 1.07]
0.90 [0.83 , 0.99]
Peto Odds Ratio
Peto, Fixed, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
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Analysis 2.77.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 77: CHD events, subgroup by any substitution
Study or Subgroup










Heterogeneity: Tau² = 0.08; Chi² = 20.25, df = 6 (P = 0.002); I² = 70%
Test for overall effect: Z = 1.97 (P = 0.05)





Test for overall effect: Z = 0.90 (P = 0.37)







Heterogeneity: Tau² = 0.01; Chi² = 4.49, df = 3 (P = 0.21); I² = 33%
Test for overall effect: Z = 0.76 (P = 0.44)






Heterogeneity: Tau² = 0.00; Chi² = 0.82, df = 2 (P = 0.66); I² = 0%






Test for overall effect: Z = 0.94 (P = 0.35)


















































































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.27 [0.14 , 0.52]
0.97 [0.69 , 1.37]
0.71 [0.55 , 0.92]
1.86 [0.82 , 4.22]
0.31 [0.10 , 1.01]
0.77 [0.56 , 1.04]
0.76 [0.57 , 1.00]
1.50 [0.62 , 3.61]
1.50 [0.62 , 3.61]
0.91 [0.73 , 1.14]
1.67 [0.41 , 6.76]
0.30 [0.09 , 0.98]
0.97 [0.87 , 1.07]
0.93 [0.78 , 1.11]
0.91 [0.73 , 1.14]
1.67 [0.41 , 6.76]
0.97 [0.87 , 1.07]
0.96 [0.88 , 1.05]
2.93 [0.31 , 27.84]
2.93 [0.31 , 27.84]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
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Analysis 2.78.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 78: CHD events, subgroup by main substitution
Study or Subgroup









Heterogeneity: Tau² = 0.07; Chi² = 17.71, df = 5 (P = 0.003); I² = 72%
Test for overall effect: Z = 1.68 (P = 0.09)





Test for overall effect: Z = 0.90 (P = 0.37)






Heterogeneity: Tau² = 0.25; Chi² = 4.31, df = 2 (P = 0.12); I² = 54%
Test for overall effect: Z = 0.54 (P = 0.59)










Test for overall effect: Z = 0.94 (P = 0.35)
























































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.27 [0.14 , 0.52]
0.97 [0.69 , 1.37]
0.71 [0.55 , 0.92]
1.86 [0.82 , 4.22]
0.77 [0.56 , 1.04]
0.79 [0.60 , 1.04]
1.50 [0.62 , 3.61]
1.50 [0.62 , 3.61]
1.67 [0.41 , 6.76]
0.30 [0.09 , 0.98]
0.97 [0.87 , 1.07]
0.82 [0.39 , 1.72]
Not estimable
2.93 [0.31 , 27.84]
2.93 [0.31 , 27.84]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
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Analysis 2.79.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 79: CHD events, subgroup by duration
Study or Subgroup
2.79.1 up to 24 months
DART 1989
Moy 2001




Heterogeneity: Tau² = 0.01; Chi² = 3.17, df = 3 (P = 0.37); I² = 5%
Test for overall effect: Z = 0.06 (P = 0.95)






Heterogeneity: Tau² = 0.04; Chi² = 3.82, df = 2 (P = 0.15); I² = 48%






Heterogeneity: Tau² = 0.04; Chi² = 4.91, df = 1 (P = 0.03); I² = 80%






Heterogeneity: Tau² = 1.37; Chi² = 5.35, df = 1 (P = 0.02); I² = 81%
Test for overall effect: Z = 0.56 (P = 0.57)




















































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
2.93 [0.31 , 27.84]
1.86 [0.63 , 5.47]
1.50 [0.49 , 4.62]
1.01 [0.76 , 1.35]
0.97 [0.69 , 1.37]
0.31 [0.10 , 1.01]
0.77 [0.56 , 1.04]
0.79 [0.55 , 1.13]
0.71 [0.55 , 0.92]
0.97 [0.87 , 1.07]
0.85 [0.63 , 1.15]
0.27 [0.14 , 0.52]
1.67 [0.41 , 6.76]
0.60 [0.10 , 3.58]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
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Analysis 2.80.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 80: CHD events, subgroup by baseline SFA
Study or Subgroup




Test for overall effect: Not applicable







Heterogeneity: Tau² = 0.00; Chi² = 1.76, df = 3 (P = 0.62); I² = 0%
Test for overall effect: Z = 0.80 (P = 0.42)





Test for overall effect: Z = 1.94 (P = 0.05)














Heterogeneity: Tau² = 0.18; Chi² = 15.59, df = 4 (P = 0.004); I² = 74%
Test for overall effect: Z = 1.00 (P = 0.32)
























































































M-H, Random, 95% CI
Not estimable
0.91 [0.73 , 1.14]
1.67 [0.41 , 6.76]
2.93 [0.31 , 27.84]
0.97 [0.87 , 1.07]
0.96 [0.88 , 1.06]
0.31 [0.10 , 1.01]
0.31 [0.10 , 1.01]
0.77 [0.56 , 1.04]
0.77 [0.56 , 1.04]
0.27 [0.14 , 0.52]
0.97 [0.69 , 1.37]
0.71 [0.55 , 0.92]
1.86 [0.63 , 5.47]
1.50 [0.49 , 4.62]
0.78 [0.49 , 1.26]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
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Analysis 2.81.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 81: CHD events, subgroup by SFA change
Study or Subgroup







Heterogeneity: Tau² = 0.00; Chi² = 1.76, df = 3 (P = 0.62); I² = 0%
Test for overall effect: Z = 0.80 (P = 0.42)




















Heterogeneity: Tau² = 0.18; Chi² = 15.59, df = 4 (P = 0.004); I² = 74%
Test for overall effect: Z = 1.00 (P = 0.32)




















































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
1.67 [0.41 , 6.76]
2.93 [0.31 , 27.84]
0.97 [0.87 , 1.07]
0.96 [0.88 , 1.06]
0.31 [0.10 , 1.01]
0.31 [0.10 , 1.01]
0.77 [0.56 , 1.04]
0.77 [0.56 , 1.04]
0.27 [0.14 , 0.52]
0.97 [0.69 , 1.37]
0.71 [0.55 , 0.92]
1.86 [0.63 , 5.47]
1.50 [0.49 , 4.62]
0.78 [0.49 , 1.26]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
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Analysis 2.82.   Comparison 2: SFA reduction vs usual diet -












Heterogeneity: Tau² = 0.02; Chi² = 9.12, df = 6 (P = 0.17); I² = 34%






Test for overall effect: Z = 0.61 (P = 0.54)






Heterogeneity: Tau² = 1.46; Chi² = 8.38, df = 2 (P = 0.02); I² = 76%
Test for overall effect: Z = 0.16 (P = 0.88)















































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.97 [0.69 , 1.37]
0.71 [0.55 , 0.92]
1.86 [0.63 , 5.47]
1.50 [0.49 , 4.62]
0.31 [0.10 , 1.01]
0.77 [0.56 , 1.04]
0.84 [0.70 , 1.02]
0.97 [0.87 , 1.07]
0.97 [0.87 , 1.07]
0.27 [0.14 , 0.52]
1.67 [0.41 , 6.76]
2.93 [0.31 , 27.84]
0.88 [0.18 , 4.36]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
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Analysis 2.83.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 83: CHD events, subgroup by CVD risk
Study or Subgroup





Heterogeneity: Tau² = 0.01; Chi² = 1.50, df = 1 (P = 0.22); I² = 33%
Test for overall effect: Z = 1.34 (P = 0.18)






Heterogeneity: Tau² = 1.46; Chi² = 8.38, df = 2 (P = 0.02); I² = 76%
Test for overall effect: Z = 0.16 (P = 0.88)










Heterogeneity: Tau² = 0.04; Chi² = 15.05, df = 6 (P = 0.02); I² = 60%
Test for overall effect: Z = 0.59 (P = 0.55)




















































































M-H, Random, 95% CI
0.77 [0.56 , 1.04]
0.93 [0.86 , 1.02]
0.90 [0.76 , 1.05]
0.27 [0.14 , 0.52]
1.67 [0.41 , 6.76]
2.93 [0.31 , 27.84]
0.88 [0.18 , 4.36]
0.91 [0.73 , 1.14]
0.97 [0.69 , 1.37]
0.71 [0.55 , 0.92]
1.86 [0.63 , 5.47]
1.50 [0.49 , 4.62]
0.31 [0.10 , 1.01]
1.14 [0.96 , 1.34]
0.94 [0.75 , 1.16]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) Women without CVD at baseline
(2) Women with CVD at baseline
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Analysis 2.84.   Comparison 2: SFA reduction vs usual diet - secondary
health events, Outcome 84: CHD events, subgroup by TC reduction
Study or Subgroup











Heterogeneity: Tau² = 0.07; Chi² = 19.84, df = 7 (P = 0.006); I² = 65%
Test for overall effect: Z = 2.03 (P = 0.04)






Heterogeneity: Tau² = 0.00; Chi² = 1.14, df = 2 (P = 0.56); I² = 0%
Test for overall effect: Z = 0.49 (P = 0.62)




Test for overall effect: Not applicable














































































M-H, Random, 95% CI
0.91 [0.73 , 1.14]
0.27 [0.14 , 0.52]
0.97 [0.69 , 1.37]
2.93 [0.31 , 27.84]
0.71 [0.55 , 0.92]
1.86 [0.63 , 5.47]
0.31 [0.10 , 1.01]
0.77 [0.56 , 1.04]
0.76 [0.58 , 0.99]
1.67 [0.41 , 6.76]
1.50 [0.49 , 4.62]
0.97 [0.87 , 1.07]
0.97 [0.88 , 1.08]
Not estimable
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
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Analysis 2.85.   Comparison 2: SFA reduction vs usual diet - secondary










Heterogeneity: Tau² = 0.02; Chi² = 5.70, df = 4 (P = 0.22); I² = 30%

























Heterogeneity: Tau² = 0.00; Chi² = 1.50, df = 2 (P = 0.47); I² = 0%
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.05; Chi² = 26.03, df = 10 (P = 0.004); I² = 62%
Test for overall effect: Z = 1.82 (P = 0.07)






























































































M-H, Random, 95% CI
0.97 [0.69 , 1.37]
0.71 [0.55 , 0.92]
1.86 [0.63 , 5.47]
1.50 [0.49 , 4.62]
0.77 [0.56 , 1.04]
0.84 [0.68 , 1.05]
0.27 [0.14 , 0.52]
0.27 [0.14 , 0.52]
0.91 [0.73 , 1.14]
0.91 [0.73 , 1.14]
0.33 [0.10 , 1.09]
0.33 [0.10 , 1.09]
1.67 [0.41 , 6.76]
2.93 [0.31 , 27.84]
0.97 [0.87 , 1.07]
0.97 [0.88 , 1.08]
0.83 [0.68 , 1.01]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
Footnotes
(1) CHD events including CHD death & MI, Prentice 2017
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Analysis 2.86.   Comparison 2: SFA reduction vs usual diet -
secondary health events, Outcome 86: DIABETES DIAGNOSES
Study or Subgroup
WHI 2006












M-H, Random, 95% CI
0.96 [0.90 , 1.02]
Risk Ratio
M-H, Random, 95% CI
0.85 0.9 1 1.1 1.2
Favours lower SFA Favours higher SFA
 
 
Comparison 3.   SFA reduction vs usual diet - secondary blood outcomes





Statistical method Effect size
3.1 Total cholesterol, mmol/L 14 7115 Mean Difference (IV, Random,
95% CI)
-0.24 [-0.36, -0.13]
3.2 TC, mmol/L, subgroup by any replace-
ment
14   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.2.1 replaced by PUFA 9 3888 Mean Difference (IV, Random,
95% CI)
-0.33 [-0.47, -0.19]
3.2.2 replace by MUFA 1 24 Mean Difference (IV, Random,
95% CI)
0.30 [-0.93, 1.53]
3.2.3 replace by CHO 6 5094 Mean Difference (IV, Random,
95% CI)
-0.18 [-0.32, -0.04]
3.2.4 replace by protein 4 4986 Mean Difference (IV, Random,
95% CI)
-0.15 [-0.27, -0.04]
3.2.5 replacement unclear 1 72 Mean Difference (IV, Random,
95% CI)
-0.34 [-0.64, -0.04]
3.3 TC, mmol/L, subgroup by main re-
placement
14   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.3.1 replaced by PUFA 8 3838 Mean Difference (IV, Random,
95% CI)
-0.28 [-0.37, -0.19]
3.3.2 replace by MUFA 1 24 Mean Difference (IV, Random,
95% CI)
0.30 [-0.93, 1.53]
3.3.3 replace by CHO 4 3181 Mean Difference (IV, Random,
95% CI)
-0.19 [-0.40, 0.01]
3.3.4 replace by protein 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.3.5 replacement unclear 1 72 Mean Difference (IV, Random,
95% CI)
-0.34 [-0.64, -0.04]
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Statistical method Effect size
3.4 LDL cholesterol, mmol/L 5 3291 Mean Difference (IV, Random,
95% CI)
-0.19 [-0.33, -0.05]
3.5 LDL, mmol/L, subgroup by any re-
placement
5   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.5.1 replaced by PUFA 1 50 Mean Difference (IV, Random,
95% CI)
-0.48 [-0.90, -0.06]
3.5.2 replace by MUFA 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.5.3 replace by CHO 3 2985 Mean Difference (IV, Random,
95% CI)
-0.16 [-0.35, 0.02]
3.5.4 replace by protein 2 2935 Mean Difference (IV, Random,
95% CI)
-0.09 [-0.15, -0.04]
3.5.5 replacement unclear 2 306 Mean Difference (IV, Random,
95% CI)
-0.29 [-0.51, -0.08]
3.6 LDL, mmol/L, subgroup by main re-
placement
5   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.6.1 replaced by PUFA 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.6.2 replace by MUFA 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.6.3 replace by CHO 3 2985 Mean Difference (IV, Random,
95% CI)
-0.16 [-0.35, 0.02]
3.6.4 replace by protein 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.6.5 replacement unclear 2 306 Mean Difference (IV, Random,
95% CI)
-0.29 [-0.51, -0.08]
3.7 HDL cholesterol, mmol/L 6 5147 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.02, 0.01]
3.8 HDL, mmol/L, subgroup by any re-
placement
6   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.8.1 replaced by PUFA 2 1905 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.04, 0.01]
3.8.2 replace by MUFA 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.8.3 replace by CHO 4 4840 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.03, 0.00]
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Statistical method Effect size
3.8.4 replace by protein 3 4790 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.03, 0.00]
3.8.5 replacement unclear 2 307 Mean Difference (IV, Random,
95% CI)
0.01 [-0.10, 0.12]
3.9 HDL, mmol/L, subgroup by main re-
placement
6   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.9.1 replaced by PUFA 1 1855 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.04, 0.02]
3.9.2 replace by MUFA 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.9.3 replace by CHO 3 2985 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.03, 0.01]
3.9.4 replace by protein 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.9.5 replacement unclear 2 307 Mean Difference (IV, Random,
95% CI)
0.01 [-0.10, 0.12]
3.10 Triglycerides, mmol/L 7 3845 Mean Difference (IV, Random,
95% CI)
-0.08 [-0.21, 0.04]
3.11 TG, mmol/L, subgroup by any re-
placement
7   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.11.1 replaced by PUFA 3 604 Mean Difference (IV, Random,
95% CI)
-0.19 [-0.35, -0.02]
3.11.2 replace by MUFA 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.11.3 replace by CHO 3 2985 Mean Difference (IV, Random,
95% CI)
-0.04 [-0.32, 0.25]
3.11.4 replace by protein 2 2935 Mean Difference (IV, Random,
95% CI)
0.01 [-0.08, 0.09]
3.11.5 replacement unclear 2 306 Mean Difference (IV, Random,
95% CI)
-0.09 [-0.52, 0.33]
3.12 TG, mmol/L, subgroup by main re-
placement
7   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.12.1 replaced by PUFA 2 554 Mean Difference (IV, Random,
95% CI)
-0.16 [-0.30, -0.01]
3.12.2 replace by MUFA 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
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Statistical method Effect size
3.12.3 replace by CHO 3 2985 Mean Difference (IV, Random,
95% CI)
-0.04 [-0.32, 0.25]
3.12.4 replace by protein 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.12.5 replacement unclear 2 306 Mean Difference (IV, Random,
95% CI)
-0.09 [-0.52, 0.33]
3.13 total cholesterol /HDL ratio 3 2985 Mean Difference (IV, Random,
95% CI)
-0.10 [-0.33, 0.13]
3.14 TC /HDL ratio, subgroup by any re-
placement
3   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.14.1 replaced by PUFA 1 50 Mean Difference (IV, Random,
95% CI)
-0.58 [-1.33, 0.17]
3.14.2 replace by MUFA 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.14.3 replace by CHO 3 2985 Mean Difference (IV, Random,
95% CI)
-0.10 [-0.33, 0.13]
3.14.4 replace by protein 2 2935 Mean Difference (IV, Random,
95% CI)
-0.09 [-0.21, 0.04]
3.14.5 replacement unclear 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.15 TC /HDL ratio, subgroup by main re-
placement
3   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.15.1 replaced by PUFA 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.15.2 replace by MUFA 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.15.3 replace by CHO 3 2985 Mean Difference (IV, Random,
95% CI)
-0.10 [-0.33, 0.13]
3.15.4 replace by protein 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.15.5 replacement unclear 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.16 LDL /HDL ratio 1   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.17 Lp(a), mmol/L 2 2882 Mean Difference (IV, Random,
95% CI)
0.00 [-0.00, 0.00]
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Statistical method Effect size
3.18 Lp(a), mmol/L, subgroup by any re-
placement
2   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.18.1 replaced by PUFA 1 50 Mean Difference (IV, Random,
95% CI)
0.00 [-1.37, 1.37]
3.18.2 replace by MUFA 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.18.3 replace by CHO 2 2882 Mean Difference (IV, Random,
95% CI)
0.00 [-0.00, 0.00]
3.18.4 replace by protein 1 2832 Mean Difference (IV, Random,
95% CI)
0.00 [-0.00, 0.00]
3.18.5 replacement unclear 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.19 Lp(a), mmol/L, subgroup by main re-
placement
2   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.19.1 replaced by PUFA 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.19.2 replace by MUFA 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.19.3 replace by CHO 2 2882 Mean Difference (IV, Random,
95% CI)
0.00 [-0.00, 0.00]
3.19.4 replace by protein 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.19.5 replacement unclear 0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.20 Insulin sensitivity 4   Mean Difference (IV, Random,
95% CI)
Subtotals only
3.20.1 HbA1c (glycosylated haemoglo-
bin), %
0 0 Mean Difference (IV, Random,
95% CI)
Not estimable
3.20.2 GTT (glucose tolerance test), glu-
cose at 2 hours, mmol/L
3 249 Mean Difference (IV, Random,
95% CI)
-1.69 [-2.55, -0.82]
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Analysis 3.1.   Comparison 3: SFA reduction vs usual diet -

















Heterogeneity: Tau² = 0.02; Chi² = 27.85, df = 11 (P = 0.003); I² = 60%
Test for overall effect: Z = 4.32 (P < 0.0001)














































































































IV, Random, 95% CI
-0.26 [-0.36 , -0.16]
-0.47 [-0.76 , -0.18]
-0.05 [-0.46 , 0.36]
Not estimable
Not estimable
0.07 [-0.34 , 0.48]
-0.58 [-1.42 , 0.26]
0.30 [-0.93 , 1.53]
-0.76 [-1.19 , -0.33]
-0.34 [-0.64 , -0.04]
-0.30 [-0.51 , -0.09]
-0.37 [-0.77 , 0.03]
-0.09 [-0.15 , -0.02]
-0.14 [-0.34 , 0.05]
-0.24 [-0.36 , -0.13]
Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours lower SFA Favours higher SFA
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Analysis 3.2.   Comparison 3: SFA reduction vs usual diet - secondary
blood outcomes, Outcome 2: TC, mmol/L, subgroup by any replacement
Study or Subgroup











Heterogeneity: Tau² = 0.01; Chi² = 9.85, df = 6 (P = 0.13); I² = 39%
Test for overall effect: Z = 4.62 (P < 0.00001)




Test for overall effect: Z = 0.48 (P = 0.63)








Heterogeneity: Tau² = 0.02; Chi² = 17.09, df = 5 (P = 0.004); I² = 71%
Test for overall effect: Z = 2.55 (P = 0.01)






Heterogeneity: Tau² = 0.01; Chi² = 8.01, df = 3 (P = 0.05); I² = 63%





Test for overall effect: Z = 2.24 (P = 0.03)











































































































































































IV, Random, 95% CI
-0.26 [-0.36 , -0.16]
-0.47 [-0.76 , -0.18]
Not estimable
Not estimable
0.07 [-0.34 , 0.48]
-0.58 [-1.42 , 0.26]
-0.76 [-1.19 , -0.33]
-0.30 [-0.51 , -0.09]
-0.37 [-0.77 , 0.03]
-0.33 [-0.47 , -0.19]
0.30 [-0.93 , 1.53]
0.30 [-0.93 , 1.53]
-0.26 [-0.36 , -0.16]
-0.05 [-0.46 , 0.36]
0.07 [-0.34 , 0.48]
-0.76 [-1.19 , -0.33]
-0.09 [-0.15 , -0.02]
-0.14 [-0.34 , 0.05]
-0.18 [-0.32 , -0.04]
-0.26 [-0.36 , -0.16]
-0.05 [-0.46 , 0.36]
-0.09 [-0.15 , -0.02]
-0.14 [-0.34 , 0.05]
-0.15 [-0.27 , -0.04]
-0.34 [-0.64 , -0.04]
-0.34 [-0.64 , -0.04]
Mean Difference
IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours lower SFA Favours higher SFA
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Analysis 3.3.   Comparison 3: SFA reduction vs usual diet - secondary
blood outcomes, Outcome 3: TC, mmol/L, subgroup by main replacement
Study or Subgroup










Heterogeneity: Tau² = 0.00; Chi² = 5.21, df = 5 (P = 0.39); I² = 4%
Test for overall effect: Z = 5.98 (P < 0.00001)




Test for overall effect: Z = 0.48 (P = 0.63)






Heterogeneity: Tau² = 0.03; Chi² = 9.48, df = 3 (P = 0.02); I² = 68%
Test for overall effect: Z = 1.89 (P = 0.06)
3.3.4 replace by protein
Subtotal (95% CI)
Heterogeneity: Not applicable





Test for overall effect: Z = 2.24 (P = 0.03)

























































































































IV, Random, 95% CI
-0.26 [-0.36 , -0.16]
-0.47 [-0.76 , -0.18]
Not estimable
Not estimable
0.07 [-0.34 , 0.48]
-0.58 [-1.42 , 0.26]
-0.30 [-0.51 , -0.09]
-0.37 [-0.77 , 0.03]
-0.28 [-0.37 , -0.19]
0.30 [-0.93 , 1.53]
0.30 [-0.93 , 1.53]
-0.05 [-0.46 , 0.36]
-0.76 [-1.19 , -0.33]
-0.09 [-0.15 , -0.02]
-0.14 [-0.34 , 0.05]
-0.19 [-0.40 , 0.01]
Not estimable
-0.34 [-0.64 , -0.04]
-0.34 [-0.64 , -0.04]
Mean Difference
IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours lower SFA Favours higher SFA
 
 
Analysis 3.4.   Comparison 3: SFA reduction vs usual diet -








Heterogeneity: Tau² = 0.01; Chi² = 6.30, df = 4 (P = 0.18); I² = 37%
Test for overall effect: Z = 2.73 (P = 0.006)

















































IV, Random, 95% CI
-0.16 [-0.52 , 0.20]
-0.29 [-0.54 , -0.04]
-0.48 [-0.90 , -0.06]
-0.30 [-0.72 , 0.12]
-0.09 [-0.15 , -0.03]
-0.19 [-0.33 , -0.05]
Mean Difference
IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours lower SFA Favours higher SFA
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Analysis 3.5.   Comparison 3: SFA reduction vs usual diet - secondary
blood outcomes, Outcome 5: LDL, mmol/L, subgroup by any replacement
Study or Subgroup




Test for overall effect: Z = 2.24 (P = 0.03)
3.5.2 replace by MUFA
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable





Heterogeneity: Tau² = 0.01; Chi² = 3.33, df = 2 (P = 0.19); I² = 40%
Test for overall effect: Z = 1.72 (P = 0.09)




Heterogeneity: Tau² = 0.00; Chi² = 0.14, df = 1 (P = 0.71); I² = 0%





Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.97); I² = 0%
Test for overall effect: Z = 2.70 (P = 0.007)

















































































IV, Random, 95% CI
-0.48 [-0.90 , -0.06]
-0.48 [-0.90 , -0.06]
Not estimable
-0.16 [-0.52 , 0.20]
-0.48 [-0.90 , -0.06]
-0.09 [-0.15 , -0.03]
-0.16 [-0.35 , 0.02]
-0.16 [-0.52 , 0.20]
-0.09 [-0.15 , -0.03]
-0.09 [-0.15 , -0.04]
-0.29 [-0.54 , -0.04]
-0.30 [-0.72 , 0.12]
-0.29 [-0.51 , -0.08]
Mean Difference
IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours lower SFA Favours higher SFA
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Analysis 3.6.   Comparison 3: SFA reduction vs usual diet - secondary blood
outcomes, Outcome 6: LDL, mmol/L, subgroup by main replacement
Study or Subgroup
3.6.1 replaced by PUFA
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable
3.6.2 replace by MUFA
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable





Heterogeneity: Tau² = 0.01; Chi² = 3.33, df = 2 (P = 0.19); I² = 40%
Test for overall effect: Z = 1.72 (P = 0.09)
3.6.4 replace by protein
Subtotal (95% CI)
Heterogeneity: Not applicable





Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.97); I² = 0%
Test for overall effect: Z = 2.70 (P = 0.007)


























































IV, Random, 95% CI
Not estimable
Not estimable
-0.16 [-0.52 , 0.20]
-0.48 [-0.90 , -0.06]
-0.09 [-0.15 , -0.03]
-0.16 [-0.35 , 0.02]
Not estimable
-0.29 [-0.54 , -0.04]
-0.30 [-0.72 , 0.12]
-0.29 [-0.51 , -0.08]
Mean Difference
IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours lower SFA Favours higher SFA
 
 
Analysis 3.7.   Comparison 3: SFA reduction vs usual diet -









Heterogeneity: Tau² = 0.00; Chi² = 3.94, df = 5 (P = 0.56); I² = 0%
Test for overall effect: Z = 1.25 (P = 0.21)
























































IV, Random, 95% CI
-0.01 [-0.04 , 0.02]
-0.05 [-0.16 , 0.06]
0.04 [-0.03 , 0.10]
-0.07 [-0.20 , 0.06]
-0.12 [-0.38 , 0.14]
-0.01 [-0.03 , 0.01]
-0.01 [-0.02 , 0.01]
Mean Difference
IV, Random, 95% CI
-0.2 -0.1 0 0.1 0.2
Favours higher SFA Favours lower SFA
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Analysis 3.8.   Comparison 3: SFA reduction vs usual diet - secondary
blood outcomes, Outcome 8: HDL, mmol/L, subgroup by any replacement
Study or Subgroup




Heterogeneity: Tau² = 0.00; Chi² = 0.77, df = 1 (P = 0.38); I² = 0%
Test for overall effect: Z = 0.91 (P = 0.36)
3.8.2 replace by MUFA
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable






Heterogeneity: Tau² = 0.00; Chi² = 1.31, df = 3 (P = 0.73); I² = 0%
Test for overall effect: Z = 1.49 (P = 0.14)





Heterogeneity: Tau² = 0.00; Chi² = 0.54, df = 2 (P = 0.76); I² = 0%





Heterogeneity: Tau² = 0.00; Chi² = 1.28, df = 1 (P = 0.26); I² = 22%
Test for overall effect: Z = 0.21 (P = 0.84)






































































































IV, Random, 95% CI
-0.01 [-0.04 , 0.02]
-0.07 [-0.20 , 0.06]
-0.01 [-0.04 , 0.01]
Not estimable
-0.01 [-0.04 , 0.02]
-0.05 [-0.16 , 0.06]
-0.07 [-0.20 , 0.06]
-0.01 [-0.03 , 0.01]
-0.01 [-0.03 , 0.00]
-0.01 [-0.04 , 0.02]
-0.05 [-0.16 , 0.06]
-0.01 [-0.03 , 0.01]
-0.01 [-0.03 , 0.00]
0.04 [-0.03 , 0.10]
-0.12 [-0.38 , 0.14]
0.01 [-0.10 , 0.12]
Mean Difference
IV, Random, 95% CI
-0.2 -0.1 0 0.1 0.2
Favours higher SFA Favours lower SFA
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Analysis 3.9.   Comparison 3: SFA reduction vs usual diet - secondary blood
outcomes, Outcome 9: HDL, mmol/L, subgroup by main replacement
Study or Subgroup




Test for overall effect: Z = 0.71 (P = 0.48)
3.9.2 replace by MUFA
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable





Heterogeneity: Tau² = 0.00; Chi² = 1.29, df = 2 (P = 0.52); I² = 0%
Test for overall effect: Z = 1.32 (P = 0.19)
3.9.4 replace by protein
Subtotal (95% CI)
Heterogeneity: Not applicable





Heterogeneity: Tau² = 0.00; Chi² = 1.28, df = 1 (P = 0.26); I² = 22%
Test for overall effect: Z = 0.21 (P = 0.84)


































































IV, Random, 95% CI
-0.01 [-0.04 , 0.02]
-0.01 [-0.04 , 0.02]
Not estimable
-0.05 [-0.16 , 0.06]
-0.07 [-0.20 , 0.06]
-0.01 [-0.03 , 0.01]
-0.01 [-0.03 , 0.01]
Not estimable
0.04 [-0.03 , 0.10]
-0.12 [-0.38 , 0.14]
0.01 [-0.10 , 0.12]
Mean Difference
IV, Random, 95% CI
-0.2 -0.1 0 0.1 0.2
Favours higher SFA Favours lower SFA
 
 
Analysis 3.10.   Comparison 3: SFA reduction vs usual diet -










Heterogeneity: Tau² = 0.01; Chi² = 12.13, df = 6 (P = 0.06); I² = 51%
Test for overall effect: Z = 1.29 (P = 0.20)































































IV, Random, 95% CI
-0.26 [-0.50 , -0.02]
0.25 [-0.22 , 0.72]
-0.34 [-0.84 , 0.16]
-0.50 [-1.05 , 0.05]
0.10 [-0.30 , 0.50]
-0.10 [-0.26 , 0.06]
0.00 [-0.00 , 0.00]
-0.08 [-0.21 , 0.04]
Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours lower SFA Favours higher SFA
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Analysis 3.11.   Comparison 3: SFA reduction vs usual diet - secondary
blood outcomes, Outcome 11: TG, mmol/L, subgroup by any replacement
Study or Subgroup





Heterogeneity: Tau² = 0.01; Chi² = 2.59, df = 2 (P = 0.27); I² = 23%
Test for overall effect: Z = 2.24 (P = 0.03)
3.11.2 replace by MUFA
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable





Heterogeneity: Tau² = 0.04; Chi² = 4.19, df = 2 (P = 0.12); I² = 52%
Test for overall effect: Z = 0.24 (P = 0.81)




Heterogeneity: Tau² = 0.00; Chi² = 1.07, df = 1 (P = 0.30); I² = 6%





Heterogeneity: Tau² = 0.04; Chi² = 1.80, df = 1 (P = 0.18); I² = 45%
Test for overall effect: Z = 0.43 (P = 0.66)































































































IV, Random, 95% CI
-0.26 [-0.50 , -0.02]
-0.50 [-1.05 , 0.05]
-0.10 [-0.26 , 0.06]
-0.19 [-0.35 , -0.02]
Not estimable
0.25 [-0.22 , 0.72]
-0.50 [-1.05 , 0.05]
0.00 [-0.00 , 0.00]
-0.04 [-0.32 , 0.25]
0.25 [-0.22 , 0.72]
0.00 [-0.00 , 0.00]
0.01 [-0.08 , 0.09]
-0.34 [-0.84 , 0.16]
0.10 [-0.30 , 0.50]
-0.09 [-0.52 , 0.33]
Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours lower SFA Favours higher SFA
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Analysis 3.12.   Comparison 3: SFA reduction vs usual diet - secondary
blood outcomes, Outcome 12: TG, mmol/L, subgroup by main replacement
Study or Subgroup




Heterogeneity: Tau² = 0.00; Chi² = 1.16, df = 1 (P = 0.28); I² = 14%
Test for overall effect: Z = 2.04 (P = 0.04)
3.12.2 replace by MUFA
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable





Heterogeneity: Tau² = 0.04; Chi² = 4.19, df = 2 (P = 0.12); I² = 52%
Test for overall effect: Z = 0.24 (P = 0.81)
3.12.4 replace by protein
Subtotal (95% CI)
Heterogeneity: Not applicable





Heterogeneity: Tau² = 0.04; Chi² = 1.80, df = 1 (P = 0.18); I² = 45%
Test for overall effect: Z = 0.43 (P = 0.66)









































































IV, Random, 95% CI
-0.26 [-0.50 , -0.02]
-0.10 [-0.26 , 0.06]
-0.16 [-0.30 , -0.01]
Not estimable
0.25 [-0.22 , 0.72]
-0.50 [-1.05 , 0.05]
0.00 [-0.00 , 0.00]
-0.04 [-0.32 , 0.25]
Not estimable
-0.34 [-0.84 , 0.16]
0.10 [-0.30 , 0.50]
-0.09 [-0.52 , 0.33]
Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours lower SFA Favours higher SFA
 
 
Analysis 3.13.   Comparison 3: SFA reduction vs usual diet -






Heterogeneity: Tau² = 0.02; Chi² = 2.65, df = 2 (P = 0.27); I² = 24%
Test for overall effect: Z = 0.83 (P = 0.40)



































IV, Random, 95% CI
0.19 [-0.35 , 0.73]
-0.58 [-1.33 , 0.17]
-0.10 [-0.17 , -0.03]
-0.10 [-0.33 , 0.13]
Mean Difference
IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours lower SFA Favours higher SFA
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Analysis 3.14.   Comparison 3: SFA reduction vs usual diet - secondary
blood outcomes, Outcome 14: TC /HDL ratio, subgroup by any replacement
Study or Subgroup




Test for overall effect: Z = 1.51 (P = 0.13)
3.14.2 replace by MUFA
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable





Heterogeneity: Tau² = 0.02; Chi² = 2.65, df = 2 (P = 0.27); I² = 24%
Test for overall effect: Z = 0.83 (P = 0.40)




Heterogeneity: Tau² = 0.00; Chi² = 1.07, df = 1 (P = 0.30); I² = 7%




Test for overall effect: Not applicable


































































IV, Random, 95% CI
-0.58 [-1.33 , 0.17]
-0.58 [-1.33 , 0.17]
Not estimable
0.19 [-0.35 , 0.73]
-0.58 [-1.33 , 0.17]
-0.10 [-0.17 , -0.03]
-0.10 [-0.33 , 0.13]
0.19 [-0.35 , 0.73]
-0.10 [-0.17 , -0.03]
-0.09 [-0.21 , 0.04]
Not estimable
Mean Difference
IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours lower SFA Favours higher SFA
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Analysis 3.15.   Comparison 3: SFA reduction vs usual diet - secondary blood
outcomes, Outcome 15: TC /HDL ratio, subgroup by main replacement
Study or Subgroup
3.15.1 replaced by PUFA
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable
3.15.2 replace by MUFA
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable





Heterogeneity: Tau² = 0.02; Chi² = 2.65, df = 2 (P = 0.27); I² = 24%
Test for overall effect: Z = 0.83 (P = 0.40)
3.15.4 replace by protein
Subtotal (95% CI)
Heterogeneity: Not applicable




Test for overall effect: Not applicable











































IV, Random, 95% CI
Not estimable
Not estimable
0.19 [-0.35 , 0.73]
-0.58 [-1.33 , 0.17]
-0.10 [-0.17 , -0.03]




IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours lower SFA Favours higher SFA
 
 
Analysis 3.16.   Comparison 3: SFA reduction vs usual diet - secondary blood outcomes, Outcome 16: LDL /HDL ratio
Study or Subgroup
STARS 1992
















IV, Random, 95% CI
-0.36 [-0.92 , 0.20]
Mean Difference
IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours lower SFA Favours higher SFA
 
 





Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.00 (P = 1.00)




























IV, Random, 95% CI
0.00 [-1.37 , 1.37]
0.00 [-0.00 , 0.00]
0.00 [-0.00 , 0.00]
Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours lower SFA Favours higher SFA
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Analysis 3.18.   Comparison 3: SFA reduction vs usual diet - secondary blood
outcomes, Outcome 18: Lp(a), mmol/L, subgroup by any replacement
Study or Subgroup




Test for overall effect: Z = 0.00 (P = 1.00)
3.18.2 replace by MUFA
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable




Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.00 (P = 1.00)








Test for overall effect: Not applicable




















































IV, Random, 95% CI
0.00 [-1.37 , 1.37]
0.00 [-1.37 , 1.37]
Not estimable
0.00 [-1.37 , 1.37]
0.00 [-0.00 , 0.00]
0.00 [-0.00 , 0.00]
0.00 [-0.00 , 0.00]
0.00 [-0.00 , 0.00]
Not estimable
Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours lower SFA Favours higher SFA
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Analysis 3.19.   Comparison 3: SFA reduction vs usual diet - secondary blood
outcomes, Outcome 19: Lp(a), mmol/L, subgroup by main replacement
Study or Subgroup
3.19.1 replaced by PUFA
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable
3.19.2 replace by MUFA
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable




Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.00 (P = 1.00)
3.19.4 replace by protein
Subtotal (95% CI)
Heterogeneity: Not applicable




Test for overall effect: Not applicable




































IV, Random, 95% CI
Not estimable
Not estimable
0.00 [-1.37 , 1.37]
0.00 [-0.00 , 0.00]




IV, Random, 95% CI
-2 -1 0 1 2
Favours lower SFA Favours higher SFA
 
 
Analysis 3.20.   Comparison 3: SFA reduction vs usual diet -
secondary blood outcomes, Outcome 20: Insulin sensitivity
Study or Subgroup
3.20.1 HbA1c (glycosylated haemoglobin), %
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable





Heterogeneity: Tau² = 0.26; Chi² = 3.61, df = 2 (P = 0.16); I² = 45%





Test for overall effect: Z = 0.00 (P = 1.00)















































IV, Random, 95% CI
Not estimable
-2.50 [-3.54 , -1.46]
-1.28 [-2.61 , 0.05]
-1.20 [-2.20 , -0.20]
-1.69 [-2.55 , -0.82]
0.00 [-0.04 , 0.04]
0.00 [-0.04 , 0.04]
Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours lower SFA Favours higher SFA
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Comparison 4.   SFA reduction vs usual diet - secondary outcomes including potential adverse e4ects





Statistical method Effect size
4.1 Cancer diagnoses 4 52294 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.83, 1.07]
4.2 Cancer deaths 5 52283 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.61, 1.64]
4.3 Weight, kg 6 43062 Mean Difference (IV, Random, 95% CI) -1.77 [-3.54, -0.01]
4.4 BMI, kg/m2 6 43894 Mean Difference (IV, Random, 95% CI) -0.42 [-0.72, -0.12]
4.5 Systolic Blood Pressure,
mmHg
5 3812 Mean Difference (IV, Random, 95% CI) -0.19 [-1.36, 0.97]
4.6 Diastolic Blood Pressure,
mmHg
5 3812 Mean Difference (IV, Random, 95% CI) -0.36 [-1.03, 0.32]
4.7 Quality of Life 1 40130 Mean Difference (IV, Random, 95% CI) 0.04 [0.01, 0.07]
 
 
Analysis 4.1.   Comparison 4: SFA reduction vs usual diet - secondary








Heterogeneity: Tau² = 0.01; Chi² = 4.47, df = 3 (P = 0.22); I² = 33%
Test for overall effect: Z = 0.91 (P = 0.37)


































M-H, Random, 95% CI
1.00 [0.21 , 4.82]
1.18 [0.86 , 1.62]
0.96 [0.91 , 1.01]
0.80 [0.66 , 0.99]
0.94 [0.83 , 1.07]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours lower SFA Favours higher SFA
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Analysis 4.2.   Comparison 4: SFA reduction vs usual diet - secondary









Heterogeneity: Tau² = 0.13; Chi² = 7.84, df = 4 (P = 0.10); I² = 49%
Test for overall effect: Z = 0.01 (P = 0.99)







































M-H, Random, 95% CI
0.66 [0.19 , 2.35]
0.50 [0.05 , 5.41]
0.16 [0.02 , 1.34]
1.81 [1.02 , 3.23]
0.98 [0.90 , 1.06]
1.00 [0.61 , 1.64]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lower SFA Favours higher SFA
 
 
Analysis 4.3.   Comparison 4: SFA reduction vs usual diet - secondary









Heterogeneity: Tau² = 2.14; Chi² = 13.06, df = 3 (P = 0.005); I² = 77%
Test for overall effect: Z = 1.97 (P = 0.05)






















































IV, Random, 95% CI
-0.20 [-2.03 , 1.63]
Not estimable
Not estimable
-8.50 [-13.77 , -3.23]
-0.70 [-0.90 , -0.50]
-2.70 [-4.56 , -0.84]
-1.77 [-3.54 , -0.01]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours lower SFA Favours higher SFA
Footnotes
(1) Change from baseline to 7,5 years
 
 
Analysis 4.4.   Comparison 4: SFA reduction vs usual diet - secondary









Heterogeneity: Tau² = 0.07; Chi² = 13.00, df = 5 (P = 0.02); I² = 62%
Test for overall effect: Z = 2.72 (P = 0.006)
























































IV, Random, 95% CI
-0.31 [-0.71 , 0.09]
-0.30 [-1.51 , 0.91]
-3.60 [-5.82 , -1.38]
-0.20 [-0.65 , 0.25]
-0.27 [-0.33 , -0.21]
-0.80 [-1.30 , -0.30]
-0.42 [-0.72 , -0.12]
Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours lower SFA Favours higher SFA
Footnotes
(1) Change to 7.5 years
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Analysis 4.5.   Comparison 4: SFA reduction vs usual diet - secondary outcomes








Heterogeneity: Tau² = 0.00; Chi² = 1.24, df = 2 (P = 0.54); I² = 0%
Test for overall effect: Z = 0.33 (P = 0.74)















































IV, Random, 95% CI
-4.81 [-13.03 , 3.41]
Not estimable
Not estimable
-0.10 [-4.12 , 3.92]
-0.10 [-1.33 , 1.13]
-0.19 [-1.36 , 0.97]
Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours lower SFA Favours higher SFA
 
 
Analysis 4.6.   Comparison 4: SFA reduction vs usual diet - secondary outcomes








Heterogeneity: Tau² = 0.00; Chi² = 1.07, df = 2 (P = 0.59); I² = 0%
Test for overall effect: Z = 1.03 (P = 0.30)















































IV, Random, 95% CI
-2.96 [-7.96 , 2.04]
Not estimable
Not estimable
-0.40 [-3.06 , 2.26]
-0.30 [-1.01 , 0.41]
-0.36 [-1.03 , 0.32]
Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours lower SFA Favours higher SFA
 
 
Analysis 4.7.   Comparison 4: SFA reduction vs usual diet - secondary





Test for overall effect: Z = 2.75 (P = 0.006)





















IV, Random, 95% CI
0.04 [0.01 , 0.07]
0.04 [0.01 , 0.07]
Mean Difference
IV, Random, 95% CI
-0.2 -0.1 0 0.1 0.2
Favours lower SFA Favours higher SFA
Footnotes
(1) Change in Global Quality of Life to trial close-out (0 worst to 10 best), Assaf 2016
 
 
A D D I T I O N A L   T A B L E S
Reduction in saturated fat intake for cardiovascular disease (Review)



























































































Number of visits Is intervention advice
only or other interven-
tion?
Black 1994 People with non-melanoma
skin cancer











Moderate Unclear Dietitian Unclear Unclear Advice?
Ley 2004 People with impaired glu-
cose intolerance or high
normal blood glucose
Moderate Small group Unclear Face-to-face Monthly meetings Advice (education, per-
sonal goal-setting, self-
monitoring)
Moy 2001 Middle-aged siblings of peo-
ple with early CHD, with at
least 1 CVD risk factor
Moderate Individual Trained
nurse
Face-to-face 6 - 8 weekly for 2 years Advice (individualised
counselling sessions)
MRC 1968 Free-living men who have
survived a 1st MI





Men with previous MI High Individual Dietitian Face-to-face
and other







Moderate Individual Diabetes di-
etitian





Men (?) with angina or fol-
lowing MI






Men (?) with angina or fol-
lowing MI








Dietitian Face-to-face Bi-weekly over 3 months fol-
lowed by monthly
Advice (individualised eat-
ing plan and counselling
sessions)










































































































































STARS 1992 Men with angina referred for
angiography






Men with angina referred for
angiography










N/A N/A Diet provided
WHI 2006 Postmenopausal women




Group Nutritionists Face-to-face 18 sessions/1st yr and quarterly
maintenance sessions after
Advice





Dietitian Face-to-face 8 bi-weekly sessions, then 3-
monthly contact and optional
monthly sessions
Advice























Black 1994 133 133 133 133 0 0 0 0 0 0
DART 1989 2033 2033 2033 2033 2033 2033 0 2033 2033 0
Houtsmuller 1979 102 0 0 102 102 0 0 102 102 0
Ley 2004 176 176 176 176 176 0 176 0 176 0
Moy 2001 267 0 0 235 235 235 235 0 267 0








































































































































MRC 1968 393 393 393 393 393 393 393 393 393 0
Oslo Diet-Heart 1966 412 412 412 412 412 412 412 412 412 0
Oxford Retinopathy 1978 249 (data not provid-
ed by arm)
0 0 0 0 0 0 0 0 0
Rose corn oil 1965 41 41 41 41 41 41 0 41 41 0
Rose olive 1965 39 39 39 39 39 39 0 39 39 0
Simon 1997 194 (data not provid-
ed by arm)
0 0 0 0 0 0 0 0 0
STARS 1992 60 55 55 55 55 0 55 0 55 0
Sydney Diet-Heart 1978 458 458 458 0 0 0 0 458 0 0
Veterans Admin 1969 846 846 846 846 846 846 846 846 846 0
WHI with CVD 2006 2277 0 2277 2277 0 2277 2277 2277 2277 0
WHI 2006 48,835 48,835 46,558 46,558 48,835 46,558 46,558 46,558 46,558 48,835
WINS 2006 2437 2437 0 0 0 0 0 0 0 0
Total Participants 58,509 55,858 53,421 53,300 53,167 52,834 50,952 53,159 53,204 48,835
Percent of participants for this outcome 100% 95% 91% 91% 91% 90% 87% 91% 91% 83%
Table 2.   Number of participants and number of outcomes for dichotomous variables (by intervention arm)  (Continued)
These numbers are the numbers of participants in each study who were available for assessment of outcomes within meta-analysis (not necessarily the number of participants
randomised within the trial).









































































































































































Black 1994 133 0 0 0 0 0 0 0 0 0
DART 1989 2033 1855 0 1855 0 0 0 0 0 0
Houtsmuller 1979 102 96 0 0 96 0 0 0 0 96
Ley 2004 176 103 103 103 103 0 103 0 0 103
Moy 2001 267 0 235 235 235 0 0 0 0 0
MRC 1968 393 177 0 0 0 0 0 0 0 0
Oslo Diet-Heart 1966 412 329 0 0 0 0 0 0 0 0
Oxford Retinopathy 1978 249 58 0 0 0 0 0 0 0 0
Rose corn oil 1965 41 22 0 0 0 0 0 0 0 0
Rose olive 1965 39 24 0 0 0 0 0 0 0 0
Simon 1997 194 72 71 72 71 0 0 0 0 0
STARS 1992 55 50 50 50 50 0 50 50 50 50
Sydney Diet-Heart 1978 458 458 0 0 458 0 0 0 0 0
Veterans Admin 1969 846 843 0 0 0 0 0 0 0 0
WHI with CVD 2006 2277 0 0 0 0 0 0 0 0 0
WHI 2006 48,835 2832 2832 2832 2832 0 2832 0 2832 2832
WINS 2006 2437 196 0 0 0 0 0 0 0 0
Total Participants 58952 7115 3291 5147 3845 0 2985 50 2882 3081
Percent of participants for this outcome 100% 12% 6% 9% 7% 0% 5% 0.1% 5% 5%








































































































































These numbers are the numbers of participants in each study who were available for assessment of outcomes within meta-analysis (not necessarily the number of participants
randomised within the trial).
HDL: high density lipoprotein
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Regression factor No. of
studies





Change in SFA as %E 8 0.01 0.05 (-0.03 to 0.13) 0.16 89%
Change in SFA as % of control 8 0.26 0.01 (-0.01 to 0.03) 0.14 89%
Baseline SFA as %E 8 0.68 -0.06 (-0.15 to 0.04) 0.19 81%
Change in TC, mmol/L 12 0.03 0.69 (0.05 to 1.33) 0.04 99%
Change in PUFA as %E 5 -0.01 -0.02 (-0.08 to 0.03) 0.25 100%
Change in MUFA as %E 5 -0.26 -0.03 (-0.14 to 0.09) 0.50 -87%
Change in CHO as %E 7 -0.11 -0.00 (-0.05 to 0.05) 0.92 -273%
Change in total fat intake as %E 9 -0.17 -0.01 (-0.03 to 0.01) 0.28 100%
Gender* 13 -0.17 -0.14 (-0.63 to 0.35) 0.55 -13%
Study duration 13 -0.47 0.00 (-0.01 to 0.02) 0.76 -24.8%
CVD risk at baseline** 13 -0.44 0.03 (-0.48 to 0.55) 0.89 -39%
Table 4.   Meta-regression of e4ects of SFA reduction on cardiovascular events 
*Gender was coded as follows: 0 = women, 1 = mixed, 2 = men





MUFA: monounsaturated fatty acid
PUFA: polyunsaturated fatty fat
SFA: saturated fatty acid
TC: total cholesterol
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Cut- o4 RR of all-
cause mor-
tality
RR of CVD mortality RR of CVD events RR of MI RR of non-fatal
MI




7%E 0.89 (0.66 to
1.20)
0.20 (0.01 to 4.15) 0.20 (0.01 to 4.15) N/A N/A N/A N/A N/A
8%E 0.89 (0.66 to
1.20)
0.20 (0.01 to 4.15) 0.20 (0.01 to 4.15) N/A N/A N/A N/A N/A
9%E 0.96 (0.83 to
1.10)










10%E 0.99 (0.90 to
1.09)










11%E 0.99 (0.88 to
1.12)










12%E 0.98 (0.91 to
1.07)










13%E 1.02 (0.83 to
1.25)










Table 5.   SFA cut-o4 data 




N/A: not applicable (no relevant studies)
RR: risk ratio
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A P P E N D I C E S
Appendix 1. Search strategies 2019
CENTRAL
#1 lipid near (low* or reduc* or modifi*)
#2 cholesterol* near (low* or modifi* or reduc*)
#3 (#1 or #2)
#4 MeSH descriptor: [Nutrition Therapy] explode all trees
#5 diet* or food* or nutrition*
#6 (#4 or #5)
#7 (#3 and #6)
#8 fat* near (low* or reduc* or modifi* or animal* or saturat* or unsaturat*)
#9 MeSH descriptor: [Diet, Atherogenic] explode all trees
#10 MeSH descriptor: [Diet Therapy] explode all trees
#11 (#7 or #8 or #9 or #10)
#12 MeSH descriptor: [Cardiovascular Diseases] this term only
#13 MeSH descriptor: [Heart Diseases] explode all trees
#14 MeSH descriptor: [Vascular Diseases] explode all trees
#15 MeSH descriptor: [Cerebrovascular Disorders] this term only
#16 MeSH descriptor: [Brain Ischemia] explode all trees
#17 MeSH descriptor: [Carotid Artery Diseases] explode all trees
#18 MeSH descriptor: [Dementia, Vascular] explode all trees
#19 MeSH descriptor: [Intracranial Arterial Diseases] explode all trees
#20 MeSH descriptor: [Intracranial Embolism and Thrombosis] explode all trees
#21 MeSH descriptor: [Intracranial Hemorrhages] explode all trees
#22 MeSH descriptor: [Stroke] explode all trees
#23 coronar* near (bypas* or gra`* or disease* or event*)
#24 cerebrovasc* or cardiovasc* or mortal* or angina* or stroke or strokes or tia or ischaem* or ischem*
#25 myocardi* near (infarct* or revascular* or ischaem* or ischem*)
#26 morbid* near (heart* or coronar* or ischaem* or ischem* or myocard*)
#27 vascular* near (peripheral* or disease* or complication*)
#28 heart* near (disease* or attack* or bypas*)
#29 (#12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28)
#30 (#11 and #29) Date added to CENTRAL trials database: 05/03/2014-15/10/2019
MEDLINE OVID
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1. (lipid$ adj5 (low$ or reduc$ or modifi$)).mp.
2. (cholesterol$ adj5 (low$ or modific$ or reduc$)).mp.
3. 1 or 2
4. exp Nutrition Therapy/
5. (diet$ or food$ or nutrition$).mp.
6. 4 or 5
7. 3 and 6
8. (fat adj5 (low$ or reduc$ or modifi$ or animal$ or saturat$ or unsatur$)).mp.
9. exp Diet, Atherogenic/
10. exp Diet Therapy/
11. 7 or 8 or 9 or 10
12. cardiovascular diseases/ or exp heart diseases/ or exp vascular diseases/
13. cerebrovascular disorders/ or exp brain ischemia/ or exp carotid artery diseases/ or exp dementia, vascular/ or exp intracranial arterial
diseases/ or exp "intracranial embolism and thrombosis"/ or exp intracranial hemorrhages/ or exp stroke/
14. (coronar$ adj5 (bypas$ or gra`$ or disease$ or event$)).mp
15. (cerebrovasc$ or cardiovasc$ or mortal$ or angina$ or stroke or strokes).mp.
16. (myocardi$ adj5 (infarct$ or revascular$ or ischaemi$ or ischemi$)).mp.
17. (morbid$ adj5 (heart$ or coronar$ or ischaem$ or ischem$ or myocard$)).mp.
18. (vascular$ adj5 (peripheral$ or disease$ or complication$)).mp.
19. (heart$ adj5 (disease$ or attack$ or bypass$)).mp.
20. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
21. 11 and 20
22. randomized controlled trial.pt.







30. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31. exp animals/ not humans.sh.
32. 30 not 31
33. 21 and 32
34. limit 33 to ed=20140305-20191015
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Embase OVID
1. cardiovascular diseases/ or exp heart diseases/ or exp vascular diseases/
2. cerebrovascular disorders/ or exp brain ischemia/ or exp carotid artery diseases/ or exp dementia, vascular/ or exp intracranial arterial
diseases/ or exp "intracranial embolism and thrombosis"/ or exp intracranial hemorrhages/ or exp stroke/
3. (coronar$ adj5 (bypas$ or gra`$ or disease$ or event$)).mp.
4. (cerebrovasc$ or cardiovasc$ or mortal$ or angina$ or stroke or strokes).mp.
5. (myocardi$ adj5 (infarct$ or revascular$ or ischaemi$ or ischemi$)).mp.
6. (morbid$ adj5 (heart$ or coronar$ or ischaem$ or ischem$ or myocard$)).mp.
7. (vascular$ adj5 (peripheral$ or disease$ or complication$)).mp.
8. (heart$ adj5 (disease$ or attack$ or bypass$)).mp.
9. or/1-8
10. (lipid$ adj5 (low$ or reduc$ or modifi$)).mp.
11. (cholesterol$ adj5 (low$ or modific$ or reduc$)).mp.
12. 10 or 11
13. (diet$ or food$ or eat$ or nutrition$).mp.
14. exp nutrition/
15. 13 or 14
16. 12 and 15
17. (fat adj5 (low$ or reduc$ or modifi$ or animal$ or saturat$ or unsatur$)).mp.
18. exp lipid diet/ or exp fat intake/ or exp low fat diet/
19. 16 or 17 or 18







27. (doubl$ adj blind$).tw.





33. double blind procedure/
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34. randomized controlled trial/
35. single blind procedure/
36. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35
37. (animal/ or nonhuman/) not human/
38. 36 not 37
39. 20 and 38
40. limit 39 to dd=20140305-20191015
Clinicaltrials.gov
Condition or disease: Cardiovascular Diseases OR CVD OR "heart disease"
Intervention/treatment: Dietary Fats OR saturated OR unsaturated OR fat
Study type: Interventional Studies (Clinical Trials)
ICTRP
Condition: Cardiovascular Diseases OR CVD OR heart disease
Intervention: Dietary Fats OR saturated OR unsaturated OR fat
W H A T ' S   N E W
 
Date Event Description
9 January 2020 New citation required but conclusions
have not changed
No new trials included, but four ongoing trials and one study
awaiting assessment, and we found new data for two of the al-
ready included trials (WHI 2006; WINS 2006). We updated assess-
ment of risk of bias, including assessment of summary risk of
bias for each trial, and carrying out sensitivity analyses omitting
trials not at low summary risk of bias. We updated assessment
of small study bias by comparing results of fixed- and random-ef-
fects meta-analyses. Data, results, GRADE assessment and con-
clusions updated.
29 December 2019 New search has been performed Searches updated to October 2019, searches of trials registers
added.
 
H I S T O R Y
Protocol first published: Issue 2, 1999
Review first published: Issue 6, 2015
 
Date Event Description
27 March 2015 New citation required and conclusions
have changed
We split a previously published review (Reduced or modi-
fied dietary fat for preventing cardiovascular disease, DOI:
10.1002/14651858.CD002137.pub3) into six smaller review up-
dates. The conclusions are therefore now focused on reduction
in saturated fat intake instead of reducing or modifying fat intake
overall on its effect on cardiovascular disease risk.
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Date Event Description
This split review update includes 15 randomised controlled tri-
als.
5 March 2014 New search has been performed The search has been updated to 5 March 2014.
 
C O N T R I B U T I O N S   O F   A U T H O R S
All authors were active in the design of the review and in providing critical revisions of the manuscript, all authors took part in assessment
of the results of the updated search, and assessment of inclusion of potentially relevant studies. All authors edited, proof-read and agreed
the final version of the review.
LH was the principal author of earlier versions (Hooper 2000; Hooper 2001; Hooper 2012; Hooper 2015a), originated and was primarily
responsible for planning and carrying out this systematic review, liaising with WHO NUGAG, carrying out the statistical analyses, and writing
the first dra` of this review.
AA, OFJ, CK, EF and LH were responsible for data extraction and assessment of validity.
D E C L A R A T I O N S   O F   I N T E R E S T
Lee Hooper: LH is a member of the World Health Organization Nutrition Guidance Expert Advisory Group (NUGAG). WHO paid for her travel,
accommodation and expenses to attend NUGAG meetings in Geneva, China and South Korea where the evidence of eCects of dietary fats
on health was discussed and guidance developed. LH's institution was given grant funding from WHO to carry out the 2019 update of this
systematic review, to update a systematic review on the relationship between total fat intake and body weight and a series of systematic
reviews on the health eCects of polyunsaturated fatty acids.
Nicole Martin: None known
Asmaa Abdelhamid: None known
Oluseyi Florence Jimoh: This review was funded by a grant from the World Health Organization.
Eve Foster: None known
Christian Kirk: None known
S O U R C E S   O F   S U P P O R T
Internal sources
• University of East Anglia, UK
Help with acquiring papers for previous versions of this review, and allowing time for Lee Hooper to work on the review
• University of Manchester, UK
Support with collection of papers for the first version of this review
External sources
• Studentship, Systematic Reviews Training Unit, Institute of Child Health, University of London, UK
Funding to support Lee Hooper to carry out the first version of the systematic review
• World Health Organization, Other
WHO funded the most recent update of this review
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
This review is the result of updating the searches for Hooper 2015a. The objective and outcomes have been widened since the protocol to
address queries by WHO NUGAG and the inclusion criteria have changed to focus on saturated fat and long-term trials (24 months instead
of six months).
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I N D E X   T E R M S
Medical Subject Headings (MeSH)
Cardiovascular Diseases  [mortality]  [*prevention & control];  Cause of Death;  Dietary Carbohydrates  [administration & dosage]; 
Dietary Fats  [*administration & dosage];  Dietary Fats, Unsaturated  [administration & dosage];  Dietary Proteins  [administration &
dosage];  Energy Intake;  Fatty Acids  [*administration & dosage];  Myocardial Infarction  [mortality]  [prevention & control];  Randomized
Controlled Trials as Topic;  Stroke  [prevention & control]
MeSH check words
Adult; Humans
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